<SEC-DOCUMENT>0001654954-16-001302.txt : 20160809
<SEC-HEADER>0001654954-16-001302.hdr.sgml : 20160809
<ACCEPTANCE-DATETIME>20160809160151
ACCESSION NUMBER:		0001654954-16-001302
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160809
DATE AS OF CHANGE:		20160809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32639
		FILM NUMBER:		161817797

	BUSINESS ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>Q2_10Q2016.htm
<DESCRIPTION>10-Q
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Washington, D.C. 20549</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">____________________________</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">FORM 10-Q</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">&#x2612;</font>&#xA0; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECURITIES EXCHANGE ACT OF 1934</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">For the quarterly period ended June 30, 2016</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">OR</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">&#x2610;&#xA0; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECURITIES EXCHANGE ACT OF 1934</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 100%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">For the transition period from &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; to &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Commission File Number 000-30929</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">___________________</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 24px">TG THERAPEUTICS, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(Exact name of registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 51%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Delaware</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(State or other jurisdiction of incorporation or organization)</font></div></td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">36-3898269</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(I.R.S. Employer Identification No.)</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 100%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr></table></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2 Gansevoort Street, 9<font style="font-size: 70%; vertical-align: top">th</font> Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">New York, New York 10014</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(Address including zip code of principal executive offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(212) 554-4484</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(Registrant's telephone number, including area code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">Yes </font>&#x2612;<font style="font-size: 13px"> No </font>&#x2B1C;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">&#x2612;</font><font style="font-size: 13px">&#xA0;</font>Yes <font style="font-size: 13px">&#x2610;</font> No</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller reporting company&#x201D; in Rule 12b-2 of the Exchange Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 67%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Large accelerated filer &#x2B1C;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 33%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Accelerated filer &#x2612;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 67%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Non-accelerated filer &#x2B1C; (Do not check if smaller reporting company)</font></div></td>
<td style="vertical-align: top; width: 33%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Smaller reporting company &#x2B1C;</font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">Yes </font>&#x2B1C;<font style="font-size: 13px"> No </font>&#x2612;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">There were 54,456,623 shares of the registrant&#x2019;s common stock, $0.001 par value, outstanding as of August 1, 2016.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG THERAPEUTICS, INC.</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FORM 10-Q</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FOR THE QUARTER ENDED JUNE 30, 2016</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TABLE OF CONTENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: rgb(204, 238, 255);">
<td colspan="2" style="vertical-align: top; width: 88%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">3</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 88%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PART I</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FINANCIAL INFORMATION</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">4</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 1</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Financial Statements:</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">4</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: -12px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Balance Sheets as of June 30, 2016 (unaudited) and December 31, 2015</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">4</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: -12px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2016 and 2015 (unaudited)</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">5</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: -12px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statement of Stockholders&#x2019; Equity for the six months ended June 30, 2016 (unaudited)</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">6</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: -12px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and 2015 (unaudited)</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">7</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Notes to Condensed Consolidated Financial Statements (unaudited)</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">8</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 2</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Management's Discussion and Analysis of Financial Condition and </font><font style="font-family: Times New Roman; font-size: 13px">Results of Operations</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">18</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 3</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Quantitative and Qualitative Disclosures About Market Risk</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">27</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 4</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Controls and Procedures</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">28</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PART II</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">OTHER INFORMATION</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">28</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 1</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Legal Proceedings</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">28</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 1A</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Risk Factors</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">28
<br></font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 12%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Item 6</font></div></td>
<td style="vertical-align: top; width: 76%;">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Exhibits</font></div></td>
<td style="vertical-align: top; width: 12%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">46</font></div></td></tr><tr>
<td style="vertical-align: top; width: 12%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 76%;">
<br></td></tr></table></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 76%">
<br></td>
<td style="vertical-align: top; width: 12%">
<br></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;<font style="font-size: 13px">2</font></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Certain matters discussed in this report, including matters discussed under the caption &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201D; may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words "anticipate," "believe," "estimate," "may," "expect," &#x201C;plan,&#x201D; &#x201C;intend&#x201D; and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially
from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions &#x201C;Risk Factors,&#x201D; &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking
statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about our:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for increases or decreases in expenses;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">use of clinical research centers and other contractors;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations as to the timing of commencing or completing pre-clinical and clinical trials and the expected outcomes of those trials;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for generating revenue or becoming profitable on a sustained basis;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations or ability to enter into marketing and other partnership agreements;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations or ability to enter into product acquisition and in-licensing transactions;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations or ability to build our own commercial infrastructure to manufacture, market and sell our drug candidates;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for the acceptance of our products by doctors, patients or payors;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">ability to compete against other companies and research institutions;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">ability to secure adequate protection for our intellectual property;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">ability to attract and retain key personnel;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">ability to obtain reimbursement for our products;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments;</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">stock price volatility; and</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">expectations for future capital requirements.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The forward-looking statements contained in this report reflect our views and assumptions only as of the date this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;3</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PART I. FINANCIAL INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 1. FINANCIAL STATEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Balance Sheets</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line-->
<br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; font-size: 13px; width: 100%; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 64%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td rowspan="1" style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;"><font style="font-weight:bold;">June</font> <font style="font-weight:bold;">30</font>, <font style="font-weight:bold;">2016</font></font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;"><font style="font-weight:bold;">December 31, 2015</font>&#xA0;</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">(Unaudited)</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">(Note 1)</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Assets</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Current assets:</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Cash and cash equivalents</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">28,577,832</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">55,061,329</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Short-term investment securities</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,680,319</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,166,512</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Interest receivable</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">133,766</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">186,021</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Prepaid research and development</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,510,025</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,151,142</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Other current assets</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">649,738<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">308,327<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total current assets</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">69,551,680</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">86,873,331</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Restricted cash</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">581,161</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">579,143</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Long-term investment securities</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">21,435,015</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,003,032</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div>Leasehold interest<br></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,968,734</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Property, plant and equipment, net</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">333,859</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">47,122</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Goodwill</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">799,391</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">799,391</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Other assets</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">127,700<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">171,182<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total assets</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">94,797,540<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">113,473,201<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Liabilities and stockholders&#x2019; equity</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Current liabilities:</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Accounts payable and accrued expenses</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">13,080,176</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;"> </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9,346,068</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;"> </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0; &#xA0; &#xA0;&#xA0; Accrued compensation</font> </div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;"><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;
796,376</font></font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">818,472&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Current portion of deferred revenue</font> </div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">152,381</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">152,381</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Notes payable</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">90,564<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">211,549<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total current liabilities</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,119,497</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">10,528,470</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Deferred rent</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">681,720</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Deferred revenue, net of current portion</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">1,295,238<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">1,371,429<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total liabilities</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">16,096,455<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">11,899,899<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Commitments and contingencies</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Stockholders&#x2019; equity:</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015)</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Common stock, $0.001 par value per share (150,000,000 shares authorized, 54,497,932 and 54,095,110 shares issued, 54,456,623 and 54,053,801 shares outstanding at June 30, 2016 and December 31, 2015, respectively)</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">54,498</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">54,095</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Contingently issuable shares</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Additional paid-in capital</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">266,762,568</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">259,887,464</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Treasury stock, at cost, 41,309 shares at June 30, 2016 and December 31, 2015</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(234,337</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(234,337</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Accumulated deficit</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(187,881,650</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(158,133,926</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total stockholders&#x2019; equity</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">78,701,085<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">101,573,302<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total liabilities and stockholders&#x2019; equity</font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">94,797,540<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 18%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">113,473,201<!--rule below paragraph--></font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">4
<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statements of Operations</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Unaudited)</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line-->
<br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 13px;">
<tr>
<td rowspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="2" rowspan="1" style="width: 28%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 90%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman;">Three months ended June 30,</font></div></font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td>
<td colspan="2" rowspan="1" style="width: 28%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 90%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman;">Six months ended June 30,</font></div></font><font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td></tr><tr>
<td style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">License revenue</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">38,095</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">38,095</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,190</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">76,190</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Costs and expenses:</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Research and development:</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Noncash compensation</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">567,157</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,359,446</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">954,082</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,697,354</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Other research and development</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">12,966,574</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">9,902,214</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">24,196,989</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">18,181,645</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total research and development</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">13,533,731</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">11,261,660</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">25,151,071</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">20,878,999</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">General and administrative:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Noncash compensation</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,081,240</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,883,540</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,393,280</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,902,660</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Other general and administrative</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">1,446,567</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">1,004,475</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">2,547,438</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">2,008,962</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:2px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Total general and administrative</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">2,527,807</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">5,888,015</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">4,940,718</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">10,911,622</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total costs and expenses</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">16,061,538</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">17,149,675</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">30,091,789</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">31,790,621</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Operating loss</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(16,023,443</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(17,111,580</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(30,015,599</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(31,714,431</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Other (income) expense:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Interest income</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(92,629</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(31,551</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(177,491</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(53,683</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Interest expense</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">220,756</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">246,526</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">463,161</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">484,183</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Change in fair value of notes payable</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(252,508</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(223,372</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(553,545</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(464,013</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:2px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Total other income</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">(124,381</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">(8,397)</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">(267,875)</font></div></font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">(33,513)</font></div></font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:4px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Net loss</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(15,899,062</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(17,103,183</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(29,747,724</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(31,680,918</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-48px;margin-right:0px;padding-bottom:4px;margin-left:48px;"><font style="font-family: Times New Roman; font-size: 13px">Basic and diluted net loss per common share</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.33</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.38</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.61</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.73</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:4px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Weighted average shares used in computing basic and diluted net loss per common share</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">48,769,948</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">45,320,637</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">48,838,731</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:4px double #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:4px double #000000;">43,216,385</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td colspan="1" style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">5
<br></font></div></div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break-->
</div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statement of Stockholders&#x2019; Equity</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(Unaudited)</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line-->
<br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 13px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="width: 18%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div></td>
<td colspan="2" rowspan="1" style="width: 18%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 5%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">&#xA0;Common Stock</font></font></div></font><font style="text-align: left; width: 5%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="2" rowspan="1" style="width: 17%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 5%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Treasury Stock</font></font></div></font><font style="text-align: left; width: 5%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">
<div><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Shares</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Amount</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Contingently issuable shares</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Additional paid-in capital</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Shares</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Amount</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold;">Accumulated</font> <font style="font-weight: bold;">Defic</font><font style="font-weight: bold;">it</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-weight: bold; font-family: Times New Roman;">Total</font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;"><a name="_hlk256596833">
<!--anchor-->
</a>Balance at January 1, 2016</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">54,095,110</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">54,095</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">6</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">259,887,464</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">41,309</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">(234,337</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">(158,133,926</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">101,573,302</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Issuance of common stock in connection with exercise of warrants</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">22,041</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">22</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">50,249</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">50,271</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Issuance of common stock in connection with conversion of notes payable</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3,201</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">30,598</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">30,601</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Issuance of restricted stock</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">14,000</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">14</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">(14</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">--</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Forfeiture of restricted stock</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">(33,231</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">(33</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">33</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">--</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Issuance of common stock in At the Market offering (net of offering costs of $122,497)</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">396,811</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">397</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3,446,876</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3,447,273</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Compensation in respect of restricted stock granted to employees, directors and consultants</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3,347,362</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">3,347,362</font><font style="text-align: left; width: 10%; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent: 0px; padding-bottom: 2px; margin-right: 0px; margin-left: 0px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Net loss</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 12px">
<div>
<div>
<div>
<div>
<div style="text-align: right; margin-left: 0px;"><font style="text-align: left; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; display: inline-block;">
<div style="text-align: right; margin-left: 0px; margin-right: -5px; text-indent: 0px"><font><font style="font-family: Times New Roman;">&#xA0;</font></font></div></font><font style="text-align: left; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></div></div></div></div></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-family: Times New Roman;">
<br></font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-family: Times New Roman;">
<br></font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-family: Times New Roman;">
<br></font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-family: Times New Roman;">
<br></font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: center; width: 80%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">
<div><font><font style="font-family: Times New Roman;">
<br></font></font></div></font><font style="text-align: left; width: 10%; padding-bottom: 2px; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">(29,747,724</font><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block;">(29,747,724</font><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 18%; vertical-align: bottom;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:4px;margin-left:12px;"><font style="font-size: 12px"><font style="font-family: Times New Roman;">Balance at June 30, 2016</font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">54,497,932</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">54,498</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 11%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">6</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">266,762,568</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 7%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">41,309</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td>
<td style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">(234,337</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td colspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">(187,881,650</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">)</font></font></div></td>
<td style="width: 12%; vertical-align: bottom;">
<div><font style="font-size: 12px"><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); display: inline-block;">78,701,085</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; vertical-align: bottom; display: inline-block;">&#xA0; </font></font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">6</font></div></div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break-->
</div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Condensed Consolidated Statements of Cash Flows</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">(Unaudited)</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line-->
<br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; font-size: 13px; width: 100%; font-family: Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 70%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 30%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Six months ended June 30,</font></div></font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="vertical-align: bottom; width: 70%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Net loss</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(29,747,724</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(31,680,918</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Noncash stock compensation expense</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,347,362</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">11,600,014</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Depreciation</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">23,319</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,805</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Amortization of premium on investment securities</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">254,132</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">205,409</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Change in fair value of notes payable</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(90,384</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">20,170</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Changes in assets and liabilities:</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in restricted cash</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,018</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,098</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in other current assets</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(5,700,293</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(5,117,040</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in leasehold interest<br></font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(1,968,734</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Decrease (increase) in accrued interest receivable</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">52,255</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(104,797</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in other assets</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(9,518</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in accounts payable and accrued expenses</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,712,012</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,018,767</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Increase in deferred rent </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">681,720</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Decrease in deferred revenue</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(76,191</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(76,191</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:2px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash used in operating activities</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(29,524,062</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(21,130,879</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Purchases of property, plant and equipment</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(310,056</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(20,280</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Investment in held-to-maturity securities</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(15,199,922</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(35,070,625</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-12px;margin-right:0px;padding-bottom:2px;margin-left:12px;"><font style="font-family: Times New Roman; font-size: 13px">Proceeds from maturity of short-term securities</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">15,000,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">7,850,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; padding-bottom:2px;text-indent:0px;margin-left:0px;margin-right:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash used in investing activities</font></div></td>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(509,978</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(27,240,905</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"> ) </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Proceeds from the exercise of warrants</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">50,271</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">992,644</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Proceeds from sale of common stock, net</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,504,261</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">51,984,879</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; padding-bottom:2px;text-indent:-24px;margin-left:24px;margin-right:0px;"><font style="font-family: Times New Roman; font-size: 13px">Financing costs</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(3,989</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(19,437</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Net cash provided by financing activities</font></div></td>
<td colspan="1" rowspan="1" style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">3,550,543</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">52,958,086</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(26,483,497</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,586,302</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">55,061,329</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">55,713,784</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:4px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">CASH AND CASH EQUIVALENTS AT END OF PERIOD</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,577,832</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">60,300,086</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">NONCASH TRANSACTIONS</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Accrued financing costs</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">47,797</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Reclassification of deferred financing costs to<font style="color: #1f497d">&#xA0;</font>additional paid-in capital</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(56,988</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(48,771</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 70%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Conversion of convertible notes payable to common stock</font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">30,601</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 15%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;7</font></div></div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break-->
</div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Notes to Condensed Consolidated Financial Statements (unaudited)</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line-->
<br></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Unless the context requires otherwise, references in this report to &#x201C;TG,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;us&#x201D; and &#x201C;our&#x201D; refer to TG Therapeutics, Inc. (formerly known as Manhattan Pharmaceuticals, Inc., or Manhattan) and our subsidiaries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 1 &#x2013; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Description of Business</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the
CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain
and Extra Terminal) inhibitors, and anti-PD-L1 and anti-GITR antibodies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article&#xA0;10 of Regulation&#xA0;S-X of the Exchange Act. Accordingly, they may not include all of the information
and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2015. The accompanying condensed
December 31, 2015 balance sheet has been derived from these statements. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of June 30, 2016, we have an accumulated deficit of approximately $187.9 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors,
including our ability to obtain regulatory approval for our drug candidates; successfully completing any post-approval regulatory obligations; and successfully commercializing our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of June 30, 2016, we had approximately $75.8 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately 18 to 24 months from June 30, 2016. The actual amount of cash that we will need to operate
is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current strategic plan, including the commercialization of any of our drug candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our common stock is listed on the <font style="color: #000000">Nasdaq Capital Market </font>and trades under the symbol &#x201C;TGTX.&#x201D;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">8
<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Recently Issued Accounting Standards</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In May 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-11, &#x201C;Rescission of SEC Guidance Because of Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&#x201D; (&#x201C;ASU 2016-11&#x201D;).&#xA0; ASU 2016-11 rescinds certain SEC guidance from the </font><font style="font-style: italic; color: #000000">FASB
Accounting Standards Codification</font><font style="color: #000000"> in response to announcements made by the SEC staff at the Emerging Issues Task Force&#x2019;s March 3, 2016 meeting.&#xA0; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Upon the adoption of ASU 2014-09:</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for gas-balancing arrangements (ASC 932-10-S99-5).</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Upon the adoption of ASU 2014-16:</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Determining the nature of a host contract related to a hybrid financial instrument issued in the form of a share under ASC 815 (ASC 815-10-S99-3).</font></div></div></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">ASU 2016-11 is effective upon the adoption of ASU 2014-09 and ASU 2014-16.&#xA0; <font style="color: #000000">The adoption of ASU 2016-11 is not expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In March 2016, the FASB issued ASU No. 2016-09, &#x201C;Simplifying the Accounting for Share-Based Payments&#x201D; (&#x201C;ASU 2016-09&#x201D;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected to significantly impact the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Use of Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results
could differ from those estimates. Such differences could be material to the consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Cash and Cash Equivalents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Restricted Cash</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We record cash pledged or held in trust as restricted cash. As of June 30, 2016 and December 31, 2015, we have approximately $0.6 million of restricted cash <font style="color: #000000">pledged to secure a line of credit as a security deposit for an </font><font style="color: #000000; background-color: #FFFFFF">Office Agreement </font><font style="color: #000000">(see Note
8)</font>.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Investment Securities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Investment securities at June 30, 2016 and December 31, 2015 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the
amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges would be included in interest and other (income) expense, net. Dividend
and interest income are recognized when earned.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Credit Risk</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term investments. The Company maintains its cash and cash equivalents, short-term investments and long-term investments with high-credit quality financial institutions. At times, such amounts may exceed
federally-insured limits.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">9
<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Revenue Recognition</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification (or &#x201C;Codification&#x201D;). We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone
payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment
is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Research and Development Costs</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Generally, research and development costs are expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of
costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting period. We review and accrue CRO expenses and clinical
trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and
depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial
contract.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Prepaid research and development in our consolidated balance sheets includes, among other things, certain costs related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of June 30, 2016 and December 31, 2015, we recorded approximately $14.5
million and $9.2 million of prepaid development and manufacturing services, respectively, in prepaid research and development related to such advance agreements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Income Taxes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than &#x201C;more likely than not,&#x201D; a valuation allowance is then created.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net
operating loss carryforwards will remain subject to examination. We recognize interest and penalties, if any, related to uncertain income tax positions in income tax expense.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;10</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Stock-Based Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the condensed consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards
that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the &#x201C;measurement date.&#x201D; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based
on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, because some of the options, restricted stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the achievement of such milestones becomes probable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Basic and Diluted Net Loss Per Common Share</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Basic net loss per share of our common stock is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially dilutive securities from stock options, stock warrants and convertible
preferred stock would have an antidilutive effect either because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 6,449,737 and 5,668,134 for the three and six months ended June 30, 2016 and 2015, respectively. <font style="color: #000000; font-family: Times New Roman">The following outstanding
shares of common stock equivalents were excluded from the computation of net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 90%; font-family: Times New Roman; font-size: 13px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="width: 65%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="2" rowspan="1" style="width: 35%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Three and Six Months Ended June 30,</font></div></font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Unvested restricted stock</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,270,084</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,431,430</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Warrants</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,164,708</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,218,749</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Shares issuable upon note conversion</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,945</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,803</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Options</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">152</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 65%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total</font></div></td>
<td style="width: 18%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">6,449,737</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 17%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">5,668,134</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Long-Lived Assets and Goodwill</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Long-lived assets are reviewed for potential impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management&#x2019;s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures.
If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Goodwill is reviewed for impairment annually, or earlier when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&#x2019;s
goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&#x2019;s goodwill is compared with the carrying amount of the unit&#x2019;s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events
or changes in circumstances suggest that the carrying value of an asset may not be recoverable.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">11
<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 2 &#x2013; CASH AND CASH EQUIVALENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following tables summarize our cash and cash equivalents at June 30, 2016 and December 31, 2015:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 90%; font-family: Times New Roman; font-size: 13px;">
<tr>
<td rowspan="1" style="width: 60%; vertical-align: bottom;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td rowspan="1" style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">June 30, 2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">December 31, 2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 60%; vertical-align: bottom;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 60%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Money market funds</font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,514,029</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,265,583</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 60%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Checking and bank deposits</font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">20,063,803</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">46,795,746</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 60%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total</font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">28,577,832</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 20%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:4px double #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">55,061,329</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 3 &#x2013; INVESTMENT SECURITIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our investments as of June 30, 2016 and December 31, 2015 are classified as held-to-maturity. Held-to-maturity investments are recorded at amortized cost.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following tables summarize our investment securities at June 30, 2016 and December 31, 2015:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 90%; font-family: Times New Roman; font-size: 13px;">
<tr>
<td rowspan="1" style="width: 44%; vertical-align: bottom;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="4" rowspan="1" style="width: 56%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">June 30, 2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="width: 44%; vertical-align: bottom;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Amortized cost, as adjusted</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Gross unrealized holding gains</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Gross unrealized holding losses</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Estimated fair value</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Short-term investments:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Obligations of domestic governmental agencies (maturing between July 2016 and June 2017) (held-to-maturity)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,680,319</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,601</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,702,920</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font>&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Long-term investments:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Obligations of domestic governmental agencies (maturing between July 2017 and January 2018) (held-to-maturity)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">21,435,015</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">80,328</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">21,515,343</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total short-term and long-term investment securities</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,115,334</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">102,929</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,218,263</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 90%; font-family: Times New Roman; font-size: 13px;">
<tr>
<td rowspan="1" style="width: 44%; vertical-align: bottom;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="4" rowspan="1" style="width: 56%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">December 31, 2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="width: 44%; vertical-align: bottom;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Amortized cost, as adjusted</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Gross unrealized holding gains</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Gross unrealized holding losses</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Estimated fair value</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Short-term investments:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,166,512</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,822</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,143,690</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="margin-left:0px;"><font>&#xA0;</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Long-term investments:</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">25,003,032</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">85,846</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">24,917,186</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 44%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total short-term and long-term investment securities</font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,169,544</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">108,668</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="width: 14%; vertical-align: bottom;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,060,876</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 4 &#x2013; FAIR VALUE MEASUREMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We measure certain financial assets and liabilities at fair value on a recurring basis in the condensed consolidated financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of
the following three categories:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 1 &#x2013; quoted prices in active markets for identical assets and liabilities;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 2 &#x2013; inputs other than Level 1 quoted prices that are directly or indirectly observable; and</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 3 &#x2013; unobservable inputs that are not corroborated by market data.</font></div></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;12</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of June 30, 2016 and December 31, 2015, the fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">At the time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (&#x201C;Manhattan&#x201D;)) with Ariston Pharmaceuticals, Inc. (&#x201C;Ariston&#x201D;) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the &#x201C;5% Notes&#x201D;) in satisfaction of several note payable issuances.&#xA0;&#xA0;The
5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share.&#xA0;&#xA0;Ariston agreed to make quarterly payments on the 5% Notes&#xA0;equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#x2019;s product candidates, AST-726 and AST-915.&#xA0;&#xA0;We have no obligations under the 5% Notes aside from (a) 50% of the net product cash flows from Ariston&#x2019;s product
candidates, if any, payable to noteholders; and (b) the conversion feature, discussed above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $16.8 million at June 30, 2016 and $19.9 million at December 31, 2015. </font>No payments have been made on the 5% Notes as of June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In December 2011, we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes&#x2019; fair value as of June
30, 2016 and December 31, 2015. The assumptions, assessments and projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our condensed consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following tables provide the fair value measurements of applicable financial liabilities as of June 30, 2016 and December 31, 2015:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin-left:auto;font-size:13px;margin-top:0px;margin-bottom:0px;width:90%;margin-right:auto;font-family:Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:52%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:48%;">
<div><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Financial liabilities at fair value as of June 30, 2016</font></div></font><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="vertical-align:bottom;width:52%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 1</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 2</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 3</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Total</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5% Notes</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin-left:auto;font-size:13px;margin-top:0px;margin-bottom:0px;width:90%;margin-right:auto;font-family:Times New Roman;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:52%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="4" rowspan="1" style="vertical-align:bottom;width:48%;">
<div><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Financial liabilities at fair value as of December 31, 2015</font></div></font><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr>
<td style="vertical-align:bottom;width:52%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 1</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 2</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Level 3</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Total</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:52%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">5% Notes</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;Total</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;13</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following table summarizes the changes in Level 3 instruments during the six months ended June 30, 2016:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin-left:auto;font-size:13px;margin-top:0px;margin-bottom:0px;width:90%;margin-right:auto;font-family:Times New Roman;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Fair value at December 31, 2015</font></div></td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">211,549</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Interest accrued on face value of 5% Notes</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">463,161</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Conversion of 5% notes</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(30,601</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; padding-bottom: 2px; text-indent: 0px; margin-left: 0px; margin-right: 0px;"><font>Change in fair value of Level 3 liabilities</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000;">(553,545</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 4px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Fair value at June 30, 2016</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statements of operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 5 - STOCKHOLDERS' EQUITY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Preferred Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, <font style="color: #000000; background-color: #FFFFFF">issuable in one or more series. Upon issuance, we can determine the rights, preferences, privileges and restrictions thereof.
These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our amended and restated certificate of incorporation authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">In December 2014, we filed a shelf registration statement on Form S-3 (the &#x201C;2015 S-3&#x201D;), which was declared effective in January 2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3, we amended our 2013 At-the-Market Issuance Sales Agreement with
MLV &amp; Co. LLC (the &#x201C;2015 ATM&#x201D;) such that we may issue and sell additional shares of our common stock, having an aggregate offering price of up to $175.0 million, from time to time through MLV &amp; Co. LLC (&#x201C;MLV&#x201D;) and FBR Capital Markets &amp; Co. (&#x201C;FBR&#x201D;, each of MLV and FBR individually an &#x201C;Agent&#x201D; and collectively the &#x201C;Agents&#x201D;), acting as the sales agents. Under the 2015 ATM we pay the Agents a commission rate of up to 3.0% of the gross proceeds
from the sale of any shares of common stock sold through the Agents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">During the six months ended June 30, 2016, we sold a total of 396,811 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $3.6 million at an average selling price of $9.00 per share, resulting in net proceeds of approximately $3.5 million after deducting commissions and other transaction
costs.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">The 2015 S-3 is currently our only active shelf registration statement. After deducting shares already sold, including under the 2015 ATM, there are approximately $178 million of common stock that remain available for sale under
the 2015 S-3. We may offer the securities under the 2015 S-3 from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that the 2015 S-3 provides us with the flexibility to raise additional capital to finance our operations as needed</font>.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;14</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Equity Incentive Plans</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 36px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (&#x201C;2012 Incentive Plan&#x201D;) was approved by stockholders in June 2015. As of June 30, 2016, no options were outstanding and up to an additional 4,183,861 shares may be issued under the 2012 Incentive Plan.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">Restricted Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting.</font> The following table summarizes restricted share activity for the six months ended June 30, 2016:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin-left:auto;font-size:13px;margin-top:0px;margin-bottom:0px;width:90%;margin-right:auto;font-family:Times New Roman;">
<tr style="">
<td rowspan="1" style="vertical-align: bottom; width: 76%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0; </font></div>
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Number of Shares</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Outstanding at December 31, 2015</font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7,359,915</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7.83</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Granted</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">14,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9.43</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Vested</font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(570,600</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">7.07</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="">
<td style="vertical-align: bottom; width: 76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Forfeited</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(33,231</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0; </font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 2px;">&#xA0; </font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 2px;">11.79</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Outstanding at June 30, 2016</font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">6,770,084</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7.85</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Total expense associated with restricted stock grants was approximately $1.6 million and $6.2 million during the three months ended June 30, 2016 and 2015, respectively, and $3.3 million, and $11.6 million during the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, there was approximately $17.3 million of total unrecognized compensation cost related
to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of 1.9 years. This amount does not include, as of June 30, 2016, 411,172 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,234,958 shares of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the measurement date. The expense is recognized over the vesting period of the award.
Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following table summarizes warrant activity for the six months ended June 30, 2016:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; width: 90%; font-family: Times New Roman; font-size: 13px;">
<tr style="">
<td rowspan="1" style="width: 52%; vertical-align: bottom;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td rowspan="1" style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Warrants</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Weighted-</font><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">average</font></div>
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">exercise price</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Aggregate Intrinsic Value</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 52%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 4px;"><font style="font-family: Times New Roman; font-size: 13px">Outstanding at December 31, 2015</font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">1,186,749</font><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">2.37</font><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font></div></td>
<td colspan="1" rowspan="1" style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; border-bottom: 4px double rgb(0, 0, 0);">11,341,452</font><font style="text-align: left; width: 10%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block; padding-bottom: 4px;">&#xA0; </font></div></td></tr><tr style="">
<td style="width: 52%; vertical-align: bottom;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Issued</font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">--</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 52%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Exercised</font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(22,041</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2.28</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td></tr><tr style="">
<td style="width: 52%; vertical-align: bottom;">
<div style="text-align: left; text-indent: 0px; padding-bottom: 2px; margin-right: 0px; margin-left: 24px;"><font style="font-family: Times New Roman; font-size: 13px">Expired</font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid; display: inline-block;">--</font><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">--</font><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom;">
<div><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 10%; padding-bottom: 2px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="width: 52%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div style="text-align: left; text-indent: 0px; padding-bottom: 4px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Outstanding at June 30, 2016</font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">&#xA0; </font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">1,164,708</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td>
<td style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">2.37</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td>
<td colspan="1" rowspan="1" style="width: 16%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
<div><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font><font style="text-align: left; width: 5%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">$</font><font style="text-align: right; width: 75%; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 4px; border-bottom-style: double; display: inline-block;">4,291,924</font><font style="text-align: left; width: 10%; padding-bottom: 4px; font-family: Times New Roman; font-size: 13px; vertical-align: bottom; display: inline-block;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Stock-Based Compensation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We did not grant any stock options during the six months ended June 30, 2016 and 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following table summarizes stock-based compensation expense information about restricted stock and stock options for the three and six months ended June 30, 2016 and 2015:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; font-size: 13px; width: 90%; font-family: Times New Roman;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align: bottom; width: 32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 34%;">
<div><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div>
<font>&#xA0; <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Three months ended June 30,</font>
<br></font></div></font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font></div></td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 34%;">
<div><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:90%;display:inline-block;">
<div>
<font>&#xA0; <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Six months ended June 30,</font>
<br></font></div></font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 32%;">
<div style="text-align: left; text-indent: -24px; margin-right: 0px; margin-left: 24px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px; font-weight: bold">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="text-align: left"><font style="vertical-align: bottom;"><font style="font-weight: bold;">2016</font> </font></font></div></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="text-align: left; font-weight: bold;">2015</font></div></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="text-align: center; font-weight: bold;">2016
<br></font></div></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="text-align: center; font-weight: bold;">2015<br></font></div></font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 32%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Stock-based compensation expense associated with restricted stock</font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,648,397</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">6,242,986<br></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,347,362</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">11,600,014
<br></font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 32%;">
<div style="text-align: left; text-indent:-24px;margin-right:0px;padding-bottom:2px;margin-left:24px;"><font style="font-family: Times New Roman; font-size: 13px">Stock-based compensation expense associated with option grants</font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;border-bottom:solid 2px #000000;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;border-bottom:solid 2px #000000;display:inline-block;">--</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">--</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;border-bottom:solid 2px #000000;display:inline-block;">&#xA0; </font><font style="text-align: right; vertical-align:bottom;width:75%;border-bottom:solid 2px #000000;display:inline-block;">--
<br></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 32%;">
<div style="padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,648,397</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,242,986</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,347,362</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 17%;">
<div><font style="text-align: left; padding-bottom:4px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: left; vertical-align:bottom;width:5%;border-bottom:double 4px #000000;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;border-bottom:double 4px #000000;display:inline-block;">11,600,014</font><font style="text-align: left; padding-bottom:4px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;15</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 6 &#x2013; NOTES PAYABLE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">The following is a summary of notes payable:</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center">
<table cellpadding="0" cellspacing="0" style="text-align: center; margin: 0px auto; font-size: 13px; width: 90%; font-family: Times New Roman;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align: bottom; width: 28%;">
<div style="padding-bottom:2px;margin-left:0px;">
<br></div></td>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 36%;">
<div><font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:94%;border-bottom:solid 2px #000;display:inline-block;">
<div><font>&#xA0; </font><font>&#xA0; </font><font><font><font style="font-weight:bold;">June 30, 2016</font></font></font></div></font><font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 36%;">
<div><font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:94%;border-bottom:solid 2px #000;display:inline-block;">
<div><font>&#xA0;<font style="font-weight:bold;">December</font> <font style="font-weight:bold;">31</font>, <font style="font-weight:bold;">201</font>5</font></div></font><font style="text-align: left; padding-bottom:2px;width:3%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 28%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Current portion, net</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Non-current portion, net</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Total</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Current portion, net</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Non-current portion, net</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Total</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align: bottom; width: 28%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Convertible 5% Notes Payable</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:solid 2px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align: bottom; width: 28%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Total</font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,564</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td>
<td colspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">211,549</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0; </font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 36px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Convertible 5% Notes Payable</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub").&#xA0; Pursuant to the terms and conditions of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the
"Merger"), with Ariston being the surviving corporation of the Merger.&#xA0; As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share.&#xA0;&#xA0;Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston&#x2019;s product candidates, AST-726 and
AST-915.&#xA0;&#xA0;<font style="color: #000000; background-color: #FFFFFF">We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#x2019;s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.</font> Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which was March 8, 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">The cumulative liability including accrued and unpaid interest of these notes was approximately $16.8 million at June 30, 2016 and $19.9 million at December 31, 2015. </font>No payments have been made on the 5% Notes as of June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In December 2011, we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments (See Note 4 for further details).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 7 &#x2013; LICENSE AGREEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">BET</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In May 2016, as part of a broader agreement with Jubilant Biosys (&#x201C;Jubilant&#x201D;), an India-based biotechnology company, we entered into a sub-license agreement (&#x201C;JBET Agreement&#x201D;) with Checkpoint Therapeutics, Inc. (&#x201C;Checkpoint&#x201D;), (see Note 8), for the development and commercialization of Jubilant&#x2019;s novel BET inhibitor program in the
field of hematological malignancies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Under the terms of the agreement,&#xA0;we paid Checkpoint an up-front licensing fee of&#xA0;$1.0 million&#xA0;and will make additional payments contingent on certain preclinical, clinical, and regulatory milestones, including commercial milestones totaling up to approximately&#xA0;$177 million&#xA0;and a single-digit royalty on net sales.&#xA0;&#xA0;TG will also provide
funding to support certain targeted research efforts at Jubilant.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;16</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">TG-1101</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize
TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">An upfront payment of $2.0 million, which was received in December 2012,<font style="color: #000000; background-color: #FFFFFF"> net of $0.3 million of&#xA0;income tax withholdings</font>, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the
first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $38,000 for each of the three months ended June 30, 2016 and 2015, and $76,000 for each of the six months ended June 30, 2016 and 2015 and, at June 30, 2016 and December 31, 2015, have deferred revenue of approximately $1.4 million and $1.5 million,
respectively, associated with this $2.0 million payment (approximately $0.2 million of which has been classified in current liabilities at June 30, 2016 and December 31, 2015).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">NOTE 8 &#x2013; RELATED PARTY TRANSACTIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">LFB Biotechnologies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &#x201C;LFB License Agreement&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Under the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred expenses of $2.3 million and $2.2 million during the three months ended June 30, 2016 and 2015, respectively, and $2.3 million and $2.4 million during the six months ended June 30, 2016 and 2015, respectively, which have been included in other
research and development expenses in the accompanying condensed consolidated statements of operations. As of June 30, 2016 and December 31, 2015, we had approximately $1.7 million and $2.1 million, respectively, recorded in accounts payable related to the LFB License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of June 30, 2016 and December
31, 2015, we recorded approximately $4.7 million and $3.0 million, respectively, in prepaid research and development for such advance payments.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Other Parties</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In March 2014, we entered into a shared services agreement (the &#x201C;Opus Shared Services Agreement&#x201D;) with Opus Point Partners Management, LLC (&#x201C;Opus&#x201D;) in which the parties agreed to share the costs of a rented facility and certain other services.&#xA0; Our Executive Chairman and Interim Chief Executive Officer is a Managing Member of Opus. During the
three and six months ended June 30, 2016, we incurred expenses of approximately $0.02 million and $0.1 million, respectively, principally for rent, related to this agreement. The Opus Shared Services Agreement is no longer in effect as we began occupying new space in April 2016. As of June 30, 2016, we had approximately $0.1 million recorded in accounts payable related to this Opus Shared Services Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">In October 2014, we entered into an agreement (the &#x201C;Office Agreement&#x201D;) with Fortress Biotech, Inc. (&#x201C;Fortress&#x201D;), to occupy approximately 45% of the 24,000 square feet of New York City office space leased by Fortress, which is now our corporate headquarters. The Office Agreement requires us to pay our respective
share of the average annual rent and other costs of the 15-year lease. We approximate an average annual rental obligation of $1.1 million under the Office Agreement. We began to occupy this new space in April 2016, with rental payments beginning in the third quarter of 2016. Mr. Weiss, our Executive Chairman and Interim CEO, is also Executive Vice Chairman of Fortress.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">17
<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="background-color: #FFFFFF">In connection with the Office Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other current assets in the accompanying condensed consolidated balance sheets as of June 30, 2016 and December 31, 2015. </font>During the six months ended June 30, 2016, <font style="background-color: #FFFFFF">we agreed
to pay Fortress $2.0 million for our portion of the build out costs,</font> which have been allocated to us at the 45% rate mentioned above. The allocated build-out costs have been recorded in Leasehold Interest and will be amortized over the 15-year term of the Office Agreement. After an initial commitment period of three (3) years, Fortress will assess actual office space utilization annually and if our utilization differs from the amount we have been billed, we will either receive credits or be assessed incremental
utilization charges.&#xA0; <font style="background-color: #FFFFFF">As of June 30, 2016, we had approximately $1.1 </font>million recorded in accounts payable related mostly to the upfront leasehold interest. <font style="background-color: #FFFFFF">Also in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for the Office Agreement, which has been recorded as restricted cash in the accompanying condensed consolidated balance sheets.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">In July 2015, we entered into a Shared Services Agreement (the &#x201C;Shared Services Agreement&#x201D;) with Fortress to share the cost of certain services such as facilities use, personnel costs and other overhead and administrative costs. This Shared Services Agreement requires us to pay our respective share of services
utilized. In connection with the Shared Services Agreement, we </font>incurred expenses of <font style="color: #000000; background-color: #FFFFFF">approximately $0.4 million for shared services for the six months ended June 30, 2016, primarily related to shared personnel.<br></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In May 2016, as part of a broader agreement with Jubilant, an India-based biotechnology company, we entered into the JBET Agreement with Checkpoint, a subsidiary of Fortress, for the development and commercialization of Jubilant&#x2019;s novel BET inhibitor program in the field of hematological malignancies. We paid Checkpoint an up-front licensing fee of $1.0 million as
part of the JBET Agreement. As of June 30, 2016, we had approximately $1.2 million recorded in accounts payable of which $1.0 million related to the licensing fee. Mr. Weiss is also the Executive Chairman of Checkpoint.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 2. MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results anticipated by our forward-looking
statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in &#x201C;Risk Factors.&#x201D; See also the &#x201C;Special Cautionary Notice Regarding Forward-Looking Statements&#x201D; set forth at the beginning of this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">You should read the following discussion and analysis in conjunction with the unaudited condensed consolidated financial statements, and the related footnotes thereto, appearing elsewhere in this report, and in conjunction with management&#x2019;s discussion and analysis and the audited consolidated financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">OVERVIEW</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the
CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET inhibitors,
and anti-PD-L1 and anti-GITR antibodies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">18
<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">TG-1101 (ublituximab)<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">TG-1101 (ublituximab) is a chimeric, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells. We hold exclusive worldwide rights to develop and commercialize TG-1101 for all indications, except for the territories of France and Belgium which have been
retained by LFB Biotechnologies, and South Korea and Southeast Asia which were licensed by us to Ildong in November 2012.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Generally, anti-CD20 antibodies are believed to exert their B-cell depleting effects through three primary mechanisms: antibody dependent cell-mediated cytotoxicity (&#x201C;ADCC&#x201D;), complement dependent cytotoxicity (&#x201C;CDC&#x201D;), and direct or programmed cell death (&#x201C;DCD&#x201D; or &#x201C;PCD&#x201D;). TG-1101 has been specifically glycoengineered to enhance
ADCC activity, which should enhance its ability to deplete B-cells and may improve its anti-cancer effects when compared to Rituxan<font style="font-size: 70%; vertical-align: top">&#xAE;</font>, the leading anti-CD20 monoclonal antibody, which had worldwide sales in 2015 of more than $7 billion.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Clinical Trials Overview and Recent Developments</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Two single-agent, dose-escalation, Phase I studies were undertaken with TG-1101 to establish an optimal dose in patients with Non-Hodgkin&#x2019;s Lymphoma (&#x201C;NHL&#x201D;) and Chronic Lymphocytic Leukemia (&#x201C;CLL&#x201D;). A two part first-in-human Phase I clinical trial was first completed in France in which TG-1101 was evaluated in relapsed or refractory CLL patients
at doses as high as 450mg per infusion. Subsequently, a single-agent Phase I study was undertaken in the US enrolling patients with both NHL and CLL, dosing patients up to 1200mg per infusion. In both studies, single agent therapy with TG-1101 was deemed well tolerated by treating investigators and displayed promising clinical activity in relapsed and refractory patients.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In oncology settings, anti-CD20 therapy is generally used in combination with other anti-cancer agents where it demonstrates maximum activity as opposed to single agent usage. As a result, subsequent clinical development for TG-1101 has focused on combination therapy. Currently, our priority combination trials for TG-1101 are:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The GENUINE Trial &#x2013; a randomized controlled Phase 3 trial evaluating TG-1101 in combination with ibrutinib, for previously treated CLL patients with high risk cytogenetics;</font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The UNITY-CLL Trial &#x2013; a randomized controlled Phase 3 trial evaluating TG-1101 in combination with TGR-1202, the Company&#x2019;s development stage PI3K delta inhibitor, for patients with front line and previously treated CLL;<br></font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">The UNITY-DLBCL Trial &#x2013; registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, in combination with TGR-1202, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL); and</font></font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"> </font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">TG-1101 + TGR-1202 + Pembrolizumab for patients with CLL.</font></font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, we have announced our intent of evaluating TG-1101 for the treatment of certain autoimmune diseases. <font style="font-family: Times New Roman; font-size: 13px">Currently, TG-1101 is being evaluated in a Phase 2 study for the treatment of Multiple Sclerosis (MS) and in an investigator initiated Phase 1 study for the treatment of acute neuromyelitis optica (NMO)
relapses, with additional autoimmune related indications planned to be studied.</font> Further details on our priority ongoing combination trials for TG-1101 are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TG-1101 + Ibrutinib Phase 3 Study Program &#x2013; The GENUINE Trial</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 + ibrutinib for the treatment of previously treated CLL patients with high risk cytogenetics. The SPA provides agreement that the Phase 3 trial design adequately
addresses objectives that would support the regulatory submission for drug approval.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The Phase 3 trial, named the GENUINE trial, is a randomized controlled clinical trial, with patients receiving either TG-1101 plus ibrutinib or ibrutinib alone. The trial will enroll approximately 330 patients, with the first 200 patients evaluated for overall response rate (ORR), and all patients followed for progression-free survival (PFS). As per the SPA, if the data
is positive, we plan to use the ORR data from the trial as the basis for submission of a Biologics License Application (BLA) for accelerated approval for TG-1101, with the PFS assessment intended to support a filing for full approval.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">19
<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TG-1101 in Combination with TGR-1202 Phase 3 Study Program &#x2013; The UNITY-CLL Trial</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In September 2015, we reached an agreement with the FDA regarding an SPA on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for the proprietary combination of TG-1101 plus TGR-1202, for the treatment of CLL. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that, if met, would support the regulatory
submission for drug approval of both TG-1101 and TGR-1202 in combination.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The Phase 3 trial, called the UNITY-CLL trial, is a randomized controlled clinical trial that includes two key objectives: first, to demonstrate contribution of each agent in the TG-1101 + TGR-1202 regimen (the combination sometimes referred to as "1303"), and second, to demonstrate superiority in Progression Free Survival (PFS) over the standard of care to support the submission
for full approval of the combination. The study will randomize patients into four treatment arms: TG-1101 + TGR-1202, TG-1101 alone, TGR-1202 alone, and an active control arm of obinutuzumab (GAZYVA<font style="font-size: 70%; vertical-align: top">&#xAE;</font>) + chlorambucil. An early interim analysis will assess contribution of each single agent in the TG-1101 + TGR-1202 combination regimen, which, if successful, will allow early termination of both single agent arms. A second interim analysis will be conducted
following full enrollment into the study, which, if positive, we plan to utilize for accelerated approval. Assuming early termination of the TG-1101 and TGR-1202 single agent arms, the study will enroll approximately 450 patients.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TG-1101 in Combination with TGR-1202 Phase 2b Registration-Directed Program &#x2013; The UNITY-DLBCL Trial</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In June 2016, we commenced a registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101 in combination with TGR-1202, as well as TGR-1202 alone, in patients with previously treated DLBCL.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 12px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; The study, entitled "A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma," is being led by Owen A. O'Connor, MD, PhD, Professor of Medicine and Experimental Therapeutics, and Director of the
Center for Lymphoid Malignancies at Columbia University Medical Center. The primary objective of the study is to assess the efficacy of TGR-1202 alone and in combination with TG-1101 in patients with previously treated DLBCL as measured by Overall Response Rate (ORR). The study will also provide important information as to the contribution of each agent, TGR-1202 and TG-1101, to the combination regimen of both agents. In addition to monitoring for safety and efficacy this study will analyze the impact of cell
of origin (GCB vs. ABC), mutational status and select biomarkers of efficacy.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">TGR-1202</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The phosphoinositide-3-kinases (&#x201C;PI3Ks&#x201D;) are a family of enzymes involved in various cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity. There are four isoforms of PI3K (alpha, beta, delta, and gamma), of which the delta isoform is strongly expressed in cells of hematopoietic origin, and
often implicated in B-cell related lymphomas.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 is an orally available PI3K delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms. TGR-1202 has demonstrated activity in several pre-clinical models and primary cells from patients with hematologic malignancies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We hold exclusive worldwide rights to develop and commercialize TGR-1202 for all indications worldwide, except for India which has been retained by Rhizen Pharmaceuticals S A.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Pre-Clinical Update TGR-1202</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In April 2016, at the American Association for Cancer Research (AACR) Annual Meeting 2016, in New Orleans, Louisiana the Company presented pre-clinical data describing the differential regulation of human T-cells by TGR-1202 in a poster presentation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Clinical Trials Overview and Recent Developments</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Initial clinical development of TGR-1202 was focused on establishing preliminary safety and efficacy in a wide variety of hematologic malignancies. Upon identification of safe and active doses of TGR-1202, a combination clinical trial program was opened, exploring TGR-1202 in combination with a variety of agents. In addition to the previously described study in combination
with TG-1101 with or without the BTK inhibitor, ibrutinib, our current combination clinical trials for TGR-1202 are:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="padding-top: 8px; ; margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 in combination with the anti-CD20 antibody, obinutuzumab (GAZYVA<font style="font-size: 70%; vertical-align: top">&#xAE;</font>) and chlorambucil in patients with CLL;</font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 in combination with the anti-CD30 antibody drug conjugate, brentuximab vedotin (ADCETRIS<font style="font-size: 70%; vertical-align: top">&#xAE;</font>), in patients with relapsed or refractory Hodgkin&#x2019;s lymphoma;</font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 in combination with the BTK inhibitor, ibrutinib, in patients with previously treated CLL and MCL; and</font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 in combination with the JAK inhibitor, ruxolitinib (JAKAFI<font style="font-size: 70%; vertical-align: top">&#xAE;</font>), in patients with previously treated Myelofibrosis or Polycythemia Vera</font></div></div></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">
<br></font></div></div></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;<font style="font-family: Times New Roman; font-size: 13px">In addition, given the favorable safety profile demonstrated to date, a trial of TGR-1202 monotherapy in patients with CLL who were previously intolerant to prior BTK or PI3K inhibitor therapy is also underway.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;20</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">Single Agent TGR-1202 in Patients with Relapsed/Refractory Hematologic Malignancies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In January 2013, the Company initiated a Phase I, open label, multi-center, first-in-human clinical trial of TGR-1202 in patients with hematologic malignancies. The study entitled TGR-1202-101, "A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies," is being run in collaboration with
the&#xA0;Sarah Cannon Research Institute&#xA0;in&#xA0;Nashville, TN with Howard &#x201C;Skip&#x201D; Burris, MD, Executive Director, Drug Development as the acting Study Chair. Enrollment is open to patients with relapsed or refractory NHL, CLL, and other select hematologic malignancies.&#xA0;As of February 2016, this study has closed to enrollment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Data from this ongoing Phase I study was most recently presented at the <font style="color: #000000">57th Annual American Society of Hematology (ASH) meeting held in December 2015<font style="color: #000000; font-family: Times New Roman; font-size: 13px">, with updated data presented as part of an integrated analysis as described below.</font></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TGR-1202 Long-term Follow-up Integrated Analysis in Patients with Relapsed/Refractory Hematologic Malignancies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In June 2016, at the 52<font style="font-size: 70%; vertical-align: top">nd</font> Annual Meeting of the American Society of Clinical Oncology (ASCO) and at the 21<font style="font-size: 70%; vertical-align: top">st</font> Congress of the European Hematology Association (EHA), the Company presented integrated data with long term follow-up from 165 patients exposed to TGR-1202
monotherapy or the combination of TGR-1202 plus TG-1101, which continued to demonstrate high response rates in CLL, NHL, and DLBCL coupled with a favorable safety profile.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TGR-1202 in Combination with obinutuzumab and chlorambucil in patients with CLL</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In March 2014, the Company initiated a Phase I/Ib, open label, multi-center, clinical trial of TGR-1202 in combination with obinutuzumab and chlorambucil in patients with CLL, both treatment na&#xEF;ve and relapsed. The study entitled TGR-GA-106, "A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination
with Obinutuzumab and Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)," is being led by Dr. Daruka Mahadevan of the West Clinic in Memphis, TN. As of February 2016, this study has completed enrollment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Data from the study was presented at the <font style="color: #000000">57th Annual American Society of Hematology (ASH) meeting held in December 2015.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TGR-1202 Combination Trials</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">TGR-1202 is being evaluated in combination with the anti-CD30 antibody drug conjugate, brentuximab vedotin, in patients with relapsed or refractory Hodgkin&#x2019;s lymphoma; in combination with the BTK inhibitor, ibrutinib, in patients with CLL and MCL; and in combination with the JAK inhibitor, ruxolitinib, in patients with Myelofibrosis or Polycythemia Vera. It is anticipated
that preliminary results from these studies will be presented at future medical conferences.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-style: italic; font-family: Times New Roman; font-size: 13px">TGR-1202 in Solid Tumors</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition to the exploration of TGR-1202 in various hematologic malignancies, a study was opened in October 2015 to evaluate TGR-1202 as a single agent as well as in combination with various chemotherapies for the treatment of select solid tumors. The study, entitled TGR-1202-102, &#x201C;A Phase I Study Evaluating the Safety and Efficacy of TGR-1202 Alone and in Combination
with either nab-paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors&#x201D; is being run in collaboration with the Sarah Cannon Research Institute in Nashville, TN with Johanna Bendell, MD, Director of GI Oncology Research as the acting study chair.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">IRAK4</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Interleukin-1 Receptor Associated Kinase 4, referred to as IRAK4, is a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldenstr&#xF6;m's Macroglobulinemia, a rare B-cell cancer, as well as in a sub-set of patients with Non-Hodgkin's
Lymphoma and Chronic Lymphocytic Leukemia. Additionally, IRAK4 is a key component of signaling pathways which regulate immune and inflammatory processes suggesting that inhibition of IRAK4 may also be useful in the treatment of autoimmune related disorders. We hold global rights to develop and commercialize the IRAK4 program, which was licensed from Ligand Pharmaceuticals. Our IRAK4 program is currently in pre-clinical development. In April 2015, we presented </font>pre-clinical data on the IRAK4 compounds at
the 2015 American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;21</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">PD-L1 and GITR</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">In March 2015, we entered into a global collaboration agreement for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Our anti-PD-L1 and anti-GITR programs are currently in pre-clinical development.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">BET</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">In May 2016, as part of a broader agreement with Jubilant Biosys (&#x201C;Jubilant&#x201D;), an India-based biotechnology company, we entered into a sub-license agreement (&#x201C;JBET Agreement&#x201D;) with Checkpoint Therapeutics, Inc. (&#x201C;Checkpoint&#x201D;), a subsidiary of Fortress, for the
development and commercialization of Jubilant&#x2019;s novel BET inhibitor program in the field of hematological malignancies.&#xA0; The BET inhibitor program is the subject of a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. &#xA0;Our BET inhibitor program is currently in pre-clinical development.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">GENERAL CORPORATE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our license revenues currently consist of license fees arising from our agreement with Ildong. We recognize upfront license fee revenues ratably over the estimated period in which we will have certain significant ongoing responsibilities under the sublicense agreement, with unamortized amounts recorded as deferred revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have not earned any revenues from the commercial sale of any of our drug candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our research and development expenses consist primarily of expenses related to in-licensing of new product candidates, fees paid to consultants and outside service providers for clinical and laboratory development, facilities-related and other expenses relating to the design, development, manufacture, testing and enhancement of our drug candidates and technologies. We expense
our research and development costs as they are incurred.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our general and administrative expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities and facilities-related expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our results of operations include non-cash compensation expenses as a result of the grants of stock options and restricted stock. Compensation expense for awards of options and restricted stock granted to employees and directors represents the fair value of the award recorded over the respective vesting periods of the individual awards. The expense is included in the respective
categories of expense in the condensed consolidated statements of operations. We expect to continue to incur significant non-cash compensation expenses.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">22<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">For awards of options and restricted stock to consultants and other third-parties, compensation expense is determined at the &#x201C;measurement date.&#x201D; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value
of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value, such as changes in market price, until the measurement
date is reached and the compensation expense is finalized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, certain restricted stock issued to employees vest upon the achievement of certain milestones; therefore, the total expense is uncertain until the milestone is probable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our clinical trials will be lengthy and expensive. Even if these trials show that our drug candidates are effective in treating certain indications, there is no guarantee that we will be able to record commercial sales of any of our drug candidates in the near future. In addition, we expect losses to continue as we continue to fund in-licensing and development of new drug
candidates. As we continue our development efforts, we may enter into additional third-party collaborative agreements and may incur additional expenses, such as licensing fees and milestone payments. In addition, we may need to establish the commercial infrastructure required to manufacture, market and sell our drug candidates following approval, if any, by the FDA, which would result in us incurring additional expenses. As a result, our quarterly results may fluctuate and a quarter-by-quarter comparison of our
operating results may not be a meaningful indication of our future performance.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">RESULTS OF OPERATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Three months ended June 30, 2016 and 2015</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">License Revenue. </font>License revenue was $38,095 for each of the three months ended June 30, 2016 and 2015. License revenue is related to the amortization of an upfront payment of $2.0 million received in 2012 associated with our license agreement with Ildong. The upfront payment from Ildong will be recognized as license revenue on a straight-line
basis through December 2025, which represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Noncash Compensation Expense (Research and Development). </font>Noncash compensation expense (research and development) related to equity incentive grants totaled $567,157 for the three months ended June 30, 2016, as compared to $1,359,446 during the comparable period in 2015. The decrease in noncash compensation expense was primarily related
to milestone-based vesting of restricted stock grants to personnel that occurred during the period ended June 30, 2015 and a decrease in the measurement date fair value of certain consultant restricted stock during the period ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other Research and Development Expenses</font>. Other research and development expenses increased by $3,064,360 to $12,966,574 for the three months ended June 30, 2016, as compared to $9,902,214 for the three months ended June 30, 2015. The increase was mainly due to a $1.0 million licensing fee for the Jubilant sub-license agreement, as
well as an increase in manufacturing and clinical trial expenses related to TGR-1202 of $0.5 million, partially offset by a decrease in manufacturing and clinical trial expenses related to TG-1101 of $0.2 million during the three months ended June 30, 2016. We expect our other research and development costs to increase for the remainder of 2016 as the enrollment of Phase 3 clinical trials increases and we prepare for launch.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Noncash Compensation Expense (General and Administrative).</font> <font style="color: #000000">Noncash compensation expense (general and administrative) related to equity incentive grants </font>decreased by $3,802,300 to $1,081,240 for the three months ended June 30, 2016<font style="color: #000000">, as compared to </font>$4,883,540 for
the three months ended June 30, 2015<font style="color: #000000">.&#xA0;</font>The decrease in noncash compensation expense was primarily related to a decrease in the measurement date fair value of certain consultant restricted stock during the three months ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other General and Administrative Expenses</font>. <font style="color: #000000">Other general and administrative expenses </font>increased by $442,092 to $1,446,567 for the three months ended June 30, 2016<font style="color: #000000">, as compared to </font>$1,004,475 for the three months ended June 30, 2015<font style="color: #000000">. The
increase was due primarily to the straight-line rent expense of our new office space, as well as increased personnel and other general and administrative costs. We expect our other general and administrative expenses to remain at a comparable level for the remainder of 2016.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other (Income) Expense</font>. Other income increased by $115,984 to $124,381 for the three months ended June 30, 2016<font style="color: #000000">, as compared to </font>$8,397 for the three months ended June 30, 2015. The increase is mainly due to an increase in interest income for the three months ended June 30, 2016.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">23<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Six months ended June 30, 2016 and 2015</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">License Revenue. </font>License revenue was $76,190 for each of the six months ended June 30, 2016 and 2015. License revenue for the six months ended June 30, 2016 and 2015 was related to the amortization of an upfront payment of $2.0 million received in 2012 associated with our license agreement with Ildong.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Noncash Compensation Expense (Research and Development).</font> Noncash compensation expense (research and development) related to equity incentive grants totaled $954,082 for the six months ended June 30, 2016, as compared to $2,697,354 during the comparable period in 2015. The decrease in noncash compensation expense was primarily related
to milestone-based vesting of restricted stock grants to non-executive personnel and a decrease in the measurement date fair value of certain consultant restricted stock during the period ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other Research and Development Expenses</font>. Other research and development expenses increased by $6,015,344 to $24,196,989 for the six months ended June 30, 2016, as compared to $18,181,645 for the six months ended June 30, 2015. The increase in other research and development expenses was due primarily to a $1.0 million licensing fee
for the Jubilant sub-license agreement, as well as an increase in manufacturing and clinical trial expenses related to TGR-1202 of $2.4 million, partially offset by a decrease in manufacturing and clinical trial expenses related to TG-1101 of $0.9 million for the six months ended June 30, 2016. We expect our other research and development costs to increase for the remainder of 2016 as enrollment of additional patients increases on our clinical trials.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Noncash Compensation Expense (General and Administrative).</font> <font style="color: #000000">Noncash compensation expense (general and administrative) related to equity incentive grants decreased by $</font>6,509,380 <font style="color: #000000">to $2,393,280</font> for the six months ended June 30, 2016<font style="color: #000000">, as
compared to $8,902,660</font> for the six months ended June 30, 2015<font style="color: #000000">.</font> The decrease in noncash compensation expense was primarily related to a decrease in the measurement date fair value of certain consultant restricted stock during the period ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other General and Administrative Expenses</font>. <font style="color: #000000">Other general and administrative expenses </font>increased by $538,476 to $2,547,438 for the six months ended June 30, 2016, as compared to $2,008,962 for the six months ended June 30, 2015<font style="color: #000000">. The increase was due primarily to the straight-line
rent expense of our new office space, as well as increased personnel and other general and administrative costs. We expect our other general and administrative expenses to remain at a comparable level for the remainder of 2016.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Other (Income) Expense</font>. Other income increased by $234,362 to $267,875 for the six months ended June 30, 2016<font style="color: #000000">, as compared to </font>$33,513 for the six months ended June 30, 2015. The increase is mainly due to an increase in interest income for the six months ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">&#xA0;LIQUIDITY AND CAPITAL RESOURCES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our primary sources of cash have been from the sale of equity securities, warrant and option exercises, and the upfront payment from our Sublicense Agreement with Ildong. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable.
Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of June 30, 2016, we had approximately $75.8 million in cash and cash equivalents, investment securities, and interest receivable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We anticipate that our cash and cash equivalents as of June 30, 2016 are sufficient to fund our anticipated operating cash requirements for </font><font style="font-family: Times New Roman; font-size: 13px">approximately 18 to 24 months from June 30, 2016. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the
timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Cash used in operating activities for the six months ended June 30, 2016 was $29,524,062 as compared to $21,130,879 for the six months ended June 30, 2015. The increase in cash used in operating activities was due primarily to increased expenditures associated with our clinical development programs for TG-1101 and TGR-1202.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">For the six months ended June 30, 2016, net cash used in investing activities was $509,978 as compared to $27,240,905 for the six months ended June 30, 2015. The decrease in net cash used in investing activities was primarily due to greater investments in held-to-maturity treasury securities during the six months ended June 30, 2015, and greater proceeds from maturity of
investments during the six months ended June 30, 2016.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">For the six months ended June 30, 2016 and 2015, net cash provided by financing activities of $3,550,543 and $52,958,086, respectively, related to our ATM program, as well as proceeds from the exercise of warrants.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">24<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">OFF-BALANCE SHEET ARRANGEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing,
liquidity, market risk or credit risk support.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CRITICAL ACCOUNTING POLICIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amount of assets and
liabilities and related disclosure of contingent assets and liabilities at the date of our financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates.
These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following: &#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Revenue Recognition</font>. We recognize license revenue in accordance with the revenue recognition guidance of the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of
the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone
payments as revenue upon the achievement of specified milestones only if (1)&#xA0;the milestone payment is non-refundable, (2)&#xA0;substantive effort is involved in achieving the milestone, (3)&#xA0;the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4)&#xA0;the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period
of performance under the contract.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Stock-Based Compensation</font>. We have granted stock options and restricted stock to employees, directors and consultants, as well as warrants to other third parties. For employee and director grants, the value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model takes
into account volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. We base our estimates of our stock price volatility on the historical volatility of our common stock and our assessment of future volatility; however, these estimates are neither predictive nor indicative of the future performance of our stock. For purposes of the calculation, we assumed that no dividends would be paid during the life of
the options and warrants. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those equity awards expected to vest. As a result, if other assumptions had been used, our recorded stock-based compensation expense could have been materially different from that reported. In addition, because some of the options and warrants issued to employees,
consultants and other third-parties vest upon the achievement of certain milestones, the total expense is uncertain.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Total compensation expense for options and restricted stock issued to consultants is determined at the &#x201C;measurement date.&#x201D; The expense is recognized over the vesting period for the options and restricted stock. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record stock-based compensation expense based on
the fair value of the equity awards at the reporting date. These equity awards are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value, such as changes in market price, until the measurement
date is reached and the compensation expense is finalized.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;25</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Accruals for Clinical Research Organization and Clinical Site Costs. </font>We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating
the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. <font style="font-family: Times New Roman">We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. &#xA0;Accrued CRO costs are subject to revisions as such trials progress
to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. </font>With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our
policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Accounting Related to Goodwill.</font> As of June 30, 2016 and December 31, 2015, there was $799,391 of goodwill on our condensed consolidated balance sheets. Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first
step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit&#x2019;s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit&#x2019;s goodwill is compared with the carrying amount of the unit&#x2019;s goodwill. If the carrying amount is greater than the
implied fair value, the carrying value of the goodwill must be written down to its implied fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We are required to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. For all of our acquisitions, various analyses, assumptions and estimates were made at the time of each acquisition that were used to determine the valuation of goodwill and intangibles. In
future years, the possibility exists that changes in forecasts and estimates from those used at the acquisition date could result in impairment indicators.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Accounting For Income Taxes</font>. In preparing our condensed consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves management estimation of our actual current tax exposure and assessment of temporary differences resulting from differing treatment
of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statements of operations. Significant
management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have fully offset our deferred tax assets with a valuation allowance. Our lack of earnings history and the uncertainty surrounding our ability to generate taxable income prior to the reversal or expiration of such deferred tax assets were the primary factors considered by management in maintaining the valuation allowance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Fair Value of 5% Notes Payable.</font> We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to
be classified and disclosed in one of three categories.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We elected the fair value option for valuing the 5% Notes. We elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;26</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">RECENTLY ISSUED ACCOUNTING STANDARDS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In May 2016, the FASB issued ASU No. 2016-11, &#x201C;Rescission of SEC Guidance Because of Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&#x201D; (&#x201C;ASU 2016-11&#x201D;).&#xA0; ASU 2016-11 rescinds certain SEC guidance from the </font><font style="font-style: italic; color: #000000">FASB
Accounting Standards Codification</font><font style="color: #000000"> in response to announcements made by the SEC staff at the Emerging Issues Task Force&#x2019;s March 3, 2016 meeting.&#xA0; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Upon the adoption of ASU 2014-09:</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Accounting for gas-balancing arrangements (ASC 932-10-S99-5).</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Upon the adoption of ASU 2014-16:</font></div></div></div>
<div style="margin-left: 120px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Determining the nature of a host contract related to a hybrid financial instrument issued in the form of a share under ASC 815 (ASC 815-10-S99-3).</font></div></div></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">ASU 2016-11 is effective upon the adoption of ASU 2014-09 and ASU 2014-16.&#xA0; <font style="color: #000000">The adoption of ASU 2016-11 is not expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In March 2016, the FASB issued ASU No. 2016-09, &#x201C;Simplifying the Accounting for Share-Based Payments&#x201D; (&#x201C;ASU 2016-09&#x201D;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected to significantly impact the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The primary objective of our investment activities is to preserve principal while maximizing our income from investments and minimizing our market risk. We invest in government and investment-grade corporate debt in accordance with our investment policy. Some of the securities in which we invest have market risk. This means that a change in prevailing interest rates, and/or
credit risk, may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the fair value of our investment will probably decline. As of June 30, 2016, our portfolio of financial instruments consists of cash equivalents, including bank deposits, and investments. Due to the short-term nature of our investments, we believe there is no material exposure to interest rate
risk, and/or credit risk, arising from our investments.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;27</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 4. CONTROLS AND PROCEDURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Evaluation of Disclosure Controls and Procedures</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of June 30, 2016, management carried out, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our disclosure controls and procedures are designed
to provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2016, our disclosure controls and procedures were effective.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Internal Control Over Financial Reporting</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">There were no changes in our internal control over financial reporting during the quarter ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 3px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PART II. OTHER INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 1. LEGAL PROCEEDINGS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ITEM 1A. RISK FACTORS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">You should carefully consider the following risks and uncertainties. If any of the following occurs, our business, financial condition or operating results could be materially harmed. These factors could cause the trading price of our common stock to decline, and you could lose all or part of your investment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">Risks Related to Our Business and Industry</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Because we have in-licensed our product candidates from third parties, any dispute with or non-performance by our licensors will adversely affect our ability to develop and commercialize the applicable product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our product candidates have been in-licensed from third parties. Under the terms of our license agreements, the licensors generally will have the right to terminate such agreement in the event of a material breach by us. The licensors will also have the right to terminate the agreement in the event we fail to use diligent and reasonable efforts to develop and commercialize
the product candidate worldwide.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If there is any conflict, dispute, disagreement or issue of non-performance between us and our licensing partners regarding our rights or obligations under the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy payment obligations under such agreement, our ability to develop and commercialize the affected product
candidate and our ability to enter into collaboration or marketing agreements for the affected product candidate may be adversely affected. Any loss of our rights under these license agreements would delay or completely terminate its product development efforts for the affected product candidate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We do not have full internal development capabilities, and are thus reliant upon our partners and third parties to generate clinical, preclinical and quality data necessary to support the regulatory applications needed to conduct clinical trials and file for marketing approval.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">28
<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In order to submit and maintain an IND, Biologics License Application (&#x201C;BLA&#x201D;), or New Drug Application (&#x201C;NDA&#x201D;) to the FDA, it is necessary to submit all information on the clinical, non-clinical, chemistry, manufacturing, controls and quality aspects of the product candidate. We rely on our third party contractors and our licensing partners to provide
a significant portion of this data. If we are unable to obtain this data, or the data is not sufficient to meet the regulatory requirements, we may experience significant delays in our development programs. Additionally, an IND must be active in each division in which we intend to conduct clinical trials. Currently we do not have an active IND for any of the IRAK4 or BET inhibitors, nor for our anti-PD-L1 and anti-GITR antibodies. Additionally, there can be no assurance given that any of the molecules under development
in our IRAK4 or BET inhibitor program or in our anti-PD-L1 and anti-GITR antibody research program will demonstrate sufficient pharmacologic properties during pre-clinical evaluation to advance to IND enabling studies, or that such IND enabling studies, if any are conducted, will provide data sufficient to support the filing of an IND, or that such IND, if filed, would be accepted by any FDA division under which we would seek to develop any product candidate. While we maintain an active IND for <font style="color: #000000">TG-1101 </font>and
TGR-1202 enabling the conduct of studies in the FDA&#x2019;s Division of Hematology and Oncology<font style="font-family: Times New Roman; font-size: 13px">, and an active IND for TG-1101 under the FDA&#x2019;s Division of Neurology,</font> there can be no assurance that we will be successful in obtaining an active IND for <font style="color: #000000">TG-1101 </font>or TGR-1202 in any other division under whose supervision we may seek to develop our product candidates, or that the FDA will allow us to continue
the development of our product candidates in those divisions where we maintain an active IND.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We are highly dependent on the success of our product candidates and cannot give any assurance that these or any future product candidates will be successfully commercialized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We are a development-stage biopharmaceutical company, and do not currently have any commercial products that generate revenues or any other sources of revenue. We may never be able to successfully develop marketable products. Our pharmaceutical development methods are unproven and may not lead to commercially viable products for any of several reasons.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If we are unable to develop, or receive regulatory approval for or successfully commercialize any of our product candidates, we will not be able to generate product revenues.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Pharmaceutical development has inherent risk. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are effective with a favorable benefit-risk profile for use in diverse populations for their target indications before we can seek regulatory approvals for their commercial sale. Success in early clinical trials
does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, there is typically an extremely high rate of failure of pharmaceutical candidates proceeding through clinical trials.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We plan on conducting additional Phase I, II and III clinical trials for <font style="color: #000000">TG-1101 and TGR-1202</font>. Early clinical results seen with <font style="color: #000000">TG-1101 and TGR-1202 </font>in a small number of patients may not be reproduced in expanded or larger clinical trials. Additionally, individually reported outcomes of patients treated
in clinical trials may not be representative of the entire population of treated patients in such studies. If the results from expansion cohorts or later trials are different from those found in the earlier studies of <font style="color: #000000">TG-1101 and TGR-1202</font>, we may need to terminate or revise our clinical development plan, which could extend the time for conducting our development program and could have a material adverse effect on our business. Our IRAK4, BET, anti-PD-L1 and anti-GITR programs
are all in pre-clinical development and no assurance can be given that they will advance into clinical development. If the results from additional pre-clinical studies or early clinical trials differ from those found in earlier studies, our clinical development plans and timelines for this program could be adversely affected which could have a material adverse effect on our business. Many drugs fail in the early stages of clinical development for safety and tolerability issues, accordingly if our pre-clinical
assets advance into clinical development, no assurance can be made that a safe and efficacious dose can be found.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If we are unable to successfully complete our clinical trial programs, or if such clinical trials take longer to complete than we project, our ability to execute our current business strategy will be adversely affected.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Whether or not and how quickly we complete clinical trials is dependent in part upon the rate at which we are able to engage clinical trial sites and, thereafter, the rate of enrollment of patients, and the rate we collect, clean, lock and analyze the clinical trial database. Patient enrollment is a function of many factors, including the size of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the study, the existence of competitive clinical trials, and whether existing or new drugs are approved for the indication we are studying. We are aware that other companies are currently conducting or planning clinical trials that seek to enroll patients with the same diseases that we are studying. Certain clinical trials are designed to continue until a pre-determined number of events have occurred in the patients enrolled. Trials such
as this are subject to delays stemming from patient withdrawal and from lower than expected event rates. They may also incur additional costs if enrollment is increased in order to achieve the desired number of events. If we experience delays in identifying and contracting with sites and/or in patient enrollment in our clinical trial programs, we may incur additional costs and delays in our development programs, and may not be able to complete our clinical trials in a cost-effective or timely manner. In addition,
conducting multi-national studies adds another level of complexity and risk. We are subject to events affecting countries outside the U.S. Negative or inconclusive results from the clinical trials we conduct or unanticipated adverse medical events could cause us to have to repeat or terminate the clinical trials.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">29<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In September 2014, we announced a Phase 3 clinical trial for TG-1101 in previously treated patients with high-risk CLL, and in September 2015 we announced a Phase 3 clinical trial for the combination of TG-1101 + TGR-1202 for patients with CLL, each of which are being conducted pursuant to SPAs with the FDA. Many companies which have been granted SPAs and/or the right to
utilize the FDA&#x2019;s Fast Track or accelerated approval process have ultimately failed to obtain final approval to market their drugs. Since we are seeking approvals under SPAs for some of our product registration strategies, based on protocol designs negotiated with the FDA, we may be subject to enhanced scrutiny. Further, any changes or amendments to a protocol that is being conducted under SPA will have to be reviewed and approved by the FDA to verify that the SPA agreement is still valid. Additionally,
even if the primary endpoint in a Phase 3 clinical trial is achieved, a SPA does not guarantee approval. The FDA may raise issues of safety, study conduct, bias, deviation from the protocol, statistical power, patient completion rates, changes in scientific or medical parameters or internal inconsistencies in the data prior to making its final decision. The FDA may also seek the guidance of an outside advisory committee prior to making its final decision. Even with &#x201C;fast track&#x201D; or &#x201C;priority
review&#x201D; status which we intend to seek for our product candidates, such designations do not necessarily mean a faster development process or regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Any product candidates we may advance into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates or any future product candidates are subject to extensive regulation by the FDA in the United States and by comparable health authorities worldwide or in foreign markets. In the United States, we are not
permitted to market our product candidates until we receive approval of a BLA or NDA from the FDA. The process of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies or regulations may change and the FDA has substantial discretion in the pharmaceutical approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the
FDA may require post-approval clinical trials or studies which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact our ability to successfully market our product candidates. Finally, the FDA may require adoption of a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. Despite the time
and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. Assuming successful clinical development, we intend to seek product approvals in countries outside the United States. As a result, we would be subject to regulation by the European Medicines Agency (&#x201C;EMA&#x201D;), as well as the other regulatory agencies in many of these countries, and other regulatory agencies around the world.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country may negatively impact the regulatory process in others. As in the United States, the regulatory approval process in Europe and in other countries is a lengthy and challenging process. The FDA, and any other regulatory body around the world can delay, limit or deny approval of a product candidate for many reasons, including:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for any indication;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the FDA may not accept clinical data from trials which are conducted by individual investigators or in countries where the standard of care is potentially different from the United States;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; or</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">30<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, recent events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and other regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Regulatory approvals for our
product candidates may not be obtained without lengthy delays, if at all.&#xA0; Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval or commercialization or limit their commercial potential.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Unacceptable adverse events caused by any of our product candidates that we take into clinical trials could cause either us or regulatory authorities to interrupt, delay, modify or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications. This, in turn, could prevent us from
commercializing the affected product candidate and generating revenues from its sale.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have not completed testing of any of our product candidates for the treatment of the indications for which we intend to seek product approval in humans, and we currently do not know the extent that adverse events, if any, will be observed in patients who receive any of our product candidates. To date, clinical trials using <font style="color: #000000">TG-1101 </font>and
TGR-1202 have demonstrated a toxicity profile that was deemed acceptable by the investigators performing such studies. Such interpretation may not be shared by future investigators or by the FDA and in the case of <font style="color: #000000">TG-1101 </font>and TGR-1202, even if deemed acceptable for oncology applications, it may not be acceptable for diseases outside the oncology setting, and likewise for any other product candidates we may develop. Additionally, the severity, duration and incidence of adverse
events may increase in larger study populations. With respect to both <font style="color: #000000">TG-1101 and TGR-1202</font>, the toxicity when manufactured under different conditions and in different formulations is not known, and it is possible that additional and/or different adverse events may appear upon the human use of those formulations and those adverse events may arise with greater frequency, intensity and duration than in the current formulation. Further, with respect to TGR-1202, although more than
300 patients have been dosed amongst all ongoing TGR-1202 studies, the full adverse effect profile of TGR-1202 is not known. It is unknown as the additional patients are exposed for longer durations to TGR-1202, whether greater frequency and/or severity of adverse events are likely to occur. Common toxicities of other drugs in the same class as TGR-1202 include high levels of liver toxicity, infections and colitis, the latter of which notably has presented with later onset, with incidence increasing with duration
of exposure. To date, the incidence of these events has been limited for TGR-1202, however no assurance can be given that this safety and tolerability profile will continue to be demonstrated in the future as higher doses, longer durations of exposure, and multiple drug combinations are explored. If any of our product candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain marketing approval and generate revenues from its sale, or even if approved for sale may lack differentiation
from competitive products, which could have a material adverse impact on our business and operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Additionally, in combination clinical development, there is an inherent risk of drug-drug interactions between combination agents which may affect each component&#x2019;s individual pharmacologic properties and the overall efficacy and safety of the combination regimen. Both TG-1101 and TGR-1202 are being evaluated in combination together, as well as with a variety of other
active anti-cancer agents, which may cause unforeseen toxicity, or impact the severity, duration, and incidence of adverse events observed compared to those seen in the single agent studies of these agents. Further, with multi-drug combinations, it is often difficult to interpret or properly assign attribution of an adverse event to any one particular agent, introducing the risk that toxicity caused by a component of a combination regimen could have a material adverse impact on the development of our product
candidates. There can be no assurances given that the combination regimens being studied will display tolerability or efficacy suitable to warrant further testing or produce data that is sufficient to obtain marketing approval.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If any of our product candidates receives marketing approval and we, or others, later identify unacceptable adverse events caused by the product, a number of significant negative consequences could result, including:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">regulatory authorities may withdraw their approval of the affected product;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">regulatory authorities may require a more significant clinical benefit for approval to offset the risk;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">regulatory authorities may require the addition of labeling statements that could diminish the usage of the product or otherwise limit the commercial success of the affected product;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we may choose to discontinue sale of the product;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we could be sued and held liable for harm caused to patients;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-style: italic; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">we may not be able to enter into collaboration agreements on acceptable terms and execute on our business model; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our reputation may suffer.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Any one or a combination of these events could prevent us from obtaining or maintaining regulatory approval and achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the affected product, which in turn could delay or prevent us from generating any revenues from the sale of the affected
product.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;31</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We may experience delays in the commencement of our clinical trials or in the receipt of data from preclinical and clinical trials conducted by third parties, which could result in increased costs and delay our ability to pursue regulatory approval.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Delays in the commencement of clinical trials and delays in the receipt of data from preclinical or clinical trials conducted by third parties could significantly impact our product development costs. Before we can initiate clinical trials in the United States for our product candidates, we need to submit the results of preclinical testing, usually in animals, to the FDA
as part of an IND, along with other information including information about product chemistry, manufacturing and controls and its proposed clinical trial protocol for our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We plan to rely on preclinical and clinical trial data from third parties, if any, for the IND submissions for our product candidates. If receipt of that data is delayed for any reason, including reasons outside of our control, it will delay our plans for IND filings, and clinical trial plans. This, in turn, will delay our ability to make subsequent regulatory filings and
ultimately, to commercialize our products if regulatory approval is obtained. If those third parties do not make this data available to us, we will likely, on our own, have to develop all the necessary preclinical and clinical data which will lead to additional delays and increase the costs of our development of our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Before we can test any product candidate in human clinical trials the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as in-vitro and animal studies to assess the potential safety and activity of the pharmaceutical product candidate. The conduct of the preclinical
tests must comply with federal regulations and requirements including good laboratory practices (&#x201C;GLP&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period.
In such a case, we must work with the FDA to resolve any outstanding concerns before the clinical trials can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The FDA may require that we conduct additional preclinical testing for any product candidate before it allows us to initiate the clinical testing under any IND, which may lead to additional delays and increase the costs of our preclinical development.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Even assuming an active IND for a product candidate, we do not know whether our planned clinical trials for any such product candidate will begin on time, or at all. The commencement of clinical trials can be delayed for a variety of reasons, including delays in:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">obtaining regulatory clearance to commence a clinical trial;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">identifying, recruiting and training suitable clinical investigators;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">reaching agreement on acceptable terms with prospective contract research organizations (&#x201C;CROs&#x201D;) and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;</font></div></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;32</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">obtaining sufficient quantities of a product candidate for use in clinical trials;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">obtaining institutional review board (&#x201C;IRB&#x201D;) or ethics committee approval to conduct a clinical trial at a prospective site;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">identifying, recruiting and enrolling patients to participate in a clinical trial;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">retaining patients who have initiated a clinical trial but may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process or personal issues; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">unexpected safety findings.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for our product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Delays in the completion of clinical testing could result in increased costs and delay our ability to generate product revenues.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate. Clinical trials may also be delayed as a result of ambiguous or negative interim results. Further, a clinical trial may be suspended or terminated by us, an IRB, an ethics committee or a Data Safety and Monitoring Committee overseeing the clinical trial, any of our clinical
trial sites with respect to that site or the FDA or other regulatory authorities due to a number of factors, including:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">unforeseen safety issues or any determination that the clinical trial presents unacceptable health risks; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">lack of adequate funding to continue the clinical trial.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Changes in regulatory requirements and guidance also may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the costs, timing and successful completion of a clinical trial. If we experience delays in the completion of, or if we must
terminate, any clinical trial of any product candidate that we advance into clinical trials, our ability to obtain regulatory approval for that product candidate will be delayed and the commercial prospects, if any, for the product candidate may be harmed. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate. Even if we ultimately commercialize any of our product candidates, other therapies for the same indications may have been introduced to
the market during the period we have been delayed and such therapies may have established a competitive advantage over our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We intend to rely on third parties to help conduct our planned clinical trials. If these third parties do not meet their deadlines or otherwise conduct the trials as required, we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We intend to use CROs to assist in the conduct of our planned clinical trials and will rely upon medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols. Our future CROs, investigators and other third parties may play a significant role in the conduct of these trials and the subsequent collection
and analysis of data from the clinical trials.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">There is no guarantee that any CROs, investigators and other third parties will devote adequate time and resources to our clinical trials or perform as contractually required. If any third parties upon whom we rely for administration and conduct of our clinical trials fail to meet expected deadlines, fail to adhere to its clinical protocols or otherwise perform in a substandard
manner, our clinical trials may be extended, delayed or terminated, and we may not be able to commercialize our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants
to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be jeopardized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">As all of our product candidates are still under development, manufacturing and process improvements implemented in the production of those product candidates may affect their ultimate activity or function.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our product candidates are in the initial stages of development and are currently manufactured in small batches for use in pre-clinical and clinical studies. Process improvements implemented to date have changed, and process improvements in the future may change, the activity profile of the product candidates, which may affect the safety and efficacy of the products. No
assurance can be given that the material manufactured from any of the optimized processes will perform comparably to the product candidates as manufactured to date and used in currently available pre-clinical data and or in early clinical trials reported in this or any previous filing. Additionally, future clinical trial results will be subject to the same level of uncertainty if, following such trials, additional process improvements are made. In addition, we have recently engaged a secondary manufacturer for
TG-1101 to meet our current clinical and future commercial needs and anticipate engaging additional manufacturing sources for TGR-1202 to meet expanded clinical trial and commercial needs. <font style="font-family: Times New Roman; font-size: 13px">While material produced from this secondary manufacturer for TG-1101 has to date demonstrated acceptable comparability, n</font>o assurance can be given that any additional manufacturers will be successful or that material manufactured by the additional manufacturers
will perform comparably to TG-1101 or TGR-1202 as manufactured to date and used in currently available pre-clinical data and or in early clinical trials reported in this or any previous filing. If a secondary manufacturer is not successful in replicating the product or experiences delays, or if regulatory authorities impose unforeseen requirements with respect to product comparability from multiple manufacturing sources, we may experience delays in clinical development.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;33</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If we fail to adequately understand and comply with the local laws and customs as we expand into new international markets, these operations may incur losses or otherwise adversely affect our business and results of operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We expect to operate a portion of our business in certain countries through subsidiaries or through supply and marketing arrangements. In those countries, where we have limited experience in operating subsidiaries and in reviewing equity investees, we will be subject to additional risks related to complying with a wide variety of national and local laws, including restrictions
on the import and export of certain intermediates, drugs, technologies and multiple and possibly overlapping tax structures. In addition, we may face competition in certain countries from companies that may have more experience with operations in such countries or with international operations generally. We may also face difficulties integrating new facilities in different countries into our existing operations, as well as integrating employees hired in different countries into our existing corporate culture.
If we do not effectively manage our operations in these subsidiaries and review equity investees effectively, or if we fail to manage our alliances, we may lose money in these countries and it may adversely affect our business and results of our operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If our competitors develop treatments for the target indications for which any of our product candidates may be approved, and they are approved more quickly, marketed more effectively or demonstrated to be more effective than our product candidates, our commercial opportunity will be reduced or eliminated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We operate in a highly competitive segment of the biotechnology and biopharmaceutical market. We face competition from numerous sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Many of our competitors have significantly greater financial, product development,
manufacturing and marketing resources. Large pharmaceutical companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. Additionally, many universities and private and public research institutes are active in cancer research, some in direct competition with us. We may also compete with these organizations to recruit scientists and clinical development personnel. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The cancer indications for which we are developing our products have a number of established therapies with which we will compete. Most major pharmaceutical companies and many biotechnology companies are aggressively pursuing new cancer development programs for the treatment of NHL, CLL, and other B-cell proliferative malignancies, including both therapies with traditional,
as well as novel, mechanisms of action. <font style="font-family: Times New Roman; font-size: 13px">Additionally, numerous established therapies exist for the autoimmune disorders for which we are developing TG-1101, including and in particular, multiple sclerosis (MS).</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If approved, we expect TG-1101 to compete directly with Roche Group&#x2019;s Rituxan<font style="font-size: 70%; vertical-align: top">&#xAE;</font> (rituximab) and Gazyva<font style="font-size: 70%; vertical-align: top">&#xAE;</font> (obinutuzumab or GA-101), and Genmab and GlaxoSmithKline&#x2019;s Arzerra<font style="font-size: 70%; vertical-align: top">&#xAE;</font> (ofatumumab)
among others, each of which is currently approved for the treatment of various diseases including NHL and CLL. In addition, a number of pharmaceutical companies are developing antibodies targeting CD20, CD19, and other B-cell associated targets, chimeric antigen receptor T-cell (CAR-T) immunotherapy, and other B-cell ablative therapy which, if approved, would potentially compete with TG-1101 <font style="font-family: Times New Roman; font-size: 13px">both in oncology settings as well as in autoimmune disorders.
Recently, positive Phase 3 data was announced for the Roche Group&#x2019;s anti-CD20 antibody ocrelizumab in the treatment of MS, which we anticipate will be filed for approval in the near term. Genmab and GSK&#x2019;s (ofatumumab) is also under clinical development for patients with MS</font>. New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;34</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">With respect to TGR-1202, there are several PI3K delta targeted compounds both approved, such as Gilead&#x2019;s Zydelig&#x2122; (idelalisib), and in development, including, but not limited to, Infinity Pharmaceuticals&#x2019; duvelisib (IPI-145) which if approved we would expect to compete directly with TGR-1202. In addition, there are numerous other novel therapies targeting
similar pathways to TGR-1202 both approved and in development, which could also compete with TGR-1202 in similar indications, such as the BTK inhibitor, ibrutinib (FDA approved for MCL, CLL, and WM and marketed by AbbVie and Janssen), the BTK inhibitor ACP-196 (under development by AstraZeneca), or the BCL-2 inhibitor ABT-199 (<font style="font-family: Times New Roman; font-size: 13px">FDA approved for CLL and marketed</font> by AbbVie and Roche).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">These developments may render our product candidates obsolete or noncompetitive. Compared to us, many of our potential competitors have substantially greater:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">research and development resources, including personnel and technology;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">regulatory experience;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">pharmaceutical development, clinical trial and pharmaceutical commercialization experience;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">experience and expertise in exploitation of intellectual property rights; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">capital resources.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than us or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop products for the treatment of lymphoma, CLL, or other B-cell and autoimmune related
disorders that are more effective, better tolerated, more useful and less costly than ours and may also be more successful in manufacturing and marketing their products. Our competitors may succeed in obtaining approvals from the FDA and foreign regulatory authorities for their product candidates sooner than we do for our products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We will also face competition from these third parties in recruiting and retaining qualified personnel, establishing clinical trial sites and enrolling patients for clinical trials and in identifying and in-licensing new product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We rely completely on third parties to manufacture our preclinical and clinical pharmaceutical supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate, and our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties
fail to obtain approval of the FDA, fail to provide us with sufficient quantities of pharmaceutical product or fail to do so at acceptable quality levels or prices.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted only after we submit a BLA or NDA to the FDA, if at all. We do not control the manufacturing process of our product candidates and are completely dependent on our contract manufacturing partners for compliance
with the FDA&#x2019;s requirements for manufacture of finished pharmaceutical products (good manufacturing practices, GMP). If our contract manufacturers cannot successfully manufacture material that conforms to our target product specifications, patent specifications, and/or the FDA&#x2019;s strict regulatory requirements of safety, purity and potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no control over the ability of our contract manufacturers
to maintain adequate quality control, quality assurance and qualified personnel. If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. No assurance can be given that a long-term, scalable manufacturer can be identified or that they can make clinical and commercial supplies of our product candidates that meets the product specifications
of previously manufactured batches, or is of a sufficient quality, or at an appropriate scale and cost to make it commercially feasible. If they are unable to do so, it could have a material adverse impact on our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, we do not have the capability to package finished products for distribution to hospitals and other customers. Prior to commercial launch, we intend to enter into agreements with one or more alternate fill/finish pharmaceutical product suppliers so that we can ensure proper supply chain management once we are authorized to make commercial sales of our product
candidates. If we receive marketing approval from the FDA, we intend to sell pharmaceutical product finished and packaged by such suppliers. We have not entered into long-term agreements with our current contract manufacturers or with any fill/finish suppliers, and though we intend to do so prior to commercial launch of our product candidates in order to ensure that we maintain adequate supplies of finished product, we may be unable to enter into such an agreement or do so on commercially reasonable terms, which
could have a material adverse impact upon our business.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;35</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In most cases, our manufacturing partners are single source suppliers. It is expected that our manufacturing partners will be sole source suppliers from single site locations for the foreseeable future. Given this, any disruption of supply from these partners could have a material, long-term impact on our ability to supply products for clinical trials or commercial sale.
If our suppliers do not deliver sufficient quantities of our product candidates on a timely basis, or at all, and in accordance with applicable specifications, there could be a significant interruption of our supply, which would adversely affect clinical development and commercialization of our products. In addition, if our current or future supply of any or our product candidates should fail to meet specifications during its stability program there could be a significant interruption of our supply of drug, which
would adversely affect the clinical development and commercialization of the product.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We currently have no marketing and sales organization and no experience in marketing pharmaceutical products. If we are unable to establish sales and marketing capabilities or fail to enter into agreements with third parties to market and sell any products we may develop, we may not be able to effectively market and sell our products
and generate product revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We do not currently have the infrastructure for the sales, marketing and distribution of our biotechnology products, and we must build this infrastructure or make arrangements with third parties to perform these functions in order to commercialize our products. We plan to either develop internally or enter into collaborations or other commercial arrangements to develop further,
promote and sell all or a portion of our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The establishment and development of a sales force, either by us or jointly with a development partner, or the establishment of a contract sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we cannot be certain that we or our development partners would be able to successfully develop this capability.
If we or our development partners are unable to establish sales and marketing capability or any other non-technical capabilities necessary to commercialize any products we may develop, we will need to contract with third parties to market and sell such products. We currently possess limited resources and may not be successful in establishing our own internal sales force or in establishing arrangements with third parties on acceptable terms, if at all.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, healthcare payors, and the medical community, the revenues that we generate from its sales will be limited.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for commercial success. The degree of market acceptance of any of our
approved products will depend on a number of factors, including:</font></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the efficacy and safety as demonstrated in clinical trials;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the clinical indications for which the product is approved;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">acceptance by physicians, major operators of cancer clinics and patients of the product as a safe and effective treatment;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the potential and perceived advantages of product candidates over alternative treatments;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the safety of product candidates seen in a broader patient group, including its use outside the approved indications;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the cost of treatment in relation to alternative treatments;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the availability of adequate reimbursement and pricing by third parties and government authorities;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">relative convenience and ease of administration;</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the prevalence and severity of adverse events; and</font></div></div></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the effectiveness of our sales and marketing efforts.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these products and we may not become or remain profitable.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;36</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials, and will face an even greater risk if we sell our product candidates commercially. Although we are not aware of any historical or anticipated product liability claims against us, if we cannot successfully defend ourselves against product liability
claims, we may incur substantial liabilities or be required to cease clinical trials of our drug candidates or limit commercialization of any approved products. An individual may bring a liability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If we cannot successfully defend our self against product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">decreased demand for our product candidates;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">impairment to our business reputation;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">withdrawal of clinical trial participants;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">costs of related litigation;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">distraction of management&#x2019;s attention from our primary business;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">substantial monetary awards to patients or other claimants;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the inability to commercialize our product candidates; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">loss of revenues.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We believe that we have obtained sufficient product liability insurance coverage for our clinical trials. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability insurance on commercially reasonable terms and with insurance
coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We intend to seek approval to market our future products in both the United States and in countries and territories outside the United States. If we obtain approval in one or more foreign countries, we will be subject to rules and regulations in those countries relating to our product. In some foreign countries, particularly in the European Union, the pricing of prescription
pharmaceuticals and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which pharmaceuticals they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">a covered benefit under its health plan;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">safe, effective and medically necessary;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">appropriate for the specific patient;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">cost-effective; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">neither experimental nor investigational.</font></div></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;37</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require that we provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and
reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Additionally, while we may seek approval of our products in combination with each other, there can be no guarantee that we will obtain coverage and reimbursement for any of our products together, or that such reimbursement will incentivize the use of our products in combination with each other as opposed to in
combination with other agents which may be priced more favorably to the medical community.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In both the United States and certain foreign countries, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methodology for many products reimbursed by Medicare, resulting in lower rates of reimbursement
for many types of drugs, and added a prescription drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. Since 2003, there have been a number of other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals. Most recently, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the &#x201C;Affordable Care Act,&#x201D; was enacted. The Affordable
Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, the increased use of comparative effectiveness research on healthcare products, reimbursement and fraud and abuse changes, and a new regulatory pathway for the approval of biosimilar biological products, all of which will impact existing government healthcare programs and will result in the development of new programs. An expansion in the government&#x2019;s role in the U.S. healthcare industry may further
lower rates of reimbursement for pharmaceutical and biotechnology products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare products and services. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies,
managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the demand for any products for which we may obtain regulatory approval;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our ability to set a price that we believe is fair for our products;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our ability to generate revenues and achieve or maintain profitability;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the level of taxes that we are required to pay; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the availability of capital.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, governments may impose price controls, which may adversely affect our future profitability.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We will need to increase the size of our organization and the scope of our outside vendor relationships, and we may experience difficulties in managing this growth.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of August 1, 2016, we had forty-nine full and part time employees. Over time, we will need to expand our managerial, operational, financial and other resources in order to manage and fund our operations and clinical trials, continue research and development activities, and commercialize our product candidates. Our management and scientific personnel, systems and facilities
currently in place may not be adequate to support our future growth. Our need to effectively manage our operations, growth, and various projects requires that we:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">manage our clinical trials effectively;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors and other third parties;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">continue to improve our operational, financial and management controls and reporting systems and procedures; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">attract and retain sufficient numbers of talented employees.</font></div></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;38</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We may utilize the services of outside vendors or consultants to perform tasks including clinical trial management, statistics and analysis, regulatory affairs, formulation development, chemistry, manufacturing, controls, and other pharmaceutical development functions. Our growth strategy may also entail expanding our group of contractors or consultants to implement these
tasks going forward. Because we rely on a substantial number of consultants, effectively outsourcing many key functions of our business, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for our product candidates or otherwise advance its business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may be unable to successfully implement the tasks
necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If we fail to attract and keep key management and clinical development personnel, we may be unable to successfully develop or commercialize our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts for our product candidates and future product candidates. We are highly dependent on the development, regulatory, commercial and financial expertise of the members of our senior management.
The loss of the services of any of our senior management could delay or prevent the further development and potential commercialization of our product candidates and, if we are not successful in finding suitable replacements, could harm our business. We do not maintain &#x201C;key man&#x201D; insurance policies on the lives of these individuals. We will need to hire additional personnel as we continue to expand our manufacturing, research and development activities.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel and we may not be able to do so in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent
years. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will impede significantly the achievement of our development objectives, our ability to raise additional capital, and our ability to implement our business strategy.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition to FDA restrictions on the marketing of pharmaceutical and biotechnology products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical and medical device industries in recent years, as well as consulting or other service agreements with physicians or other potential referral sources. These
laws include anti-kickback statutes and false claims statutes that prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or, in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally-financed healthcare programs, and knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly
making, or causing to be made, a false statement to get a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn
narrowly, and any practices we adopt may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#x2019;s products from reimbursement under government programs, criminal fines and imprisonment. Any challenge to its business practices under these laws could have a material adverse effect on our business, financial condition, and results of operations.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;39</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We use biological and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We use hazardous materials, including chemicals and biological agents and compounds, which could be dangerous to human health and safety or the environment. Our operations also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with
applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our pharmaceutical development efforts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. If one of our employees was accidentally injured from the use, storage, handling or disposal of these materials or wastes, the medical costs related to his or her treatment would be covered by our workers&#x2019; compensation insurance policy. However,
we do not carry specific biological or hazardous waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, or operations otherwise affected.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">All product candidate development timelines and projections in this report are based on the assumption of further financing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The timelines and projections in this report are predicated upon the assumption that we will raise additional financing in the future to continue the development of our product candidates. In the event we do not successfully raise subsequent financing, our product development activities will necessarily be curtailed commensurate with the magnitude of the shortfall. If our
product development activities are slowed or stopped, we would be unable to meet the timelines and projections outlined in this filing. Failure to progress our product candidates as anticipated will have a negative effect on our business, future prospects, and ability to obtain further financing on acceptable terms (if at all), and the value of the enterprise.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">Risks Relating to Acquisitions</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Acquisitions, investments and strategic alliances that we may make in the future may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We may seek to expand our business through the acquisition of, investments in and strategic alliances with companies, technologies, products, and services. Acquisitions, investments and strategic alliances involve a number of special problems and risks, including, but not limited to:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">difficulty integrating acquired technologies, products, services, operations and personnel with the existing businesses;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">diversion of management&#x2019;s attention in connection with both negotiating the acquisitions and integrating the businesses;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">strain on managerial and operational resources as management tries to oversee larger operations;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">difficulty implementing and maintaining effective internal control over financial reporting at businesses that we acquire, particularly if they are not located near our existing operations;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">exposure to unforeseen liabilities of acquired companies;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">potential costly and time-consuming litigation, including stockholder lawsuits;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">potential issuance of securities to equity holders of the company being acquired with rights that are superior to the rights of holders of our common stock or which may have a dilutive effect on our stockholders;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">risk of loss of invested capital;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the need to incur additional debt or use cash; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the requirement to record potentially significant additional future operating costs for the amortization of intangible assets.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As a result of these or other problems and risks, businesses we acquire may not produce the revenues, earnings, or business synergies that we anticipated, and acquired products, services, or technologies might not perform as we expected. As a result, we may incur higher costs and realize lower revenues than we had anticipated. We may not be able to successfully address these
problems and we cannot assure you that the acquisitions will be successfully identified and completed or that, if acquisitions are completed, the acquired businesses, products, services, or technologies will generate sufficient revenue to offset the associated costs or other negative effects on our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Any of these risks can be greater if an acquisition is large relative to our size. Failure to effectively manage our growth through acquisitions could adversely affect our growth prospects, business, results of operations, financial condition and cash flows.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;40</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">Risks Relating to Our Intellectual Property</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Our success depends upon our ability to protect our intellectual property and proprietary technologies, and the intellectual property protection for our product candidates depends significantly on third parties.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our commercial success depends on obtaining and maintaining patent protection and trade secret protection for our product candidates and their formulations and uses, as well as successfully defending these patents against third-party challenges. If any of our licensors or partners fails to appropriately prosecute and maintain patent protection for these product candidates,
our ability to develop and commercialize these product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. This failure to properly protect the intellectual property rights relating to these product candidates could have a material adverse effect on our financial condition and results of operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Currently, the composition of matter patent and several method of use patents for <font style="color: #000000">TG-1101 </font>and TGR-1202 in various indications and settings have been applied for but have not yet been issued, or have been issued in certain territories but not under all jurisdictions in which such applications have been filed. While composition of matter
patents have been granted in the US for TG-1101 and TGR-1202, no patents to date have been issued for our IRAK4 inhibitor and anti-PD-L1 and anti-GITR programs. There can be no guarantee that any of these patents for which an application has already been filed, nor any patents filed in the future for our product candidates will be granted in any or all jurisdictions in which there were filed, or that all claims initially included in such patent applications will be allowed in the final patent that is issued.
The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in protecting our product candidates by obtaining and defending patents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">These risks and uncertainties include the following:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the patent applications that we or our partners file may not result in any patents being issued;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked or circumvented, or otherwise may not provide any competitive advantage;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">as of March 16, 2013, the U.S. converted from a &#x201C;first to invent&#x201D; to a &#x201C;first to file&#x201D; system. If we do not win the filing race, we will not be entitled to inventive priority;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our competitors, many of which have substantially greater resources than we do, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate its ability to make, use, and sell our potential products either in the United States or in international markets;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">countries other than the United States may have less restrictive patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If patents are not issued that protect our product candidates, it could have a material adverse effect on our financial condition and results of operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition to patents, we and our partners also rely on trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, third parties may still obtain
this information or we may be unable to protect its rights. If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Patent protection and other intellectual property protection are crucial to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">If we or our partners are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our commercial success also depends upon our ability and the ability of any of our future collaborators to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which
we are developing products, some of which may be directed at claims that overlap with the subject matter of our intellectual property. For example, Roche has the Cabilly patents in the U.S. that block the commercialization of antibody products derived from a single cell line, like <font style="color: #000000">TG-1101</font>. Also, Roche, Biogen Idec, and Genentech hold patents for the use of anti-CD20 antibodies utilized in the treatment of CLL in the U.S. While these patents have been challenged, to the best
of our knowledge, those matters were settled in a way that permitted additional anti-CD20 antibodies to be marketed for CLL. If those patents are still enforced at the time we are intending to launch <font style="color: #000000">TG-1101</font>, then we will need to either prevail in a litigation to challenge those patents or negotiate a settlement agreement with the patent holders. If we are unable to do so we may be forced to delay the launch of <font style="color: #000000">TG-1101 </font>or launch at the risk
of litigation for patent infringement, which may have a material adverse effect on our business and results of operations.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">41<br></font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we are not aware.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any collaborators of ours infringe their intellectual property rights, we may have to:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">obtain licenses, which may not be available on commercially reasonable terms, if at all;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">abandon an infringing product candidate or redesign its products or processes to avoid infringement;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">pay substantial damages, including treble damages and attorneys&#x2019; fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes on or violates the third party&#x2019;s rights;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">pay substantial royalties, fees and/or grant cross licenses to our technology; and/or</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">defend litigation or administrative proceedings which may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">No assurance can be given that patents issued to third parties do not exist, have not been filed, or could not be filed or issued, which contain claims covering its products, technology or methods that may encompass all or a portion of our products and methods. Given the number of patents issued and patent applications filed in our technical areas or fields, we believe there
is a risk that third parties may allege they have patent rights encompassing our products or methods.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Other product candidates that we may in-license or acquire could be subject to similar risks and uncertainties.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which typically are very expensive, time-consuming and disruptive of day-to-day business operations. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not
valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. The adverse result could also put related patent applications at risk of not issuing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Interference proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (&#x201C;PTO&#x201D;) may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license
rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully
as in the United States.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.
If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We may be subject to claims that our consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to it.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As is common in the biotechnology and pharmaceutical industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants were previously employed at, may have previously been, or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. Although no claims against us are currently pending, we may be subject to claims that these consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and day-to-day business operations.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;42</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">Risks Relating to Our Finances and Capital Requirements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We will need to raise additional capital to continue to operate our business.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">As of June 30, 2016, we had net cash, cash equivalents, investment securities and interest receivable of approximately $75.8 million. We believe that our cash and cash equivalents and investments will sustain our operations for approximately 18 to 24 months from June 30, 2016. As a result, we will need additional capital to continue our operations beyond that time. Required
additional sources of financing to continue our operations in the future might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned preclinical and clinical trials or obtain approval of any of our product candidates from the FDA or any foreign regulatory authorities. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts and forego attractive business
opportunities. Any additional sources of financing will likely involve the issuance of our equity securities, which would have a dilutive effect to stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Currently, none of our product candidates have been approved by the FDA or any foreign regulatory authority for sale. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and amounts raised in future offerings or financings.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We have a history of operating losses, expect to continue to incur losses, and are unable to predict the extent of future losses or when we will become profitable, if ever.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have not yet applied for or demonstrated an ability to obtain regulatory approval for or commercialize a product candidate. Our short operating history makes it difficult to evaluate our business prospects and consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing
pharmaceutical or biotechnology products. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in the early stages of operations and the competitive environment in which we operate.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have never been profitable and, as of June 30, 2016, we had an accumulated deficit of $187.9 million. We have generated operating losses in all periods since we were incorporated. We expect to make substantial expenditures resulting in increased operating costs in the future and our accumulated deficit will increase significantly as we expand development and clinical
trial efforts for our product candidates. Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets and stockholders&#x2019; equity. Because of the risks and uncertainties associated with product development, we are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We have not generated any revenue from our product candidates and may never become profitable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our ability to become profitable depends upon our ability to generate significant continuing revenues. To obtain significant continuing revenues, we must succeed, either alone or with others, in developing, obtaining regulatory approval for and manufacturing and marketing our product candidates (or utilize early access programs to generate such revenue). To date, our product
candidates have not generated any revenues, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but not limited to:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">successful completion of preclinical studies of our product candidates;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">successful commencement and completion of clinical trials of our product candidates and any future product candidates we advance into clinical trials;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">achievement of regulatory approval for our product candidates and any future product candidates we advance into clinical trials (unless we successfully utilize early access programs which allow for revenue generation prior to approval);</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-weight: bold; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">manufacturing commercial quantities of our products at acceptable cost levels if regulatory approvals are obtained;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">successful sales, distribution and marketing of our future products, if any; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our entry into collaborative arrangements or co-promotion agreements to market and sell our products.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">If we are unable to generate significant continuing revenues, we will not become profitable and we may be unable to continue our operations without continued funding.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs or commercialization efforts.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We expect to spend substantial amounts on development, including significant amounts on conducting clinical trials for our product candidates, manufacturing clinical supplies and expanding our pharmaceutical development programs. We expect that our monthly cash used by operations will continue to increase for the next several years. We anticipate that we will continue to
incur operating losses for the foreseeable future.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;43</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We will require substantial additional funds to support our continued research and development activities, as well as the anticipated costs of preclinical studies and clinical trials, regulatory approvals, and eventual commercialization. We anticipate that we will incur operating losses for the foreseeable future. We have based these estimates, however, on assumptions that
may prove to be wrong, and we could expend our available financial resources much faster than we currently expect. Further, we will need to raise additional capital to fund our operations and continue to conduct clinical trials to support potential regulatory approval of marketing applications. Future capital requirements will also depend on the extent to which we acquire or in-license additional product candidates. We currently have no commitments or agreements relating to any of these types of transactions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The amount and timing of our future funding requirements will depend on many factors, including, but not limited to, the following:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the progress of our clinical trials, including expenses to support the trials and milestone payments that may become payable under our license agreements;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the costs and timing of regulatory approvals;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the costs and timing of clinical and commercial manufacturing supply arrangements for each product candidate;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the costs of establishing sales or distribution capabilities;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the success of the commercialization of our products;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">our ability to establish and maintain strategic collaborations, including licensing and other arrangements;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the costs involved in enforcing or defending patent claims or other intellectual property rights; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the extent to which we in-license or invest in other indications or product candidates.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Until we can generate a sufficient amount of product revenue and achieve profitability, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. If we were to be unable to raise additional capital, we would have to significantly
delay, scale back or discontinue one or more of our pharmaceutical development programs. We also may be required to relinquish, license or otherwise dispose of rights to product candidates or products that it would otherwise seek to develop or commercialize itself on terms that are less favorable than might otherwise be available.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We may raise additional funds through public or private equity offerings, debt financings or licensing arrangements. To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing we enter into may involve covenants that restrict our operations, including limitations on
our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions, among other restrictions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, if we raise additional funds through licensing arrangements, it may be necessary to relinquish potentially valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may
be required to delay, significantly curtail or eliminate the development of one or more of our product candidates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">Risks Related to Our Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We are controlled by current officers, directors and principal stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Our directors, executive officers, their affiliates, and our principal stockholders beneficially own approximately 58% percent of our outstanding voting stock, including shares underlying outstanding options and warrants. Our directors, officers and principal stockholders, taken as a whole, have the ability to exert substantial influence over the election of our Board of
Directors and&#xA0;the outcome of issues submitted to our stockholders.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;44</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">Our stock price is, and we expect it to remain, volatile, which could limit investors&#x2019; ability to sell stock at a profit.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in price in response to various factors, many of which are beyond our control. These factors include:</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">publicity regarding actual or potential clinical results relating to products under development by our competitors or us;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">delay or failure in initiating, completing or analyzing nonclinical or clinical trials or the unsatisfactory design or results of these trials;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">achievement or rejection of regulatory approvals by our competitors or us;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">announcements of technological innovations or new commercial products by our competitors or us;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">developments concerning proprietary rights, including patents;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">developments concerning our collaborations;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">regulatory developments in the United States and foreign countries;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">economic or other crises and other external factors;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">period-to-period fluctuations in our revenues and other results of operations;</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">changes in financial estimates by securities analysts; and</font></div></div></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">sales of our common stock.</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We will not be able to control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">In addition, the stock market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating
performance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of your stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">We have never paid dividends on our common stock and do not anticipate paying any dividends for the foreseeable future. You should not rely on an investment in our stock if you require dividend income. Further, you will only realize income on an investment in our stock in the event you sell or otherwise dispose of your shares at a price higher than the price you paid for
your shares. Such a gain would result only from an increase in the market price of our common stock, which is uncertain and unpredictable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">Certain anti-takeover provisions in our charter documents and Delaware law could make a third-party acquisition of us difficult. This could limit the price investors might be willing to pay in the future for our common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Provisions in our amended and restated certificate of incorporation and restated bylaws could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, or control us. These factors could limit the price that certain investors might be willing to pay in the future for shares of our
common stock. Our amended and restated certificate of incorporation allows us to issue preferred stock without the approval of our stockholders. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of such holders. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock. Our restated bylaws eliminate
the right of stockholders to call a special meeting of stockholders, which could make it more difficult for stockholders to effect certain corporate actions. Any of these provisions could also have the effect of delaying or preventing a change in control.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">On July 18, 2014, the Board of Directors declared a distribution of one right for each outstanding share of common stock. The rights may have certain anti-takeover effects. The rights will cause substantial dilution to a person or group that attempts to acquire us on terms not approved by the Board of Directors unless the offer is conditioned on a substantial
number of rights being acquired. However, the rights should not interfere with any merger, statutory share exchange or other business combination approved by the Board of Directors since the rights may be terminated by us upon resolution of the Board of Directors. Thus, the rights are intended to encourage persons who may seek to acquire control of the Company to initiate such an acquisition through negotiations with the Board of Directors. However, the effect of the rights may be to discourage a third party
from making a partial tender offer or otherwise attempting to obtain a substantial equity position in the equity securities of, or seeking to obtain control of, the Company. To the extent any potential acquirers are deterred by the rights, the rights may have the effect of preserving incumbent management in office.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="page-break-after: always">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;45</font></div>
<div style="text-align: center; display: inline-block; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-weight: bold; font-family: Times New Roman">ITEM 6. EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 144px; margin-right: 0px; text-indent: -96px"><font style="font-family: Times New Roman; font-size: 13px">The exhibits listed on the Exhibit Index are included with this report.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">10.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">Sublicense Agreement by and between TG Therapeutics, Inc. and Checkpoint Therapeutics, Inc., dated May 26, 2016.*</font></font></div></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0; </font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0; </font></div></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">31.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated August 9, 2016.</font></div></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">31.2</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated August 9, 2016.</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">32.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Executive Officer pursuant to 18 U.S.C. &#xA7;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated <font style="font-family: Times New Roman">August 9, 2016.</font> </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">32.2</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Financial Officer pursuant to 18 U.S.C. &#xA7;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated <font style="font-family: Times New Roman">August 9, 2016.</font> </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">101</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">The following financial information from the Company&#x2019;s Quarterly Report on Form 10-Q for the period ended June 30, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statement of Stockholders&#x2019; Equity, (iv) the
Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (filed herewith).</font></div></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;"><font style="font-family: Times New Roman; font-size: 13px">* Subject to a request for confidential treatment.</font>
<br></font></div>
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">46<br></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 4%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td colspan="2" style="vertical-align: top; width: 52%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">TG THERAPEUTICS, INC.</font></div></td></tr><tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div></td>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div></td>
<td style="vertical-align: top; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div></td></tr><tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman">Date: </font>August<font style="font-family: Times New Roman"> 9</font>, 2016<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></font></div></td>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">By:&#xA0;&#xA0;</font></div></td>
<td style="vertical-align: top; width: 48%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">/s/ Sean A. Power</font></div></td></tr><tr style="background-color: #ffffff">
<td colspan="2" style="vertical-align: top; width: 52%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Sean A. Power </font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Chief Financial Officer</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Principal Financial and Accounting Officer</font></div></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;47</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">EXHIBIT INDEX</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">The following exhibits are included as part of this Quarterly Report on Form 10-Q:</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">10.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px">Sublicense Agreement by and between TG Therapeutics, Inc. and Checkpoint Therapeutics, Inc., dated May 26, 2016.*</font>&#xA0; </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0; </font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0; </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">31.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated August 9, 2016.</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">31.2</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated August 9, 2016.</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">32.1</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Executive Officer pursuant to 18 U.S.C. &#xA7;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated <font style="font-family: Times New Roman">August 9, 2016.</font> </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">32.2</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Certification of Chief Financial Officer pursuant to 18 U.S.C. &#xA7;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated <font style="font-family: Times New Roman">August 9, 2016.</font> </font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 85%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td></tr><tr>
<td style="vertical-align: top; width: 7%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 8%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">101</font></div></td>
<td style="vertical-align: top; width: 85%">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">The following financial information from the Company&#x2019;s Quarterly Report on Form 10-Q for the period ended June 30, 2016, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statement of Stockholders&#x2019; Equity, (iv) the
Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (filed herewith).</font></div></td></tr></table></div>
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;</font></div>
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px;">&#xA0;48</font></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 4%">
<br></td>
<td style="vertical-align: top; width: 3%">
<br></td>
<td style="vertical-align: top; width: 93%">
<br></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>Exhibit31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;<font style="font-weight: bold">Exhibit 31.1</font>
<br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I, Michael S. Weiss, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">1.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;a)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;b)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;c)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;d)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">5.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of&#xA0; directors (or persons performing the equivalent functions):</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;a)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;b)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Date: August 9, 2016</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Michael S. Weiss</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 42%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Michael S. Weiss </font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Executive Chairman, Interim Chief Executive Officer and President &#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Principal Executive Officer </font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: rgb(0, 0, 0);">
<!--page break-->
</div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>Exhibit31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div></div>
<div style="text-align: right; margin-left: 24px; margin-right: 0px; text-indent: -24px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">Exhibit 31.2</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-size: 13px; font-family: Times New Roman">CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I, Sean A. Power, certify that:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">1.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">2.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">3.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">4.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;a)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;b)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;c)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;d)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 1%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">5.</font></div></td>
<td style="vertical-align: top; width: 99%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;a)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 4%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;b)</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 93%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-size: 13px; font-family: Times New Roman">
<tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Date: August 9, 2016</font></div></td>
<td style="vertical-align: top; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;&#xA0;</font></div></td>
<td style="vertical-align: top; width: 57%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Sean A. Power</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 43%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 57%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Sean A. Power </font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Chief Financial Officer</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Principal Financial and Accounting Officer</font></div></td></tr></table></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: rgb(0, 0, 0);">
<!--page break-->
</div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>Exhibit32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div></div>
<div style="text-align: justify; padding-bottom: 10.7px; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 32.1</font></font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">STATEMENT OF CHIEF EXECUTIVE OFFICER OF</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG THERAPEUTICS, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;In connection with the quarterly report of TG Therapeutics, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission (the &#x201C;Report&#x201D;), I, Michael S. Weiss, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#xA7; 1350,
as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">1)&#xA0;&#xA0;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>
<div style="text-align: left; margin-left: 72px; margin-right: 36px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">2)&#xA0; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div>
<div style="text-align: left; margin-left: 72px; margin-right: 36px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 40%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman">Date: </font>August 9, 2016</font></div></td>
<td style="vertical-align: top; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">/s/ Michael S. Weiss</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 42%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Michael S. Weiss </font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Executive Chairman, Interim Chief Executive Officer and President &#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Principal Executive Officer</font></div></td></tr></table></div>
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: rgb(0, 0, 0);">
<!--page break-->
</div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>Exhibit32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div></div>
<div style="text-align: justify; padding-bottom: 10.7px; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 32.2</font></font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">STATEMENT OF CHIEF FINANCIAL OFFICER OF</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG THERAPEUTICS, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">AS ADOPTED PURSUANT TO</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECTION&#xA0;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;In connection with the quarterly report of TG Therapeutics, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission (the &#x201C;Report&#x201D;), I, Sean A. Power, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#xA7; 1350, as
adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">1)&#xA0;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </font></div>
<div style="text-align: left; margin-left: 72px; margin-right: 36px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">2)&#xA0;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div>
<div style="text-align: left; margin-left: 72px; margin-right: 36px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 41%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman">Date: </font>August 9, 2016</font></div></td>
<td style="vertical-align: top; width: 1%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">/s/ Sean A. Power</font></div></td></tr><tr>
<td colspan="2" style="vertical-align: top; width: 42%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></td>
<td style="vertical-align: top; width: 58%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Sean A. Power</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">C</font><font style="font-family: Times New Roman; font-size: 13px">hief Financial Officer</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Principal Financial and Accounting Officer</font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: rgb(0, 0, 0);">
<!--page break-->
</div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>Exhibit10-1_Sublicense.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2016 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 11px">&#xA0; </font></div></div></div>
<div style="text-align: left; padding-bottom: 13.3px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission.</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Exhibit No. 10.1</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SUBLICENSE AGREEMENT</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">THIS SUBLICENSE AGREEMENT</font> (the &#x201C;<font style="font-weight: bold">Agreement</font>&#x201D;) is dated as of May 26, 2016 (the &#x201C;<font style="font-weight: bold">Effective Date</font>&#x201D;) by and between Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street,
9<font style="font-size: 70%; vertical-align: top">th</font> Floor, New York, New York 10014 (&#x201C;<font style="font-weight: bold">Checkpoint</font>&#x201D;), and TG Therapeutics, Inc., a Delaware corporation with its place of business at 2 Gansevoort Street, 9<font style="font-size: 70%; vertical-align: top">th</font> Floor, New York, New York 10014 (&#x201C;<font style="font-weight: bold">TGTX</font>&#x201D;). Checkpoint, on the one hand, and TGTX, on the other hand, shall each be referred to herein as a &#x201C;<font style="font-weight: bold">Party</font>&#x201D;
or, collectively, as the &#x201C;<font style="font-weight: bold">Parties</font>.&#x201D;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">RECITALS:</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS, </font>Checkpoint is party to that certain license agreement (the &#x201C;License Agreement&#x201D;) dated the date hereof with Jubilant Biosys Limited (&#x201C;Licensor&#x201D;); and</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS, </font>Jubilant is the owner of certain rights in Licensor Technology; and</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS, </font>Jubilant has licensed rights to the Licensor Technology to Checkpoint; and</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS,</font> Checkpoint is permitted under Section 2.1 of the License Agreement to grant sublicenses of the rights granted to it under the Licensor Technology; and</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS,</font> TGTX is engaged in the research, development, manufacturing and commercialization of pharmaceutical products, and TGTX is interested in developing and commercializing products containing or comprising the Compounds; and</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">WHEREAS, </font>TGTX desires to sublicense from Checkpoint, and Checkpoint wishes to sublicense to TGTX, on an exclusive basis, the right to use Licensor Technology to Develop and Commercialize products containing the Compounds in the Territory and for a defined field of use.</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">NOW, THEREFORE,</font> in consideration of the foregoing and of the various promises and undertakings set forth herein, the Parties agree as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE I.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">DEFINITIONS</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">Unless otherwise specifically provided herein, the following terms shall have the following meanings:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Abandoned Patent</font>&#x201D; is defined in Section&#xA0;6.1(b).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Abandoned Terminated Country</font>&#x201D; is defined in Section&#xA0;6.1(b).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Abandonment</font>&#x201D; or &#x201C;<font style="font-weight: bold">Abandon</font>&#x201D; is defined in Section&#xA0;6.1(b).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Affiliate</font>&#x201D; means a Person or entity that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. For the purposes of this Section&#xA0;1.4,
the word &#x201C;<font style="font-weight: bold">control</font>&#x201D; (including, with correlative meaning, the terms &#x201C;<font style="font-weight: bold">controlled</font> <font style="font-weight: bold">by</font>&#x201D; or &#x201C;<font style="font-weight: bold">under common control with</font>&#x201D;) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of at least 50% of the voting
stock of such entity, or by contract or otherwise.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#x201C;<font style="font-weight: bold">BLA</font>&#x201D; means a Biologics License Application under the United States&#x2019; Public Health Services Act and Federal Food, Drug and Cosmetics Act, each as amended, and the regulations
promulgated thereunder, or a comparable filing seeking Regulatory Approval in any country.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Business Day</font>&#x201D; means any day other than Saturday, Sunday, or a day that is a federal legal holiday in the U.S.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.7.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Calendar Quarter</font>&#x201D; means each three -month period commencing January&#xA0;1, April&#xA0;1, July&#xA0;1 or October&#xA0;1, provided however that (a)&#xA0;the first Calendar Quarter of the
Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b)&#xA0;the last Calendar Quarter of the Term shall end upon the termination or expiration of this Agreement.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.8.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Calendar Year</font>&#x201D; means the period beginning on the 1st of January and ending on the 31st of December of the same year, provided however that (a)&#xA0;the first Calendar Year of the Term shall
commence on the Effective Date and end on December&#xA0;31 of the same calendar year as the Effective Date, and (b)&#xA0;the last Calendar Year of the Term shall commence on January&#xA0;1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or expiration of this Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.9.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">cGCP</font>&#x201D; means current Good Clinical Practices (a)&#xA0;as promulgated under 21 C.F.R. Parts 11, 50, 54, 56, 312 and 314, as the same may be amended or re-enacted from time to time and (b)&#xA0;required
by law in countries other than the United States where clinical studies are conducted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.10.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">cGLP</font>&#x201D; means current Good Laboratory Practices (a)&#xA0;as promulgated under 21 C.F.R. Part 58, as the same may be amended or re-enacted from time to time and (b)&#xA0;as required by law
in countries other than the United States where non-clinical laboratory studies are conducted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.11.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">cGMP</font>&#x201D; means current Good Manufacturing Practices (a)&#xA0;as promulgated under 21 C.F.R. Parts 210 and 211, as the same may be amended or re-enacted from time to time and (b)&#xA0;as required
by law in countries other than the United States where pharmaceutical product Manufacturing is conducted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.12.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Clinical Trial</font>&#x201D; means any Phase 1 Trial, Phase 2 Trial, Phase 3 Trial, or Post-Marketing Study, as applicable.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.13.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Combination Product</font>&#x201D; means (a)&#xA0;a product containing a Licensed Product together with one or more other active ingredients that have independent biologic or chemical activity when present
alone that are sold as a single unit, or (b)&#xA0;a Licensed Product together with one or more products, devices, pieces of equipment or components thereof, that are sold as a single package at a single price.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.14.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Commercialization</font>&#x201D; or &#x201C;<font style="font-weight: bold">Commercialize</font>&#x201D; means (a)&#xA0;any and all activities undertaken at any time for a particular Licensed Product and
that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, (b)&#xA0;seeking Pricing Approvals and Reimbursement Approvals for such Licensed Product, (c)&#xA0;Post-Marketing Studies and (d)&#xA0;interacting with Regulatory Authorities regarding the foregoing (a)&#xA0;through (c).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.15.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Commercially Reasonable Efforts</font>&#x201D; means the carrying out of obligations or tasks in a manner consistent with the efforts a Party (which in no event shall be less than the level of efforts
and resources standard in the pharmaceutical industry for a company similar in size and scope to such Party) consistent with its normal business practices devotes to research, development or marketing of a pharmaceutical product or products of similar market potential, profit potential resulting from its own research efforts or for its own benefit, taking into account technical, regulatory and intellectual property factors, target product profiles, product labeling, past performance, costs, economic return, the
regulatory environment and competitive market conditions in the therapeutic or market niche. Sublicensees shall be measured to the standard of Commercially Reasonable Efforts of the Party from whom they directly or indirectly licensed.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.16.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Competing Product</font>&#x201D; means BRD4 inhibitors.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.17.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Compound</font>&#x201D; means (i) the compounds set forth on <font style="text-decoration: underline">Schedule 1</font> attached hereto and (ii) any all compounds structurally related to such compounds
that are Covered by Licensor Patents set forth in <font style="text-decoration: underline">Schedule 2</font> hereto.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.18.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Controlled</font>&#x201D; means, with respect to (a)&#xA0;Patent Rights, (b)&#xA0;Know-How or (c)&#xA0;biological, chemical or physical material, that a Party or one of its Affiliates owns or has a license
or sublicense to such Patent Rights, Know-How or material (or in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to, such Patent Rights, Know-How or material as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.19.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Covered</font>&#x201D; means that the use, manufacture, sale, offer for sale, development, commercialization or importation of the subject matter in question by an unlicensed entity would infringe a
Valid Claim of a Patent Right; provided that infringement of any Valid Claim of a pending patent application shall be determined as if such Valid Claim were issued or granted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.20.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development</font>&#x201D; or &#x201C;<font style="font-weight: bold">Develop</font>&#x201D; means, with respect to a Licensed Product, (a)&#xA0;all non-clinical and clinical drug development activities
that are undertaken after the Effective Date up to and including the date of obtaining Regulatory Approval of such Licensed Product including (i)&#xA0;the conduct of Clinical Trials, toxicology and pharmacology testing, test method development and stability testing, process development (&#x201C;Process Development&#x201D;) (including the Manufacture of validation and engineering batches), formulation development, delivery system development, quality assurance and quality control development, analytical method development,
human clinical studies and regulatory affairs activities and statistical analysis and report writing; (ii) the preparation of Clinical Trial design and operations; and (iii) preparing and filing Drug Approval Applications, (b)&#xA0;all activities related to the optimization of a commercial-grade Manufacturing process for the Manufacture of Licensed Product including, test method development and stability testing, formulation, validation, productivity, trouble shooting and next generation formulation, process
development, Manufacturing scale-up, development-stage Manufacturing, and quality assurance/quality control development and (c)&#xA0;any and all other activities that may be necessary or useful to obtain Regulatory Approval. When used as a verb, &#x201C;Developing&#x201D; means to engage in Development and &#x201C;Developed&#x201D; has a corresponding meaning.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.21.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Inventions</font>&#x201D; shall mean any inventions, improvements and Know-how (i) developed, generated, discovered, conceived or reduced to practice in whole or part by TGTX or its Affiliates,
whether or not patentable, during the performance of the Development, relating to the development, use or manufacture of a (x) Compound or (y) Licensed Product, but only such distinct unit of such Licensed Product that contains no active ingredients other than Compounds, and (ii) solely owned by TGTX or its Affiliates. Development Inventions excludes Research Inventions.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.22.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Milestones</font>&#x201D; means Milestones 1 through 5 in the table listing the Milestones in Section 5.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.23.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Patents</font>&#x201D; means all Patent Rights Controlled by TGTX or its Affiliates Covering Development Inventions.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.24.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Plan</font>&#x201D; means, with respect to a Compound and/or any Licensed Product, a high level non-binding written plan for, the Development activities anticipated to be conducted by TGTX
or its Affiliates for such Compound and/or Licensed Product, as such written plan may be amended, modified or updated in accordance with Section&#xA0;3.2. Topics that may be covered in the plan include (a)&#xA0;the Clinical Trials that are expected to be conducted, and the expected timeline for conducting such Clinical Trials; (b)&#xA0;the expected Drug Approval Applications to be required and prepared, and the expected timetable for making such Drug Approval Applications; (c)&#xA0;the proposed timelines for
Manufacturing, Manufacturing scale-up, formulation, filling and/or shipping of the Product, and in each case the budgeted funding for such development activities.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.25.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Program</font>&#x201D; means the Development activities to be conducted by TGTX during the Term with respect to the Compounds.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.26.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Development Report</font>&#x201D; means with respect to a period, a report that summarizes: (a)&#xA0;significant Development activities conducted during such period and results obtained with respect
to Compounds and Licensed Products (including the status of and plans for all Clinical Trials), (b)&#xA0;Significant Development Events applicable to the Compounds and/or Licensed Products, (c)&#xA0;a summary of all Development Inventions conceived or reduced to practice by TGTX over such period, and (d)&#xA0;an estimate of the expected timing of any Development Milestones with respect to the Licensed Products.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.27.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Drug Approval Application</font>&#x201D; means, with respect to a Licensed Product in the Territory, an application for Regulatory Approval for such product in a country in the Territory. For purposes
of clarity, Drug Approval Application shall include, without limitation, (a)&#xA0;an NDA or BLA (for U.S.) or MAA (for Europe); (b)&#xA0;a counterpart of an NDA, BLA or MAA in any country or region in the Territory; and (c)&#xA0;all supplements (including supplemental applications such as sNDAs) and amendments to the foregoing.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.28.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">EMA</font>&#x201D; means the European Medicines Agency or any successor agency.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.29.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Expert</font>&#x201D; is defined in Section&#xA0;11.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.30.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">European Commission</font>&#x201D; means the authority within the European Union that has the legal authority to grant Regulatory Approvals in the European Union based on input received from the EMA
or other competent Regulatory Authorities.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.31.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">EU</font>&#x201D; means the member states of the European Union as of the Effective Date, as it is constituted on the Effective Date and as it may be expanded from time to time after the Effective Date.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.32.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">FDA</font>&#x201D; means the United States Food and Drug Administration, or a successor federal agency thereto.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.33.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">FD&amp;C Act</font>&#x201D; means that federal statute entitled the Federal Food, Drug, and Cosmetic Act and enacted in 1938 as Public Law 75-717, as such may have been amended, and which is contained
in Title&#xA0;21 of the C.F.R. Section&#xA0;301 et&#xA0;seq.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.34.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Field</font>&#x201D; means all prophylactic, palliative, therapeutic or diangnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without
limitation, all Leukemia&#x2019;s, Lymphoma&#x2019;s, Multipe Myeloma and Waldenstrom&#x2019;s Macroglobulinemia.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.35.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">First Commercial Sale</font>&#x201D; means, with respect to a Licensed Product in any country, the first commercial sale, transfer or disposition of such Licensed Product in the Field in such country
to a Third Party by TGTX, an Affiliate of TGTX and/or a Sublicensee, and shall include and mean to occur where the first commercial sale, transfer or disposition of any Licensed Product in that country takes place after Regulatory Approval therefor has been obtained in such country.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.36.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">GAAP</font>&#x201D; means United States generally accepted accounting principles.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.37.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Generic Product</font>&#x201D; refers to any pharmaceutical product that is introduced in the applicable country by an entity other than TGTX or its Affiliates or Sublicensees, which contains the same
or equivalent (by FDA or other Regulatory Authority standards, on a country-by-country basis) active pharmaceutical ingredient(s) as contained in a Licensed Product sold by TGTX or its Affiliate or Sublicensee in such country, including any such pharmaceutical product that is AB-rated or determined to be bioequivalent to a Licensed Product by the FDA or is otherwise substitutable for a Licensed Product or is similarly rated by other Regulatory Authorities outside the United States, on a country-by-country basis.
For the avoidance of doubt, a Generic Product will not necessarily infringe a Licensor Patent.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.38.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Governmental Body</font>&#x201D; means any: (a)&#xA0;nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&#xA0;federal,
state, local, municipal, foreign or other government; (c)&#xA0;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d)&#xA0;multi-national or supranational organization or body; or (e)&#xA0;individual, entity or body exercising, or entitled to exercise, any executive,
legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.39.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Hatch-Waxman Act</font>&#x201D; means the Drug Price Competition and Patent Term Restoration Act of 1984, as amended.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.40.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Know-How</font>&#x201D; means any scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain or otherwise
publicly known, including, without limitation, discoveries, inventions, trade secrets, databases, practices, protocols, regulatory filings, methods, processes, techniques, software, works of authorship, plans, concepts, ideas, biological and other materials, reagents, specifications, formulations, formulae, data (including, but not limited to, pharmacological, biological, chemical, toxicological, clinical and analytical information, quality control, trial and stability data), case reports forms, data analyses,
reports, studies and procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development), summaries and information contained in submissions to and information from ethical committees, the FDA or other Regulatory Authorities, and manufacturing process and development information, results and data, whether or not patentable, all to the extent not claimed or disclosed in a patent or pending patent application. The fact that an item is known to
the public shall not be taken to exclude the possibility that a compilation including the item, and/or a development relating to the item, is (and remains) not known to the public. &#x201C;Know-How&#x201D; includes any rights including copyright, moral, trade secret, database or design rights protecting such Know-How. &#x201C;Know-How&#x201D; excludes Patent Rights.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.41.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">IND</font>&#x201D; shall mean any Investigational New Drug Application (including any amendments thereto) filed with the FDA pursuant to 21 C.F.R. &#xA7;321 before the commencement of clinical trials
of a Licensed Product, or any comparable filings with any Regulatory Authority in any other jurisdiction.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.42.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Launch</font>&#x201D; means the First Commercial Sale of a Licensed Product by TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.43.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Law</font>&#x201D; or &#x201C;<font style="font-weight: bold">Laws</font>&#x201D; means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect
of law of any Governmental Body.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.44.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Licensed Product</font>&#x201D; means any product, that contains or comprises, in part or in whole, a Compound (alone or with one or more other active ingredients), in any dosage form, formulation, presentation
or package configuration.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.45.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Licensor Know-How</font>&#x201D; means any and all Know-How that (a)&#xA0;is Controlled by Licensor or any of its Affiliates as of the Effective Date or at any time thereafter during the Term and (b)&#xA0;pertains
to the Manufacture, use or sale of Licensed Products, including Research Inventions (other than Research Patents).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.46.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Licensor Patents</font>&#x201D; means all Patent Rights (i)&#xA0;that are Controlled by Licensor or any of its Affiliates as of the effective date of the License Agreement that Cover the Compound or
a Licensed Product, or their Manufacture, sale or use, including the patent applications listed on <font style="text-decoration: underline">Schedule 2</font> attached hereto, (ii) consisting of Research Patents, and (iii) any Patent Rights arising from the patents and patent applications described in the foregoing subclauses (i)&#xA0;and (ii).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.47.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Licensor Technology</font>&#x201D; means the Licensor Patents and the Licensor Know-How.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.48.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Major Countries</font>&#x201D; means Japan, the United States, England, Germany and France.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.49.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Manufacture</font>&#x201D; means all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of Licensed Product or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.50.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Market</font>&#x201D; means to promote, advertise, distribute, market, offer to sell and/or sell for purposes of a commercial sale, and &#x201C;<font style="font-weight: bold">Marketing</font>&#x201D;
and &#x201C;<font style="font-weight: bold">Marketed</font>&#x201D; have a corresponding meaning.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.51.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Marketing Plan</font>&#x201D; is defined in Section&#xA0;3.7.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.52.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Milestone</font>&#x201D; is defined in Section&#xA0;5.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.53.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Milestone Payment</font>&#x201D; is defined in Section&#xA0;5.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.54.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#x201C;<font style="font-weight: bold">NDA</font>&#x201D; means a New Drug Application filed with the FDA pursuant to 21 C.F.R. &#xA7;200, as such regulations may be amended from time to time, for approval by such agency for the sale
of Licensed Products in the U.S., and all supplements filed pursuant to the requirements of the FDA (including all documents, data and other information concerning a Licensed Product that are necessary for, or included in, FDA approval to market a Licensed Product).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.55.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Net Sales</font>&#x201D; means the gross amount invoiced or otherwise charged by TGTX, its Affiliates and Sublicensees (&#x201C;Selling Party&#x201D;) to Third Parties for sales of a Licensed Product,
less:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Normal and customary trade, quantity, cash and discounts and credits allowed and taken;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Discounts, refunds, rebates, chargebacks, retroactive price adjustments and any other allowances given and taken which effectively reduce the net selling price, including, without limitation, Medicaid rebates, institutional rebates or volume discounts;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Product returns and allowances granted to such Third Party;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Normal and customary administrative fees paid to group purchasing organizations (e.g., Medicare) and government-mandated rebates;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Shipping, handling, freight, postage, insurance and transportation charges, but all only to the extent included as a separate line item in the gross amount invoiced;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Any tax, tariff or duties properly imposed on the production, sale, delivery or use of the Licensed Product, including, without limitation, sales, use, excise or value added taxes and customs and duties;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(g)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Allowances for reasonable and verifiable distribution expenses; and</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(h)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Bad debt actually written off during the accounting period, as reported by the Selling Party in accordance with GAAP, applied on a consistent basis.</font></div></div></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Licensed Products are considered &#x201C;sold&#x201D; when billed out or invoiced or, in the event such Licensed Products are not billed out or invoiced, when the consideration for sale of the Products is received. If a sale, transfer or other disposition with respect to Licensed Products involves consideration other than cash or is not at arm&#x2019;s
length, then the Net Sales from such sale, transfer or other disposition shall be calculated from the average selling price for such Licensed Product during the Calendar Quarter in the country where such sale, transfer or disposition took place. Notwithstanding the foregoing, Net Sales shall not include, and shall be deemed zero with respect to: (i)&#xA0;Licensed Products used by TGTX, its Affiliates or Sublicensees for their internal use (without receipt of value in excess of the cost of goods), (ii) the distribution
of promotional samples of Licensed Products provided free of charge, (iii) Licensed Products provided free of charge or at a price not to exceed the cost of goods by TGTX for Clinical Trials or research, development or evaluation purposes, or (iv) sales of Licensed Products among TGTX and its Sublicensees and their respective Affiliates for resale (provided such Affiliate or Sublicensee is not the end user).</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Net Sales of any Licensed Product that is part of a Combination Product shall be determined on a country-by-country basis as follows: the Net Sales of the Combination Product (prior to application of the following adjustment) shall be multiplied by the fraction A/(A+B), where A is the net selling price in such country of a Licensed Product without
the additional active ingredient in the Combination Product, if sold separately for the same dosage as contained in the Combination Product, and B is the net selling price in such country of any other active ingredients in the combination if sold separately for the same dosage (or form) as contained in the Combination Product. All net selling prices of the elements of such Combination Product shall be calculated as the average net selling price of the said elements during the applicable accounting period for
which the Net Sales are being calculated. In the event that, in any country, no separate sale of either such above-designated Licensed Product (containing only such Licensed Product and no other active ingredients) or any one or more of the active ingredients included in such Combination Product are made during the accounting period in which the sale was made or if the net selling price for an active ingredient cannot be determined for an accounting period, Net Sales for purposes of determining payments under
this Agreement shall be calculated by multiplying the sales price of the Combination Product by a mutually agreed percentage based on the relative contribution of the Licensed Product and the other additional active ingredients.</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Notwithstanding anything to the contrary, in the case of discounts on &#x201C;bundles&#x201D; of separate products or services which include Licensed Products (such &#x201C;bundles&#x201D; including but not limited to (w) situations where the Licensed Product is sold at a discount to induce the sale of other related or unrelated products, (x) contingent
arrangements involving drugs that share the same NDC (whether the same or different package sizes), drugs with different NDCs, (y) circumstances in which a discount is conditioned on the achievement of some other performance requirement for the Licensed Product (e.g. achievement of market share or placement on a formulary tier), or (z) otherwise where the resulting price concessions or discounts are greater than those which would have been available had the bundled products been purchased separately or outside
the bundled arrangement), TGTX may calculate Net Sales and royalties due hereunder by applying a discount to the price of a Licensed Product equal to the average percentage discount of all products of TGTX, its Affiliate(s), or Sublicensee(s) in a particular &#x201C;bundle&#x201D;, calculated as follows:</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Average percentage</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">discount on a = [1 - (X/Y)] x 100</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">particular &#x201C;bundle&#x201D;</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">where X equals the total discounted price of a particular &#x201C;bundle&#x201D; of products, and Y equals the sum of the undiscounted bona fide list prices of each unit of every product in such &#x201C;bundle&#x201D;. If a Licensed Product in a &#x201C;bundle&#x201D; is not sold separately, and no bona fide list price exists for such Licensed Product,
TGTX and Checkpoint shall, for purposes of calculating Net Sales and royalties due hereunder, negotiate in good faith a reasonable imputed list price for such Licensed Product and Net Sales with respect thereto shall be based on such imputed list price..</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Undefined terms in the definition of Net Sales shall be construed in accordance with GAAP but only to the extent consistent with the express terms of the definition of Net Sales.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.56.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Paragraph&#xA0;IV Certification</font>&#x201D; means a certification pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417), as amended, which shall include
but not be limited to any such certification pursuant to 21 U.S.C. &#xA7;355(b)(2)(A)(iv) or 21 U.S.C. &#xA7;355(j)(2)(A)(vii)(IV), or any reasonably similar or equivalent certification or notice in the United States or any jurisdiction outside the United States, included in (or made with respect to or in connection with) a Regulatory Filing concerning a Licensed Product and challenging the validity, infringement, or enforceability of any Licensor Patent.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.57.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Patent Prosecution</font>&#x201D; means, with respect to any Patent Right (a)&#xA0;preparing, filing and prosecuting applications (of all types), (b)&#xA0;paying filing, issuance and maintenance fees,
(c)&#xA0;managing and conducting any interference, opposition, invalidation, re-issue, reexamination, renovations, nullification, post-grant review, inter partes review, derivation proceeding, cancellation proceeding or other similar administrative proceeding or administrative appeal thereof and (d)&#xA0;subject to Sections&#xA0;6.3(d) and 6.4(f), settling any interference, opposition, revocation, nullification or cancellation proceeding. A Party responsible for Patent Prosecution shall be responsible for all
of its fees and expenses incurred in connection therewith (including, without limitation, attorneys&#x2019; fees).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.58.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Patent Right</font>&#x201D; means: (a)&#xA0;an issued or granted patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination, extension or
renewal thereof; (b)&#xA0;a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c)&#xA0;all counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.59.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Person</font>&#x201D; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency
or political subdivision thereof.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.60.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Phase I Trial</font>&#x201D; means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the
Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.61.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Phase II Trial</font>&#x201D; means a clinical trial of a Licensed Product in human patients commenced after identifying the maximum tolerated dose, or a lower dose if it is determined to be the optimal
dose by TGTX, conducted primarily for the purpose of obtaining sufficient information about the Licensed Product&#x2019;s safety and efficacy to permit the design of a Phase III Trial.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.62.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Phase III Trial</font>&#x201D; means a clinical trial of a Licensed Product in human patients, which trial is designed (a)&#xA0;to establish that the Licensed Product is safe and efficacious for its
intended use; (b)&#xA0;to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; (c)&#xA0;to be, either by itself or together with one or more other clinical trials having a comparable design and size, the pivotal human clinical trial in support of an application for Regulatory Approval or label expansion of the Licensed Product, and (d)&#xA0;consistent with 21 CFR &#xA7;&#xA0;312.21(c) (as hereafter modified or amended), or with
respect to a jurisdiction other than the United States, a similar clinical study.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.63.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Phase IV Clinical Trial</font>&#x201D; or &#x201C;<font style="font-weight: bold">Post-Marketing Study</font>&#x201D; means a post-marketing human clinical trial for a Licensed Product commenced after
receipt of a Regulatory Approval in the country for which such trial is being conducted and that is conducted within the parameters of the Regulatory Approval for the Product. Phase IV Clinical Trials may include, without limitation, epidemiological studies, modeling and pharmacoeconomic studies, investigator-sponsored clinical trials of Product and post-marketing surveillance studies.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.64.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Pivotal Clinical Trial</font>&#x201D; means (a)&#xA0;a Phase III Trial or, (b)&#xA0;a Phase II Trial to the extent: (i)&#xA0;in the United States, the protocol for that Phase II Trial shall have been
reviewed by the FDA under its current Special Protocol Assessment Guidelines (or equivalent guidelines issued in the future), and any comments from the FDA on that protocol are incorporated in the final protocol for that Phase II Trial or are resolved to the FDA&#x2019;s satisfaction as evidenced by further written communications from the FDA; or (ii) a process with a comparable result &#x2013; acceptance of a Phase II Trial protocol as &#x201C;potentially pivotal&#x201D; &#x2013; has occurred with the EMA or other
Regulatory Authorities in the EU; or (iii) based on the results of that Phase II Trial, either the FDA or the EMA has determined that the Phase II Trial can be considered as a pivotal clinical trial for purposes of obtaining Regulatory Approval.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.65.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Pricing Approval</font>&#x201D; means any approval or authorization of any Governmental Body or Regulatory Authority establishing prices for a Licensed Product in a jurisdiction in the Territory.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.66.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Product Trademarks</font>&#x201D; means the Trademark(s) to be used in connection with the Commercialization of Licensed Products in the Territory and any registrations thereof or any pending applications
relating thereto (excluding, in any event, any trademarks, service marks, names or logos that include any corporate name or logo of the Parties or their Affiliates).</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.67.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Proprietary Materials</font>&#x201D; means any tangible chemical, biological or physical materials that are conceived or reduced to practice by TGTX in the conduct of the Development Program and/or in
connection with the Commercialization of Licensed Products.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.68.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Regulatory Authority</font>&#x201D; means (a)&#xA0;the FDA, (b)&#xA0;the EMA or the European Commission, or (c)&#xA0;any regulatory body with similar regulatory authority over pharmaceutical or biotechnology
products in any other jurisdiction anywhere in the world.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.69.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Regulatory Approval</font>&#x201D; means the license or marketing approval necessary as a prerequisite for Marketing a product in a country in the Territory. For the avoidance of doubt, Regulatory Approval
outside of the United States shall include any Pricing Approval or marketing approval needed prior to the sale of a Licensed Product in the Field.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.70.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Regulatory Filing</font>&#x201D; shall mean any filing or application with any Regulatory Authority, including INDs, NDAs and BLAs and their foreign equivalents with respect to a Licensed Product.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.71.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Reimbursement Approval</font>&#x201D; means any approval or authorization of any Regulatory Authority or Governmental Body for establishing a health insurance or drug reimbursement scheme for a Licensed
Product in a jurisdiction in the Territory.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.72.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#x201C;<font style="font-weight: bold">Research Inventions</font>&#x201D; shall mean any inventions, discoveries, improvements, processes, techniques, Know-How, information and data developed, generated, discovered, conceived or reduced
to practice during the performance of the Work Plan (as defined in Section&#xA0;4.1) and relating to the Compounds, whether or not patentable.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.73.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Research Patents</font>&#x201D; means all Patent Rights Covering Research Inventions.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.74.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Response</font>&#x201D; shall have the meaning set forth in Section&#xA0;11.1.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.75.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Royalty Term</font>&#x201D; means, and determined on a Licensed Product-by-Licensed Product and country-by-country basis, the period commencing from the First Commercial Sale of a given Licensed Product
in such country and ending on the expiry of the last-to-expire Licensor Patent containing a Valid Claim Covering such Licensed Product in such country.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.76.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Significant Development Event</font>&#x201D; means any of the following material Development events, a summary of which shall be included in any Development Report: (a)&#xA0;any material interaction
and/or written correspondence between TGTX or its Sublicensees and any Regulatory Authority with respect to a Compound or a Licensed Product; (b)&#xA0;any material event with respect to any Clinical Trial involving the Compound and/or a Licensed Product, including any such event that is ongoing as of the date of the applicable Development Report, or is reasonably expected to occur or be initiated within twelve (12)&#xA0;months of the date of the applicable Development Report; and (c)&#xA0;any material result
obtained in the conduct of any Clinical Trial involving a Compound and/or a Licensed Product during the period covered by the Development Report. For purposes of this definition, &#x201C;material&#x201D; shall be defined as any event and/or result which have had or may have a significant impact on the activities and timelines defined in the Development Plan of a Licensed Product.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.77.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">sNDA</font>&#x201D; means a supplemental New Drug Application, as defined in the FD&amp;C Act and applicable regulations promulgated thereunder.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.78.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Sublicense</font>&#x201D; means an agreement under which Licensee grants a sublicense under the license set forth in Section&#xA0;2.1.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.79.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Sublicensee</font>&#x201D; means a Third Party or Affiliate to which TGTX has, pursuant to Section&#xA0;2.2, granted sublicense rights under any of the license rights granted under Section&#xA0;2.1.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.80.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Tax</font>&#x201D; or &#x201C;<font style="font-weight: bold">Taxes</font>&#x201D; means any federal, state, local or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp,
occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.81.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Technical Dispute</font>&#x201D; shall have the meaning set forth in Section&#xA0;11.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.82.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Terminated Country(ies)</font>&#x201D; is defined in Section&#xA0;10.9.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.83.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Territory</font>&#x201D; means worldwide.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.84.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Third Party</font>&#x201D; means any Person other than Licensor, Checkpoint, TGTX or their Affiliates.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.85.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Third Party Action</font>&#x201D; means any claim or action made by a Third Party against a Party that claims that a Licensed Product&#x2019;s use, Development, manufacture or sale by TGTX or its Sublicensees
infringes such Third Party&#x2019;s intellectual property rights in the Territory.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.86.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Trademark</font>&#x201D; shall include any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, service
mark, trade name, logo, design mark or domain name, whether or not registered.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">1.87.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">United States</font>&#x201D; or &#x201C;<font style="font-weight: bold">U.S.&#x201D; </font>means the United States of America and its territories and possessions.</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px">1.88.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Valid Claim</font>&#x201D; means a
claim of any pending Patent Right (including patent applications) or any issued, unexpired United States or granted foreign patent that has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal can be taken, and that has not been explicitly disclaimed, or admitted in writing to be invalid or unenforceable or of a scope not covering a particular product or service through reissue, disclaimer or otherwise,
provided that if a particular claim has not issued within eight (8)&#xA0;years of its initial filing, it shall not be considered a Valid Claim for purposes of this Agreement unless and until such claim is included in an issued or granted Patent, notwithstanding the foregoing definition.</font></font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE II.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">LICENSES AND OTHER RIGHTS</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Grant of License to TGTX. </font>Checkpoint, on behalf of itself and its Affiliates, hereby grants to TGTX and its Affiliates, and TGTX and its Affiliates hereby accept, an exclusive (even as to Checkpoint),
royalty-bearing right and license (with the right to grant sublicenses in accordance with the provisions of Section&#xA0;2.2) under the Licensor Technology to research, Develop, have Developed, Manufacture, have Manufactured, use, import, Commercialize and have Commercialized the Compound and Licensed Products in and for the Field and Territory.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Grant of Sublicenses by TGTX. </font>The rights and licenses granted in Section&#xA0;2.1 includes the right to grant sublicenses through multiple tiers of Sublicensees directly or through Sublicensees, provided:
(i)&#xA0;TGTX shall enter into a Sublicense with each of its Sublicensees that contains terms and conditions that are consistent in all material respects with the terms and conditions of this Agreement and that provide that upon termination of this Agreement with respect to a country covered by such Sublicense, Checkpoint and Licnesor are third party beneficiaries of such Sublicense;<font style="font-weight: bold">&#xA0;</font>(ii) each Sublicensee agrees in writing with TGTX to maintain accurate and complete
books and records and permit Checkpoint and Licensor to review such books and records (including through the audit provisions of this Agreement); and (iii) such Sublicense agreement permits TGTX or a Sublicensee to assign to Checkpoint (or Licensor, as required) such Sublicense agreement. Notwithstanding the foregoing sentence, it is not required that a Sublicense include provisions for the Sublicensee to pay Royalties or make milestone payments directly to Checkpoint or to provide royalty reports directly to
Checkpoint. TGTX shall be and remain fully responsible for the compliance by Sublicensees with the terms and conditions of this Agreement applicable to such Sublicensees. TGTX shall not be relieved of its obligations pursuant to this Agreement as a result of such Sublicense, except to the extent such obligations are satisfactorily performed by any such sublicensee. With respect to each Sublicense (and any amendments thereto), TGTX shall forward to Checkpoint (x)&#xA0;a copy of any Sublicense and any amendments
thereto, and (y)&#xA0;a certificate in writing that the Sublicense (and any amendments thereto) are in compliance with the terms of this Agreement and the License Agreement, within twenty (20) days following the full execution thereof, provided that TGTX shall have the right to remove from such copy any confidential information therein.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Bankruptcy Code. </font>All rights and licenses granted under or pursuant to this Agreement by Checkpoint to TGTX are, and shall otherwise be deemed to be, for purposes of Section&#xA0;365(n) of the U.S. Bankruptcy
Code, licenses of rights to &#x201C;intellectual property&#x201D; as defined under Section&#xA0;101 of the U.S. Bankruptcy Code. The Parties agree that TGTX, as a sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Technology Transfer. </font>As soon as reasonably practicable after the Effective Date, but in no event later than thirty (30)&#xA0;days following the Effective Date, Checkpoint will provide to TGTX a copy
of all Licensor Know-How (including but not limited to any preclinical data, clinical data, assays and associated materials, protocols, and procedures pertaining to Licensor&#x2019;s Development of the Licensed Products as of the Effective Date). All such transfers will be done in a reasonably secure manner using either encrypted media or encrypted transfer technology, or, if paper utilizing secure courier or tracked delivery processes. If, during the term of this Agreement Checkpoint possesses Licensor Know-How
not previously provided to TGTX, it shall, within thirty (30)&#xA0;days after it comes into possession of such Licensor Know-How, provide copies of such Know-How to TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Non-Compete. </font>On a country-by-country basis during the Royalty Term for each country (and with respect to an Abandoned Terminated Country, the Royalty Term for the United States), TGTX, its Affiliates
and its Sublicensees shall not directly or indirectly engage in the research, development, Manufacture or commercialization of a Competing Product in such country. On a country-by-country basis during the Royalty Term for each country, Checkpoint, its Affiliates shall not directly or indirectly engage in the research, development, Manufacture or commercialization of a Competing Product in such country. This Section 2.5 shall not apply to Competing Products or prospective Competing Products acquired after the
Effective Date by either Party or its Affiliates through acquisition of or merger with a Third Party or by purchase of substantially all of the assets of a Third Party.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE III.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.1&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<font style="font-weight: bold">Objective of Development Program and Diligence by Checkpoint.</font></font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Pursuant to the Development Program, TGTX, itself or through or with its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Develop and to Commercialize at least one Licensed Product in and for the Field in each of the
Major Countries and use Commercially Reasonable Efforts to Develop and to Commercialize at least one&#xA0; Licensed Product in and for the Field in at least one country that is not a Major Country. In addition, TGTX shall <font style="font-size: 13px">&#xA0;</font>use Commercially Reasonable Efforts to Develop and to Commercialize the Licensed Products in and for the Field in the rest of the Territory; provided, however, for the sake of clarity, TGTX will not be in breach or violation of its requirement to use
such Commercially Reasonable Efforts in a country (other than such Major Countries and such other one country that is not a Major Country), if the Development and/or Commercialization in such country is not economically prudent or feasible as reasonably determined by TGTX in its sole discretion.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX and/or its Affiliates and Sublicensees shall perform Development of the Licensed Product in good scientific manner and in compliance in all material respects with all applicable Laws and with cGLPs, cGMPs and cGCPs (or, if and as appropriate
under the circumstances, International Conference on Harmonization (&#x201C;<font style="font-weight: bold">ICH</font>&#x201D;) guidance (or other comparable regulation and guidance of any Regulatory Authority in the Territory).</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Development Plan and Report.</font> Within ninety (90)&#xA0;days of the Effective Date, TGTX shall provide Checkpoint a Development Plan. Within twenty (20)&#xA0;days of the end of each Calendar Year, TGTX
shall prepare and provide to Checkpoint an updated Development Plan detailing any amendments, modifications and/or updates to any existing Development Plan along with a Development Report. For the avoidance of doubt, Development Plans are nonbinding and TGTX shall not be in breach of this Agreement if it does not Develop the Compound or Licensed Products in accordance with any Development Plan. Upon Regulatory Approval of a Licensed Product for a particular Major Country, TGTX&#x2019;s obligations under this Section
3.2 shall terminate for that country.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Authority. </font>As between TGTX and Checkpoint, TGTX shall have the exclusive right, and sole decision-making authority, to Develop, manufacture and Commercialize any Licensed Products in and for the Field
(either itself or through its Affiliates, agents, subcontractors and/or Sublicensees).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Costs and Expenses. </font>As between Checkpoint and TGTX, (a) TGTX shall be solely responsible for all costs and expenses related to clinical Development, Manufacture and Commercialization of the Licensed
Products, including without limitation costs and expenses associated with all clinical trials, drug supply and regulatory filings and proceedings relating to Licensed Products in the Field, (b) the costs of all IND enabling work, including without limitation, all pre-clinical toxicology, pharmacology, CMC, and other work required for the filing of an IND shall be Shared Development Expenses; however, Shared Development Expenses shall include only external costs incurred and each Party shall be responsible for
its own internal costs (personnel, overhead, etc.) incurred in connection with an IND filing, (c) each Party shall pay the costs of filing their own IND, and (d) all CMC and formulation development costs shall be Shared Development Expenses. Shared Development Expenses shall be borne 50% by Checkpoint and 50% by TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Regulatory. </font>TGTX and Sublicensees shall be responsible for, and shall control all filings and interactions with Regulatory Authorities with respect to the Licensed Products in and for the Field, and
TGTX and its Sublicensees shall control and coordinate all clinical and regulatory strategy for the Licensed Products in and for the Field.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Manufacturing. </font>During the Term, TGTX and its Sublicensees shall have the sole obligation and responsibility, and at their sole cost and expense, for all aspects of Manufacturing, including without limitation,
testing packaging and labeling the Licensed Products in and for the Field, and any costs associated with storage, release and Third Party logistics. TGTX and Sublicensees may engage contract Manufacturers to Manufacture (including labeling, packaging and testing) the Product. As a part of such responsibilities, TGTX covenants and agrees to use Commercially Reasonable Efforts to obtain the right under any agreement with a Third Party providing for the Manufacture or distribution of the Product to assign such agreement
to Checkpoint, or at Checkpoint&#x2019;s election, to Licensor or any Affiliate of Licensor, upon termination of this Agreement in the circumstance where the provisions of Section 10.7 are applicable. TGTX shall or shall cause all Manufacturing to be done in accordance with cGMP and applicable Law.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.7.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Marketing. </font>Following receipt of Marketing Approval for a Licensed Product in a jurisdiction in the Territory in and for the Field and during the remainder of the Term:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX shall be solely responsible to Market the Licensed Product in and for the Field in the Territory using Commercially Reasonable Efforts. As used in this Section, &#x201C;TGTX&#x201D; includes its Affiliates and Sublicensees.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">At least once per calendar year following the first Regulatory Approval of a Licensed Product in a jurisdiction, TGTX shall provide to licensor a high level written status report summarizing the material Marketing activities conducted by TGTX
and its Affiliates (but not its Sublicensees) pertaining to the Licensed Product in and for the Field.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0; &#xA0;&#xA0; &#xA0;&#xA0; ARTICLE IV.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<a name="_DV_M24">
<!--anchor-->
</a></font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">LICENSOR RESEARCH</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">4.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Overview. </font>As part of the License Agreement, Licensor and Checkpoint entered into a research project (the &#x201C;<font style="font-weight: bold">Research Project</font>&#x201D;) described in <font style="text-decoration: underline">Schedule
4</font> hereto (the &#x201C;<font style="font-weight: bold">Work Plan</font>&#x201D;), whereby the Licensor agreed to use Commercially Reasonable Efforts to conduct and complete the Research Project in accordance with the timeline set forth in the Work Plan. Upon completion of all of the tasks set forth in the Work Plan, Licensor shall deliver to Checkpoint, and Checkpoint shall deliver to TGTX, the deliverables set forth in the Work Plan. All Licensor Know-How generated in connection with such Research Project
shall be delivered to TGTX within thirty (30)&#xA0;days following its receipt from the Licensor and shall deemed Licensor Know-How sublicensed to TGTX hereunder.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">4.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Payment. </font>Fees and<font style="font-weight: bold">&#xA0;</font>expenses incurred by Checkpoint for Licensor&#x2019;s performance of the Research Project, which are outlined in the Work Plan, shall be Shared
Development Expenses and borne 50% by Checkpoint and 50% by TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">4.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Status. </font>Checkpoint shall promptly provide to TGTX all Licensor written reports received by Checkpoint regarding the deliverables provided in the Work Plan and use reasonable efforts to keep TGTX updated
on the status of the work and deliverables.</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0; &#xA0; &#xA0; 4.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Research Inventions. </font>Notwithstanding anything to the
contrary contained in the Work Plan, Licensor shall own all right, title and interest in and to the Research Inventions, including, without limitation, all Research Patents and all other intellectual property rights appurtenant to the Research Inventions. Research Patents shall be Licensor Patents and come within the ambit of the license of Section&#xA0;4.1.</font>
<br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE V.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Financial Provisions</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;5.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">License Fee. </font>TGTX shall pay to Checkpoint
a non-refundable, non-creditable license fee of one million U.S. dollars ($1,000,000) within thirty (30) days of the Effective Date. As of the Effective Date, there are no pending performance obligations on Checkpoint to receive the license fee.</font> &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;
<br></font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;&#xA0; 5.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Milestone Payments. </font>TGTX shall, with respect to
the first Licensed Product to achieve a milestone event below (a &#x201C;<font style="font-weight: bold">Milestone</font>&#x201D;), pay to Checkpoint the respective non-refundable and non-creditable milestone payment (&#x201C;<font style="font-weight: bold">Milestone Payment</font>&#x201D;) under the column &#x201C;First Achievement Milestone Payment&#x201D; within twenty (20)&#xA0;days following TGTX&#x2019;s receipt of actual knowledge of such achievement. In the event a Milestone (other than the first Milestone listed
below) is achieved by a Second Licensed Product (as defined below), TGTX shall pay to Checkpoint the respective milestone payment under the column &#x201C;Second Product Milestone Payment&#x201D; within twenty (20) days following TGTX&#x2019;s receipt of actual knowledge of such achievement. For avoidance of doubt, each Milestone Payment in the table below shall only be paid once under this Agreement, regardless of the number of times such Milestone may be achieved. &#x201C;<font style="font-weight: bold">Second
Licensed Product</font>&#x201D; means, with respect to a Milestone, a Licensed Product containing a Compound that was not contained in the Licensed Product that first achieved such Milestone. For clarity, with respect to each Milestone, a Second Product Milestone cannot be triggered by a Licensed Product containing the same Compound that achieved the respective First Achievement Milestone, even if for a different indication. By way of further clarification, with respect to a Licensed Product contained in a Combination
Product, the Net Sales that trigger the Milestone Payment will be that portion of Net Sales attributable to the Licensed Product as provided in the definition of &#x201C;Net Sales&#x201D;. Notwithstanding the table below, upon achievement of a Development Milestone, payments for such Development milestone and all prior Development Milestones shall be due and payable to the extent not already paid.</font>
<br></font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:auto;width:90%;font-size:13px;font-family:Times New Roman;margin-left:auto;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Milestone Event</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">First Achievement Milestone Payment</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td>
<td rowspan="1" style="border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;width:12%;vertical-align:bottom;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:2px solid #000000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">Second Product Milestone Payment</font></div></font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">1.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*&#xA0; </font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">N/A</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">2.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*.</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">3.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align: bottom; width: 12%; border-left: 0.5pt solid rgb(0, 0, 0);">
<div style="padding-bottom: 2px;">
<div>
<div>
<div style="margin-left: 0px;"><font style="text-align: left; padding-bottom:2px;vertical-align:bottom;display:inline-block;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font><font style="text-align: center; vertical-align:bottom;border-bottom:2px solid #000000;display:inline-block;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">$&#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0; &#xA0;&#xA0; &#xA0; &#xA0; &#xA0;&#xA0;<font style="font-size: 70%; vertical-align: top"> *</font> (subject
to the below)</font></div></font><font style="text-align: center; padding-bottom:2px;vertical-align:bottom;display:inline-block;">&#xA0; </font></div></div></div></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">4.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">5.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">6.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">7.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">8.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">9.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">10.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*.</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">11.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*.</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:2px solid #000000;">&#xA0; </font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:2px solid #000000;">12.</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">*.</font></font></div></td>
<td style="vertical-align:bottom;width:12%;border-left:0.5pt solid #000000;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td>
<td style="border-left:0.5pt solid #000000;vertical-align:bottom;border-right:0.5pt solid #000000;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0; </font><font style="text-align: left; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:2px solid #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;"><font style="font-size: 70%; vertical-align: top">&#xA0; </font></font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 12px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="vertical-align: bottom;">&#xA0;Within twenty (20) days of achieving a Milestone, TGTX shall provide written notice to Checkpoint of such achievement. If at any time Checkpoint disputes whether a Development Milestone has been achieved, the matter shall be referred for resolution in accordance with Section&#xA0;11.2 as a Technical Dispute.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="vertical-align: bottom;">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-family: Times New Roman;"><font style="vertical-align: bottom;">&#x2217;</font> Confidential material redacted and filed separately with the Commission.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-size: 13px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000"><font style="font-size: 13px">
<!--page break line-->
</font></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-size: 13px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px">&#xA0;In the event that TGTX achieves Milestone 3 set forth above, and Checkpoint, in its discretino, determines that, as a result it can proceed immedieatly to * with respect to Checkpoint's Development outside of the Field, or if both parties co-sponsor * meeting Milestone 3 set forth above, then TGTX's First Achievement Milestone
Payment in Milestone 3 shall be reduced in half to $*.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-size: 12px"><font style="font-family: Times New Roman;">&#xA0;</font></font></font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-size: 12px"><font style="font-family: Times New Roman;">5.3.</font><font id="tab2" style="letter-spacing: 12px; color: black;">&#xA0;</font><font style="font-family: Times New Roman;"><font style="font-weight: bold;">Royalty Payments for Licensed Product</font>.</font></font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="vertical-align: bottom;"><font style="vertical-align: bottom;"><font style="vertical-align: bottom;">(a)&#xA0;In addition to those payments due to Checkpoint under 5.1 and 5.2 above, TGTX shall pay to Checkpoint a royalty at a rate of * percent (*%) on the Calendar Year, worldwide aggregate Net Sales of all Licensed Products during the Licensed Product-by-Licensed
Product and country-by-country Royalty Terms by TGTX and its Affiliates and Sublicensees (but excluding Net Sales of a given Licensed Product in a given country after its applicable Royalty Term).</font></font></font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="vertical-align: bottom;"><font style="vertical-align: bottom;">(b)&#xA0;On a Licensed</font> Product-by-Licensed Product and country-by-country basis upon expiration of the Royalty Term, for a Licensed Product in a country, the rights, licenses and sublicenses granted to TGTX hereunder with respect to such Licensed Product in such country shall continue in effect but become exclusive fully paid-up, royalty-free, transferable
(to the extent not transferable previously), perpetual and irrevocable, provided that TGTX shall remain liable for any unpaid Milestone Payments and any royalty payments previously owed or accrued. For the avoidance of doubt, in a country where no Licensor Patent containing a Valid Claim covering a Licensed Product has ever existed nor ever exists, no royalties shall be due.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="vertical-align: bottom;">5.4. &#xA0;&#xA0; <font style="font-weight: bold">Timing of Payment. </font>Payments in the nature of royalties payable under Section&#xA0;5.3(a) shall be payable on actual Net Sales and shall accrue at the time provided therefor by GAAP. Payments in the nature of royalty obligations that have accrued during a particular Calendar Quarter shall be paid, on a Calendar Quarter basis, within 45&#xA0;days
after the end of each Calendar Quarter commencing with the Calendar Quarter in which the First Commercial Sale occurred.
<br></font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 0px; text-indent: 60px; margin-right: 0px;"><font style="font-size: 12px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="vertical-align: bottom;">&#x2217;</font> Confidential material redacted and filed separately with the Commission.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Royalty Reports and Records Retention. </font>Within forty-five (45)&#xA0;days after the end of each Calendar Quarter during which Licensed Products have been sold, TGTX shall deliver to Checkpoint, together
with the applicable royalty/payment in the nature of royalties payment due, a written report, on a Licensed Product-by-Licensed Product and country-by-country basis, of Net Sales for such Calendar Quarter. Such report shall (i)&#xA0;total Net Sales for each Licensed Product and Combination Product (including an itemization of the deductions applied to such gross sales to derive such Net Sales and if a Licensed Product is part of a Combination Product the percentage of the Combination Product&#x2019;s Net Sales
attributed to the Licensed Product) during the relevant Calendar Quarter, in each case on a dosage-by-dosage, country-by-country basis, including a summary of currency exchange rates used in the calculations, and (ii) the calculation of royalties due on the foregoing. In addition for any Sublicense, the report shall provide the information in clauses&#xA0;(i) through (ii) above. Such report shall be deemed &#x201C;Confidential Information&#x201D; of TGTX subject to the obligations of Article&#xA0;VII of this Agreement.
For three years after each sale of a Licensed Product, TGTX shall keep (and shall cause its Affiliates and Sublicensees to keep) complete and accurate records of such sale in sufficient detail to confirm the accuracy of the royalty or royalty/payment in the nature of royalties calculations hereunder.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Audits</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Upon the written request of Checkpoint, and not more than once in each Calendar Year, TGTX shall permit an independent certified public accounting firm (&#x201C;<font style="font-weight: bold">Auditors</font>&#x201D;) of nationally recognized
standing selected by Checkpoint and reasonably acceptable to TGTX, at Checkpoint&#x2019;s expense, to have access to and to review, during normal business hours upon reasonable prior written notice, the applicable records of TGTX and its Affiliates or Sublicensees to verify the accuracy of the royalty reports and the Milestone Payments for Milestones which are not Development Milestones. Such review may cover: (i)&#xA0;the records for sales made in any Calendar Year ending not more than three years before the
date of such request, and (ii) only those periods that have not been subject to a prior audit. The accounting firm shall disclose to Checkpoint only whether the royalty reports and Milestone Payments are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Checkpoint by the Auditors. This right to audit shall remain in effect during the Term of this Agreement and for a period of two (2)&#xA0;years after the termination of this Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">If such accounting firm concludes that additional royalties or Milestone Payments were owed during such period, TGTX shall pay the additional royalties and Milestone Payments within 20&#xA0;days after the date such public accounting firm delivers
to TGTX such accounting firm&#x2019;s written report. If such accounting firm concludes that an overpayment was made, such overpayment shall be fully creditable against amounts payable in subsequent payment periods or at TGTX&#x2019;s request, shall be reimbursed to TGTX within 30&#xA0;days after the date such public accounting firm delivers such report to TGTX. Checkpoint shall pay for the cost of any audit by Checkpoint, unless TGTX has underpaid Checkpoint by $50,000 or more for a specific royalty period, in
which case TGTX shall pay for the reasonable costs of audit.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Each Party shall treat all information that it receives under this Section&#xA0;5.6 in accordance with the confidentiality provisions of Article&#xA0;VII of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality
agreement with the audited Party obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, except to the extent necessary for a Party to enforce its rights under the Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.7.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Mode of Payment and Currency. </font>All payments to Checkpoint under this Agreement, whether or not in respect of Net Sales or milestone events, shall be made by deposit of U.S. Dollars in the requisite amount
to such bank account as Checkpoint may from time to time designate by advance written notice to TGTX. Conversion of sales or expenses recorded in local currencies to Dollars will be performed in a manner consistent with TGTX&#x2019;s normal practices used to prepare its audited financial statements for external reporting purposes, provided that such practices use a widely accepted source of published exchange rates. These practices are set forth on <font style="text-decoration: underline">Schedule 5</font> attached
hereto. Based on the resulting Net Sales in U.S. Dollars, the then applicable royalties/payment in the nature of royalties shall be calculated.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.8.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Late Payments. </font>If a Party does not receive payment of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until
the date of payment at a rate equal to the lesser of (a)&#xA0;U.S. Dollar one-month LIBOR as of the date such payment was due (taken from a widely accepted source of published interest rates), plus three (3)&#xA0;percentage points, or (b)&#xA0;the maximum rate permissible under applicable Law. Accrual and payment of interest shall not be deemed to excuse or cure breaches of contract arising from late payment or nonpayment.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.9.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Taxes. </font>All amounts due hereunder exclude all applicable sales, use, and other taxes and duties, and TGTX shall be responsible for payment of all such taxes (other than based on Checkpoint&#x2019;s income)
and duties and any related penalties and interest, arising from the payment of amounts due under this Agreement. The Parties agree to cooperate with one another and use Commercially Reasonable Efforts to avoid or reduce tax withholding or similar obligations in respect of payments in the nature of royalties, Milestone Payments, and other payments made by TGTX to Checkpoint under this Agreement. To the extent TGTX is required to withhold taxes on any payment to Checkpoint, TGTX shall pay the amounts of such taxes
to the proper governmental authority in a timely manner and promptly transmit to Checkpoint official receipts issued by the appropriate taxing authority and/or an official tax certificate, or such other evidence as Checkpoint may reasonably request, to establish that such taxes have been paid. Checkpoint shall provide TGTX any tax forms that may be reasonably necessary in order for TGTX to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Checkpoint shall use
Commercially Reasonable Efforts to provide any such tax forms to TGTX at least 45&#xA0;days before the due date for any payment for which Checkpoint desires that TGTX apply a reduced withholding rate. Each Party shall provide the others with reasonable assistance to enable the recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or
value added tax. Notwithstanding the foregoing, if TGTX transfers or sublicenses any rights under this Agreement, Drug Approval Applications or Regulatory Approvals, Development Inventions or relocates or assigns this Agreement and as a result TGTX or its assignee is required to withhold or deduct any taxes by any government outside the United States, any subdivision thereof, or any other governmental unit within the territory of such government (such taxes collectively referred to as &#x201C;<font style="font-weight: bold">Charges</font>&#x201D;),
in excess of Charges that Checkpoint would otherwise be required to pay had such transfer, relocation, or assignment not been made, or Checkpoint is required to pay any Charge imposed by any government outside the United States in excess of Charges that Checkpoint would otherwise be required to pay had such transfer or assignment not been made, TGTX shall pay such additional amounts so that payments received by Checkpoint net of all Charges, shall equal the amount to which Checkpoint would have been entitled
had there been no such Charges, provided, however that TGTX shall have no obligation to pay any additional amount to the extent that the Charges are imposed by reason of Checkpoint failing to provide a form or similar other evidence reasonably requested by TGTX that would allow for a reduction or exemption of such Charges that Checkpoint is legally able to provide (including, for the avoidance of doubt, Checkpoint&#x2019;s qualification for the benefit of an applicable income tax convention).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; padding-bottom: 8px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE VI.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px; padding-bottom: 8px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Inventions and Patents</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;">6.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Patent Prosecution and Maintenance.</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a) &#xA0;&#xA0;&#xA0;&#xA0; <font style="font-weight: bold">Patents. </font>TGTX shall reimburse Checkpoint up to $25,000 in expenses (including attorney&#x2019;s fees) paid by Checkpoint to Licensor for filing of patent applications (national, international or PCT) included in the Licensor Patents and filed prior to the Effective Date within thirty
(30) days of receipt of Checkpoint&#x2019;s invoice for such expenses. As between TGTX and Checkpoint, Checkpoint shall be solely responsible for Patent Prosecution of the Licensor Patents in the Territory. Checkpoint shall keep TGTX informed of material actions with respect to the filing and prosecution of Licensor Patents or related proceedings (e.g. interferences, oppositions, reexaminations, reissues, revocations or nullifications) in a timely manner, and shall reasonably consider the advice of TGTX and its
patent counsel, and Checkpoint will authorize its patent counsel to speak directly with TGTX and its counsel. Checkpoint shall not abandon prosecution or maintenance of any Licensor Patent in the Territory without first notifying TGTX in a reasonably timely manner of Checkpoint&#x2019;s intention and reason therefor, and providing TGTX with reasonable opportunity to consider to assume, with no obligation to do so, responsibility for prosecution and maintenance of such Licensor Patent in the Territory as set forth
in Section&#xA0;6.1(b).<font style="font-weight: bold">&#xA0;</font>TGTX <font style="color: #000000">shall reimburse Checkpoint for 50% of the reasonable</font> out-of-pocket expenses incurred by Checkpoint in filing, prosecuting and maintaining the Licensor Patents in the Territory. Payments are due within thirty (30) days of receipt of Checkpoint&#x2019;s invoice for such expenses.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; (b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Abandonment. </font>If Checkpoint provides TGTX with written notification
that it will no longer support or pursue the filing, prosecution, or maintenance (&#x201C;<font style="font-weight: bold">Abandonment</font>&#x201D; and when uses as a verb &#x201C;<font style="font-weight: bold">Abandon</font>&#x201D;) of a specified Licensor Patent in a particular country (an &#x201C;<font style="font-weight: bold">Abandoned Patent</font>&#x201D;) in the Territory, then (a)&#xA0;Checkpoint&#x2019;s responsibility for such filing, prosecution, or maintenance of the Abandoned Patent in such country,
and the fees and costs related thereto, will terminate on the earlier of (x)&#xA0;the date forty-five (45)&#xA0;Calendar Days after TGTX&#x2019;s receipt of such written notice from Checkpoint or (y)&#xA0;TGTX&#x2019;s assumption of the filing, prosecution and maintenance of such Abandoned Patent in such country at TGTX&#x2019;s sole expense. If TGTX does not assume the filing, prosecution and maintenance of such Abandoned Patent in such country within forty-five (45) Calendar days after TGTX&#x2019;s receipt of
such written notice from Checkpoint, &#xA0;the specified Abandoned Patent shall no longer be deemed a Licensor Patent hereunder. If Checkpoint Abandons all Licensor Patents in a country in the Territory, without the assumption by TGTX of the filing, prosecution and maintenance of any such Licensor Patent in such country, Licensor by notice to Checkpoint may terminate such country from the License Agreement and such country will become an &#x201C;<font style="font-weight: bold">Abandoned Terminated Country</font>&#x201D;
under this Agreement. Following Licensor&#x2019;s notice to Checkpoint, which shall be promptly sent to TGTX, TGTX&#x2019;s (and its Sublicensees&#x2019;) rights to any Licensor Patents in such country shall terminate. If TGTX assumes an Abandoned Patent, thereafter TGTX shall be solely responsible for Patent Prosecution of the Abandoned Patent in the Territory. Except as provided below, TGTX shall assume and have sole responsibility for Patent Prosecution for the Abandoned Patent in the Territory. TGTX will, to
the extent reasonably practicable, provide Licensor a reasonable opportunity to review and comment on any material patent filings or correspondence with patent authorities pertaining to the Abandoned Patents, provided that all decisions with respect to Patent Prosecution of the Abandoned Patents shall be made by TGTX in its sole reasonable discretion. TGTX shall not abandon prosecution or maintenance of any Abandoned Patent without first notifying Licensor in a reasonably timely manner of TGTX&#x2019;s intention
and reason therefor, and providing Licensor with reasonable opportunity to consider to assume, with no obligation to do so, responsibility for prosecution and maintenance of such Abandoned Patent.</font>
<br></font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">6.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Certification under Drug Price Competition and Patent Restoration Act. </font>Each of Checkpoint and TGTX shall immediately give written notice to the other of any Paragraph&#xA0;IV Certification.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">6.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Enforcement of Patents</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Notice. </font>If either Party becomes aware of (i)&#xA0;any actual, potential, or alleged infringement of any of the rights to Licensor Patents under this Agreement with respect to Licensed Products in the
Field, (ii) misappropriation of any Licensor Know-How that materially adversely affects exploitation of Licensed Products in the Field, or (iii) a Paragraph&#xA0;IV Certification (each of subclauses (i), (ii) and (iii), an &#x201C;<font style="font-weight: bold">Infringement</font>&#x201D;) and, such Party shall give to the other Party prompt and reasonably detailed written notice of such actual, potential, or alleged Infringement. Notwithstanding the foregoing, each Party shall notify the other Party within two
(2)&#xA0;Business Days of its receipt of, or receipt of notice of, any Paragraph&#xA0;IV Certification. This Section&#xA0;6.3 sets forth the rights of the Parties to commence and prosecute an action relating to such Third Party Infringement (an &#x201C;<font style="font-weight: bold">Offensive Enforcement Action</font>&#x201D;).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Right to Bring an Action for Licensor&#x2019;s Patents. </font>Checkpoint and Licensor shall have (i)&#xA0;the right, but not the obligation to undertake control of, and manage and prosecute, compromise or settle,
including selection of counsel (collectively, &#x201C;<font style="font-weight: bold">Prosecute</font>&#x201D;), any Offensive Enforcement Action relating to a Paragraph&#xA0;IV Certification and (ii) the right but not the obligation to Prosecute any other Offensive Infringement Action. If Checkpoint has not exercised their first right to Prosecute a non Paragraph&#xA0;IV Offensive Infringement Action within one hundred twenty (120) days of receipt of notice of the same, or a Paragraph&#xA0;IV Offensive Infringement
Action within ten (10) days of receipt of notice of same, Checkpoint shall within five (5)&#xA0;days notify TGTX in writing and TGTX may, by written notice to Checkpoint no later than five (5) days following TGTX&#x2019;s receipt of notice from Checkpoint, Prosecute such action (either such Party who Prosecutes such action, the &#x201C;<font style="font-weight: bold">Prosecuting Party</font>&#x201D;). The non-Prosecuting Party may, in its sole discretion and at its expense, join in any Offensive Infringement Action
and in such case shall reasonably cooperate with the Prosecuting Party. At the Prosecuting Party&#x2019;s request the non-Prosecuting Party shall provide the Prosecuting Party with all relevant documentation (as may be requested by the Prosecuting Party) evidencing that the Prosecuting Party is validly empowered by the non-Prosecuting Party to initiate an Offensive Infringement Action. The non-Prosecuting Party shall be under the obligation to join the Prosecuting Party in its Offensive Infringement Action if
the Prosecuting Party determines that this is necessary to demonstrate &#x201C;standing to sue&#x201D;, provided that the Prosecuting Party shall pay the fees (including attorneys&#x2019; fees) if the non-Prosecuting Party retains its own counsel. The Prosecuting Party shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to this Section&#xA0;6.3 (but not the non-Prosecuting Party&#x2019;s counsel). Checkpoint&#x2019;s or TGTX&#x2019;s rights under this Section may be exercised
by their respective Affiliates or in TGTX&#x2019;s case, Sublicensees.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Costs and expenses of an Action. </font>Subject to Section&#xA0;6.3(b) and (f), each Party involved in an Action under Section&#xA0;6.3(b) shall pay its own costs and expenses incurred in connection with such
Action.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Settlement. </font>No Party shall settle or otherwise compromise (or resolve by consent to the entry of judgment upon) any Offensive Infringement Action or Patent Prosecution by admitting that any Licensor Patent
is to any extent invalid or unenforceable or any settlement (or consent to the entry of a judgment) that entails any payment by the other Party, any license, covenant not to sue relating to, dedication to the public of, abandonment of, any Licensor Technology or would otherwise grant any rights to Manufacture, use, sell or otherwise commercialize a Competing Product, or materially adversely affect the rights of the other Party, without the other Party&#x2019;s prior written consent.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Reasonable Assistance. </font>Each Party (if it is not the Party Prosecuting or defending Licensor&#x2019;s Patent Rights) shall provide reasonable assistance to the other Party, including providing access to
relevant documents and other evidence and making its employees and consultants available, subject to the other Party&#x2019;s reimbursement of any reasonable out-of-pocket expenses incurred on an on-going basis by the non-enforcing or non-defending Party in providing such assistance.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Distribution of Amounts Recovered. </font>Any amounts recovered by the Party initiating an Offensive Infringement Action pursuant to this Section&#xA0;6.3, whether by settlement or judgment, shall be allocated
in the following order: (i)&#xA0;to reimburse the Prosecuting Party for any costs incurred; (ii) to reimburse the non-Prosecuting Party and Licensor for its costs incurred in such Offensive Infringement Action, if it joins (as opposed to taking over) such Offensive Infringement Action; and (iii) the remaining amount of such recovery shall (A)&#xA0;if TGTX (or a Sublicensee) is the Prosecuting Party in the Offensive Infringement Action, the remainder shall be allocated to TGTX and the portion thereof attributable
to &#x201C;lost sales&#x201D; shall be deemed to be Net Sales for the Calendar Quarter in which the amount is actually received by TGTX and TGTX shall pay to Checkpoint a royalty on such portion based on the royalty rates set forth in Section&#xA0;5.3(a), and the portion thereof not attributable to &#x201C;lost sales&#x201D; shall be allocated to TGTX, (B)&#xA0;if Checkpoint is the Prosecuting Party then the remaining amount of the recovery shall be retained by Checkpoint. and (C)&#xA0;if Licensor is the Prosecuting
Party then the remaining amount of the recovery shall be retained by the Licensor.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(g)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Irrespective of whether Checkpoint, TGTX or the Licensor decide to take any action under Section&#xA0;6.3(b), the payment obligations under Section&#xA0;5 shall remain unaffected.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">6.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Third Party Actions Claiming Infringement</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Notice. </font>If either Checkpoint or TGTX becomes aware of any Third Party Action, such Party shall promptly notify the other of all details regarding such claim or action that is reasonably available to such
Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Duty to Defend. </font>Subject to the respective indemnity obligations of the Parties set forth in Article&#xA0;IX, TGTX shall have the obligation, at its sole cost and expense, to defend a Third Party Action
described in Section&#xA0;6.4(a) and (subject to Section&#xA0;6.4(f)) to compromise or settle such Third Party Action. TGTX shall have the sole and exclusive right to select counsel for such Third Party Action.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Consultation. </font>The Party defending a Third Party Action shall be the &#x201C;<font style="font-weight: bold">Controlling Party</font>&#x201D;. The Controlling Party shall consult with the non-Controlling
Party, pursuant to an appropriate joint defense or common interest agreement, on all material aspects of the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in decision-making and formulation of defense strategy. The Parties shall reasonably cooperate with each other in all such actions or proceedings. The non-Controlling Party will be entitled to join the Third Party Action and be represented by independent counsel of its own choice at its own expense.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Appeal. </font>Subject to the respective indemnity obligations of the Parties set forth in Article&#xA0;IX, in the event that a judgment in a Third Party Action is entered against Licensor or Checkpoint, and
an appeal is available, the Controlling Party shall, in the absence of the non-Controlling Party&#x2019;s written consent to the contrary, have the obligation to file such appeal. If applicable Law requires the non-Controlling Party&#x2019;s involvement in an appeal, the non-Controlling Party shall be a nominal party in the appeal and shall provide reasonable cooperation to such Party at such Party&#x2019;s expense.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Costs and expenses of an Action. </font>Subject to the respective indemnity obligations of the Parties set forth in Article&#xA0;IX, the Controlling Party shall pay all costs and expenses associated with such
Third Party Action other than the expenses of the other Party if the other Party elects to join such Third Party Action, (as provided in the last sentence of Section&#xA0;6.4(c)). For the avoidance of doubt, all damage and liability awards and settlement payments shall be paid by the Controlling Party subject to the respective indemnity obligations of the Parties set forth in Article&#xA0;IX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">No Settlement without Consent. </font>Neither Checkpoint or TGTX shall settle or otherwise compromise (or resolve by consent to the entry of judgment upon) any Third Party Action or Patent Prosecution by admitting
that any Licensor Patent is to any extent invalid or unenforceable or that any Licensed Product, or its use, Development, importation, manufacture or sale infringes such Third Party&#x2019;s intellectual property rights, or entering into a settlement providing for a license, covenant not to sue relating to, dedication to the public of, abandonment of, any Licensor Technology or would otherwise grant any rights to Manufacture, use, sell or otherwise commercialize a Competing Product or materially adversely affects
the rights of the other Party, in each case without the other Party&#x2019;s prior written consent.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(g)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The payment obligations under Section&#xA0;5 shall remain unaffected during or following any Third Party Action.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">6.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Trademark Infringement</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">With respect to any and all claims instituted by Third Parties against Licensor, Checkpoint or TGTX or any of their respective Affiliates or Sublicensees for Trademark infringement involving the Marketing of the Licensed Products, TGTX, its
Sublicensees and Affiliates shall be solely responsible for, and indemnify Licensor and Checkpoint against, any and all Losses arising out of or resulting from the use of any Trademarks.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">In
the event that a Party becomes aware of actual or threatened infringement of a Trademark used by TGTX, its Sublicensees or Affiliates in connection with a Licensed Product in the Field, that Party shall promptly notify the other Party in writing. TGTX, its Sublicensees and its Affiliates shall have the right but not the obligation to bring an action with respect to such infringement against any Third Party for infringement of a Trademark used in connection with a Licensed Product in the Field. TGTX shall bear
all out-of-pocket costs and expenses of the action (including court costs, reasonable fees of attorneys, accountants and other experts and other expenses of litigation or proceedings) and shall be entitled to any recovery in such infringement action.&#xA0;&#xA0;&#xA0;
<br></font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE VII.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CONFIDENTIALITY</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">7.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Confidentiality Obligations. </font>The Parties agree that, for the Term and for five (5)&#xA0;years thereafter, each Party will keep completely confidential and will not disclose, and will not use for any
purpose except for the purposes contemplated by this Agreement, any Confidential Information of the other Party. &#x201C;<font style="font-weight: bold">Confidential Information</font>&#x201D; means all information and know-how and any tangible embodiments thereof provided by or on behalf of one Party to the other Party either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing under this Agreement, which may include data, knowledge, practices, processes,
ideas, research plans, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or business; provided that, information or know-how of a Party will not be deemed Confidential Information of such Party for purposes of this Agreement if such information or know-how: (a)&#xA0;was already known to the receiving
Party, other than under an obligation of confidentiality or non-use, at the time of disclosure to such receiving Party, as can be shown by written records; (b)&#xA0;was generally available or known to parties reasonably skilled in the field to which such information or know-how pertains, or was otherwise part of the public domain, at the time of its disclosure to such receiving Party; (c)&#xA0;became generally available or known to parties reasonably skilled in the field to which such information or know-how
pertains, or otherwise became part of the public domain, after its disclosure to such receiving Party through no fault of the receiving Party; (d)&#xA0;was disclosed to such receiving Party, other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation to the disclosing Party not to disclose such information or know-how to others, as can be shown by written records; or (e)&#xA0;was independently discovered or developed by such receiving Party, as can be shown by its written
records, without the use or benefit of, or reliance on, Confidential Information belonging to the disclosing Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">7.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Authorized Disclosure. </font>Each Party may disclose Confidential Information of the other Party to the extent that such disclosure is:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">made in response to a valid order of a court of competent jurisdiction; provided, however, that in each case such disclosing Party will, to the extent reasonably practicable, (i)&#xA0;first have given written notice to the other Party and
given such other Party a reasonable opportunity to take appropriate action and (ii) cooperate with such other Party as necessary to obtain an appropriate protective order or other protective remedy or treatment; provided, further, that in each case, the Confidential Information disclosed in response to such court or governmental order will be limited to that information which is legally required to be disclosed in response to such court or governmental order, as determined in good faith by counsel to the Party
that is obligated to disclose Confidential Information pursuant to such order;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">otherwise required to be disclosed by any applicable law, rule, or regulation (including, without limitation, the U.S. and foreign securities laws and the rules and regulations promulgated thereunder) or the requirements of any stock exchange
to which a Party is subject; provided, however, that the Party that is so required will provide such other Party with written notice of such disclosure reasonably in advance thereof to the extent reasonably practicable and reasonable measures will be taken to assure confidential treatment of such information, including such measures as may be reasonably requested by the disclosing Party with respect to such Confidential Information;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">is in such Party&#x2019;s or its Affiliates&#x2019; financial statements or the notes thereto and is required under the applicable accounting standard or under regulation;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">made by such Party, in connection with the performance of this Agreement, to such Party&#x2019;s Affiliates, licensees or sublicensees, directors, officers, employees, consultants, representatives or agents, or to other Third Parties, in each
case on a need to know basis and solely to use such information for business purposes relevant to and permitted by this Agreement, and provided that (i)&#xA0;each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure obligations no less than substantially as restrictive as those set forth in this Agreement and (ii) the Party making such disclosure shall be liable for such Third Parties&#x2019; compliance with such obligations; or</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">made by such Party to existing or potential acquirers, existing or potential collaborators, licensees, licensors, sublicensees, investment bankers, accountants, attorneys, existing or potential investors, merger candidates, partners, venture
capital firms or other financial institutions or investors for use of such information for business purposes relevant to this Agreement or for due diligence in connection with the financing, licensing or acquisition of such Party (or such Party&#x2019;s acquisition of, or merger with, a Third Party), and provided that (i)&#xA0;each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure obligations (or in the case of attorneys or accountants, an
equivalent professional duty of confidentiality) at least as restrictive as those set forth in this Agreement and (ii) the Party making such disclosure shall be liable for such Third Parties&#x2019; compliance with such obligations.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">7.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Publicity</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The Parties recognize that each Party may from time to time desire to issue press releases and make public statements or disclosures regarding the subject matter of this Agreement. In such event, the Party desiring to issue an additional press
release or make a public statement or disclosure shall provide the other Party with a copy of the proposed press release, statement or disclosure for review and approval in advance, provided, however, that if in the reasonable opinion of a Party&#x2019;s legal counsel a press release or disclosure in respect of this Agreement is required to satisfy applicable Law or applicable stock exchange rule or regulation, such Party shall submit the proposed press release or disclosure in writing to the other Party as far
in advance as reasonably practicable (and in no event less than two (2)&#xA0;Business Days prior to the anticipated date of disclosure if reasonably practicable,) so as to provide a reasonable opportunity to comment thereon (and such comments shall be considered in good faith). Once any public statement or disclosure has been made in accordance with Section&#xA0;7.3(b) or this Section&#xA0;7.3(a), then either Party may appropriately communicate information contained in such permitted statement or disclosure.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Notwithstanding the provisions of Section&#xA0;7.3(a):</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">To the extent a Party determines in good faith that it is required by applicable Laws or the rules or regulations of a stock exchange on which the securities of the disclosing Party are listed to publicly file, or otherwise disclose, this
Agreement or any of its terms to or with a Regulatory Authority or Governmental Body, such disclosing Party shall provide a proposed redacted form of this Agreement to the other Party within a reasonable amount of time prior to filing or disclosure (and in any event at least five (5)&#xA0;Business Days before filing or disclosure) for the other Party to review and comment upon such redacted form. The Party making such filing, registration, notification or disclosure shall consider in good faith the reviewing
Party&#x2019;s reasonable comments regarding such redacted form and shall use commercially reasonable efforts to seek confidential treatment for the redacted terms, to the extent such confidential treatment is applicable and reasonably available consistent with applicable Laws or the rules or regulations of the applicable stock exchange. Each Party shall be responsible for its own legal and other external costs in connection with any such filing, registration or notification.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Each Party may disclose to any actual or potential or actual investor, lender, investment bank or other bank, acquirer, acquisition or merger target, licensee, licensor, or other strategic partner to the extent necessary or useful in connection
with the evaluation or negotiation of a potential transaction or contractual relationship, or performance of obligations or enforcement of rights under such a transaction or relationship, in each case pursuant to a written obligation of confidentiality and non-use substantially as stringent as those set forth in this Article&#xA0;VII, a complete copy of this Agreement or any of the terms thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE VIII.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">8.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Representations and Warranties of Checkpoint. </font>Checkpoint represents and warrants to TGTX as of the Effective Date that:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Checkpoint is a corporation, duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, with full corporate power and authority to operate its properties and to carry on its business as presently
conducted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Checkpoint has full power and authority to execute, deliver and perform this Agreement. There are no liens or other encumbrances on the Licensor Technology or any part thereof which would interfere with the rights granted, or assignment of
assets, to TGTX hereunder. This Agreement constitutes the legally binding and valid obligation of Checkpoint, enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, moratorium and other laws affecting creditors&#x2019; rights generally.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The execution, delivery and performance by Checkpoint of this Agreement and the consummation of the transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any
contract or agreement to which Checkpoint or any Affiliate thereof is a party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">There is no action, suit, proceeding or investigation pending or, to Checkpoint&#x2019;s and its Affiliates&#x2019; knowledge, currently threatened in writing against or affecting Checkpoint or any Affiliate thereof that questions the validity
of this Agreement or the right of Checkpoint to enter into this Agreement or consummate the transactions contemplated hereby and, to Checkpoint&#x2019;s and its Affiliates&#x2019; knowledge, there is no basis for the foregoing.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority, or any Third Party, on the part of Checkpoint or any Affiliate thereof
is required in connection with the execution, delivery and performance of this Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Checkpoint has disclosed in writing to TGTX all Patent Rights owned or Controlled by Licensor or its Affiliates as of the Effective Date that Cover any Licensed Products incorporating Compound thereof in the Field, or which relate to Developing,
manufacturing or Commercializing Licensed Products, and all such Patent Rights are set forth on <font style="text-decoration: underline">Schedule 2</font> attached hereto.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">8.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Representations and Warranties of TGTX. </font>TGTX represents and warrants to Checkpoint as of the Effective Date and also covenants with respect to Section&#xA0;8.2(d) or 8.2(g), that:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX is a corporation, duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, with full corporate power and authority to operate its properties and to carry on its business as presently
conducted.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX has full power and authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and valid obligations of TGTX, enforceable in accordance with their terms, except as such enforcement may be limited
by applicable bankruptcy, moratorium and other laws affecting creditors&#x2019; rights generally.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The execution, delivery and performance by TGTX of this Agreement and the consummation of the transactions contemplated thereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any contract
or agreement material to TGTX, its business or its assets.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Without limiting any other term or provision of this Agreement, TGTX shall comply with all applicable Laws in performing this Agreement, including all laws and regulations concerning corrupt practices or which in any manner prohibit the giving
of any financial or other advantage including all Marketing activities conducted by it or its Affiliates, including, without limitation, the Federal Health Care Programs Anti-Kickback Law, Title&#xA0;42 of the U.S. Code Section&#xA0;1420a-7(b)(b), and any comparable or similar state anti-kickback laws or regulations, and all federal, state and foreign health care fraud and abuse statute and regulations, except where the failure to so comply would not reasonably be expected to have a material adverse effect on
the Licensed Patents or Net Sales.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of TGTX is required in connection with the execution,
delivery and performance of this Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">There is no action, suit, proceeding or investigation pending or, to TGTX&#x2019;s knowledge, currently threatened against or affecting TGTX or that questions the validity of this Agreement, or the right of TGTX to enter into this Agreement
or consummate the transactions contemplated hereby and, to TGTX&#x2019;s knowledge, there is no reasonable basis for the foregoing.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(g)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX will notify Checkpoint in writing if it determines that it will or does (i) permanently cease all Development, Manufacture and Commercialization of Licensed Products in the Field or (ii) suspend all Development, Manufacture and Commercialization
of Licensed Products in the Field for more than nine (9) months (&#x201C;<font style="font-weight: bold">Notice of Termination or Suspension</font>&#x201D;).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">8.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Disclaimer. </font>EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, INCLUDING SECTIONS 8.1 AND 8.2, AS APPLICABLE, THE PARTIES MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED,
EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES EACH SPECIFICALLY DISCLAIM ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE, OR AS TO THE SUCCESS OR LIKELIHOOD OF SUCCESS OF THE RESEARCH, DEVELOPMENT OR COMMERCIALIZATION OF LICENSED PRODUCT UNDER THIS AGREEMENT.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE IX.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Indemnification by TGTX. </font>TGTX shall indemnify, defend and hold harmless (i) Licensor and its Affiliates, and each of their respective employees, officers, directors and agents (the &#x201C;<font style="font-weight: bold">Licensor
Indemnitees</font>&#x201D;) and (ii) Checkpoint and its Affiliates and each of their respective employees, officers, directors and agents (the &#x201C;<font style="font-weight: bold">Checkpoint Indemnitees</font>&#x201D;) against any and all liabilities, damages, penalties, fines, losses, costs and expenses (including reasonable attorneys&#x2019; fees and expenses) (individually and collectively, &#x201C;<font style="font-weight: bold">Losses</font>&#x201D;) to the extent arising out of any and all Third Party claims,
demands, actions or other proceedings (each, a &#x201C;<font style="font-weight: bold">Claim</font>&#x201D;) arising out of (a)&#xA0;the testing, use, Development or Commercialization of a Compound or any Licensed Product by or on behalf of TGTX, any of the TGTX Indemnitees or any Sublicensee, (b)&#xA0;TGTX&#x2019;s, its Affiliates&#x2019; or its Sublicensees&#x2019; material breach of this Agreement, (c)&#xA0;misappropriation or infringement of, or the use of, any Product Trademarks, (d) TGTX&#x2019;s or its Affiliates&#x2019;
breach or noncompliance with the terms of any Sublicense arising prior to or as a result of the termination of this Agreement, or (e)&#xA0;TGTX&#x2019;s, its Affiliates&#x2019; or its Sublicensees&#x2019; gross negligence or willful misconduct, excluding, in the case of each of (a)-(d) above, any Claim or Loss with respect to which Checkpoint has an obligation to indemnify TGTX Indemnitees pursuant to Section&#xA0;9.2.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Indemnification by Checkpoint. </font>Checkpoint shall indemnify, defend and hold TGTX and its Affiliates and each of their respective agents, employees, officers and directors (the &#x201C;<font style="font-weight: bold">TGTX
Indemnitees</font>&#x201D;) harmless from and against any and Losses to the extent arising out of any and all Claims arising out of (a)&#xA0;Checkpoint&#x2019;s material breach of this Agreement, (b) the use, Development or Commercialization of a Compound or any Licensed Product by or on behalf of Checkpoint or any of the Checkpoint Indemnitees or any licensee thereof (specifically excluding product liability claims arising out of Licensed Product sold or distributed by TGTX, its Affiliates or Sublicensee), or
(c)&#xA0;Checkpoint&#x2019;s gross negligence, willful misconduct, excluding, in the case of each of (a)-(c) above, any Claim or Loss with respect to which TGTX has an obligation to indemnify Checkpoint Indemnitees pursuant to Section&#xA0;9.1.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Procedure</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The Party or other Person intending to claim indemnification under this Article&#xA0;IX (an &#x201C;Indemnified Party&#x201D;) shall promptly notify the opposed Party (the &#x201C;Indemnifying Party&#x201D;) of any Claim in respect of which the
Indemnified Party intends to claim such indemnification (provided, that no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying Party has suffered actual prejudice directly caused by the delay or other deficiency), and the Indemnifying Party shall assume the defense thereof (with counsel selected by the Indemnifying Party and reasonably satisfactory
to the Indemnified Party) whether or not such Claim is rightfully brought; provided, however, that an Indemnified Party shall have the right to retain its own counsel and to participate in the defense thereof, with the fees and expenses to be paid by the Indemnified Party unless the Indemnifying Party does not assume the defense or unless a representation of both the Indemnified Party and the Indemnifying Party by the same counsel would be inappropriate due to the actual or potential differing interests between
them, in which case the reasonable fees and expenses of counsel retained by the Indemnified Party shall be paid by the Indemnifying Party. (Provided, that in no event shall the Indemnifying Party be required to pay for more than one separate counsel no matter the number or circumstances of all Indemnified Parties.)</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">If the Indemnifying Party shall fail to timely assume the defense of and reasonably defend such Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred
and on demand) the fees and expenses of counsel retained by the Indemnified Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(c)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment) without the written consent of the Indemnifying Party. Also, if the Indemnifying Party shall control
the defense of any such Claim, the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the entry of judgment upon) such Claim unless (i)&#xA0;there is no finding or admission of any violation of law or any violation of the rights of any person by an Indemnified Party, no requirement
that the Indemnified Party admit negligence, fault or culpability, and no adverse effect on any other claims that may be made by or against the Indemnified Party and (ii) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from taking) any action.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">The Indemnified Party, and its employees and agents, shall cooperate fully with the Indemnifying Party and its legal representatives in the investigations of any Claim.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Regardless of who controls the defense, each Party hereto shall reasonably cooperate in the defense as may be requested.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Expenses. </font>As the Parties intend complete indemnification, all costs and expenses of enforcing any provision of this Article&#xA0;IX shall also be reimbursed by the Indemnifying Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Limitation of Liability. </font>IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES OR LOST PROFITS ARISING
OUT OF A BREACH OF THIS AGREEMENT, PROVIDED THAT, NOTWITHSTANDING ANYTHING TO THE CONTRARY, THE FOREGOING SHALL NOT BE CONSTRUED TO LIMIT THE INDEMNITY OBLIGATIONS SET FORTH IN SECTIONS 9.1 AND 9.2, OR EITHER PARTY&#x2019;S LIABILITY FOR A BREACH OF ARTICLE VII.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">9.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Insurance. </font>During the term of this Agreement and for a period of five (5)&#xA0;years after its expiration or earlier termination (measured by termination or expiration of the last Licensed Product for
a country whose Royalty Term is in effect), TGTX shall obtain insurance as follows. The insurance shall insure TGTX against all liability related to its activities relating to the Development, Manufacture or sale of Licensed Products subject to this Agreement, subject to the limits set forth above. The insurance above, shall be in amounts that are reasonable and customary in the pharmaceutical industry for the Territory, but in no event shall any TGTX&#x2019;s liability insurance relating to commercial Manufacture,
sale or distribution of a Licensed Product provide coverage less than two million U.S. dollars (U.S. $2,000,000) per occurrence (or claim) and an annual aggregate of two million U.S. dollars (U.S. $2,000,000). Policies for the Development, commercial Manufacture, sale or distribution of a Licensed Product shall include a contractual endorsement naming Checkpoint and Licensor as an additional insured in relation to liabilities arising from its obligations under the terms of this Agreement and require the insurance
carriers to provide Checkpoint with no less than thirty (30) days&#x2019; written notice of any change in the terms or coverage of the policies or their cancellation.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE X.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TERM AND TERMINATION</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Term and Expiration. </font>The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article&#xA0;X, shall continue in full force and effect, on a
country-by-country and Licensed Product-by-Licensed Product basis until the Royalty Term in such country with respect to such Licensed Product expires, at which time this Agreement shall expire in its entirety with respect to such Licensed Product in such country (the &#x201C;<font style="font-weight: bold">Term</font>&#x201D;).</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination upon Material Breach. </font>If a Party breaches any of its material obligations under this Agreement (a &#x201C;<font style="font-weight: bold">Material Breach</font>&#x201D;), the other Party may
give to the breaching Party a written notice specifying the nature of the Material Breach, requiring it to cure such Material Breach, and, if desired, stating its intention to terminate this Agreement if such Material Breach is not cured. If such Material Breach is not capable of being cured, or is capable of being cured but nonetheless has not within 60&#xA0;days after the receipt of such notice been cured, then the non-breaching Party (in addition to and not in lieu of all other available rights and remedies)
be entitled to at its option either (a)&#xA0;terminate this Agreement immediately by written notice to the other Party, or (b)&#xA0;continue this Agreement in full force and effect and seek any legal or equitable remedies that the non-breaching Party may have.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Insolvency. </font>Either Party (i.e., the non-insolvent Party) may terminate this Agreement, if, at any time, a petition in bankruptcy or insolvency or for reorganization or for an arrangement
or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or if the other Party proposes a written agreement of composition or extension of substantially all of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60)&#xA0;days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if
the other Party shall make an assignment of substantially all of its assets for the benefit of creditors.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Patent Challenge. </font>Checkpoint will be permitted to terminate this Agreement by written notice effective upon receipt if TGTX or its Affiliates or its Sublicensees, directly or indirectly
through assistance granted to a Third Party, commence any interference or opposition proceeding, challenge in a legal or administrative proceeding the validity or enforceability of, or oppose in a legal or administrative proceeding any extension of or the grant of a supplementary protection certificate with respect to, any Licensor Patents (a &#x201C;Patent Challenge&#x201D;). TGTX will include provisions in all agreements granting Sublicenses of TGTX&#x2019;s rights hereunder (other than agreements with manufacturers,
services providers, distributors and other agents) providing that if the Sublicensee or its Affiliates undertake a Patent Challenge with respect to any Licensor Patents under which the Sublicensee is Sublicensed, TGTX will be permitted to terminate such Sublicense agreement. If a Sublicensee of TGTX (or an Affiliate of such Sublicensee) undertakes a Patent Challenge of any such Licensor Patent Rights under which such Sublicensee is sublicensed, then TGTX upon receipt of notice from Checkpoint of such Patent Challenge
will terminate the applicable Sublicense agreement. If TGTX fails to so terminate such Sublicense agreement, Checkpoint may terminate TGTX&#x2019;s right to Sublicense in the country(ies) covered by such Sublicense agreement and any Sublicenses previously granted in such country(ies) shall automatically terminate. In connection with such Sublicense termination, TGTX shall cooperate with Checkpoint&#x2019;s reasonable requests to cause such a terminated Sublicensee to discontinue activities with respect to the Licensed
Product in such country(ies).</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Convenience</font>. This Agreement may be terminated by TGTX at any time for its convenience upon sixty (60) days prior written notice to Checkpoint.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Suspension of Development</font>. If prior to Regulatory Approval of a Licensed Product, TGTX or its Affiliates provides Notice of Termination or Suspension, then Checkpoint may terminate this
Agreement on thirty (30) days&#x2019; notice to TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.7.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Good Scientific Reason. </font>TGTX may terminate this Agreement with respect to any specific Compound and the related Licensed Product upon sixty (60)&#xA0;days&#x2019; prior written notice
to Checkpoint if (i)&#xA0;such Compound or Licensed Product has an adverse safety profile or causes serious adverse reactions; or (ii) TGTX reasonably determines that such Licensed Product will not qualify for Regulatory Approval in the United States.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.8.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Termination for Abandonment. </font>If Checkpoint Abandons all Licensor Patents in a country, and TGTX does not assume the filing, prosecution and maintenance of such Abandoned Patent in such country, then
Checkpoint may terminate the Agreement with respect to such country on thirty (30)&#xA0;days&#x2019; written notice to TGTX.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">10.9.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Effects of Termination/Expiration</font>.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(a)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">If this Agreement is terminated by TGTX under Sections 10.3, 10.5 or 10.7, or by Checkpoint under Sections 10.3, 10.4, 10.6 or 10.8, with respect to one or more Licensed Products (&#x201C;Terminated Products&#x201D;), in all or any countries
of the Territory (the &#x201C;<font style="font-weight: bold">Terminated Country(ies)</font>&#x201D;):</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Any and all licenses granted by Checkpoint to TGTX under this Agreement with respect to the Terminated Products shall terminate in their entirety or with respect to the Terminated Country(ies), as the case may be, on the effective date of
such termination;</font></div>
<div style="margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Upon Checkpoint&#x2019;s written request, TGTX shall transfer the following assets (collectively, the &#x201C;<font style="font-weight: bold">Transferred</font> <font style="font-weight: bold">Product Assets</font>&#x201D;) to Checkpoint without charge (except
as provided in Section 10.9(c), below), provided that Checkpoint shall be responsible for all of costs and expenses incurred by TGTX in connection with such transfer:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 192px"><font style="font-family: Times New Roman; font-size: 13px">(1)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX shall promptly transfer to Checkpoint, at Checkpoint&#x2019;s expense, copies of all data, reports, records and documentation and materials that both (i) it Controls and (ii) relate solely to the unit of the Terminated Product that contains
no active ingredients other than Compounds (&#x201C;Covered Product&#x201D;) (e.g. a tablet that contains other active ingredients would not be a distinct unit but if the Terminated Products consisted of two tablets one could be a distinct unit), in such Terminated Country(ies), provided that TGTX shall redact information to the extent possible not relating to the Compound or Covered Product;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 192px"><font style="font-family: Times New Roman; font-size: 13px">(2)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX shall, to the extent transferable, assign and transfer to Checkpoint all of its and its Affiliates&#x2019; right, title and interest in and to all Regulatory Approvals and Drug Approval Applications and Regulatory Filings that it solely
owns, prepared (whether completed or partially completed), filed and/or granted solely for terminated Compounds and Covered Products in such Terminated Country(ies), and TGTX shall promptly file with any applicable Regulatory Authority notice of such transfer and assignment;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 192px"><font style="font-family: Times New Roman; font-size: 13px">(3)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">TGTX shall, to the extent of its Control, transfer to Checkpoint all relevant records and materials in TGTX&#x2019;s possession containing Confidential Information relating solely to the terminated Compounds and Covered Product in such Terminated
Country(ies), provided, however, that TGTX may keep one copy of such Confidential Information for archival purposes only and such Confidential Information shall be Confidential Information of Checkpoint;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 192px"><font style="font-family: Times New Roman; font-size: 13px">(4)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">To the extent TGTX solely owns any right, title and interest in any Trademarks, trade names and/or logos under which only the terminated Covered Product has been or is being marketed or sold in the Terminated Country(ies) (excluding for avoidance
of doubt the TGTX&#x2019;s or its Affiliates corporate Trademarks), or internet domain registrations for any such Trademarks or tradenames (excluding for avoidance of doubt domain name registrations incorporating the TGTX&#x2019;s or its Affiliates corporate Trademarks (in whole or in part)), TGTX shall assign the same to Checkpoint;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 156px; text-indent: -24px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;(iii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">At Checkpoint&#x2019;s request, TGTX shall assign to Checkpoint, any clinical trial agreements (to the extent assignable without the written consent of the other parties to such clinical trial agreements)
with respect solely to such terminated Compound and Licensed Product in such Terminated Country(ies), provided that Checkpoint agrees to assume all liabilities under such clinical trial agreements pursuant to a form of assumption agreement mutually agreed upon by Checkpoint and TGTX.;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 120px; text-indent: -12px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0; &#xA0; &#xA0;&#xA0;&#xA0; (iv)</font><font id="tab2" style="letter-spacing: 12px;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><a name="_BPDC_PR_INS_1008">
<!--anchor-->
</a>Any transfers under this Section&#xA0;10.9(a) shall be transferred on an &#x201C;as-is&#x201D; basis, and all documents and information transferred to Checkpoint, to the extent solely related to the terminated Licensed Product or Compound, shall be deemed Checkpoint&#x2019;s Confidential Information;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 120px; text-indent: -12px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0; &#xA0; &#xA0; (v)</font><font id="tab2" style="letter-spacing: 12px;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Checkpoint&#x2019;s and TGTX&#x2019;s restrictive covenants in Sections&#xA0;2.5 (except if termination is pursuant to Section&#xA0;10.8) shall terminate with respect to the terminated Licensed
Product in such Terminated Country(ies); and</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 120px; text-indent: -12px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; (vi)</font><font id="tab2" style="letter-spacing: 12px;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">If at the time of such termination or thereafter, no license granted by TGTX or its Affiliates under the Development Inventions or Development Patents to a Sublicensee under a Sublicense
agreement (or options to acquire such a license) is in effect with respect to (A) a Terminated Product, (B) a Terminated Country or (C) a Terminated Product in a Terminated Country, then upon Checkpoint&#x2019;s written request to TGTX, TGTX, on behalf of itself and its Affiliates, shall grant, and shall be deemed to have granted without further action required, to Checkpoint and its Affiliates, or upon Checkpoint&#x2019;s election, to Licensor or an Affiliate of Licensor, an exclusive royalty-bearing (as provided
in Section 10.9(c), non-transferable (except in connection with an assignment of this Agreement permitted pursuant to Section 12.2), sublicensable, perpetual license or sublicense (with respect to rights licensed by Third Parties to TGTX), under all Development Inventions and Development Patents Controlled by TGTX, to Develop and Manufacture, in the case of (A) above, the Terminated Product in the Territory, in the case of (B) above the Terminated Product or Licensed Product in the Terminated Countries, and in
the case of (C) above, the Terminated Product in the Terminated Countries.</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 84px; text-indent: -12px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">(b)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">If this Agreement is terminated by TGTX under Section&#xA0;10.2 or if this Agreement is terminated by Checkpoint under Section 10.2, then in addition to any other remedies available to such Party:</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">All licenses granted by TGTX to Checkpoint under this Agreement shall terminate; and</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">All licenses granted by Checkpoint to TGTX shall terminate.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0; (c)&#xA0;&#xA0; If this Agreement is terminated by TGTX under Section 10.7, or by Checkpoint under Sections 10.6 or 10.8, in each case, with respect to a Terminated Product or Terminated Country or in its entirety, then following issuance
of a request under Sections 10.9(a)(ii), 10.9(a)(iii) or 10.9(a)(vi), Checkpoint shall pay TGTX </font><font style="font-family: Times New Roman; font-size: 13px">(x) <font style="font-size: 70%; vertical-align: top">&#x2217;</font>% of Sublicensing Royalty Revenue (as defined below), but in no event greater than the royalties that would be payable by Checkpoint pursuant to the royalty rates provided below in this Section 10.9(c) (applying such rates to Net Sales by Existing Sublicensees (as defined below)), </font><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">and
(y) a royalty (the <font style="font-weight: bold">Reverse Royalty</font>&#x201D;) on Net Sales of Licensed Products (expressly excluding Net Sales by Existing Sublicensees) during the Reverse Royalty Term (as defined below) as follows:</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; </font><font style="font-family: Times New Roman; font-size: 13px">(i)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;if
the termination occurs before completion (where &#x201C;completion&#x201D; means receipt of a final study report meeting the guidelines of the International Conference on Harmonization) of a Phase III Study for a Licensed Product, then <font style="font-size: 70%; vertical-align: top">*</font> percent (<font style="font-size: 70%; vertical-align: top">*</font>%) royalty on Net Sales;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> Confidential material redacted and filed separately with the Commission.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 96px; margin-right: 0px; text-indent: 48px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;(ii)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; if the termination occurs after completion (where &#x201C;completion&#x201D; means receipt of a final study report meeting the guidelines of the International Conference on Harmonization) of a Phase III Study for a Licensed Product but before approval of an NDA or BLA for such Licensed Product
in such country, then a <font style="font-size: 70%; vertical-align: top">* </font>percent (<font style="font-size: 70%; vertical-align: top">*</font>%) royalty on Net Sales; or</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 96px; margin-right: 0px; text-indent: 48px;"><font style="font-family: Times New Roman; font-size: 13px">(iii)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;if the termination occurs after approval of an NDA or BLA for a Licensed Product, then a <font style="font-size: 70%; vertical-align: top">*</font> percent (<font style="font-size: 70%; vertical-align: top">*</font>%) royalty on Net Sales.</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">&#x201C;<font style="font-weight: bold">Reverse Royalty Term</font>&#x201D; means, and determined on a Licensed Product-by-Licensed Product and country-by-country basis, the period commencing from the First Commercial Sale of a given Licensed Product in such country and ending on the expiry of the last-to-expire Licensor Patent containing a Valid Claim
Covering such Licensed Product in such country.</font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">For purposes of this Section 10.9(c), the definition of &#x201C;Net Sales,&#x201D; and Sections 5.4 through 5.9 shall apply <font style="font-style: italic">mutatis mutandis</font> to the calculation, payment, recording, and auditing of Checkpoint&#x2019;s obligations to pay Reverse Royalties under this Section 10.9 as they apply to TGTX and, solely
for such purpose, each reference in each such Section (and any related definitions) to TGTX shall be deemed to be a reference to Checkpoint, and (y) a Sublicensee shall be deemed to be a reference to a licensee or sublicensee of Checkpoint or any of its Affiliates (and expressly excluding Existing Sublicensees) with respect to the Licensed Product. Notwithstanding the foregoing, no Reverse Royalty shall be due or payable by Checkpoint relating to Net Sales of Sublicensees under any Sublicense in effect at the
date of termination of this Agreement (Sublicensees under such Sublicenses, &#x201C;<font style="font-weight: bold">Existing Sublicensees</font>&#x201D;). <font style="font-weight: bold; color: #000000">&#x201C;Sublicensing Royalty Revenue&#x201D;</font><font style="color: #000000"> means sales-based royalties, and minimum sales royalties, each as actually received by Checkpoint or its Affiliate from an Existing Sublicensee as consideration for the grant of rights to Patent Rights. </font></font></div>
<div style="text-align: justify; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">In no event shall Checkpoint transfer (i) its, right, title or interest in Patent Rights Covering a terminated Compound or Licensed Product or (ii) any of the Transferred Assets, unless the assignee assumes Checkpoint&#x2019;s obligations to pay royalties under this Section 10.9 pursuant to a commercially reasonable assignment and assumption agreement
providing that (x) TGTX is a third party beneficiary to such agreement for the purpose of enforcing such payment obligations and (y) any further assignment by such assignee is subject to the requirements set forth in this paragraph.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px;"> </font>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(d)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Articles&#xA0;I (Definitions), VI (Patents and Infringement), VII (Confidentiality), IX (Indemnification; Limitation of Liability; Insurance), XI (Dispute Resolution) and XII (Miscellaneous Provisions) and Section 2.5 (but only with respect
to TGTX in connection with a termination under Section 10.8), Sections&#xA0;5.1, 5.3(b), 5.5 (Royalty Reports and Records Retention), 5.6 (Audits), 5.8 (Late Payments), 5.9 (Taxes) and 10.9 (Effects of Termination/Expiration) hereof shall survive the expiration or termination of this Agreement for any reason. A termination of any Compound from this Agreement shall also terminate the related Licensed Product and termination of any Licensed Product shall terminate the related Compound.</font></div><font style="font-family: Times New Roman; font-size: 13px;">
<br></font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> Confidential material redacted and filed separately with the Commission.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(e)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Termination or expiration of this Agreement shall not relieve the Parties of any liability that accrued hereunder before the effective date of such termination or expiration. In addition, termination or expiration of this Agreement shall not preclude either Party
from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party&#x2019;s right to obtain performance of any obligation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(f)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Effect on Sublicenses.</font></div>
<div style="margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Upon the termination of this Agreement in its entirety, each Sublicense which provides for its survival upon such termination shall survive such termination (but in no event for longer than the period TGTX&#x2019;s licenses hereunder would have been in effect had
termination not occurred) and remain in full force and effect, with Checkpoint or upon Checkpoint&#x2019;s election, to Licensor or an Affiliate of Licensor, as the Sublicensee&#x2019;s direct licensor solely with respect to the Licensor Technology (&#x201C;<font style="font-weight: bold">Surviving Sublicense</font>&#x201D;). Upon Checkpoint&#x2019;s written request, provided that a Surviving Sublicense does not include licenses to products other than Licensed Products, TGTX shall assign a Surviving Sublicense to
Checkpoint or upon Checkpoint&#x2019;s election, to Licensor or an Affiliate of Licensor. If a Surviving Sublicense includes licenses to products other than Licensed Products, TGTX shall require that the terms of such Surviving Sublicense permits the assignment in part to Checkpoint or upon Checkpoint&#x2019;s election, to Licensor or an Affiliate of Licensor, relating to the Licensor Technology and shall, upon Checkpoint&#x2019;s written request, assign to Checkpoint or upon Checkpoint&#x2019;s election, to Licensor
or an Affiliate of Licensor, the portion of such Surviving Sublicense pertaining to the Licensor Technology.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Upon the termination of this Agreement with respect to a Terminated Product in a Terminated Country, each Sublicense that includes such Terminated Product in such Terminated Country which provides for its survival upon such termination shall survive such termination
(but in no event for longer than the period TGTX&#x2019;s licenses hereunder would have been in effect had termination not occurred) and remain in full force and effect, with (i) Checkpoint or upon Checkpoint&#x2019;s election, Licensor or an Affiliate of Licensor, as the Sublicensee&#x2019;s direct licensor solely with respect to the Licensor Technology and the portion of such Sublicense that includes such Terminated Product in such Terminated Country (&#x201C;<font style="font-weight: bold">Surviving Partial Sublicenses</font>&#x201D;)
and (ii) TGTX continuing as the Sublicensee&#x2019;s direct licensor with respect to all other rights granted under such Sublicense. Upon such termination, Checkpoint and Licensor shall be third party beneficiaries of the Surviving Partial Sublicense with respect to the portion thereof pertaining solely to the Terminated Products in the Terminated Countries. Each Sublicense that provides for survival as set forth in this Section shall provide for such third party beneficiary status.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(iii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">With respect to each Surviving Sublicense and Surviving Partial Sublicense, in the absence of written notice from Checkpoint to a Sublicensee under a Surviving Sublicense or Surviving Partial Sublicense provided within forty five (45) days of the termination of
this Agreement electing to continue the payment terms under such Sublicense, in which case such Sublicense payment terms shall continue, the Sublicensee&#x2019;s payment obligations with respect to its exercise of its surviving rights to the Licensor Technology (but not with respect to its exercise or enjoyment of any other rights or assets) thereunder shall, in lieu of any payment obligations set forth in the Sublicense, be the corresponding payment obligations set forth in this Agreement, provided that (a) with
respect to Milestone Payments under such Sublicense where such Sublicense is for less than the entire Territory and the Milestone Payment is based on cumulative worldwide Net Sales, the portion of such Milestone Payment for which such Sublicensee shall be liable shall be such Milestone Payment multiplied by: (I) cumulative Net Sales in such Sublicensee&#x2019;s territory (and not worldwide Net Sales) divided by (II) cumulative worldwide Net Sales and (b) with respect to royalties payable under such Sublicense,
if the royalty set forth in such Sublicense is equal to or greater than five percent (5%) of such Sublicensee&#x2019;s Net Sales, then such amount shall be payable under such Sublicense in accordance with the terms thereof (in lieu of any royalty payments pursuant to the terms of Section 5.3(a)), and if such royalty is less than five percent (5%) of such Sublicensee&#x2019;s Net Sales, then the royalty payable under such Sublicense shall be the amounts set forth in Section 5.3(a) (in lieu of any royalty payments
pursuant to the terms of such Sublicense) and the royalty tiers will, for the avoidance of doubt, be achieved based on worldwide Net Sales as calculated in accordance with this Agreement, and Checkpoint shall notify such Sublicensee within thirty (30) days following it becoming aware of a Net Sales tier higher than the then-current Net Sale tier applying to the calculation of royalties pursuant to Section 5.3(a). Notwithstanding the foregoing, within thirty (30) days after the effective date of termination of
this Agreement, Checkpoint shall have the right to terminate a Sublicense granted to an Affiliate of TGTX.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="margin-left: 0px; text-indent: 96px"><font style="font-family: Times New Roman; font-size: 13px">(g)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Termination of the License Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(i)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Upon the termination of the License Agreement in its entirety, this Agreement will remain in full force and effect, with Licensor as TGTX&#x2019;s direct licensor solely with respect to the Licensor Technology (&#x201C;<font style="font-weight: bold">Surviving
Agreement</font>&#x201D;), and in the event of such a termination of the License Agreement, Checkpoint has the right to assign, in whole or in part, the Surviving Agreement to Licensor.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(ii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">Upon the termination of the License Agreement with respect to a Terminated Product in a Terminated Country, this Agreement will remain in full force and effect, with (i) Licensor as TGTX&#x2019;s direct licensor solely with respect to the
Licensor Technology and the portion of this Agreement that includes such Terminated Product in such Terminated Country (&#x201C;<font style="font-weight: bold">Surviving Partial Agreement</font>&#x201D;) and (ii) Checkpoint continuing as TGTX&#x2019;s direct licensor with respect to all other rights granted under such Surviving Partial Agreement. Upon such termination, Licensor shall be a third party beneficiary of the Surviving Partial Agreement with respect to the portion thereof pertaining solely to the Terminated
Products in the Terminated Countries.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 144px"><font style="font-family: Times New Roman; font-size: 13px">(iii)</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">With respect to the Surviving Agreement and Surviving Partial Agreement, the payment terms under this Agreement will continue, except that payment with respect to the Licensed Products will be made directly to Licensor and not Checkpoint.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE XI.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">DISPUTE RESOLUTION</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">11.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">General. </font>Checkpoint and TGTX shall endeavor to resolve any claim or controversy arising out of the threatened breach, breach, enforcement, interpretation, termination or validity of this Agreement informally
by good faith negotiation between the senior executives, officers or management of Checkpoint and TGTX. Either Party may give the other Party written notice of any claim or controversy not resolved in the normal course of business (the &#x201C;<font style="font-weight: bold">Disputing Party Notice</font>&#x201D;). Within thirty (30)&#xA0;calendar days after the delivery of the Disputing Party Notice, the receiving Party shall submit to the other Party a written response (the &#x201C;<font style="font-weight: bold">Response</font>&#x201D;).
The Disputing Party Notice and Response shall include a statement of each Party&#x2019;s position and a summary of the arguments supporting that position. Within thirty (30)&#xA0;days after the Disputing Party Notice, such designated senior executives, officers or management of Checkpoint and TGTX shall meet at a mutually acceptable time and place and thereafter as often as they reasonably deem necessary to attempt to resolve the claim or controversy. If such efforts do not result in mutually satisfactory resolution
of the dispute, the matter shall be referred to the chief executive officers of Checkpoint and TGTX, or their designees. The chief executive officers, or their designees, as the case may be, shall negotiate in good faith to resolve such dispute in a mutually satisfactory manner for up to thirty additional (30)&#xA0;days, or such longer period of time to which the chief executive officers may agree. All negotiations pursuant to this Article&#xA0;11 are confidential and without prejudice and shall be treated as
compromise and settlement negotiations for purposes of applicable rules of evidence. If the chief executive officers, or their designees, as the case may be,are unable to determine a resolution in the time frame set forth above, the matter may be resolved through arbitration in accordance with the provisions set forth in Section&#xA0;11.2, in the event of a Technical Dispute or Section&#xA0;11.3, in the event of other disputes, as applicable, upon notice by a Party on the other Party specifically requesting such
arbitration. This Article&#xA0;11 shall not prohibit a Party from seeking injunctive relief from a court of competent jurisdiction in the event of a breach or prospective breach of this Agreement by any Party which would cause irreparable harm to the other Party.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">11.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Technical Disputes. </font>In the event a dispute over (i)&#xA0;whether a Milestone has been achieved, (ii) whether TGTX has used Commercially Reasonable Efforts to Develop the Licensed Product, (iii) the
proper allocation of Net Sales to a Licensed Product where the Licensed Product is sold as part of a Combination Product, or (iv) the Combination Percentage (each, a &#x201C;<font style="font-weight: bold">Technical Dispute</font>&#x201D;) is not resolved in accordance with the negotiation and mediation dispute resolution processes described in Section&#xA0;11.1 above, then either Party may submit the matter to expert intervention in accordance with this Section&#xA0;11.2. Any such intervention may be initiated
by a Party by written notice to the other Party specifying the subject of the requested intervention. The Technical Dispute hearings shall be convened in New York, New York and shall be resolved by one expert, to be mutually selected by the Parties; or if the Parties fail to agree on the expert within ten (10)&#xA0;business days following the date of such written notice, then the Parties shall cause their respective nominees to select a third individual within ten (10)&#xA0;business days to serve as the expert
(the &#x201C;<font style="font-weight: bold">Expert</font>&#x201D;). The Expert shall be required to have pharmaceutical industry experience specifically related to conducting formulation development activities and clinical trials, and shall not be any employee, agent or consultant of any Party or an Affiliate of any Party at such time, or otherwise involved (whether by contract or otherwise) in the affairs of any Party at such time. Each Party simultaneously shall submit to the Expert its proposal with respect
to its position on the resolution of the Technical Dispute without having seen the other Party&#x2019;s proposal, along with a discussion document explaining the rationale therefor. The Expert shall have the right to meet with the Parties, either alone or together, and shall have the right to request additional information and documents from each Party. The Expert shall select only one of the Parties&#x2019; proposals based on the Expert&#x2019;s determination of which proposal is more consistent with the Expert&#x2019;s
opinion on the resolution of the Technical Dispute (and consistent with the terms of this Agreement), and shall provide a brief written rationale for such selection. The Expert&#x2019;s decision shall be final and shall be binding upon the Parties under this Agreement. The Parties shall submit their documentation to the Expert within fifteen (15)&#xA0;days of selection of the Expert and provide any requested additional information and documents within ten (10)&#xA0;days of such request. The Expert shall make his
or her decision within fifteen (15)&#xA0;days of such submission (extended by the Expert in his discretion to provide adequate time to review requested documents but in no event shall the decision be made more than thirty (30)&#xA0;days after submission).</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; 11.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Other Disputes. </font>Where a Party has served a written notice upon the
other requesting arbitration of a dispute that is not subject to Section&#xA0;11.2, any such dispute shall be submitted to final and binding arbitration under the then current commercial arbitration rules of the American Arbitration Association (the &#x201C;<font style="font-weight: bold">AAA</font>&#x201D;) in accordance with this Section&#xA0;11.3. The place of arbitration of any dispute shall be New York, New York. Such arbitration shall be conducted by one (1)&#xA0;arbitrator mutually agreed by the Parties
but if such agreement cannot be reached within ten (10)&#xA0;days of the commencement of the arbitration, then an arbitrator appointed by the AAA. The arbitrator shall be a person with relevant experience in the pharmaceutical industry. The arbitration proceeding shall be held as soon as practicable but in any event within ninety (90)&#xA0;days of appointment of the arbitrator. Any award rendered by the arbitrators shall be final and binding upon the Parties. Judgment upon any award rendered may be entered in
any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. The arbitrator shall render a formal, binding, non-appealable resolution and award as expeditiously as possible, but not more than thirty (30)&#xA0;days after the hearing. Each Party shall pay its own expenses of arbitration, and the expenses of the arbitrator shall be equally shared between the Parties unless the arbitrators assess as part of their award
all or any part of the arbitration expenses of a Party (including reasonable attorneys&#x2019; fees) against the other Party. A Party may make application to the Arbitrator for the award and recovery of its fees and expenses (including reasonable attorneys&#x2019; fees).</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">ARTICLE XII.</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">MISCELLANEOUS PROVISIONS</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.1.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Relationship of the Parties. </font>Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. No Party
shall have any right or authority to commit or legally bind any other Party in any way whatsoever including, without limitation, the making of any agreement, representation or warranty and each Party agrees to not purport to do so.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.2.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Assignment. </font>Neither Party may assign this Agreement, or any of its rights or obligations hereunder without the other Party&#x2019;s prior written consent, provided that each Party will, notwithstanding
anything to the contrary, be entitled, without the other Party&#x2019;s prior written consent, to assign or transfer this Agreement: (i)&#xA0;in connection with the transfer or sale of all or substantially all of such Party&#x2019;s assets or business (or that portion thereof related to the subject matter of this Agreement) to a Third Party, (ii) in the event of such Party&#x2019;s merger, consolidation, reorganization, with or into a Third Party, change of control or similar transaction, with a Third Party, or
(iii) to an Affiliate of such Party, provided that in the case of an assignment to an Affiliate, the assigning Party shall remain primarily liable for the obligations of such Affiliate except where the non-assigning Party provided its prior written consent to such assignment, such consent to not be unreasonably withheld or delayed (in which case the assigning Party shall not remain primarily liable). Any permitted assignee of either Party will, as a condition to such assignment, assume all obligations of its
assignor arising under this Agreement following such assignment. Any purported assignment by a Party of this Agreement, or any of such Party&#x2019;s rights or obligations hereunder, in violation of this Section&#xA0;12.2 will be void ab initio.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.3.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Further Actions. </font>Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.4.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Force Majeure. </font>Except for TGTX&#x2019;s obligation to pay the agreed amounts to Checkpoint, no Party shall be liable to any other Party or be deemed to have breached or defaulted under this Agreement
for failure or delay in the performance of any of its obligations under this Agreement (other than obligations for the payment of money) for the time and to the extent such failure or delay is caused by or results from acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, omissions or delays in acting by a governmental authority, acts of a government or an agency thereof or judicial orders or decrees or restrictions or
any other like reason which is beyond the control of the respective Party (a &#x201C;<font style="font-weight: bold">Force Majeure Event</font>&#x201D;). The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and shall use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its
obligations hereunder as soon as practicable, and the time for performance shall be extended for a number of days equal to the duration of the force majeure. The Party not subject to the Force Majeure Event may terminate this Agreement if such Force Majeure Event exists for 90&#xA0;days in any 365-day period on ten (10)&#xA0;days&#x2019; notice to the other Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.5.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Entire Agreement of the Parties; Amendments. </font>This Agreement and the Schedules hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof
and cancel and supersede any and all prior or contemporaneous negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter (provided, that any and all previous nondisclosure/nonuse obligations are not superseded and remain in full force and effect in addition to the nondisclosure/nonuse provisions hereof). Each Party acknowledges that it has not relied, in deciding whether to enter into this Agreement on this Agreement&#x2019;s expressly
stated terms and conditions, on any representations, warranties, agreements, commitments or promises which are not expressly set forth within this Agreement. No modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.6.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Governing Law. </font>This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, excluding application of any conflict of laws principles. With respect to docketing
an arbitration award or seeking injunctive relief, each Party (a)&#xA0;irrevocably submits to the exclusive jurisdiction in the United States District Court for the Southern District of New York located in New York, New York and any State courts sitting in New York, New York (collectively, the &#x201C;Courts&#x201D;), and (b)&#xA0;agrees not to raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in any of the Courts, irrevocably waives any claim that
such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, that such Courts do not have any jurisdiction over such Party. The United Nations Convention on Contracts for the International Sale of Goods will not apply to this Agreement.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;&#xA0; &#xA0;&#xA0;12.7.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Notices and Deliveries. </font>All notices required or permitted
to be given under this Agreement shall be in writing and shall be deemed given upon receipt if delivered personally or mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by prepaid express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by the notice; provided that notices of a change of address shall be effective only upon receipt thereof):</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">If to Checkpoint, addressed to:</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Checkpoint Therapeutics, Inc.</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2 Gansevoort Street, 9<font style="font-size: 70%; vertical-align: top">th</font> Floor</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">New York, NY 10014</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Attention: President</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; padding-bottom: 16px; margin-left: 48px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">If to TGTX, addressed to:</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">TG Therapeutics, Inc</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">2 Gansevoort Street, 9<font style="font-size: 70%; vertical-align: top">th</font> Floor</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">New York, NY 10014</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Attention: President</font></div>
<div style="text-align: left; margin-left: 96px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.8.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Waiver. </font>No waiver of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of the waiving Party. A waiver
by a Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.9.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Rights and Remedies are Cumulative. </font>Except to the extent expressly set forth herein, all rights, remedies, undertakings, obligations and agreements contained in or available upon violation of this Agreement
shall be cumulative and none of them shall be in limitation of any other remedy or right authorized in law or in equity, or any undertaking, obligation or agreement of the applicable Party.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.10.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Severability. </font>This Agreement is severable. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision
of this Agreement is held to be to any extent prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement (or of such provision). The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.11.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Third Party Beneficiaries. </font>The terms and provisions of this Agreement are intended solely for the benefit of each Party hereto and their respective successors or permitted assigns and it is not the
intention of the Parties to confer third-party beneficiary rights upon any other person, including without limitation Sublicensees. If a provision provides a benefit to a Sublicensee or indemnitee, such benefits can only be enforced through a Party or by a separate agreement between such Person and the Party or Parties providing the benefit.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.12.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Equitable Relief. </font>Each Party recognizes that the covenants and agreements herein and their continued performance as set forth in this Agreement are necessary and critical to protect the legitimate
interests of the other Party, that the other Party would not have entered into this Agreement in the absence of such covenants and agreements and the assurance of continued performance as set forth in this Agreement, and that a Party&#x2019;s breach or threatened breach of such covenants and agreements may cause the opposed Party irreparable harm and significant injury, the amount of which will be extremely difficult to estimate and ascertain, thus potentially making any remedy at law or in damages inadequate.
Therefore, each Party agrees that an opposed Party shall be entitled to seek specific performance, an order restraining any breach or threatened breach of Article&#xA0;VII or Section&#xA0;2.5 and all other provisions of this Agreement, and any other equitable relief (including but not limited to temporary, preliminary and/or permanent injunctive relief). This right shall be in addition to and not exclusive of any other remedy available to such other Party at law or in equity.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.13.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Interpretation. </font>The language used in this Agreement is the language chosen by the Parties to express their mutual intent, and no provision of this Agreement shall be interpreted for or against a Party
because that Party or its attorney drafted the provision.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.14.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Construction. </font>The words &#x201C;include,&#x201D; &#x201C;includes&#x201D; and &#x201C;including&#x201D; shall be deemed to be followed by the phrase &#x201C;without limitation.&#x201D; All references herein
to Articles, Sections and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require.</font></div>
<div style="padding-bottom: 16px; ; margin-left: 0px; text-indent: 48px"><font style="font-family: Times New Roman; font-size: 13px">12.15.</font><font id="tab2" style="letter-spacing: 12px; color: black">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Counterparts. </font>This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A portable document
format (.pdf) copy of this Agreement, including the signature pages, will be deemed an original.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-style: italic">&#xA0;[the remainder of this page has been left blank intentionally]</font>
<br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">IN WITNESS WHEREOF,</font> the Parties have caused this Sublicense Agreement to be executed and delivered by their respective duly authorized officers as of the day and year first above written.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold">&#xA0;Checkpoint Therapeutics, Inc.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 25%;">
<tr>
<td style="width: 10%;">
<div><font>&#xA0;By:</font></div></td>
<td style="width: 50%;">
<div><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px;"><font style="text-decoration: underline">/s/ James F. Oliviero</font></font></div></td></tr><tr>
<td style="width: 10%;">
<div><font>&#xA0;Name:</font></div></td>
<td style="width: 50%;">
<div><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px;"><font style="text-decoration: underline">James F. Oliviero</font></font></div></td></tr><tr>
<td style="width: 10%;">
<div><font>&#xA0;Title:</font></div></td>
<td style="width: 50%;">
<div><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px;"><font style="text-decoration: underline">President &amp; CEO</font></font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold">TG Therapeutics, Inc.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<table cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td style="width: 10%;">
<div><font>&#xA0;By:</font></div></td>
<td style="width: 50%;">
<div><font style="text-decoration: underline"><font style="text-decoration: underline;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px;">/s/ Michael S. Weiss</font></font></div></td></tr><tr>
<td style="width: 10%;">
<div><font>&#xA0;Name:</font></div></td>
<td style="width: 50%;">
<div><font style="text-decoration: underline"><font style="text-decoration: underline;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px; text-decoration: underline;">Michael S. Weiss</font></font></div></td></tr><tr>
<td style="width: 10%;">
<div><font>&#xA0;Title:</font></div></td>
<td style="width: 50%;">
<div><font style="text-decoration: underline"><font style="text-decoration: underline;">&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px; text-decoration: underline;">Chief Executive Officer</font></font></div></td></tr></table></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 1</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Compounds</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">JBET070</font></div></div></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">JBET050</font></div></div></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 2</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Licensor Patents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Case</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">No.</font></div></td>
<td style="vertical-align: top; width: 11%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Title</font></div></td>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Country</font></div></td>
<td style="vertical-align: top; width: 10%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Status</font></div></td>
<td style="vertical-align: top; width: 15%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Application No.</font></div></td>
<td style="vertical-align: top; width: 13%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Filing Date</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Publication No.</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Publication Date</font></div></td></tr><tr>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">1</font></div></td>
<td style="vertical-align: top; width: 11%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font></font></div></td>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 10%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 15%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 13%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">N/A</font></div></td></tr><tr>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">2</font></div></td>
<td style="vertical-align: top; width: 11%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 9%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 10%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 15%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 13%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 16%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">N/A</font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">NOTE: The complete specification and PCT application for <font style="font-size: 70%; vertical-align: top">* </font>under progress and shall be filed on or before <font style="font-size: 70%; vertical-align: top">*</font>.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> <font style="font-size: 13px">Confidential material redacted and filed separately with the Commission.</font></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 3</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">[Reserved]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 4<br></font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Work Plan<br></font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">* </font></div>&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"> </font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">
<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;"> </font>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> <font style="font-size: 13px">Confidential material redacted and filed separately with the Commission.</font></font></div><font style="font-family: Times New Roman; font-size: 13px;">
<br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 5</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TGTX&#x2019;s Exchange Rate Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">Net Sales and royalties payable shall be expressed in United States Dollars equivalent, calculated using the simple average of the exchange rate published in the Wall Street Journal on the last day of each month of the Reporting Period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 6</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">[Reserved]</font></div>&#xA0; </div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">
<br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line-->
</div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div></div></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Schedule 7</font></div>
<div style="text-align: center; padding-bottom: 16px; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Success Criteria for Toxicology Study</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> studies will comprise the following:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 54%; border-left: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Activities</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-top: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Success Criteria</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 54%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 54%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 54%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 54%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">*</font>*</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td></tr><tr>
<td style="vertical-align: middle; width: 54%; border-left: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">*</font>*</font></div></td>
<td style="vertical-align: top; width: 46%; border-left: 0.5pt solid #000000; border-right: 0.5pt solid #000000; border-bottom: 2px solid #000000">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div></td></tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">*</font><font style="font-size: 70%; vertical-align: top">*</font><font style="font-style: italic">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">*</font>.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">Any dispute as to whether <font style="font-size: 70%; vertical-align: top">* </font>studies meet the success criteria will be resolved pursuant to Section 11.2.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 70%; vertical-align: top; font-family: Times New Roman">*</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 9.1px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top">&#x2217;</font> <font style="font-size: 13px">Confidential material redacted and filed separately with the Commission.</font></font></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>tgtx-20160630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:tgtx="http://tgtherapeuticsinc.com/20160630">
    <link:schemaRef xlink:href="tgtx-20160630.xsd" xlink:type="simple" />
    <xbrli:context id="P01_01_2016To03_31_2016">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2014">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To12_31_2015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_AristonMemberusgaapBusinessAcquisitionAxis_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:AristonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_TgOneOneZeroOneMemberdeiLegalEntityAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:TgOneOneZeroOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_OpusMemberdeiLegalEntityAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:OpusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_OpusMemberdeiLegalEntityAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:OpusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_SharedServicesAgreementMembertgtxAgreementTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:AgreementTypeAxis">tgtx:SharedServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_LfbLicenseAgreementMembertgtxAgreementTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:AgreementTypeAxis">tgtx:LfbLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_LfbLicenseAgreementMembertgtxAgreementTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:AgreementTypeAxis">tgtx:LfbLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_RestrictedStockMemberusgaapAwardTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn12_31_2015_WarrantMemberusgaapFinancialInstrumentAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="PAsOn03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_TgOneOneZeroOneMemberdeiLegalEntityAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:TgOneOneZeroOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2016To03_31_2016_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_ConvertibleDebtSecuritiesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30_custom_LfbLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:AgreementTypeAxis">tgtx:LfbLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_custom_LfbLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:AgreementTypeAxis">tgtx:LfbLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_custom_OpusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:OpusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_custom_TgOneOneZeroOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:TgOneOneZeroOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30_custom_TgOneOneZeroOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:TgOneOneZeroOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_ATM2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:ATM2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_IncentivePlan2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:IncentivePlan2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_OfficeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_OfficeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_FortressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:FortressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_JBETAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:JBETAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_JBETAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:JBETAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88268719">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88315910">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-06-30_custom_JBETAgreementMember89277968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:JBETAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-03-01to2010-03-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-03-01</xbrli:startDate>
        <xbrli:endDate>2010-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-10-03_custom_OfficeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-10-31_custom_OfficeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:OfficeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SqFt">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <dei:DocumentType contextRef="P01_01_2016To03_31_2016">10-Q</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2016To03_31_2016">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2016To03_31_2016">2016-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2016To03_31_2016">2016</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2016To03_31_2016">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="P01_01_2016To03_31_2016">TG THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2016To03_31_2016">0001001316</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2016To03_31_2016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="P01_01_2016To03_31_2016">Accelerated Filer</dei:EntityFilerCategory>
    <dei:TradingSymbol contextRef="P01_01_2016To03_31_2016">TGTX</dei:TradingSymbol>
    <us-gaap:ShortTermInvestments contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">25680319</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">22166512</us-gaap:ShortTermInvestments>
    <us-gaap:InterestReceivableCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">133766</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">186021</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">649738</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">308327</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">69551680</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">86873331</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">333859</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">47122</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">127700</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">171182</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">94797540</us-gaap:Assets>
    <us-gaap:Assets contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">113473201</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">13080176</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">9346068</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">1295238</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">1371429</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">16096455</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">11899899</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">54498</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">54095</us-gaap:CommonStockValue>
    <tgtx:ContingentlyIssuableShares contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>
    <tgtx:ContingentlyIssuableShares contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>
    <us-gaap:AdditionalPaidInCapital contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">266762568</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">259887464</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">234337</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">234337</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">-187881650</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">-158133926</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">94797540</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">113473201</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">581161</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">579143</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LongTermInvestments contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">21435015</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">25003032</us-gaap:LongTermInvestments>
    <us-gaap:NotesPayableCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">90564</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">211549</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="PAsOn03_31_2016_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">90564</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2015_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">211549</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">14119497</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">10528470</us-gaap:LiabilitiesCurrent>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">8514029</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">8265583</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:Cash contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">20063803</us-gaap:Cash>
    <us-gaap:Cash contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">46795746</us-gaap:Cash>
    <us-gaap:HeldToMaturitySecurities contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">47115334</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">47169544</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="AsOf2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">21435105</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="AsOf2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" decimals="0">22166512</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="AsOf2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">25003032</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="AsOf2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88268719" unitRef="USD" decimals="0">25680319</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">102929</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="From2016-01-01to2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">80328</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="P01_01_2015To12_31_2015" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="From2015-01-01to2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="From2015-01-01to2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="From2016-01-01to2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88315910" unitRef="USD" decimals="0">22601</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="From2016-01-01to2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="P01_01_2015To12_31_2015" unitRef="USD" decimals="0">108668</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="From2015-01-01to2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" decimals="0">22822</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="From2015-01-01to2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">85846</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="From2016-01-01to2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88315910" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">47218263</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">47060876</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="AsOf2016-06-30_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">21515343</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="AsOf2015-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" decimals="0">22143690</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="AsOf2015-12-31_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_OtherLongTermInvestmentsMember" unitRef="USD" decimals="0">24917186</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="AsOf2016-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_USGovernmentAgenciesDebtSecuritiesMember88268719" unitRef="USD" decimals="0">25702920</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">90564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">211549</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">90564</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">211549</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">90564</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">211549</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn03_31_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">90564</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2015_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="USD" decimals="0">211549</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2016" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2015" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2016" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2015" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:LongTermNotesPayable contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="PAsOn03_31_2016_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2015_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">90564</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">211549</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="PAsOn03_31_2016_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">90564</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="PAsOn12_31_2015_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" unitRef="USD" decimals="0">211549</us-gaap:NotesPayable>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">681720</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2015" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">54497932</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">54095110</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">54456623</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">54053801</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares contextRef="PAsOn03_31_2016" unitRef="shares" decimals="INF">41309</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="PAsOn12_31_2015" unitRef="shares" decimals="INF">41309</us-gaap:TreasuryStockShares>
    <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">14510025</tgtx:PrepaidResearchAndDevelopment>
    <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">9151142</tgtx:PrepaidResearchAndDevelopment>
    <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn03_31_2016_LfbGroupMembertgtxPlacementAgencyAgreementAxis" unitRef="USD" decimals="0">4700000</tgtx:PrepaidResearchAndDevelopment>
    <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn12_31_2015_LfbGroupMembertgtxPlacementAgencyAgreementAxis" unitRef="USD" decimals="0">3000000</tgtx:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidRent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">1968734</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">0</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="AsOf2016-06-30_custom_OfficeAgreementMember" unitRef="USD" decimals="0">100000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="AsOf2016-06-30_custom_FortressMember" unitRef="USD" decimals="0">2000000</us-gaap:PrepaidRent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">78701085</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">101573302</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">54095</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">259887464</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-234337</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-158133926</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">54498</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">266762568</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-234337</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-187881650</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LicensesRevenue contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">76190</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">76190</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="P01_01_2016To03_31_2016_TgOneOneZeroOneMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">76000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="P01_01_2015To03_31_2015_TgOneOneZeroOneMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">76000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">38095</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">38095</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2016-04-01to2016-06-30_custom_TgOneOneZeroOneMember" unitRef="USD" decimals="0">38000</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2015-04-01to2015-06-30_custom_TgOneOneZeroOneMember" unitRef="USD" decimals="0">38000</us-gaap:LicensesRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">25151071</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">20878999</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">11261660</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">13533731</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">24196989</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">18181645</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2015To03_31_2015_LfbLicenseAgreementMembertgtxAgreementTypeAxis" unitRef="USD" decimals="0">2400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2016To03_31_2016_LfbLicenseAgreementMembertgtxAgreementTypeAxis" unitRef="USD" decimals="0">2300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">9902214</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">12966574</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2015-04-01to2015-06-30_custom_LfbLicenseAgreementMember" unitRef="USD" decimals="0">2200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="From2016-04-01to2016-06-30_custom_LfbLicenseAgreementMember" unitRef="USD" decimals="0">2300000</us-gaap:OtherResearchAndDevelopmentExpense>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">954082</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">2697354</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">1359446</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">567157</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">4940718</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">10911622</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">5888015</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">2527807</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">2547438</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">2008962</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">1004475</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">1446567</us-gaap:OtherGeneralAndAdministrativeExpense>
    <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">2393280</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">8902660</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">4883540</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>
    <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">1081240</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>
    <us-gaap:OperatingExpenses contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">30091789</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">31790621</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">17149675</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">16061538</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-30015599</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-31714431</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-17111580</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-16023443</us-gaap:OperatingIncomeLoss>
    <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">553545</tgtx:ChangeInFairValueOfNonCurrentNotePayable>
    <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">464013</tgtx:ChangeInFairValueOfNonCurrentNotePayable>
    <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">223372</tgtx:ChangeInFairValueOfNonCurrentNotePayable>
    <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">252508</tgtx:ChangeInFairValueOfNonCurrentNotePayable>
    <us-gaap:InterestExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">463161</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">484183</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">246526</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">220756</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">177491</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">53683</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">31551</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">92629</us-gaap:InterestIncomeOther>
    <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">267875</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">33513</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">8397</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">124381</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-29747724</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-31680918</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-01-01to2016-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-29747724</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">-17103183</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">-15899062</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2016To03_31_2016" unitRef="USD_per_Share" decimals="INF">-0.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2015To03_31_2015" unitRef="USD_per_Share" decimals="INF">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-04-01to2015-06-30" unitRef="USD_per_Share" decimals="INF">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="USD_per_Share" decimals="INF">-0.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2016To03_31_2016" unitRef="shares" decimals="INF">48838731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2015To03_31_2015" unitRef="shares" decimals="INF">43216385</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-04-01to2015-06-30" unitRef="shares" decimals="INF">45320637</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-04-01to2016-06-30" unitRef="shares" decimals="INF">48769948</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">54095110</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">41309</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">54497932</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2016_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">41309</us-gaap:SharesOutstanding>
    <tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">22041</tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">50271</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">22</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">50249</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">14000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">14</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-14</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3347362</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">11600014</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="0">6200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">1600000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">23319</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">5805</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">254132</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">205409</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">90384</tgtx:ChangeInFairValueOfNotesPayable>
    <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-20170</tgtx:ChangeInFairValueOfNotesPayable>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">2018</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">2098</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">5700293</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">5117040</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInPrepaidRent contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">1968734</us-gaap:IncreaseDecreaseInPrepaidRent>
    <us-gaap:IncreaseDecreaseInPrepaidRent contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInPrepaidRent>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-52255</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">104797</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">9518</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3712012</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">4018767</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-76191</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-76191</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-29524062</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-21130879</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">310056</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">20280</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <tgtx:PaymentsToAcquireHeldToMaturitySecuritiesShortTerm contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">15199922</tgtx:PaymentsToAcquireHeldToMaturitySecuritiesShortTerm>
    <tgtx:PaymentsToAcquireHeldToMaturitySecuritiesShortTerm contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">35070625</tgtx:PaymentsToAcquireHeldToMaturitySecuritiesShortTerm>
    <tgtx:ProceedsFromMaturities contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">15000000</tgtx:ProceedsFromMaturities>
    <tgtx:ProceedsFromMaturities contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">7850000</tgtx:ProceedsFromMaturities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-509978</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-27240905</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">50271</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">992644</us-gaap:ProceedsFromWarrantExercises>
    <tgtx:NetProceedsFromSharesNewIssuesOverallotments contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3504261</tgtx:NetProceedsFromSharesNewIssuesOverallotments>
    <tgtx:NetProceedsFromSharesNewIssuesOverallotments contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">51984879</tgtx:NetProceedsFromSharesNewIssuesOverallotments>
    <us-gaap:PaymentsOfFinancingCosts contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3989</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">19437</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3550543</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">52958086</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-26483497</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">4586302</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">28577832</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">55061329</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2014" unitRef="USD" decimals="0">55713784</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2015" unitRef="USD" decimals="0">60300086</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We are a biopharmaceutical company focused on&#13;the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,&#13;the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered&#13;monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also&#13;developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic&#13;origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical&#13;development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1&#13;receptor-associated kinase 4) inhibitors, BET (Bromodomain and Extra Terminal) inhibitors, and anti-PD-L1 and anti-GITR antibodies.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We also actively evaluate complementary products,&#13;technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received&#13;approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our&#13;drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The accompanying unaudited condensed consolidated&#13;financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial&#13;information and with the instructions to Quarterly Report on Form 10-Q and Article&amp;#160;10 of Regulation&amp;#160;S-X of the Exchange&#13;Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements.&#13;All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation&#13;of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements&#13;should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for&#13;the year ended December 31, 2015. The accompanying condensed December 31, 2015 balance sheet has been derived from these statements.&#13;The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may&#13;be expected for the entire fiscal year or any other interim period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We have incurred operating losses since our inception&#13;and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of June 30, 2016,&#13;we have an accumulated deficit of approximately $187.9 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our major sources of cash have been proceeds&#13;from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates&#13;and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become&#13;profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for&#13;our drug candidates; successfully completing any post-approval regulatory obligations; and successfully commercializing our drug&#13;candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues&#13;from our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;As of June 30, 2016, we had approximately&#13;$75.8 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash&#13;equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately 18  to&#13;24 months from June 30, 2016. The actual amount of cash that we will need to operate is subject to many factors, including,&#13;but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon&#13;significant future financing to provide the cash necessary to execute our current strategic plan, including the&#13;commercialization of any of our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our common stock is listed on the Nasdaq Capital&#13;Market and trades under the symbol &amp;#147;TGTX.&amp;#148;&lt;br clear="all" /&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In May 2016, the&#13;Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued ASU No. 2016-11, &amp;#147;Rescission of SEC Guidance Because of&#13;Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&amp;#148;&#13;(&amp;#147;ASU 2016-11&amp;#148;).&amp;#160; ASU 2016-11 rescinds certain SEC guidance from the &lt;i&gt;FASB Accounting Standards&#13;Codification&lt;/i&gt; in response to announcements made by the SEC staff at the Emerging Issues Task Force&amp;#146;s March 3, 2016&#13;meeting.&amp;#160; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics: &lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Upon the adoption of ASU 2014-09:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for gas-balancing arrangements (ASC 932-10-S99-5).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Upon the adoption of ASU 2014-16&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Determining the nature of a host contract related to a hybrid financial instrument issued in the&#13;form of a share under ASC 815 (ASC 815-10-S99-3).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;ASU 2016-11 is effective upon the adoption of&#13;ASU 2014-09 and ASU 2014-16.&amp;#160; The adoption of ASU 2016-11 is not expected to have a material impact on the Company&amp;#146;s&#13;condensed consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In March 2016, the FASB issued ASU No. 2016-09, &amp;#147;Simplifying the Accounting for Share-Based Payments&amp;#148; (&amp;#147;ASU&#13;2016-09&amp;#148;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both&#13;public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,&#13;as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after&#13;December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected&#13;to significantly impact the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Other pronouncements issued by the FASB or other&#13;authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The preparation of financial statements in conformity&#13;with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the&#13;disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and&#13;expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material&#13;to the consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We treat liquid investments with original maturities&#13;of three months or less when purchased as cash and cash equivalents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We record cash pledged or held in trust as restricted&#13;cash. As of June 30, 2016 and December 31, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line&#13;of credit as a security deposit for an &lt;font style="background-color: white"&gt;Office Agreement &lt;/font&gt;(see Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Investment Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Investment securities at June 30, 2016 and December&#13;31, 2015 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity&#13;securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities&#13;are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are&#13;amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest&#13;method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;A decline in the market value of any investment&#13;security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The&#13;impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges&#13;would be included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Financial instruments that potentially subject&#13;the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term&#13;investments. The Company maintains its cash and cash equivalents, short-term investments and long-term investments with high-credit&#13;quality financial institutions. At times, such amounts may exceed federally-insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We recognize license revenue in accordance with&#13;the revenue recognition guidance of the FASB Accounting Standards Codification (or &amp;#147;Codification&amp;#148;). We analyze each&#13;element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include&#13;payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties&#13;on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements&#13;unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings&#13;process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement&#13;of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the&#13;milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement&#13;of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone&#13;payment and recognize it as revenue over the estimated period of performance under the contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Generally, research and development costs are&#13;expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and&#13;development activities are deferred and amortized over the period that the goods are delivered or the related services are performed,&#13;subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations,&#13;or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices&#13;received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.&#13;Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting&#13;period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of&#13;those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress&#13;to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With&#13;respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract.&#13;Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment&#13;of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the&#13;recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals&#13;related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified&#13;in the specific clinical study or trial contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Prepaid research and development in our consolidated&#13;balance sheets includes, among other things, certain costs related to development and manufacturing services. These development&#13;and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of June&#13;30, 2016 and December 31, 2015, we recorded approximately $14.5 million and $9.2 million of prepaid development and manufacturing&#13;services, respectively, in prepaid research and development related to such advance agreements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Income taxes are accounted for under the asset&#13;and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,&#13;operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected&#13;to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect&#13;on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment&#13;date. If the likelihood of realizing the deferred tax assets or liability is less than &amp;#147;more likely than not,&amp;#148; a valuation&#13;allowance is then created.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We, and our subsidiaries, file income tax returns&#13;in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination&#13;for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss&#13;carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.&#13;We recognize interest and penalties, if any, related to uncertain income tax positions in income tax expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We recognize all share-based payments to employees&#13;and non-employee directors (as compensation for service) as noncash compensation expense in the condensed consolidated financial&#13;statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value&#13;of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at&#13;the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;For share-based payments to consultants and other&#13;third-parties (including related parties), noncash compensation expense is determined at the &amp;#147;measurement date.&amp;#148; The&#13;expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation&#13;expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards&#13;to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated&#13;based on the then current fair value, at each subsequent reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In addition, because some of the options, restricted&#13;stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total&#13;expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the&#13;achievement of such milestones becomes probable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Basic net loss per share of our common stock&#13;is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding&#13;for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially&#13;dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either&#13;because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money&#13;and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the&#13;calculation were 6,449,737 and 5,668,134 for the three and six months ended June 30, 2016 and 2015, respectively. The following&#13;outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common&#13;stockholders for the periods presented because including them would have been antidilutive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three and Six Months Ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font-size: 8pt"&gt;Unvested restricted stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,270,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,431,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,164,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,218,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon note conversion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,803&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,449,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,668,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets and Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Long-lived assets are reviewed for potential&#13;impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may&#13;not be recoverable. Management&amp;#146;s policy in determining whether an impairment indicator exists, a triggering event, comprises&#13;measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of&#13;a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds&#13;its estimated future cash flows, an impairment charge is recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Goodwill is reviewed for impairment annually,&#13;or earlier when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process.&#13;The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying&#13;value of the reporting unit is greater than fair value, the unit&amp;#146;s goodwill may be impaired, and the second step must be&#13;completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting&#13;unit&amp;#146;s goodwill is compared with the carrying amount of the unit&amp;#146;s goodwill. If the carrying amount is greater than&#13;the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to&#13;perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value&#13;of an asset may not be recoverable.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following tables summarize our cash and cash&#13;equivalents at June 30, 2016 and December 31, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%"&gt;&lt;font style="font-size: 8pt"&gt;Money market funds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,514,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,265,583&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Checking and bank deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,063,803&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;46,795,746&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,577,832&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;55,061,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our investments as of June 30, 2016 and December&#13;31, 2015 are classified as held-to-maturity. Held-to-maturity investments are recorded at amortized cost.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following tables summarize our investment&#13;securities at June 30, 2016 and December 31, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amortized cost, as adjusted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Estimated fair value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Short-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between July 2016 and June 2017) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,680,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,601&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,702,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Long-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between July 2017 and January 2018) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,435,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;80,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,515,343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total short-term and long-term investment securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,115,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;102,929&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,218,263&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amortized cost, as adjusted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Estimated fair value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Short-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,166,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,143,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Long-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,003,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,846&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,917,186&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total short-term and long-term investment securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,169,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;108,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,060,876&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We measure certain financial assets and liabilities&#13;at fair value on a recurring basis in the condensed consolidated financial statements. The fair value hierarchy ranks the quality&#13;and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities&#13;carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 1 &amp;#150; quoted prices in active markets for identical assets and liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 2 &amp;#150; inputs other than Level 1 quoted prices that are directly or indirectly observable; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 3 &amp;#150; unobservable inputs that are not corroborated by market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;As of June 30, 2016 and December 31, 2015, the&#13;fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying&#13;value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;At the&#13;time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (&amp;#147;Manhattan&amp;#148;)) with Ariston Pharmaceuticals,&#13;Inc. (&amp;#147;Ariston&amp;#148;) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the &amp;#147;5% Notes&amp;#148;)&#13;in satisfaction of several note payable issuances.&amp;#160;&amp;#160;The 5% Notes and accrued and unpaid interest thereon are convertible&#13;at the option of the holder into common stock at the conversion price of $1,125 per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly&#13;payments on the 5% Notes&amp;#160;equal to 50% of the net product cash flow received from the exploitation or commercialization of&#13;Ariston&amp;#146;s product candidates, AST-726 and AST-915.&amp;#160;&amp;#160;We have no obligations under the 5% Notes aside from (a) 50%&#13;of the net product cash flows from Ariston&amp;#146;s product candidates, if any, payable to noteholders; and (b) the conversion feature,&#13;discussed above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;The cumulative&#13;liability including accrued and unpaid interest of the 5% Notes was approximately $16.8 million at June 30, 2016 and $19.9 million&#13;at December 31, 2015. &lt;/font&gt;No payments have been made on the 5% Notes as of June 30, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In December 2011, we elected the fair value option&#13;for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that&#13;market participants use in evaluating these financial instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;As of December 31, 2013, as a result of expiring&#13;intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we&#13;have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature&#13;was used to estimate the 5% Notes&amp;#146; fair value as of June 30, 2016 and December 31, 2015. The assumptions, assessments and&#13;projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of&#13;different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could&#13;result in significantly different estimates of fair value and the differences could be material to our condensed consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following tables provide the fair value measurements&#13;of applicable financial liabilities as of June 30, 2016 and December 31, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Financial liabilities at fair value as of June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Financial liabilities at fair value as of December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The Level 3 amounts above represent the fair&#13;value of the 5% Notes and related accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following table summarizes the changes in&#13;Level 3 instruments during the six months ended June 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 88%"&gt;&lt;font style="font-size: 8pt"&gt;Fair value at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Interest accrued on face value of 5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;463,161&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Conversion of 5% notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(30,601&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in fair value of Level 3 liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(553,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fair value at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The change in the fair value of the Level 3 liabilities&#13;is reported in other (income) expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our amended and restated certificate of incorporation&#13;authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common&#13;stock, &lt;font style="background-color: white"&gt;issuable in one or more series. Upon issuance, we can determine the rights, preferences,&#13;privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights,&#13;voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series&#13;or the designation of such series, any or all of which may be greater than the rights of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our amended and restated certificate of incorporation&#13;authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;In December&#13;2014, we filed a shelf registration statement on Form S-3 (the &amp;#147;2015 S-3&amp;#148;), which was declared effective in January&#13;2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3,&#13;we amended our 2013 At-the-Market Issuance Sales Agreement with MLV &amp;#38; Co. LLC (the &amp;#147;2015 ATM&amp;#148;) such that we may&#13;issue and sell additional shares of our common stock, having an aggregate offering price of up to $175.0 million, from time to&#13;time through MLV &amp;#38; Co. LLC (&amp;#147;MLV&amp;#148;) and FBR Capital Markets &amp;#38; Co. (&amp;#147;FBR&amp;#148;, each of MLV and FBR individually&#13;an &amp;#147;Agent&amp;#148; and collectively the &amp;#147;Agents&amp;#148;), acting as the sales agents. Under the 2015 ATM we pay the Agents&#13;a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the Agents.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;During&#13;the six months ended June 30, 2016, we sold a total of 396,811 shares of common stock under the 2015 ATM for aggregate total gross&#13;proceeds of approximately $3.6 million at an average selling price of $9.00 per share, resulting in net proceeds of approximately&#13;$3.5 million after deducting commissions and other transaction costs.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"&gt;The&#13;2015 S-3 is currently our only active shelf registration statement. After deducting shares already sold, including under the 2015&#13;ATM, there are approximately $178 million of common stock that remain available for sale under the 2015 S-3. We may offer the&#13;securities under the 2015 S-3 from time to time in response to market conditions or other circumstances if we believe such a plan&#13;of financing is in the best interests of our stockholders. We believe that the 2015 S-3 provides us with the flexibility to raise&#13;additional capital to finance our operations as needed.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Equity Incentive Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The TG Therapeutics, Inc. Amended and Restated&#13;2012 Incentive Plan (&amp;#147;2012 Incentive Plan&amp;#148;) was approved by stockholders in June 2015. As of June 30, 2016, no options&#13;were outstanding and up to an additional 4,183,861 shares may be issued under the 2012 Incentive Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Restricted Stock&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Certain employees, directors and consultants&#13;have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table&#13;summarizes restricted share activity for the six months ended June 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%; background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,359,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(570,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(33,231&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,770,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Total expense associated with restricted stock&#13;grants was approximately $1.6 million and $6.2 million during the three months ended June 30, 2016 and 2015, respectively, and&#13;$3.3 million,  and $11.6 million during the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, there&#13;was approximately $17.3 million of total unrecognized compensation cost related to unvested time-based restricted stock, which&#13;is expected to be recognized over a weighted-average period of 1.9 years. This amount does not include, as of June 30, 2016, 411,172&#13;shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,234,958 shares&#13;of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the measurement&#13;date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount&#13;of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting&#13;date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following table summarizes warrant activity&#13;for the six months ended June 30, 2016:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted-average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 55%; background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,186,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,341,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,164,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,291,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based&#13;Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;did not grant any stock options during the six months ended June 30, 2016 and 2015.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: normal 8pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"&gt;The&#13;following table summarizes stock-based compensation expense information about restricted stock and stock options for the three&#13;and six months ended June 30, 2016 and 2015:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;b&gt;Three months ended June 30,&lt;/b&gt; &lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;b&gt;Six months ended June 30,&lt;/b&gt; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; font-size: 8pt; text-align: left"&gt;Stock-based compensation expense associated with restricted stock&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;1,648,397&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;6,242,986&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;3,347,362&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,600,014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 8pt; text-align: left; padding-bottom: 1pt"&gt;Stock-based compensation expense associated with option grants&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;1,648,397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;6,242,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;3,347,362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,600,014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The following is a summary of notes payable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31&lt;/b&gt;, &lt;b&gt;201&lt;/b&gt;5&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Current portion,&amp;#160;net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-current portion, net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Current portion,&amp;#160;net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-current portion, net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 34%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible 5% Notes Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Convertible 5% Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;On March 8, 2010, Manhattan entered into&#13;an Agreement and Plan of Merger (the &amp;#34;Merger Agreement&amp;#34;) by and among Manhattan, Ariston and Ariston Merger Corp., a&#13;Delaware corporation and wholly-owned subsidiary of Manhattan (the &amp;#34;Merger Sub&amp;#34;).&amp;#160; Pursuant to the terms and conditions&#13;of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the &amp;#34;Merger&amp;#34;), with Ariston being&#13;the surviving corporation of the Merger.&amp;#160; As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The 5% Notes and accrued and unpaid interest&#13;thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share.&amp;#160;&amp;#160;Ariston&#13;agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization&#13;of Ariston&amp;#146;s product candidates, AST-726 and AST-915.&amp;#160;&amp;#160;&lt;font style="background-color: white"&gt;We have no obligation&#13;under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&amp;#146;s product candidates, if any, payable to&#13;noteholders; and b) the conversion feature, discussed above.&lt;/font&gt; Interest accrues monthly, is added to principal on an annual&#13;basis, every March 8, and is payable at maturity, which was March 8, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;The&#13;cumulative liability including accrued and unpaid interest of these notes was approximately $16.8 million at June 30, 2016 and&#13;$19.9 million at December 31, 2015. &lt;/font&gt;No payments have been made on the 5% Notes as of June 30, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In December 2011, we elected the fair&#13;value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions&#13;that market participants use in evaluating these financial instruments (See Note 4 for further details).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <tgtx:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;BET&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In May 2016, as part of a broader agreement with&#13;Jubilant Biosys (&amp;#147;Jubilant&amp;#148;), an India-based biotechnology company, we entered into a sub-license agreement (&amp;#147;JBET&#13;Agreement&amp;#148;) with Checkpoint Therapeutics, Inc. (&amp;#147;Checkpoint&amp;#148;), (see Note 8), for the&#13;development and commercialization of Jubilant&amp;#146;s novel BET inhibitor program in the field of hematological malignancies.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Under the terms of the agreement,&amp;#160;we&#13;paid Checkpoint an up-front licensing fee of&amp;#160;$1.0 million&amp;#160;and will make additional payments contingent on certain&#13;preclinical, clinical, and regulatory milestones, including commercial milestones totaling up to approximately&amp;#160;$177&#13;million&amp;#160;and a single-digit royalty on net sales.&amp;#160;TG will also provide funding to support certain targeted&#13;research efforts at Jubilant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;TG-1101&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In November 2012, we entered into an exclusive&#13;(within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea&#13;and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including&#13;the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand,&#13;Philippines, Vietnam, and Myanmar.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;An upfront payment of $2.0 million, which was&#13;received in December 2012,&lt;font style="background-color: white"&gt; net of $0.3 million of&amp;#160;income tax withholdings&lt;/font&gt;, is&#13;being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of&#13;the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is&#13;earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense&#13;agreement. We recorded license revenue of approximately $38,000 for each of the three months ended June 30, 2016 and 2015, and&#13;$76,000 for each of the six months ended June 30, 2016 and 2015 and, at June 30, 2016 and December 31, 2015, have deferred revenue&#13;of approximately $1.4 million and $1.5 million, respectively, associated with this $2.0 million payment (approximately $0.2 million&#13;of which has been classified in current liabilities at June 30, 2016 and December 31, 2015).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;We may receive up to an&#13;additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong&#13;will make royalty payments to us on net sales of TG-1101 in the sublicense territory.&lt;/p&gt;</tgtx:LicenseAgreementDisclosureTextBlock>
    <tgtx:LiquidityDisclosure1PolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We have incurred operating losses since our inception&#13;and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of June 30, 2016,&#13;we have an accumulated deficit of approximately $187.9 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our major sources of cash have been proceeds&#13;from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates&#13;and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become&#13;profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for&#13;our drug candidates; successfully completing any post-approval regulatory obligations; and successfully commercializing our drug&#13;candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues&#13;from our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;As of June 30, 2016, we had approximately&#13;$75.8 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash&#13;equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately 18 to&#13;24 months from June 30, 2016. The actual amount of cash that we will need to operate is subject to many factors, including,&#13;but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon&#13;significant future financing to provide the cash necessary to execute our current strategic plan, including the&#13;commercialization of any of our drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Our common stock is listed on the Nasdaq Capital&#13;Market and trades under the symbol &amp;#147;TGTX.&amp;#148;&lt;/p&gt;</tgtx:LiquidityDisclosure1PolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The preparation of financial statements in conformity&#13;with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the&#13;disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and&#13;expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material&#13;to the consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We treat liquid investments with original maturities&#13;of three months or less when purchased as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We record cash pledged or held in trust as restricted&#13;cash. As of June 30, 2016 and December 31, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line&#13;of credit as a security deposit for an &lt;font style="background-color: white"&gt;Office Agreement &lt;/font&gt;(see Note 8).&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Investment securities at June 30, 2016 and December&#13;31, 2015 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity&#13;securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities&#13;are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are&#13;amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest&#13;method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;A decline in the market value of any investment&#13;security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The&#13;impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges&#13;would be included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Financial instruments that potentially subject&#13;the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term&#13;investments. The Company maintains its cash and cash equivalents, short-term investments and long-term investments with high-credit&#13;quality financial institutions. At times, such amounts may exceed federally-insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We recognize license revenue in accordance with&#13;the revenue recognition guidance of the FASB Accounting Standards Codification (or &amp;#147;Codification&amp;#148;). We analyze each&#13;element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include&#13;payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties&#13;on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements&#13;unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings&#13;process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement&#13;of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the&#13;milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement&#13;of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone&#13;payment and recognize it as revenue over the estimated period of performance under the contract.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Generally, research and development costs are&#13;expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and&#13;development activities are deferred and amortized over the period that the goods are delivered or the related services are performed,&#13;subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations,&#13;or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices&#13;received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.&#13;Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting&#13;period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of&#13;those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress&#13;to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With&#13;respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract.&#13;Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment&#13;of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the&#13;recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals&#13;related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified&#13;in the specific clinical study or trial contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Prepaid research and development in our consolidated&#13;balance sheets includes, among other things, certain costs related to development and manufacturing services. These development&#13;and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of June&#13;30, 2016 and December 31, 2015, we recorded approximately $14.5 million and $9.2 million of prepaid development and manufacturing&#13;services, respectively, in prepaid research and development related to such advance agreements.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Income taxes are accounted for under the asset&#13;and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,&#13;operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected&#13;to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect&#13;on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment&#13;date. If the likelihood of realizing the deferred tax assets or liability is less than &amp;#147;more likely than not,&amp;#148; a valuation&#13;allowance is then created.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We, and our subsidiaries, file income tax returns&#13;in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination&#13;for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss&#13;carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.&#13;We recognize interest and penalties, if any, related to uncertain income tax positions in income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We recognize all share-based payments to employees&#13;and non-employee directors (as compensation for service) as noncash compensation expense in the condensed consolidated financial&#13;statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value&#13;of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at&#13;the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;For share-based payments to consultants and other&#13;third-parties (including related parties), noncash compensation expense is determined at the &amp;#147;measurement date.&amp;#148; The&#13;expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation&#13;expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards&#13;to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated&#13;based on the then current fair value, at each subsequent reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In addition, because some of the options, restricted&#13;stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total&#13;expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the&#13;achievement of such milestones becomes probable.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Basic net loss per share of our common stock&#13;is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding&#13;for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially&#13;dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either&#13;because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money&#13;and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the&#13;calculation were 6,449,737 and 5,668,134 for the three and six months ended June 30, 2016 and 2015, respectively. The following&#13;outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common&#13;stockholders for the periods presented because including them would have been antidilutive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three and Six Months Ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font-size: 8pt"&gt;Unvested restricted stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,270,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,431,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,164,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,218,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon note conversion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,803&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,449,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,668,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Long-lived assets are reviewed for potential&#13;impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may&#13;not be recoverable. Management&amp;#146;s policy in determining whether an impairment indicator exists, a triggering event, comprises&#13;measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of&#13;a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds&#13;its estimated future cash flows, an impairment charge is recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Goodwill is reviewed for impairment annually,&#13;or earlier when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process.&#13;The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying&#13;value of the reporting unit is greater than fair value, the unit&amp;#146;s goodwill may be impaired, and the second step must be&#13;completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting&#13;unit&amp;#146;s goodwill is compared with the carrying amount of the unit&amp;#146;s goodwill. If the carrying amount is greater than&#13;the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to&#13;perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value&#13;of an asset may not be recoverable.&lt;/p&gt;</tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three and Six Months Ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font-size: 8pt"&gt;Unvested restricted stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,270,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,431,430&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,164,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,218,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shares issuable upon note conversion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,803&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;152&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,449,737&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,668,134&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 64%"&gt;&lt;font style="font-size: 8pt"&gt;Money market funds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,514,029&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,265,583&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Checking and bank deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,063,803&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;46,795,746&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,577,832&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;55,061,329&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following tables summarize our investment&#13;securities at June 30, 2016 and December 31, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amortized cost, as adjusted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Estimated fair value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Short-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between July 2016 and June 2017) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,680,319&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,601&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,702,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Long-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between July 2017 and January 2018) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,435,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;80,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,515,343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total short-term and long-term investment securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,115,334&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;102,929&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,218,263&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Amortized cost, as adjusted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Gross unrealized holding losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Estimated fair value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Short-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,166,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,143,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Long-term investments:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,003,032&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,846&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,917,186&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total short-term and long-term investment securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,169,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;108,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,060,876&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following tables provide the fair value measurements&#13;of applicable financial liabilities as of June 30, 2016 and December 31, 2015:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Financial liabilities at fair value as of June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Financial liabilities at fair value as of December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 52%"&gt;&lt;font style="font-size: 8pt"&gt;5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 88%"&gt;&lt;font style="font-size: 8pt"&gt;Fair value at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;211,549&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Interest accrued on face value of 5% Notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;463,161&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Conversion of 5% notes&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(30,601&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Change in fair value of Level 3 liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(553,545&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Fair value at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;90,564&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 76%; background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,359,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;14,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(570,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.07&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(33,231&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11.79&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,770,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <tgtx:ScheduleOfWarrantsActivityTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted-average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 55%; background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,186,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,341,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(22,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;--&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="background-color: #CCEEFF"&gt;&lt;font style="font-size: 8pt"&gt;Outstanding at June 30, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,164,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2.37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,291,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</tgtx:ScheduleOfWarrantsActivityTableTextBlock>
    <tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;b&gt;Three months ended June 30,&lt;/b&gt; &lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;b&gt;Six months ended June 30,&lt;/b&gt; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; font-size: 8pt; text-align: left"&gt;Stock-based compensation expense associated with restricted stock&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;1,648,397&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;6,242,986&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%; font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 8pt; text-align: right"&gt;3,347,362&lt;/td&gt;&lt;td style="width: 1%; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,600,014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 8pt; text-align: left; padding-bottom: 1pt"&gt;Stock-based compensation expense associated with option grants&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;1,648,397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;6,242,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;3,347,362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,600,014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2016To03_31_2016">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;&lt;b&gt;June 30, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="11" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31&lt;/b&gt;, &lt;b&gt;201&lt;/b&gt;5&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Current portion,&amp;#160;net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Non-current portion, net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Current portion,&amp;#160;net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Non-current portion, net&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 28%; font-size: 8pt; text-align: left; padding-bottom: 1pt"&gt;Convertible 5% Notes Payable&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;90,564&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;90,564&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;211,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 8pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right"&gt;211,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;90,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;90,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;211,549&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right"&gt;211,549&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">90564</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">211549</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">463161</tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-553545</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <tgtx:ConversionOfNotes contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-30601</tgtx:ConversionOfNotes>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">7359915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">6770084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">570600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="shares" decimals="INF">33231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="INF">7.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="INF">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="INF">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="INF">7.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD_per_Share" decimals="INF">11.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2015_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">1186749</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">1164708</us-gaap:ClassOfWarrantOrRightOutstanding>
    <tgtx:WarrantOrRightIssued contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightIssued>
    <tgtx:WarrantOrRightExercised contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">22041</tgtx:WarrantOrRightExercised>
    <tgtx:WarrantOrRightExpired contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightExpired>
    <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn12_31_2015_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">11341452</tgtx:WarrantOrRightAggregateIntrinsicValue>
    <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD" decimals="0">4291924</tgtx:WarrantOrRightAggregateIntrinsicValue>
    <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2015_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD_per_Share" decimals="INF">2.37</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>
    <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD_per_Share" decimals="INF">2.37</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>
    <tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD_per_Share" decimals="INF">2.28</tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice>
    <tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD_per_Share" decimals="INF">0</tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice>
    <tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapFinancialInstrumentAxis" unitRef="USD_per_Share" decimals="INF">0</tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice>
    <tgtx:ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">-56988</tgtx:ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital>
    <tgtx:ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">-48771</tgtx:ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital>
    <tgtx:AccruedFinancingCosts contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">0</tgtx:AccruedFinancingCosts>
    <tgtx:AccruedFinancingCosts contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">47797</tgtx:AccruedFinancingCosts>
    <tgtx:ConversionOfConvertibleNotesPayableToCommonStock contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">30601</tgtx:ConversionOfConvertibleNotesPayableToCommonStock>
    <tgtx:ConversionOfConvertibleNotesPayableToCommonStock contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">0</tgtx:ConversionOfConvertibleNotesPayableToCommonStock>
    <tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">30601</tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable>
    <tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">3</tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable>
    <tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">30598</tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable>
    <tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">3201</tgtx:IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">-33</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">33</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">-33231</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3447273</tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts>
    <tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">397</tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts>
    <tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">3446876</tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts>
    <tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares contextRef="P01_01_2016To03_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="shares" decimals="INF">396811</tgtx:IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">3347362</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2016To03_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="USD" decimals="0">3347362</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn03_31_2016_LfbGroupMembertgtxPlacementAgencyAgreementAxis" unitRef="USD" decimals="0">1700000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn12_31_2015_LfbGroupMembertgtxPlacementAgencyAgreementAxis" unitRef="USD" decimals="0">2100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn03_31_2016_OpusMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2016-06-30_custom_OfficeAgreementMember" unitRef="USD" decimals="0">1100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2016-06-30_custom_JBETAgreementMember" unitRef="USD" decimals="0">1200000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="P01_01_2016To03_31_2016_OpusMemberdeiLegalEntityAxis" unitRef="USD" decimals="0">100000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="P01_01_2016To03_31_2016_SharedServicesAgreementMembertgtxAgreementTypeAxis" unitRef="USD" decimals="0">400000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="From2016-04-01to2016-06-30_custom_OpusMember" unitRef="USD" decimals="0">20000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DeferredRevenue contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">1400000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">1500000</us-gaap:DeferredRevenue>
    <us-gaap:RestrictedStockExpense contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">3347362</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="P01_01_2015To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">11600014</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2016-04-01to2016-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">1648397</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2015-04-01to2015-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">6242986</us-gaap:RestrictedStockExpense>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">75800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RestrictedCashAndInvestments contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">600000</us-gaap:RestrictedCashAndInvestments>
    <tgtx:PrepaidManufacturing contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">14500000</tgtx:PrepaidManufacturing>
    <tgtx:PrepaidManufacturing contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">9200000</tgtx:PrepaidManufacturing>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To03_31_2016" unitRef="shares" decimals="INF">6449737</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015" unitRef="shares" decimals="INF">5668134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">5270084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To03_31_2016_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">1164708</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-06-30_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="INF">14945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To03_31_2016_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-06-30_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">4431430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">1218749</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015_ConvertibleDebtSecuritiesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">17803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="shares" decimals="INF">152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockOptionPlanExpense contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="P01_01_2015To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2016-04-01to2016-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2015-04-01to2015-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2016To03_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">3347362</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2015To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="USD" decimals="0">11600014</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-04-01to2016-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">1648397</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-04-01to2015-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">6242986</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">17300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2016To03_31_2016">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2016-01-01to2016-06-30_custom_ATM2015Member" unitRef="shares" decimals="INF">396811</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tgtx:CommonStockAvailableForSale contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">178000000</tgtx:CommonStockAvailableForSale>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-06-30_custom_IncentivePlan2012Member" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2016-06-30_custom_IncentivePlan2012Member" unitRef="shares" decimals="INF">4183861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn03_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="USD" decimals="0">16800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="USD" decimals="0">19900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="P01_01_2016To03_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Percent" decimals="INF">.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="P01_01_2015To12_31_2015_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Percent" decimals="INF">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2011-01-01to2011-12-31_us-gaap_ConvertibleNotesPayableMember" unitRef="Percent" decimals="INF">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <tgtx:UpfrontFeeReceivedFromSubLicense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2000000</tgtx:UpfrontFeeReceivedFromSubLicense>
    <tgtx:UpfrontFeeReceivedFromSubLicense contextRef="From2016-01-01to2016-06-30_custom_JBETAgreementMember" unitRef="USD" decimals="0">1000000</tgtx:UpfrontFeeReceivedFromSubLicense>
    <tgtx:UpfrontFeeReceivedFromSubLicense contextRef="From2016-01-01to2016-06-30_custom_JBETAgreementMember89277968" unitRef="USD" decimals="0">1000000</tgtx:UpfrontFeeReceivedFromSubLicense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">300000</us-gaap:IncomeTaxExpenseBenefit>
    <tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">5000000</tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones>
    <tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones contextRef="From2016-01-01to2016-06-30_custom_JBETAgreementMember89277968" unitRef="USD" decimals="0">177000000</tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones>
    <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="From2016-01-01to2016-06-30_custom_OfficeAgreementMember">P15Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
    <us-gaap:ProceedsFromFeesReceived contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived contextRef="From2016-04-01to2016-06-30" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromFeesReceived>
    <tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt contextRef="P01_01_2016To03_31_2016_AristonMemberusgaapBusinessAcquisitionAxis_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Percent" decimals="INF">.50</tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_31_2016_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="USD_per_Share" decimals="INF">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <tgtx:SaleOfStockConsiderationReceivedOnTransactionGross contextRef="From2016-01-01to2016-06-30_custom_ATM2015Member" unitRef="USD" decimals="0">3600000</tgtx:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2016-01-01to2016-06-30_custom_ATM2015Member" unitRef="USD" decimals="0">3500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2010-03-01to2010-03-31_us-gaap_ConvertibleNotesPayableMember">2015-03-08</us-gaap:DebtInstrumentMaturityDate>
    <tgtx:AverageAnnualRentalPayments contextRef="AsOf2014-10-03_custom_OfficeAgreementMember" unitRef="USD" decimals="0">1100000</tgtx:AverageAnnualRentalPayments>
    <us-gaap:SecurityDeposit contextRef="AsOf2014-10-31_custom_OfficeAgreementMember" unitRef="USD" decimals="0">600000</us-gaap:SecurityDeposit>
    <tgtx:PercentageOfOccupancy contextRef="AsOf2014-10-03_custom_OfficeAgreementMember" unitRef="Percent" decimals="INF">0.45</tgtx:PercentageOfOccupancy>
    <us-gaap:AreaOfLand contextRef="AsOf2014-10-31_custom_OfficeAgreementMember" unitRef="SqFt" decimals="INF">24000</us-gaap:AreaOfLand>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-08-01" unitRef="shares" decimals="INF">54456623</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">796376</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">818472</us-gaap:DeferredCompensationLiabilityCurrent>
    <tgtx:IncreaseDecreaseInDeferredRent contextRef="P01_01_2016To03_31_2016" unitRef="USD" decimals="0">681720</tgtx:IncreaseDecreaseInDeferredRent>
    <tgtx:IncreaseDecreaseInDeferredRent contextRef="P01_01_2015To03_31_2015" unitRef="USD" decimals="0">0</tgtx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In May 2016, the&#13;Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued ASU No. 2016-11, &amp;#147;Rescission of SEC Guidance Because of&#13;Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&amp;#148;&#13;(&amp;#147;ASU 2016-11&amp;#148;).&amp;#160; ASU 2016-11 rescinds certain SEC guidance from the &lt;i&gt;FASB Accounting Standards&#13;Codification&lt;/i&gt; in response to announcements made by the SEC staff at the Emerging Issues Task Force&amp;#146;s March 3, 2016&#13;meeting.&amp;#160; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Upon the adoption of ASU 2014-09:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Accounting for gas-balancing arrangements (ASC 932-10-S99-5).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Upon the adoption of ASU 2014-16&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Determining the nature of a host contract related to a hybrid financial instrument issued in the&#13;form of a share under ASC 815 (ASC 815-10-S99-3).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;ASU 2016-11 is effective upon the adoption of&#13;ASU 2014-09 and ASU 2014-16.&amp;#160; The adoption of ASU 2016-11 is not expected to have a material impact on the Company&amp;#146;s&#13;condensed consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In March 2016, the FASB issued ASU No. 2016-09, &amp;#147;Simplifying the Accounting for Share-Based Payments&amp;#148; (&amp;#147;ASU&#13;2016-09&amp;#148;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both&#13;public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,&#13;as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after&#13;December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected&#13;to significantly impact the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Other pronouncements issued by the FASB or other&#13;authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated&#13;financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;LFB&#13;Biotechnologies&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC,&#13;all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &amp;#147;LFB License Agreement&amp;#148;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Under&#13;the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred expenses&#13;of $2.3 million and $2.2 million during the three months ended June 30, 2016 and 2015, respectively, and $2.3 million and $2.4&#13;million during the six months ended June 30, 2016 and 2015, respectively, which have been included in other research and development&#13;expenses in the accompanying condensed consolidated statements of operations. As of June 30, 2016 and December 31, 2015, we had&#13;approximately $1.7 million and $2.1 million, respectively, recorded in accounts payable related to the LFB License Agreement.&#13;In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require&#13;payments in advance of services performed or goods delivered. Accordingly, as of June 30, 2016 and December 31, 2015, we recorded&#13;approximately $4.7 million and $3.0 million, respectively, in prepaid research and development for such advance payments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Other&#13;Parties&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;March 2014, we entered into a shared services agreement (the &amp;#147;Opus Shared Services Agreement&amp;#148;) with Opus Point Partners&#13;Management, LLC (&amp;#147;Opus&amp;#148;) in which the parties agreed to share the costs of a rented facility and certain other services.&amp;#160;&#13;Our Executive Chairman and Interim Chief Executive Officer is a Managing Member of Opus. During the three and six months ended&#13;June 30, 2016, we incurred expenses of approximately $0.02 million and $0.1 million, respectively, principally for rent, related&#13;to this agreement. The Opus Shared Services Agreement is no longer in effect as we began occupying new space in April 2016. As&#13;of June 30, 2016, we had approximately $0.1 million recorded in accounts payable related to this Opus Shared Services Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;In&#13;October 2014, we entered into an agreement (the &amp;#147;Office Agreement&amp;#148;) with Fortress Biotech, Inc. (&amp;#147;Fortress&amp;#148;),&#13;to occupy approximately 45% of the 24,000 square feet of New York City office space leased by Fortress, which is now our corporate&#13;headquarters. The Office Agreement requires us to pay our respective share of the average annual rent and other costs of the 15-year&#13;lease. We approximate an average annual rental obligation of $1.1 million under the Office Agreement. We began to occupy this&#13;new space in April 2016, with rental payments beginning in the third quarter of 2016. Mr. Weiss, our Executive Chairman and Interim&#13;CEO, is also Executive Vice Chairman of Fortress.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;In&#13;connection with the Office Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other&#13;current assets in the accompanying condensed consolidated balance sheets as of June 30, 2016 and December 31, 2015. &lt;/font&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the six months ended June 30, 2016, &lt;font style="background-color: white"&gt;we agreed to pay Fortress $2.0 for our portion&#13;of the build out costs&lt;/font&gt;, which have been allocated to us at the 45% rate mentioned above. The allocated build-out costs have&#13;been recorded in Leasehold Interest and will be amortized over the 15-year term of the Office Agreement. After an&#13;initial commitment period of three (3) years, Fortress will assess actual office space utilization annually and if our&#13;utilization differs from the amount we have been billed, we will either receive credits or be assessed incremental&#13;utilization charges.&amp;#160; &lt;font style="background-color: white"&gt;As of June 30, 2016, we had approximately $1.1 &lt;/font&gt;million&#13;recorded in accounts payable related mostly to the upfront leasehold interest. &lt;font style="background-color: white"&gt;Also&#13;in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for&#13;the Office Agreement, which has been recorded as restricted cash in the accompanying condensed consolidated&#13;balance sheets.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;In&#13;July 2015, we entered into a Shared Services Agreement (the &amp;#147;Shared Services Agreement&amp;#148;) with Fortress to share the&#13;cost of certain services such as facilities use, personnel costs and other overhead and administrative costs. This Shared Services&#13;Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we &lt;/font&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;incurred&#13;expenses of &lt;font style="background-color: white"&gt;approximately $0.4 million for shared services for the six months ended June&#13;30, 2016, primarily related to shared personnel.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;&lt;/font&gt;In&#13;May 2016, as part of a broader agreement with Jubilant, an India-based biotechnology company, we entered into the JBET Agreement&#13;with Checkpoint, a subsidiary of Fortress, for the development and commercialization of Jubilant&amp;#146;s novel BET inhibitor program&#13;in the field of hematological malignancies. We paid Checkpoint an up-front licensing fee of $1.0 million as part of the JBET Agreement.&#13;As of June 30, 2016, we had approximately $1.2 million recorded in accounts payable of which $1.0 million related to the licensing&#13;fee. Mr. Weiss is also the Executive Chairman of Checkpoint.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <tgtx:LeaseholdInterest contextRef="PAsOn03_31_2016" unitRef="USD" decimals="0">1968734</tgtx:LeaseholdInterest>
    <tgtx:LeaseholdInterest contextRef="PAsOn12_31_2015" unitRef="USD" decimals="0">0</tgtx:LeaseholdInterest>
    <tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows contextRef="P01_01_2016To03_31_2016">18 to 24 months</tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows>
    <tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows contextRef="P01_01_2015To03_31_2015">18 to 24 months</tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows>
    <tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows contextRef="P01_01_2015To12_31_2015">18 to 24 months</tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlows>
    <tgtx:BusinessDescriptionPolicyTextBlock contextRef="P01_01_2016To03_31_2016">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We are a biopharmaceutical company focused on&#13;the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,&#13;the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered&#13;monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also&#13;developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic&#13;origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical&#13;development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1&#13;receptor-associated kinase 4) inhibitors, BET (Bromodomain and Extra Terminal) inhibitors, and anti-PD-L1 and anti-GITR antibodies.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;We also actively evaluate complementary products,&#13;technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received&#13;approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our&#13;drug candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The accompanying unaudited condensed consolidated&#13;financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial&#13;information and with the instructions to Quarterly Report on Form 10-Q and Article&amp;#160;10 of Regulation&amp;#160;S-X of the Exchange&#13;Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements.&#13;All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation&#13;of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements&#13;should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for&#13;the year ended December 31, 2015. The accompanying condensed December 31, 2015 balance sheet has been derived from these statements.&#13;The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may&#13;be expected for the entire fiscal year or any other interim period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;</tgtx:BusinessDescriptionPolicyTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>tgtx-20160630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6kps7xRiXgen8uKYXQsSauE6aPtxZp8eZlBuWpwbbmaPyEsuB5ntiJ/YjnmwUEG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:tgtx="http://tgtherapeuticsinc.com/20160630" elementFormDefault="qualified" targetNamespace="http://tgtherapeuticsinc.com/20160630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document And Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" id="CondensedConsolidatedStatementOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
	  <link:definition>00000008 - Disclosure - CASH AND CASH EQUIVALENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecurities" id="InvestmentSecurities">
	  <link:definition>00000009 - Disclosure - INVESTMENT SECURITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000010 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000011 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000012 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreements" id="LicenseAgreements">
	  <link:definition>00000013 - Disclosure - LICENSE AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000014 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000015 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
	  <link:definition>00000018 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" id="InvestmentSecuritiesTables">
	  <link:definition>00000019 - Disclosure - INVESTMENT SECURITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/NotesPayableTables" id="NotesPayableTables">
	  <link:definition>00000022 - Disclosure - NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
	  <link:definition>00000025 - Disclosure - CASH AND CASH EQUIVALENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" id="InvestmentSecuritiesDetails">
	  <link:definition>00000026 - Disclosure - INVESTMENT SECURITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>00000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
	  <link:definition>00000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000029 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetails" id="NotesPayableDetails">
	  <link:definition>00000033 - Disclosure - NOTES PAYABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000034 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" id="LicenseAgreementsDetailsTextual">
	  <link:definition>00000035 - Disclosure - LICENSE AGREEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
	  <link:definition>00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="tgtx-20160630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tgtx-20160630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tgtx-20160630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tgtx-20160630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
    <element id="tgtx_ContingentlyIssuableShares" name="ContingentlyIssuableShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_NonCashCompensationResearchAndDevelopmentExpenses" name="NonCashCompensationResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" name="NonCashCompensationGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ChangeInFairValueOfNonCurrentNotePayable" name="ChangeInFairValueOfNonCurrentNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ChangeInFairValueOfNotesPayable" name="ChangeInFairValueOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" name="PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ProceedsFromMaturities" name="ProceedsFromMaturities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_NetProceedsFromSharesNewIssuesOverallotments" name="NetProceedsFromSharesNewIssuesOverallotments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LiquidityDisclosure1PolicyTextBlock" name="LiquidityDisclosure1PolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" name="ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ScheduleOfWarrantsActivityTableTextBlock" name="ScheduleOfWarrantsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" name="ScheduleOfShareBasedCompensationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ConversionOfNotes" name="ConversionOfNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightIssued" name="WarrantOrRightIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightExercised" name="WarrantOrRightExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightExpired" name="WarrantOrRightExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightAggregateIntrinsicValue" name="WarrantOrRightAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" name="WarrantOrRightOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" name="WarrantOrRightExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" name="WarrantOrRightIssuedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" name="WarrantOrRightExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" name="ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AccruedFinancingCosts" name="AccruedFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ConversionOfConvertibleNotesPayableToCommonStock" name="ConversionOfConvertibleNotesPayableToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" name="IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" name="IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" name="IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" name="IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PrepaidManufacturing" name="PrepaidManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_CommonStockAvailableForSale" name="CommonStockAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_UpfrontFeeReceivedFromSubLicense" name="UpfrontFeeReceivedFromSubLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" name="AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" name="PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AverageAnnualRentalPayments" name="AverageAnnualRentalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LeaseholdInterest" name="LeaseholdInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows" name="PeriodAnticipatedSufficientToFundOperatingCashFlows" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_BusinessDescriptionPolicyTextBlock" name="BusinessDescriptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ManhattanAndAristonPharmaceuticalsMergerMember" name="ManhattanAndAristonPharmaceuticalsMergerMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_CorporateMilestoneMember" name="CorporateMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ConvertibleNotesMember" name="ConvertibleNotesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AristonMember" name="AristonMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_TgOneOneZeroOneMember" name="TgOneOneZeroOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LfbGroupMember" name="LfbGroupMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_OpusMember" name="OpusMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_DeskAgreementMember" name="DeskAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ContingentlyIssuableShareMember" name="ContingentlyIssuableShareMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IncentivePlanMember" name="IncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_NonEmployeeRestrictedStockMember" name="NonEmployeeRestrictedStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_SharedServicesAgreementMember" name="SharedServicesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_GlobalCollaborationAgreementMember" name="GlobalCollaborationAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LfbLicenseAgreementMember" name="LfbLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AtmMember" name="AtmMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ATM2015Member" name="ATM2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IncentivePlan2012Member" name="IncentivePlan2012Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_OfficeAgreementMember" name="OfficeAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_FortressMember" name="FortressMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_JBETAgreementMember" name="JBETAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_CompensationAxis" name="CompensationAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="tgtx_CompensationDomain" name="CompensationDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LicenseAgreementAbstract" name="LicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_EquityIncentivePlansRestrictedStockActivityTable" name="EquityIncentivePlansRestrictedStockActivityTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" name="EquityIncentivePlansRestrictedStockActivityLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_EquityIncentivePlansWarrantActivityTable" name="EquityIncentivePlansWarrantActivityTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_EquityIncentivePlansWarrantActivityLineItems" name="EquityIncentivePlansWarrantActivityLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_StockBasedCompensationTable" name="StockBasedCompensationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_NotesPayableTable" name="NotesPayableTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_NotesPayableLineItems" name="NotesPayableLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_NotesPayableDetailsNarrativeAbstract" name="NotesPayableDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_LicenseAgreementTable" name="LicenseAgreementTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="tgtx_LicenseAgreementLineItems" name="LicenseAgreementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_IssuancePeriodAxis" name="IssuancePeriodAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="tgtx_IssuancePeriodDomain" name="IssuancePeriodDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_PlacementAgencyAgreementAxis" name="PlacementAgencyAgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="tgtx_PlacementAgencyAgreementDomain" name="PlacementAgencyAgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_ResearchDevelopmentExpensesAxis" name="ResearchDevelopmentExpensesAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="tgtx_ResearchDevelopmentExpensesDomain" name="ResearchDevelopmentExpensesDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_AgreementTypeAxis" name="AgreementTypeAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="tgtx_AgreementTypeNameDomain" name="AgreementTypeNameDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_OperatingLeaseInitialCommitmentPeriod" name="OperatingLeaseInitialCommitmentPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems" name="FairValueMeasurementChangesInLevel3InstrumentsLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable" name="FairValueMeasurementChangesInLevel3InstrumentsTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>tgtx-20160630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:href="tgtx-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:href="tgtx-20160630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:href="tgtx-20160630.xsd#InvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:href="tgtx-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:href="tgtx-20160630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:href="tgtx-20160630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:href="tgtx-20160630.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:href="tgtx-20160630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:href="tgtx-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:href="tgtx-20160630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:href="tgtx-20160630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:href="tgtx-20160630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:href="tgtx-20160630.xsd#LicenseAgreementsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactionsDetailsTextual" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document And Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidResearchAndDevelopment" xlink:label="loc_tgtxPrepaidResearchAndDevelopment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_tgtxPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LeaseholdInterest" xlink:label="loc_tgtxLeaseholdInterest" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_tgtxLeaseholdInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShares" xlink:label="loc_tgtxContingentlyIssuableShares" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_tgtxContingentlyIssuableShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationResearchAndDevelopmentExpenses" xlink:label="loc_tgtxNonCashCompensationResearchAndDevelopmentExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_tgtxNonCashCompensationResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:label="loc_tgtxNonCashCompensationGeneralAndAdministrativeExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_tgtxNonCashCompensationGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxChangeInFairValueOfNonCurrentNotePayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_tgtxChangeInFairValueOfNonCurrentNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaapInvestmentIncomeAmortizationOfPremium" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapInvestmentIncomeAmortizationOfPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncreaseDecreaseInDeferredRent" xlink:label="loc_tgtxIncreaseDecreaseInDeferredRent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_tgtxIncreaseDecreaseInDeferredRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidRent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidRent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNotesPayable" xlink:label="loc_tgtxChangeInFairValueOfNotesPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_tgtxChangeInFairValueOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:label="loc_tgtxPaymentsToAcquireHeldToMaturitySecuritiesShortTerm" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_tgtxPaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ProceedsFromMaturities" xlink:label="loc_tgtxProceedsFromMaturities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_tgtxProceedsFromMaturities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NetProceedsFromSharesNewIssuesOverallotments" xlink:label="loc_tgtxNetProceedsFromSharesNewIssuesOverallotments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_tgtxNetProceedsFromSharesNewIssuesOverallotments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - CASH AND CASH EQUIVALENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:title="00000009 - Disclosure - INVESTMENT SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:title="00000010 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:title="00000013 - Disclosure - LICENSE AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:title="00000018 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:title="00000019 - Disclosure - INVESTMENT SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:title="00000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:title="00000025 - Disclosure - CASH AND CASH EQUIVALENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:title="00000026 - Disclosure - INVESTMENT SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:title="00000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:title="00000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:title="00000029 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:title="00000033 - Disclosure - NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNotesPayable" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNotesPayable" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:title="00000035 - Disclosure - LICENSE AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:title="00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tgtx-20160630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:href="tgtx-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:href="tgtx-20160630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:href="tgtx-20160630.xsd#InvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:href="tgtx-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:href="tgtx-20160630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:href="tgtx-20160630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:href="tgtx-20160630.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:href="tgtx-20160630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:href="tgtx-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:href="tgtx-20160630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:href="tgtx-20160630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:href="tgtx-20160630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:href="tgtx-20160630.xsd#LicenseAgreementsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactionsDetailsTextual" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document And Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShareMember" xlink:label="loc_tgtxContingentlyIssuableShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_tgtxContingentlyIssuableShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationAxis" xlink:label="loc_tgtxCompensationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_tgtxCompensationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationDomain" xlink:label="loc_tgtxCompensationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tgtxCompensationAxis" xlink:to="loc_tgtxCompensationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationDomain" xlink:label="loc_tgtxCompensationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_tgtxCompensationAxis" xlink:to="loc_tgtxCompensationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_tgtxStockIssuedDuringPeriodValueExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxStockIssuedDuringPeriodValueExerciseOfWarrants_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_tgtxStockIssuedDuringPeriodSharesExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxStockIssuedDuringPeriodSharesExerciseOfWarrants_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" xlink:label="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayable_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" xlink:label="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" xlink:label="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" xlink:label="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - CASH AND CASH EQUIVALENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:title="00000009 - Disclosure - INVESTMENT SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:title="00000010 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:title="00000013 - Disclosure - LICENSE AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:title="00000018 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:title="00000019 - Disclosure - INVESTMENT SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:title="00000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesLineItems" xlink:label="loc_tgtxSignificantAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesTable" xlink:label="loc_tgtxSignificantAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_tgtxSignificantAccountingPoliciesLineItems" xlink:to="loc_tgtxSignificantAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:title="00000025 - Disclosure - CASH AND CASH EQUIVALENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:title="00000026 - Disclosure - INVESTMENT SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:label="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="loc_us-gaapOtherLongTermInvestmentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapOtherLongTermInvestmentsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="loc_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains" xlink:label="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingGains_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingGains_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses" xlink:label="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingLosses_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingLosses_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:title="00000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaapFairValueByBalanceSheetGroupingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:title="00000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:title="00000029 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" xlink:label="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityTable" xlink:label="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityLineItems" xlink:label="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityTable" xlink:label="loc_tgtxEquityIncentivePlansWarrantActivityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssued" xlink:label="loc_tgtxWarrantOrRightIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightIssued_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercised" xlink:label="loc_tgtxWarrantOrRightExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExercised_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpired" xlink:label="loc_tgtxWarrantOrRightExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExpired_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightIssuedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightIssuedWeightedAverageExercisePrice_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightExercisedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExercisedWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightExpiredWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExpiredWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:label="loc_tgtxWarrantOrRightAggregateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightAggregateIntrinsicValue_40" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockBasedCompensationTable" xlink:label="loc_tgtxStockBasedCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_tgtxStockBasedCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxStockBasedCompensationTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ATM2015Member" xlink:label="loc_tgtxATM2015Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tgtxATM2015Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncentivePlan2012Member" xlink:label="loc_tgtxIncentivePlan2012Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tgtxIncentivePlan2012Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:label="loc_tgtxSaleOfStockConsiderationReceivedOnTransactionGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxSaleOfStockConsiderationReceivedOnTransactionGross_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CommonStockAvailableForSale" xlink:label="loc_tgtxCommonStockAvailableForSale_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxCommonStockAvailableForSale_100" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:title="00000033 - Disclosure - NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableLineItems" xlink:label="loc_tgtxNotesPayableLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableTable" xlink:label="loc_tgtxNotesPayableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_tgtxNotesPayableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxNotesPayableTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConvertibleNotesMember" xlink:label="loc_tgtxConvertibleNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_tgtxConvertibleNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapNotesPayableCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapLongTermNotesPayable_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapNotesPayable_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AristonMember" xlink:label="loc_tgtxAristonMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_tgtxAristonMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:label="loc_tgtxPercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxPercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:title="00000035 - Disclosure - LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementLineItems" xlink:label="loc_tgtxLicenseAgreementLineItems" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementTable" xlink:label="loc_tgtxLicenseAgreementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_tgtxLicenseAgreementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_JBETAgreementMember" xlink:label="loc_tgtxJBETAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxJBETAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_TgOneOneZeroOneMember" xlink:label="loc_tgtxTgOneOneZeroOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxTgOneOneZeroOneMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapLicensesRevenue_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_UpfrontFeeReceivedFromSubLicense" xlink:label="loc_tgtxUpfrontFeeReceivedFromSubLicense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_tgtxUpfrontFeeReceivedFromSubLicense_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapDeferredRevenue_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:label="loc_tgtxAdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_tgtxAdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:title="00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OpusMember" xlink:label="loc_tgtxOpusMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxOpusMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodAxis" xlink:label="loc_tgtxIssuancePeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxIssuancePeriodAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodDomain" xlink:label="loc_tgtxIssuancePeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tgtxIssuancePeriodAxis" xlink:to="loc_tgtxIssuancePeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodDomain" xlink:label="loc_tgtxIssuancePeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_tgtxIssuancePeriodAxis" xlink:to="loc_tgtxIssuancePeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementAxis" xlink:label="loc_tgtxPlacementAgencyAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxPlacementAgencyAgreementAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementDomain" xlink:label="loc_tgtxPlacementAgencyAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tgtxPlacementAgencyAgreementAxis" xlink:to="loc_tgtxPlacementAgencyAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementDomain" xlink:label="loc_tgtxPlacementAgencyAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_tgtxPlacementAgencyAgreementAxis" xlink:to="loc_tgtxPlacementAgencyAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbGroupMember" xlink:label="loc_tgtxLfbGroupMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxLfbGroupMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_DeskAgreementMember" xlink:label="loc_tgtxDeskAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxDeskAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OfficeAgreementMember" xlink:label="loc_tgtxOfficeAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxOfficeAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FortressMember" xlink:label="loc_tgtxFortressMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxFortressMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_JBETAgreementMember" xlink:label="loc_tgtxJBETAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxJBETAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesAxis" xlink:label="loc_tgtxResearchDevelopmentExpensesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxResearchDevelopmentExpensesAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesDomain" xlink:label="loc_tgtxResearchDevelopmentExpensesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tgtxResearchDevelopmentExpensesAxis" xlink:to="loc_tgtxResearchDevelopmentExpensesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesDomain" xlink:label="loc_tgtxResearchDevelopmentExpensesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_tgtxResearchDevelopmentExpensesAxis" xlink:to="loc_tgtxResearchDevelopmentExpensesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeAxis" xlink:label="loc_tgtxAgreementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxAgreementTypeAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeNameDomain" xlink:label="loc_tgtxAgreementTypeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_tgtxAgreementTypeAxis" xlink:to="loc_tgtxAgreementTypeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeNameDomain" xlink:label="loc_tgtxAgreementTypeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_tgtxAgreementTypeAxis" xlink:to="loc_tgtxAgreementTypeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbLicenseAgreementMember" xlink:label="loc_tgtxLfbLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxLfbLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SharedServicesAgreementMember" xlink:label="loc_tgtxSharedServicesAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxSharedServicesAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_GlobalCollaborationAgreementMember" xlink:label="loc_tgtxGlobalCollaborationAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxGlobalCollaborationAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidResearchAndDevelopment" xlink:label="loc_tgtxPrepaidResearchAndDevelopment_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxPrepaidResearchAndDevelopment_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AverageAnnualRentalPayments" xlink:label="loc_tgtxAverageAnnualRentalPayments_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxAverageAnnualRentalPayments_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSecurityDeposit_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfOccupancy" xlink:label="loc_tgtxPercentageOfOccupancy_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxPercentageOfOccupancy_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaapLesseeLeasingArrangementsOperatingLeasesTermOfContract_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLesseeLeasingArrangementsOperatingLeasesTermOfContract_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAreaOfLand_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OperatingLeaseInitialCommitmentPeriod" xlink:label="loc_tgtxOperatingLeaseInitialCommitmentPeriod_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxOperatingLeaseInitialCommitmentPeriod_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPrepaidRent_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_UpfrontFeeReceivedFromSubLicense" xlink:label="loc_tgtxUpfrontFeeReceivedFromSubLicense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxUpfrontFeeReceivedFromSubLicense_250" xlink:type="arc" order="12" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>tgtx-20160630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="us-gaap_OtherLongTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestmentsMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermInvestmentsMember_lbl" xml:lang="en-US">Other Long-term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConvertibleNotesMember" xlink:label="tgtx_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ConvertibleNotesMember" xlink:to="tgtx_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AristonMember" xlink:label="tgtx_AristonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AristonMember" xlink:to="tgtx_AristonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_AristonMember_lbl" xml:lang="en-US">Ariston [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_TgOneOneZeroOneMember" xlink:label="tgtx_TgOneOneZeroOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_TgOneOneZeroOneMember" xlink:to="tgtx_TgOneOneZeroOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_TgOneOneZeroOneMember_lbl" xml:lang="en-US">TG One One Zero One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbGroupMember" xlink:label="tgtx_LfbGroupMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LfbGroupMember" xlink:to="tgtx_LfbGroupMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LfbGroupMember_lbl" xml:lang="en-US">Lfb Group [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementAxis" xlink:label="tgtx_PlacementAgencyAgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PlacementAgencyAgreementAxis" xlink:to="tgtx_PlacementAgencyAgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PlacementAgencyAgreementAxis_lbl" xml:lang="en-US">Placement Agency Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OpusMember" xlink:label="tgtx_OpusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_OpusMember" xlink:to="tgtx_OpusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_OpusMember_lbl" xml:lang="en-US">Opus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShareMember" xlink:label="tgtx_ContingentlyIssuableShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ContingentlyIssuableShareMember" xlink:to="tgtx_ContingentlyIssuableShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ContingentlyIssuableShareMember_lbl" xml:lang="en-US">Contingently Issuable Share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SharedServicesAgreementMember" xlink:label="tgtx_SharedServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SharedServicesAgreementMember" xlink:to="tgtx_SharedServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_SharedServicesAgreementMember_lbl" xml:lang="en-US">Shared Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeAxis" xlink:label="tgtx_AgreementTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AgreementTypeAxis" xlink:to="tgtx_AgreementTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_AgreementTypeAxis_lbl" xml:lang="en-US">Agreement Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbLicenseAgreementMember" xlink:label="tgtx_LfbLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LfbLicenseAgreementMember" xlink:to="tgtx_LfbLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LfbLicenseAgreementMember_lbl" xml:lang="en-US">LFB License Agreement [] [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Share Issuable Upon Note Conversion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ATM2015Member" xlink:label="tgtx_ATM2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ATM2015Member" xlink:to="tgtx_ATM2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ATM2015Member_lbl" xml:lang="en-US">2015 ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncentivePlan2012Member" xlink:label="tgtx_IncentivePlan2012Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IncentivePlan2012Member" xlink:to="tgtx_IncentivePlan2012Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IncentivePlan2012Member_lbl" xml:lang="en-US">2012 Incentive Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OfficeAgreementMember" xlink:label="tgtx_OfficeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_OfficeAgreementMember" xlink:to="tgtx_OfficeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_OfficeAgreementMember_lbl" xml:lang="en-US">Office Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FortressMember" xlink:label="tgtx_FortressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FortressMember" xlink:to="tgtx_FortressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_FortressMember_lbl" xml:lang="en-US">Fortress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_JBETAgreementMember" xlink:label="tgtx_JBETAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_JBETAgreementMember" xlink:to="tgtx_JBETAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_JBETAgreementMember_lbl" xml:lang="en-US">JBET Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_DocumentAndEntityInformationAbstract" xlink:label="tgtx_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_DocumentAndEntityInformationAbstract" xlink:to="tgtx_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidResearchAndDevelopment" xlink:label="tgtx_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PrepaidResearchAndDevelopment" xlink:to="tgtx_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LeaseholdInterest" xlink:label="tgtx_LeaseholdInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LeaseholdInterest" xlink:to="tgtx_LeaseholdInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LeaseholdInterest_lbl" xml:lang="en-US">Leasehold interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Current portion of deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value per share (150,000,000 shares authorized, 54,497,932 and 54,095,110 shares issued, 54,456,623 and 54,053,801 shares outstanding at June 30, 2016 and December 31, 2015, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShares" xlink:label="tgtx_ContingentlyIssuableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ContingentlyIssuableShares" xlink:to="tgtx_ContingentlyIssuableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ContingentlyIssuableShares_lbl" xml:lang="en-US">Contingently issuable shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, at cost, 41,309 shares at June 30, 2016 and December 31, 2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">License revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and development:</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationResearchAndDevelopmentExpenses" xlink:label="tgtx_NonCashCompensationResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonCashCompensationResearchAndDevelopmentExpenses" xlink:to="tgtx_NonCashCompensationResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NonCashCompensationResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Noncash compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative:</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:label="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:to="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Noncash compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (income) expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="tgtx_ChangeInFairValueOfNonCurrentNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:to="tgtx_ChangeInFairValueOfNonCurrentNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tgtx_ChangeInFairValueOfNonCurrentNotePayable_lbl" xml:lang="en-US">Change in fair value of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares used in computing basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationAxis" xlink:label="tgtx_CompensationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_CompensationAxis" xlink:to="tgtx_CompensationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_CompensationAxis_lbl" xml:lang="en-US">Compensation [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock in connection with exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock in connection with exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" xlink:label="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" xlink:to="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable_lbl" xml:lang="en-US">Issuance of common stock in connection with conversion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" xlink:label="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" xlink:to="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares_lbl" xml:lang="en-US">Issuance of common stock in connection with conversion of notes payable (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Forfeiture of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Forfeiture of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" xlink:label="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" xlink:to="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock in At the Market offering (net of offering costs of $122,497)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" xlink:label="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" xlink:to="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares_lbl" xml:lang="en-US">Issuance of common stock in At the Market offering (net of offering costs of $122,497) (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation in respect of restricted stock granted to employees, directors and consultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Noncash stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xml:lang="en-US">Amortization of premium on investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNotesPayable" xlink:label="tgtx_ChangeInFairValueOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNotesPayable" xlink:to="tgtx_ChangeInFairValueOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tgtx_ChangeInFairValueOfNotesPayable_lbl" xml:lang="en-US">Change in fair value of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase in restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase in other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent_lbl" xml:lang="en-US">Increase in leasehold interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Decrease (increase) in accrued interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase in other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncreaseDecreaseInDeferredRent" xlink:label="tgtx_IncreaseDecreaseInDeferredRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IncreaseDecreaseInDeferredRent" xlink:to="tgtx_IncreaseDecreaseInDeferredRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Increase in deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Decrease in deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:label="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:to="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_lbl" xml:lang="en-US">Investment in held-to-maturity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ProceedsFromMaturities" xlink:label="tgtx_ProceedsFromMaturities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ProceedsFromMaturities" xlink:to="tgtx_ProceedsFromMaturities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ProceedsFromMaturities_lbl" xml:lang="en-US">Proceeds from maturity of short-term securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NetProceedsFromSharesNewIssuesOverallotments" xlink:label="tgtx_NetProceedsFromSharesNewIssuesOverallotments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NetProceedsFromSharesNewIssuesOverallotments" xlink:to="tgtx_NetProceedsFromSharesNewIssuesOverallotments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NetProceedsFromSharesNewIssuesOverallotments_lbl" xml:lang="en-US">Proceeds from sale of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract" xlink:label="us-gaap_NonmonetaryTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionsAbstract" xlink:to="us-gaap_NonmonetaryTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonmonetaryTransactionsAbstract_lbl" xml:lang="en-US">NONCASH TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AccruedFinancingCosts" xlink:label="tgtx_AccruedFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AccruedFinancingCosts" xlink:to="tgtx_AccruedFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_AccruedFinancingCosts_lbl" xml:lang="en-US">Accrued financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" xlink:label="tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" xlink:to="tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital_lbl" xml:lang="en-US">Reclassification of deferred financing costs to&#160;additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConversionOfConvertibleNotesPayableToCommonStock" xlink:label="tgtx_ConversionOfConvertibleNotesPayableToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ConversionOfConvertibleNotesPayableToCommonStock" xlink:to="tgtx_ConversionOfConvertibleNotesPayableToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ConversionOfConvertibleNotesPayableToCommonStock_lbl" xml:lang="en-US">Conversion of convertible notes payable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementAbstract" xlink:label="tgtx_LicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementAbstract" xlink:to="tgtx_LicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementDisclosureTextBlock" xlink:label="tgtx_LicenseAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementDisclosureTextBlock" xlink:to="tgtx_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_BusinessDescriptionPolicyTextBlock" xlink:label="tgtx_BusinessDescriptionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_BusinessDescriptionPolicyTextBlock" xlink:to="tgtx_BusinessDescriptionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_BusinessDescriptionPolicyTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LiquidityDisclosure1PolicyTextBlock" xlink:label="tgtx_LiquidityDisclosure1PolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LiquidityDisclosure1PolicyTextBlock" xlink:to="tgtx_LiquidityDisclosure1PolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LiquidityDisclosure1PolicyTextBlock_lbl" xml:lang="en-US">Liquidity Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Investment Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" xlink:label="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" xlink:to="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock_lbl" xml:lang="en-US">Impairment Of Tangible and Intangible Asset Including Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xml:lang="en-US">Held-to-maturity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Change In Level Three Fair Value During Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ScheduleOfWarrantsActivityTableTextBlock" xlink:label="tgtx_ScheduleOfWarrantsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ScheduleOfWarrantsActivityTableTextBlock" xlink:to="tgtx_ScheduleOfWarrantsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ScheduleOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" xlink:label="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" xlink:to="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesTable" xlink:label="tgtx_SignificantAccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SignificantAccountingPoliciesTable" xlink:to="tgtx_SignificantAccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesLineItems" xlink:label="tgtx_SignificantAccountingPoliciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SignificantAccountingPoliciesLineItems" xlink:to="tgtx_SignificantAccountingPoliciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows" xlink:label="tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows" xlink:to="tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows_lbl" xml:lang="en-US">Period Anticipated Sufficient To Fund Operating Cash Flow</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="us-gaap_RestrictedCashAndInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestments" xlink:to="us-gaap_RestrictedCashAndInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestments_lbl" xml:lang="en-US">Restricted Cash and Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidManufacturing" xlink:label="tgtx_PrepaidManufacturing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PrepaidManufacturing" xlink:to="tgtx_PrepaidManufacturing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PrepaidManufacturing_lbl" xml:lang="en-US">Prepaid Manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Checking and bank deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_lbl" xml:lang="en-US">Schedule of Held-to-maturity Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xml:lang="en-US">Schedule of Held-to-maturity Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentTypeAxis_2_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="us-gaap_HeldToMaturitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xml:lang="en-US">Amortized cost, as adjusted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains" xlink:label="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains" xlink:to="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains_lbl" xml:lang="en-US">Gross unrealized holding gains</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses" xlink:label="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses" xlink:to="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses_lbl" xml:lang="en-US">Gross unrealized holding losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xml:lang="en-US">Estimated fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">5% Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value at December 31, 2015</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" xlink:label="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" xlink:to="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings_lbl" xml:lang="en-US">Interest accrued on face value of 5% Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConversionOfNotes" xlink:label="tgtx_ConversionOfNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ConversionOfNotes" xlink:to="tgtx_ConversionOfNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ConversionOfNotes_lbl" xml:lang="en-US">Conversion of 5% notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value of Level 3 liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value at March 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityTable" xlink:label="tgtx_EquityIncentivePlansRestrictedStockActivityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansRestrictedStockActivityTable" xlink:to="tgtx_EquityIncentivePlansRestrictedStockActivityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_EquityIncentivePlansRestrictedStockActivityTable_lbl" xml:lang="en-US">Equity Incentive Plans Restricted Stock Activity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" xlink:label="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems_lbl" xml:lang="en-US">Equity Incentive Plans Restricted Stock Activity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding at Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Shares, Outstanding at Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding at Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityTable" xlink:label="tgtx_EquityIncentivePlansWarrantActivityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansWarrantActivityTable" xlink:to="tgtx_EquityIncentivePlansWarrantActivityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_EquityIncentivePlansWarrantActivityTable_lbl" xml:lang="en-US">Equity Incentive Plans Warrant Activity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityLineItems" xlink:label="tgtx_EquityIncentivePlansWarrantActivityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansWarrantActivityLineItems" xlink:to="tgtx_EquityIncentivePlansWarrantActivityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_EquityIncentivePlansWarrantActivityLineItems_lbl" xml:lang="en-US">Equity Incentive Plans Warrant Activity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants, Outstanding at Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssued" xlink:label="tgtx_WarrantOrRightIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightIssued" xlink:to="tgtx_WarrantOrRightIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightIssued_lbl" xml:lang="en-US">Warrants, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercised" xlink:label="tgtx_WarrantOrRightExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExercised" xlink:to="tgtx_WarrantOrRightExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tgtx_WarrantOrRightExercised_lbl" xml:lang="en-US">Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpired" xlink:label="tgtx_WarrantOrRightExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExpired" xlink:to="tgtx_WarrantOrRightExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tgtx_WarrantOrRightExpired_lbl" xml:lang="en-US">Warrants, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants, Outstanding at Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted - average exercise price, Outstanding at Beginning Balance (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted - average exercise price, Issued (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted - average exercise price, Exercised (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" xlink:label="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted - average exercise price, Expired (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted - average exercise price, Outstanding at Ending Balance (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:label="tgtx_WarrantOrRightAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:to="tgtx_WarrantOrRightAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tgtx_WarrantOrRightAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at Beginning Balance (in dollars)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:to="tgtx_WarrantOrRightAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tgtx_WarrantOrRightAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at Ending Balance (in dollars)</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockBasedCompensationTable" xlink:label="tgtx_StockBasedCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_StockBasedCompensationTable" xlink:to="tgtx_StockBasedCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_StockBasedCompensationTable_lbl" xml:lang="en-US">Stock Based Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Stock-based compensation expense associated with restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock-based compensation expense associated with option grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares sold under plan</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:label="tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="tgtx_SaleOfStockConsiderationReceivedOnTransactionGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_SaleOfStockConsiderationReceivedOnTransactionGross_lbl" xml:lang="en-US">Gross proceeds from sale off common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Net proceeds from sale off common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Compensation, Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CommonStockAvailableForSale" xlink:label="tgtx_CommonStockAvailableForSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_CommonStockAvailableForSale" xlink:to="tgtx_CommonStockAvailableForSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_CommonStockAvailableForSale_lbl" xml:lang="en-US">Common stock available for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableTable" xlink:label="tgtx_NotesPayableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NotesPayableTable" xlink:to="tgtx_NotesPayableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NotesPayableTable_lbl" xml:lang="en-US">Notes Payable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableLineItems" xlink:label="tgtx_NotesPayableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NotesPayableLineItems" xlink:to="tgtx_NotesPayableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NotesPayableLineItems_lbl" xml:lang="en-US">Notes Payable [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_2_lbl" xml:lang="en-US">Notes payable, Current portion, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, Non-current portion, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:label="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:to="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_lbl" xml:lang="en-US">Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementTable" xlink:label="tgtx_LicenseAgreementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementTable" xlink:to="tgtx_LicenseAgreementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LicenseAgreementTable_lbl" xml:lang="en-US">License Agreement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementLineItems" xlink:label="tgtx_LicenseAgreementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementLineItems" xlink:to="tgtx_LicenseAgreementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_LicenseAgreementLineItems_lbl" xml:lang="en-US">License Agreement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_UpfrontFeeReceivedFromSubLicense" xlink:label="tgtx_UpfrontFeeReceivedFromSubLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_UpfrontFeeReceivedFromSubLicense" xlink:to="tgtx_UpfrontFeeReceivedFromSubLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_UpfrontFeeReceivedFromSubLicense_lbl" xml:lang="en-US">Upfront Fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:label="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:to="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_lbl" xml:lang="en-US">Additional Amount Receivable On Achievement Of Pre Specified Milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Proceeds from Fees Received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodAxis" xlink:label="tgtx_IssuancePeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IssuancePeriodAxis" xlink:to="tgtx_IssuancePeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IssuancePeriodAxis_lbl" xml:lang="en-US">Issuance Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_DeskAgreementMember" xlink:label="tgtx_DeskAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_DeskAgreementMember" xlink:to="tgtx_DeskAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_DeskAgreementMember_lbl" xml:lang="en-US">Desk Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesAxis" xlink:label="tgtx_ResearchDevelopmentExpensesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ResearchDevelopmentExpensesAxis" xlink:to="tgtx_ResearchDevelopmentExpensesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ResearchDevelopmentExpensesAxis_lbl" xml:lang="en-US">Research Development Expenses [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_GlobalCollaborationAgreementMember" xlink:label="tgtx_GlobalCollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_GlobalCollaborationAgreementMember" xlink:to="tgtx_GlobalCollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_GlobalCollaborationAgreementMember_lbl" xml:lang="en-US">Global Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Costs and Expenses, Related Party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PrepaidResearchAndDevelopment" xlink:to="tgtx_PrepaidResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tgtx_PrepaidResearchAndDevelopment_2_lbl" xml:lang="en-US">Prepaid Research And Development</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AverageAnnualRentalPayments" xlink:label="tgtx_AverageAnnualRentalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AverageAnnualRentalPayments" xlink:to="tgtx_AverageAnnualRentalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_AverageAnnualRentalPayments_lbl" xml:lang="en-US">Average Annual Rental Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfOccupancy" xlink:label="tgtx_PercentageOfOccupancy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PercentageOfOccupancy" xlink:to="tgtx_PercentageOfOccupancy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PercentageOfOccupancy_lbl" xml:lang="en-US">Percentage of Occupancy</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OperatingLeaseInitialCommitmentPeriod" xlink:label="tgtx_OperatingLeaseInitialCommitmentPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_OperatingLeaseInitialCommitmentPeriod" xlink:to="tgtx_OperatingLeaseInitialCommitmentPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_OperatingLeaseInitialCommitmentPeriod_lbl" xml:lang="en-US">Operating Lease, Initial Commitment Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid Rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_UpfrontFeeReceivedFromSubLicense" xlink:to="tgtx_UpfrontFeeReceivedFromSubLicense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tgtx_UpfrontFeeReceivedFromSubLicense_2_lbl" xml:lang="en-US">Upfront Fee Received From Sub License</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:to="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones_doc" xml:lang="en-US">Reflects potential milestone payments to be received upon achievement of pre-specified milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_AverageAnnualRentalPayments" xlink:to="tgtx_AverageAnnualRentalPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_AverageAnnualRentalPayments_doc" xml:lang="en-US">The yearly payments due under the lease entered into in connection with the possession of the office space.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_BusinessDescriptionPolicyTextBlock" xlink:to="tgtx_BusinessDescriptionPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_BusinessDescriptionPolicyTextBlock_doc" xml:lang="en-US">Reflects the description of business of the entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:to="tgtx_ChangeInFairValueOfNonCurrentNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ChangeInFairValueOfNonCurrentNotePayable_doc" xml:lang="en-US">The change in the fair value of non current notes payable recognized during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNotesPayable" xlink:to="tgtx_ChangeInFairValueOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ChangeInFairValueOfNotesPayable_doc" xml:lang="en-US">The change in fair value of notes payable during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ContingentlyIssuableShares" xlink:to="tgtx_ContingentlyIssuableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ContingentlyIssuableShares_doc" xml:lang="en-US">The shares issuable for merger of companies</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_EquityIncentivePlansRestrictedStockActivityLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_EquityIncentivePlansWarrantActivityLineItems" xlink:to="tgtx_EquityIncentivePlansWarrantActivityLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_EquityIncentivePlansWarrantActivityLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems" xlink:to="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable" xlink:to="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable_doc" xml:lang="en-US">Fair value disclosures related to financial assets (as defined) and financial liabilities (as defined) contained in the entity's balance sheet. Disclosures contained in this table include the changes in level 3 instruments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" xlink:to="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings_doc" xml:lang="en-US">Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" xlink:to="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock_doc" xml:lang="en-US">Disclosure related to policy for impairment of tangible and intangible asset including goodwill.</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncentivePlanMember" xlink:label="tgtx_IncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IncentivePlanMember" xlink:to="tgtx_IncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_IncentivePlanMember_doc" xml:lang="en-US">represents incentives plan of 2012</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IncreaseDecreaseInDeferredRent" xlink:to="tgtx_IncreaseDecreaseInDeferredRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_IncreaseDecreaseInDeferredRent_doc" xml:lang="en-US">Change during the period in carrying value for deferred rent due within one year or operating cycle.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementAbstract" xlink:to="tgtx_LicenseAgreementAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_LicenseAgreementAbstract_doc" xml:lang="en-US">License Agreement [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementDisclosureTextBlock" xlink:to="tgtx_LicenseAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_LicenseAgreementDisclosureTextBlock_doc" xml:lang="en-US">The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_LicenseAgreementLineItems" xlink:to="tgtx_LicenseAgreementLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_LicenseAgreementLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NetProceedsFromSharesNewIssuesOverallotments" xlink:to="tgtx_NetProceedsFromSharesNewIssuesOverallotments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_NetProceedsFromSharesNewIssuesOverallotments_doc" xml:lang="en-US">Represents the net proceeds from issuance of common stock over-allotments during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:to="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_doc" xml:lang="en-US">The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonCashCompensationResearchAndDevelopmentExpenses" xlink:to="tgtx_NonCashCompensationResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_NonCashCompensationResearchAndDevelopmentExpenses_doc" xml:lang="en-US">The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period.</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonEmployeeRestrictedStockMember" xlink:label="tgtx_NonEmployeeRestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonEmployeeRestrictedStockMember" xlink:to="tgtx_NonEmployeeRestrictedStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_NonEmployeeRestrictedStockMember_doc" xml:lang="en-US">represents restricted shares outstanding issued to non-employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NotesPayableLineItems" xlink:to="tgtx_NotesPayableLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_NotesPayableLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_OperatingLeaseInitialCommitmentPeriod" xlink:to="tgtx_OperatingLeaseInitialCommitmentPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_OperatingLeaseInitialCommitmentPeriod_doc" xml:lang="en-US">The duration of initial lease commitment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:to="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_doc" xml:lang="en-US">Amount of cash outflow (inflow) through acquisition (sale) of short-term held-to-maturity securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PercentageOfOccupancy" xlink:to="tgtx_PercentageOfOccupancy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PercentageOfOccupancy_doc" xml:lang="en-US">Occupancy percentage of the office space.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PlacementAgencyAgreementAxis" xlink:to="tgtx_PlacementAgencyAgreementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PlacementAgencyAgreementAxis_doc" xml:lang="en-US">Represents Placement Agency Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementDomain" xlink:label="tgtx_PlacementAgencyAgreementDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PlacementAgencyAgreementDomain" xlink:to="tgtx_PlacementAgencyAgreementDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PlacementAgencyAgreementDomain_doc" xml:lang="en-US">Represents Placement Agency Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PrepaidManufacturing" xlink:to="tgtx_PrepaidManufacturing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PrepaidManufacturing_doc" xml:lang="en-US">Represents the amount of prepaid manufacturing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PrepaidResearchAndDevelopment" xlink:to="tgtx_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ProceedsFromMaturities" xlink:to="tgtx_ProceedsFromMaturities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ProceedsFromMaturities_doc" xml:lang="en-US">The cash inflow associated with the maturities of held-to-maturity securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" xlink:to="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of Share based compensation expense during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ScheduleOfWarrantsActivityTableTextBlock" xlink:to="tgtx_ScheduleOfWarrantsActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_ScheduleOfWarrantsActivityTableTextBlock_doc" xml:lang="en-US">Tabular disclosure for warrants activity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SignificantAccountingPoliciesLineItems" xlink:to="tgtx_SignificantAccountingPoliciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_SignificantAccountingPoliciesLineItems_doc" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_SignificantAccountingPoliciesTable" xlink:to="tgtx_SignificantAccountingPoliciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_SignificantAccountingPoliciesTable_doc" xml:lang="en-US">Schedule reflecting the organisation and summary of significant accounting policies.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xml:lang="en-US">Represents the number of shares of stock issued during the period due to the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants_doc" xml:lang="en-US">Represents the value of stock issued during the period due to the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_UpfrontFeeReceivedFromSubLicense" xlink:to="tgtx_UpfrontFeeReceivedFromSubLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_UpfrontFeeReceivedFromSubLicense_doc" xml:lang="en-US">Represents amount received for sub license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:to="tgtx_WarrantOrRightAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightAggregateIntrinsicValue_doc" xml:lang="en-US">Reflects the aggregate intrinsic value of warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExercised" xlink:to="tgtx_WarrantOrRightExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightExercised_doc" xml:lang="en-US">Reflects the number of warrants exercised during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Reflects the weighted average exercise price of warrants Exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExpired" xlink:to="tgtx_WarrantOrRightExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightExpired_doc" xml:lang="en-US">Reflects the number of warrants expired during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice_doc" xml:lang="en-US">Reflects the weighted average exercise price of warrants Expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightIssued" xlink:to="tgtx_WarrantOrRightIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightIssued_doc" xml:lang="en-US">Reflects the number of warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice_doc" xml:lang="en-US">Reflects the weighted average exercise price of warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Reflects the weighted average exercise price of warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:to="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt_doc" xml:lang="en-US">Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:to="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NonCashCompensationGeneralAndAdministrativeExpenses_3_lbl" xml:lang="en-US">NonCashCompensationGeneralAndAdministrativeExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:to="tgtx_ChangeInFairValueOfNonCurrentNotePayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ChangeInFairValueOfNonCurrentNotePayable_3_lbl" xml:lang="en-US">ChangeInFairValueOfNonCurrentNotePayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_ChangeInFairValueOfNotesPayable" xlink:to="tgtx_ChangeInFairValueOfNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_ChangeInFairValueOfNotesPayable_3_lbl" xml:lang="en-US">ChangeInFairValueOfNotesPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:to="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm_3_lbl" xml:lang="en-US">PaymentsToAcquireHeldToMaturitySecuritiesShortTerm</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExercised" xlink:to="tgtx_WarrantOrRightExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightExercised_3_lbl" xml:lang="en-US">WarrantOrRightExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightExpired" xlink:to="tgtx_WarrantOrRightExpired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightExpired_3_lbl" xml:lang="en-US">WarrantOrRightExpired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">WarrantOrRightOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:to="tgtx_WarrantOrRightAggregateIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_WarrantOrRightAggregateIntrinsicValue_4_lbl" xml:lang="en-US">WarrantOrRightAggregateIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems" xlink:to="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems_2_lbl" xml:lang="en-US">FairValueMeasurementChangesInLevel3InstrumentsLineItems</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable" xlink:to="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_FairValueMeasurementChangesInLevel3InstrumentsTable_2_lbl" xml:lang="en-US">FairValueMeasurementChangesInLevel3InstrumentsTable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_IncentivePlanMember" xlink:to="tgtx_IncentivePlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_IncentivePlanMember_2_lbl" xml:lang="en-US">IncentivePlanMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_NonEmployeeRestrictedStockMember" xlink:to="tgtx_NonEmployeeRestrictedStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_NonEmployeeRestrictedStockMember_2_lbl" xml:lang="en-US">NonEmployeeRestrictedStockMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tgtx_PlacementAgencyAgreementDomain" xlink:to="tgtx_PlacementAgencyAgreementDomain_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tgtx_PlacementAgencyAgreementDomain_2_lbl" xml:lang="en-US">PlacementAgencyAgreementDomain</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tgtx-20160630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 160765 06302016 10Q2.xfr; Date: 2016%2D08%2D09T18:20:13Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:href="tgtx-20160630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:href="tgtx-20160630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="tgtx-20160630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:href="tgtx-20160630.xsd#InvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:href="tgtx-20160630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:href="tgtx-20160630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:href="tgtx-20160630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:href="tgtx-20160630.xsd#LicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:href="tgtx-20160630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:href="tgtx-20160630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:href="tgtx-20160630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="tgtx-20160630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:href="tgtx-20160630.xsd#CashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:href="tgtx-20160630.xsd#InvestmentSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:href="tgtx-20160630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="tgtx-20160630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:href="tgtx-20160630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:href="tgtx-20160630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:href="tgtx-20160630.xsd#LicenseAgreementsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:href="tgtx-20160630.xsd#RelatedPartyTransactionsDetailsTextual" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document And Entity Information">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_DocumentAndEntityInformationAbstract" xlink:label="loc_tgtxDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidResearchAndDevelopment" xlink:label="loc_tgtxPrepaidResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_tgtxPrepaidResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaapLongTermInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLongTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LeaseholdInterest" xlink:label="loc_tgtxLeaseholdInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_tgtxLeaseholdInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShares" xlink:label="loc_tgtxContingentlyIssuableShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_tgtxContingentlyIssuableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationResearchAndDevelopmentExpenses" xlink:label="loc_tgtxNonCashCompensationResearchAndDevelopmentExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_tgtxNonCashCompensationResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NonCashCompensationGeneralAndAdministrativeExpenses" xlink:label="loc_tgtxNonCashCompensationGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_tgtxNonCashCompensationGeneralAndAdministrativeExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNonCurrentNotePayable" xlink:label="loc_tgtxChangeInFairValueOfNonCurrentNotePayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_tgtxChangeInFairValueOfNonCurrentNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ContingentlyIssuableShareMember" xlink:label="loc_tgtxContingentlyIssuableShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_tgtxContingentlyIssuableShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationAxis" xlink:label="loc_tgtxCompensationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_tgtxCompensationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CompensationDomain" xlink:label="loc_tgtxCompensationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxCompensationAxis" xlink:to="loc_tgtxCompensationDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_tgtxStockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxStockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_tgtxStockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxStockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" xlink:label="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" xlink:label="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" xlink:label="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" xlink:label="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxIssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaapInvestmentIncomeAmortizationOfPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInvestmentIncomeAmortizationOfPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ChangeInFairValueOfNotesPayable" xlink:label="loc_tgtxChangeInFairValueOfNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_tgtxChangeInFairValueOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidRent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidRent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncreaseDecreaseInDeferredRent" xlink:label="loc_tgtxIncreaseDecreaseInDeferredRent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_tgtxIncreaseDecreaseInDeferredRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:label="loc_tgtxPaymentsToAcquireHeldToMaturitySecuritiesShortTerm" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_tgtxPaymentsToAcquireHeldToMaturitySecuritiesShortTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ProceedsFromMaturities" xlink:label="loc_tgtxProceedsFromMaturities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_tgtxProceedsFromMaturities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NetProceedsFromSharesNewIssuesOverallotments" xlink:label="loc_tgtxNetProceedsFromSharesNewIssuesOverallotments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_tgtxNetProceedsFromSharesNewIssuesOverallotments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionsAbstract" xlink:label="loc_us-gaapNonmonetaryTransactionsAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNonmonetaryTransactionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AccruedFinancingCosts" xlink:label="loc_tgtxAccruedFinancingCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonmonetaryTransactionsAbstract" xlink:to="loc_tgtxAccruedFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" xlink:label="loc_tgtxReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonmonetaryTransactionsAbstract" xlink:to="loc_tgtxReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConversionOfConvertibleNotesPayableToCommonStock" xlink:label="loc_tgtxConversionOfConvertibleNotesPayableToCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonmonetaryTransactionsAbstract" xlink:to="loc_tgtxConversionOfConvertibleNotesPayableToCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - CASH AND CASH EQUIVALENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecurities" xlink:title="00000009 - Disclosure - INVESTMENT SECURITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurements" xlink:title="00000010 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayable" xlink:title="00000012 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreements" xlink:title="00000013 - Disclosure - LICENSE AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementAbstract" xlink:label="loc_tgtxLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementDisclosureTextBlock" xlink:label="loc_tgtxLicenseAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementAbstract" xlink:to="loc_tgtxLicenseAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/SubsequentEvents" xlink:title="00000015 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_BusinessDescriptionPolicyTextBlock" xlink:label="loc_tgtxBusinessDescriptionPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxBusinessDescriptionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LiquidityDisclosure1PolicyTextBlock" xlink:label="loc_tgtxLiquidityDisclosure1PolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxLiquidityDisclosure1PolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" xlink:label="loc_tgtxImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables" xlink:title="00000018 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables" xlink:title="00000019 - Disclosure - INVESTMENT SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaapHeldToMaturitySecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapHeldToMaturitySecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables" xlink:title="00000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityTables" xlink:title="00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ScheduleOfWarrantsActivityTableTextBlock" xlink:label="loc_tgtxScheduleOfWarrantsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_tgtxScheduleOfWarrantsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock" xlink:label="loc_tgtxScheduleOfShareBasedCompensationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_tgtxScheduleOfShareBasedCompensationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesTable" xlink:label="loc_tgtxSignificantAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxSignificantAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SignificantAccountingPoliciesLineItems" xlink:label="loc_tgtxSignificantAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxSignificantAccountingPoliciesTable" xlink:to="loc_tgtxSignificantAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows" xlink:label="loc_tgtxPeriodAnticipatedSufficientToFundOperatingCashFlows" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxPeriodAnticipatedSufficientToFundOperatingCashFlows" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="loc_us-gaapRestrictedCashAndInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashAndInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidManufacturing" xlink:label="loc_tgtxPrepaidManufacturing" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_tgtxPrepaidManufacturing" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails" xlink:title="00000025 - Disclosure - CASH AND CASH EQUIVALENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails" xlink:title="00000026 - Disclosure - INVESTMENT SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:label="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:label="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:label="loc_us-gaapOtherLongTermInvestmentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapOtherLongTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesTable" xlink:to="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentAgenciesDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="loc_us-gaapUSGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaapHeldToMaturitySecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains" xlink:label="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingGains" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingGains" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses" xlink:label="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesUnrecognizedHoldingLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails" xlink:title="00000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaapFairValueByBalanceSheetGroupingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueByBalanceSheetGroupingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1" xlink:title="00000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" xlink:label="loc_tgtxFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_tgtxFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConversionOfNotes" xlink:label="loc_tgtxConversionOfNotes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_tgtxConversionOfNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails" xlink:title="00000029 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityTable" xlink:label="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansRestrictedStockActivityLineItems" xlink:label="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:to="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansRestrictedStockActivityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityTable" xlink:label="loc_tgtxEquityIncentivePlansWarrantActivityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_tgtxEquityIncentivePlansWarrantActivityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_EquityIncentivePlansWarrantActivityLineItems" xlink:label="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:to="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssued" xlink:label="loc_tgtxWarrantOrRightIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercised" xlink:label="loc_tgtxWarrantOrRightExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpired" xlink:label="loc_tgtxWarrantOrRightExpired" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightIssuedWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightIssuedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightExpiredWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightExpiredWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:label="loc_tgtxWarrantOrRightAggregateIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_WarrantOrRightAggregateIntrinsicValue" xlink:label="loc_tgtxWarrantOrRightAggregateIntrinsicValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxEquityIncentivePlansWarrantActivityLineItems" xlink:to="loc_tgtxWarrantOrRightAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_StockBasedCompensationTable" xlink:label="loc_tgtxStockBasedCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_tgtxStockBasedCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxStockBasedCompensationTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxStockBasedCompensationTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ATM2015Member" xlink:label="loc_tgtxATM2015Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tgtxATM2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IncentivePlan2012Member" xlink:label="loc_tgtxIncentivePlan2012Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_tgtxIncentivePlan2012Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:label="loc_tgtxSaleOfStockConsiderationReceivedOnTransactionGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxSaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_CommonStockAvailableForSale" xlink:label="loc_tgtxCommonStockAvailableForSale" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxCommonStockAvailableForSale" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetails" xlink:title="00000033 - Disclosure - NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableTable" xlink:label="loc_tgtxNotesPayableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_tgtxNotesPayableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableLineItems" xlink:label="loc_tgtxNotesPayableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableTable" xlink:to="loc_tgtxNotesPayableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ConvertibleNotesMember" xlink:label="loc_tgtxConvertibleNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_tgtxConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_NotesPayableDetailsNarrativeAbstract" xlink:label="loc_tgtxNotesPayableDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxNotesPayableDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AristonMember" xlink:label="loc_tgtxAristonMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_tgtxAristonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:label="loc_tgtxPercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_tgtxPercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual" xlink:title="00000035 - Disclosure - LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementAbstract" xlink:label="loc_tgtxLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementTable" xlink:label="loc_tgtxLicenseAgreementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementAbstract" xlink:to="loc_tgtxLicenseAgreementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LicenseAgreementLineItems" xlink:label="loc_tgtxLicenseAgreementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_tgtxLicenseAgreementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_JBETAgreementMember" xlink:label="loc_tgtxJBETAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxJBETAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_TgOneOneZeroOneMember" xlink:label="loc_tgtxTgOneOneZeroOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxTgOneOneZeroOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_UpfrontFeeReceivedFromSubLicense" xlink:label="loc_tgtxUpfrontFeeReceivedFromSubLicense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_tgtxUpfrontFeeReceivedFromSubLicense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:label="loc_tgtxAdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_tgtxAdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxLicenseAgreementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual" xlink:title="00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OpusMember" xlink:label="loc_tgtxOpusMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_tgtxOpusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodAxis" xlink:label="loc_tgtxIssuancePeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxIssuancePeriodAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_IssuancePeriodDomain" xlink:label="loc_tgtxIssuancePeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxIssuancePeriodAxis" xlink:to="loc_tgtxIssuancePeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementAxis" xlink:label="loc_tgtxPlacementAgencyAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxPlacementAgencyAgreementAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PlacementAgencyAgreementDomain" xlink:label="loc_tgtxPlacementAgencyAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementAxis" xlink:to="loc_tgtxPlacementAgencyAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbGroupMember" xlink:label="loc_tgtxLfbGroupMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxLfbGroupMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_DeskAgreementMember" xlink:label="loc_tgtxDeskAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxDeskAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OfficeAgreementMember" xlink:label="loc_tgtxOfficeAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxOfficeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_FortressMember" xlink:label="loc_tgtxFortressMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxFortressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_JBETAgreementMember" xlink:label="loc_tgtxJBETAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxPlacementAgencyAgreementDomain" xlink:to="loc_tgtxJBETAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesAxis" xlink:label="loc_tgtxResearchDevelopmentExpensesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxResearchDevelopmentExpensesAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_ResearchDevelopmentExpensesDomain" xlink:label="loc_tgtxResearchDevelopmentExpensesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxResearchDevelopmentExpensesAxis" xlink:to="loc_tgtxResearchDevelopmentExpensesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeAxis" xlink:label="loc_tgtxAgreementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_tgtxAgreementTypeAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AgreementTypeNameDomain" xlink:label="loc_tgtxAgreementTypeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxAgreementTypeAxis" xlink:to="loc_tgtxAgreementTypeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_LfbLicenseAgreementMember" xlink:label="loc_tgtxLfbLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxLfbLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_SharedServicesAgreementMember" xlink:label="loc_tgtxSharedServicesAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxSharedServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_GlobalCollaborationAgreementMember" xlink:label="loc_tgtxGlobalCollaborationAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_tgtxAgreementTypeNameDomain" xlink:to="loc_tgtxGlobalCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PrepaidResearchAndDevelopment" xlink:label="loc_tgtxPrepaidResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxPrepaidResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_AverageAnnualRentalPayments" xlink:label="loc_tgtxAverageAnnualRentalPayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxAverageAnnualRentalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_PercentageOfOccupancy" xlink:label="loc_tgtxPercentageOfOccupancy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxPercentageOfOccupancy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaapLesseeLeasingArrangementsOperatingLeasesTermOfContract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_OperatingLeaseInitialCommitmentPeriod" xlink:label="loc_tgtxOperatingLeaseInitialCommitmentPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxOperatingLeaseInitialCommitmentPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPrepaidRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="tgtx-20160630.xsd#tgtx_UpfrontFeeReceivedFromSubLicense" xlink:label="loc_tgtxUpfrontFeeReceivedFromSubLicense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_tgtxUpfrontFeeReceivedFromSubLicense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6738046048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Aug. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TG THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,456,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744003776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,577,832<span></span>
</td>
<td class="nump">$ 55,061,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment securities</a></td>
<td class="nump">25,680,319<span></span>
</td>
<td class="nump">22,166,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">133,766<span></span>
</td>
<td class="nump">186,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">14,510,025<span></span>
</td>
<td class="nump">9,151,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">649,738<span></span>
</td>
<td class="nump">308,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,551,680<span></span>
</td>
<td class="nump">86,873,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">581,161<span></span>
</td>
<td class="nump">579,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment securities</a></td>
<td class="nump">21,435,015<span></span>
</td>
<td class="nump">25,003,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LeaseholdInterest', window );">Leasehold interest</a></td>
<td class="nump">1,968,734<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">333,859<span></span>
</td>
<td class="nump">47,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">799,391<span></span>
</td>
<td class="nump">799,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">127,700<span></span>
</td>
<td class="nump">171,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,797,540<span></span>
</td>
<td class="nump">113,473,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">13,080,176<span></span>
</td>
<td class="nump">9,346,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">796,376<span></span>
</td>
<td class="nump">818,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">152,381<span></span>
</td>
<td class="nump">152,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">90,564<span></span>
</td>
<td class="nump">211,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,119,497<span></span>
</td>
<td class="nump">10,528,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">681,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,295,238<span></span>
</td>
<td class="nump">1,371,429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,096,455<span></span>
</td>
<td class="nump">11,899,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of June 30, 2016 and December 31, 2015)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share (150,000,000 shares authorized, 54,497,932 and 54,095,110 shares issued, 54,456,623 and 54,053,801 shares outstanding at June 30, 2016 and December 31, 2015, respectively)</a></td>
<td class="nump">54,498<span></span>
</td>
<td class="nump">54,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ContingentlyIssuableShares', window );">Contingently issuable shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">266,762,568<span></span>
</td>
<td class="nump">259,887,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 41,309 shares at June 30, 2016 and December 31, 2015</a></td>
<td class="num">(234,337)<span></span>
</td>
<td class="num">(234,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(187,881,650)<span></span>
</td>
<td class="num">(158,133,926)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">78,701,085<span></span>
</td>
<td class="nump">101,573,302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 94,797,540<span></span>
</td>
<td class="nump">$ 113,473,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares issuable for merger of companies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_LeaseholdInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_LeaseholdInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6738116368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,497,932<span></span>
</td>
<td class="nump">54,095,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,456,623<span></span>
</td>
<td class="nump">54,053,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">41,309<span></span>
</td>
<td class="nump">41,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742240976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue</a></td>
<td class="nump">$ 38,095<span></span>
</td>
<td class="nump">$ 38,095<span></span>
</td>
<td class="nump">$ 76,190<span></span>
</td>
<td class="nump">$ 76,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and development:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_NonCashCompensationResearchAndDevelopmentExpenses', window );">Noncash compensation</a></td>
<td class="nump">567,157<span></span>
</td>
<td class="nump">1,359,446<span></span>
</td>
<td class="nump">954,082<span></span>
</td>
<td class="nump">2,697,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">12,966,574<span></span>
</td>
<td class="nump">9,902,214<span></span>
</td>
<td class="nump">24,196,989<span></span>
</td>
<td class="nump">18,181,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">13,533,731<span></span>
</td>
<td class="nump">11,261,660<span></span>
</td>
<td class="nump">25,151,071<span></span>
</td>
<td class="nump">20,878,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_NonCashCompensationGeneralAndAdministrativeExpenses', window );">Noncash compensation</a></td>
<td class="nump">1,081,240<span></span>
</td>
<td class="nump">4,883,540<span></span>
</td>
<td class="nump">2,393,280<span></span>
</td>
<td class="nump">8,902,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative</a></td>
<td class="nump">1,446,567<span></span>
</td>
<td class="nump">1,004,475<span></span>
</td>
<td class="nump">2,547,438<span></span>
</td>
<td class="nump">2,008,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">2,527,807<span></span>
</td>
<td class="nump">5,888,015<span></span>
</td>
<td class="nump">4,940,718<span></span>
</td>
<td class="nump">10,911,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">16,061,538<span></span>
</td>
<td class="nump">17,149,675<span></span>
</td>
<td class="nump">30,091,789<span></span>
</td>
<td class="nump">31,790,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(16,023,443)<span></span>
</td>
<td class="num">(17,111,580)<span></span>
</td>
<td class="num">(30,015,599)<span></span>
</td>
<td class="num">(31,714,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(92,629)<span></span>
</td>
<td class="num">(31,551)<span></span>
</td>
<td class="num">(177,491)<span></span>
</td>
<td class="num">(53,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">220,756<span></span>
</td>
<td class="nump">246,526<span></span>
</td>
<td class="nump">463,161<span></span>
</td>
<td class="nump">484,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ChangeInFairValueOfNonCurrentNotePayable', window );">Change in fair value of notes payable</a></td>
<td class="num">(252,508)<span></span>
</td>
<td class="num">(223,372)<span></span>
</td>
<td class="num">(553,545)<span></span>
</td>
<td class="num">(464,013)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="num">(124,381)<span></span>
</td>
<td class="num">(8,397)<span></span>
</td>
<td class="num">(267,875)<span></span>
</td>
<td class="num">(33,513)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (15,899,062)<span></span>
</td>
<td class="num">$ (17,103,183)<span></span>
</td>
<td class="num">$ (29,747,724)<span></span>
</td>
<td class="num">$ (31,680,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares used in computing basic and diluted net loss per common share</a></td>
<td class="nump">48,769,948<span></span>
</td>
<td class="nump">45,320,637<span></span>
</td>
<td class="nump">48,838,731<span></span>
</td>
<td class="nump">43,216,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ChangeInFairValueOfNonCurrentNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the fair value of non current notes payable recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ChangeInFairValueOfNonCurrentNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_NonCashCompensationGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_NonCashCompensationGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_NonCashCompensationResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_NonCashCompensationResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6738500720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - 6 months ended Jun. 30, 2016 - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Contingently Issuable Share [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 54,095<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 259,887,464<span></span>
</td>
<td class="num">$ (234,337)<span></span>
</td>
<td class="num">$ (158,133,926)<span></span>
</td>
<td class="nump">$ 101,573,302<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">54,095,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common stock in connection with exercise of warrants</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock in connection with exercise of warrants (in shares)</a></td>
<td class="nump">22,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable', window );">Issuance of common stock in connection with conversion of notes payable</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares', window );">Issuance of common stock in connection with conversion of notes payable (in shares)</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock (in shares)</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeiture of restricted stock</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Forfeiture of restricted stock (in shares)</a></td>
<td class="num">(33,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts', window );">Issuance of common stock in At the Market offering (net of offering costs of $122,497)</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,446,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,447,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares', window );">Issuance of common stock in At the Market offering (net of offering costs of $122,497) (in shares)</a></td>
<td class="nump">396,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation in respect of restricted stock granted to employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,347,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,747,724)<span></span>
</td>
<td class="num">(29,747,724)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2016</a></td>
<td class="nump">$ 54,498<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 266,762,568<span></span>
</td>
<td class="num">$ (234,337)<span></span>
</td>
<td class="num">$ (187,881,650)<span></span>
</td>
<td class="nump">$ 78,701,085<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2016</a></td>
<td class="nump">54,497,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_IssuanceOfCommonStockInConnectionWithConversionOfNotesPayableInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of stock issued during the period due to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of stock issued during the period due to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tgtx_ContingentlyIssuableShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tgtx_ContingentlyIssuableShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6738489040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (29,747,724)<span></span>
</td>
<td class="num">$ (31,680,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Noncash stock compensation expense</a></td>
<td class="nump">3,347,362<span></span>
</td>
<td class="nump">11,600,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">23,319<span></span>
</td>
<td class="nump">5,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premium on investment securities</a></td>
<td class="nump">254,132<span></span>
</td>
<td class="nump">205,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ChangeInFairValueOfNotesPayable', window );">Change in fair value of notes payable</a></td>
<td class="num">(90,384)<span></span>
</td>
<td class="nump">20,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted cash</a></td>
<td class="num">(2,018)<span></span>
</td>
<td class="num">(2,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase in other current assets</a></td>
<td class="num">(5,700,293)<span></span>
</td>
<td class="num">(5,117,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">Increase in leasehold interest</a></td>
<td class="num">(1,968,734)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Decrease (increase) in accrued interest receivable</a></td>
<td class="nump">52,255<span></span>
</td>
<td class="num">(104,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="num">(9,518)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued expenses</a></td>
<td class="nump">3,712,012<span></span>
</td>
<td class="nump">4,018,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_IncreaseDecreaseInDeferredRent', window );">Increase in deferred rent</a></td>
<td class="nump">681,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenue</a></td>
<td class="num">(76,191)<span></span>
</td>
<td class="num">(76,191)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(29,524,062)<span></span>
</td>
<td class="num">(21,130,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(310,056)<span></span>
</td>
<td class="num">(20,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm', window );">Investment in held-to-maturity securities</a></td>
<td class="num">(15,199,922)<span></span>
</td>
<td class="num">(35,070,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ProceedsFromMaturities', window );">Proceeds from maturity of short-term securities</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">7,850,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(509,978)<span></span>
</td>
<td class="num">(27,240,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">50,271<span></span>
</td>
<td class="nump">992,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_NetProceedsFromSharesNewIssuesOverallotments', window );">Proceeds from sale of common stock, net</a></td>
<td class="nump">3,504,261<span></span>
</td>
<td class="nump">51,984,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing costs</a></td>
<td class="num">(3,989)<span></span>
</td>
<td class="num">(19,437)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,550,543<span></span>
</td>
<td class="nump">52,958,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(26,483,497)<span></span>
</td>
<td class="nump">4,586,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">55,061,329<span></span>
</td>
<td class="nump">55,713,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">28,577,832<span></span>
</td>
<td class="nump">60,300,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionsAbstract', window );"><strong>NONCASH TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AccruedFinancingCosts', window );">Accrued financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital', window );">Reclassification of deferred financing costs to&#160;additional paid-in capital</a></td>
<td class="num">(56,988)<span></span>
</td>
<td class="num">(48,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ConversionOfConvertibleNotesPayableToCommonStock', window );">Conversion of convertible notes payable to common stock</a></td>
<td class="nump">$ 30,601<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_AccruedFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_AccruedFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ChangeInFairValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in fair value of notes payable during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ChangeInFairValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ConversionOfConvertibleNotesPayableToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ConversionOfConvertibleNotesPayableToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for deferred rent due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_NetProceedsFromSharesNewIssuesOverallotments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the net proceeds from issuance of common stock over-allotments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_NetProceedsFromSharesNewIssuesOverallotments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow (inflow) through acquisition (sale) of short-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ProceedsFromMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturities of held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ProceedsFromMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ReclassificationOfDeferredFinancingCostsToadditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6593049280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Description of Business</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a biopharmaceutical company focused on
the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,
the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered
monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also
developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic
origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical
development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1
receptor-associated kinase 4) inhibitors, BET (Bromodomain and Extra Terminal) inhibitors, and anti-PD-L1 and anti-GITR antibodies.</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also actively evaluate complementary products,
technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received
approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our
drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The accompanying unaudited condensed consolidated
financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial
information and with the instructions to Quarterly Report on Form 10-Q and Article&#160;10 of Regulation&#160;S-X of the Exchange
Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements.
All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation
of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for
the year ended December 31, 2015. The accompanying condensed December 31, 2015 balance sheet has been derived from these statements.
The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may
be expected for the entire fiscal year or any other interim period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Liquidity and Capital Resources</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have incurred operating losses since our inception
and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of June 30, 2016,
we have an accumulated deficit of approximately $187.9 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our major sources of cash have been proceeds
from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates
and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become
profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for
our drug candidates; successfully completing any post-approval regulatory obligations; and successfully commercializing our drug
candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues
from our drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of June 30, 2016, we had approximately
$75.8 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash
equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately 18  to
24 months from June 30, 2016. The actual amount of cash that we will need to operate is subject to many factors, including,
but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon
significant future financing to provide the cash necessary to execute our current strategic plan, including the
commercialization of any of our drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is listed on the Nasdaq Capital
Market and trades under the symbol &#147;TGTX.&#148;<br clear="all" /></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Recently Issued Accounting Standards</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2016, the
Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU No. 2016-11, &#147;Rescission of SEC Guidance Because of
Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&#148;
(&#147;ASU 2016-11&#148;).&#160; ASU 2016-11 rescinds certain SEC guidance from the <i>FASB Accounting Standards
Codification</i> in response to announcements made by the SEC staff at the Emerging Issues Task Force&#146;s March 3, 2016
meeting.&#160; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics: </p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Upon the adoption of ASU 2014-09:</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for gas-balancing arrangements (ASC 932-10-S99-5).</font></td></tr></table>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Upon the adoption of ASU 2014-16</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Determining the nature of a host contract related to a hybrid financial instrument issued in the
form of a share under ASC 815 (ASC 815-10-S99-3).</font></td></tr></table>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ASU 2016-11 is effective upon the adoption of
ASU 2014-09 and ASU 2014-16.&#160; The adoption of ASU 2016-11 is not expected to have a material impact on the Company&#146;s
condensed consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In March 2016, the FASB issued ASU No. 2016-09, &#147;Simplifying the Accounting for Share-Based Payments&#148; (&#147;ASU
2016-09&#148;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both
public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after
December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected
to significantly impact the Company.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other pronouncements issued by the FASB or other
authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated
financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Use of Estimates</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The preparation of financial statements in conformity
with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material
to the consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We treat liquid investments with original maturities
of three months or less when purchased as cash and cash equivalents.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Restricted Cash</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We record cash pledged or held in trust as restricted
cash. As of June 30, 2016 and December 31, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line
of credit as a security deposit for an <font style="background-color: white">Office Agreement </font>(see Note 8).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Investment Securities</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Investment securities at June 30, 2016 and December
31, 2015 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity
securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities
are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are
amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest
method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A decline in the market value of any investment
security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The
impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges
would be included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Credit Risk</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term
investments. The Company maintains its cash and cash equivalents, short-term investments and long-term investments with high-credit
quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We recognize license revenue in accordance with
the revenue recognition guidance of the FASB Accounting Standards Codification (or &#147;Codification&#148;). We analyze each
element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include
payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties
on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements
unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings
process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement
of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the
milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement
of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone
payment and recognize it as revenue over the estimated period of performance under the contract.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Research and Development Costs</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Generally, research and development costs are
expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and
development activities are deferred and amortized over the period that the goods are delivered or the related services are performed,
subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations,
or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices
received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting
period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of
those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress
to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With
respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract.
Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment
of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the
recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals
related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified
in the specific clinical study or trial contract.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prepaid research and development in our consolidated
balance sheets includes, among other things, certain costs related to development and manufacturing services. These development
and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of June
30, 2016 and December 31, 2015, we recorded approximately $14.5 million and $9.2 million of prepaid development and manufacturing
services, respectively, in prepaid research and development related to such advance agreements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Income Taxes</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment
date. If the likelihood of realizing the deferred tax assets or liability is less than &#147;more likely than not,&#148; a valuation
allowance is then created.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We, and our subsidiaries, file income tax returns
in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination
for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss
carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
We recognize interest and penalties, if any, related to uncertain income tax positions in income tax expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We recognize all share-based payments to employees
and non-employee directors (as compensation for service) as noncash compensation expense in the condensed consolidated financial
statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value
of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at
the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For share-based payments to consultants and other
third-parties (including related parties), noncash compensation expense is determined at the &#147;measurement date.&#148; The
expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards
to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated
based on the then current fair value, at each subsequent reporting date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, because some of the options, restricted
stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total
expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the
achievement of such milestones becomes probable.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Basic and Diluted Net Loss Per Common Share</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Basic net loss per share of our common stock
is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding
for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially
dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either
because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money
and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the
calculation were 6,449,737 and 5,668,134 for the three and six months ended June 30, 2016 and 2015, respectively. The following
outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common
stockholders for the periods presented because including them would have been antidilutive:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Three and Six Months Ended June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 65%"><font style="font-size: 8pt">Unvested restricted stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 8pt">5,270,084</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">4,431,430</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,164,708</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,218,749</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon note conversion</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">14,945</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">17,803</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">152</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">6,449,737</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">5,668,134</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Long-Lived Assets and Goodwill</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Long-lived assets are reviewed for potential
impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may
not be recoverable. Management&#146;s policy in determining whether an impairment indicator exists, a triggering event, comprises
measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of
a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds
its estimated future cash flows, an impairment charge is recognized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Goodwill is reviewed for impairment annually,
or earlier when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process.
The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying
value of the reporting unit is greater than fair value, the unit&#146;s goodwill may be impaired, and the second step must be
completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting
unit&#146;s goodwill is compared with the carrying amount of the unit&#146;s goodwill. If the carrying amount is greater than
the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to
perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value
of an asset may not be recoverable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901185392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following tables summarize our cash and cash
equivalents at June 30, 2016 and December 31, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%"><font style="font-size: 8pt">Money market funds</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 8pt">8,514,029</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 8pt">8,265,583</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Checking and bank deposits</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,063,803</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">46,795,746</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">28,577,832</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">55,061,329</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6734523376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENT SECURITIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our investments as of June 30, 2016 and December
31, 2015 are classified as held-to-maturity. Held-to-maturity investments are recorded at amortized cost.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following tables summarize our investment
securities at June 30, 2016 and December 31, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Amortized cost, as adjusted</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding gains</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding losses</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Estimated fair value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Short-term investments:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%"><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between July 2016 and June 2017) (held-to-maturity)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">25,680,319</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,601</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">25,702,920</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;Long-term investments:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between July 2017 and January 2018) (held-to-maturity)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">21,435,015</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">80,328</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">21,515,343</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total short-term and long-term investment securities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,115,334</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">102,929</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,218,263</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Amortized cost, as adjusted</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding gains</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding losses</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Estimated fair value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Short-term investments:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%"><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,166,512</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,822</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,143,690</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;Long-term investments:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">25,003,032</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">85,846</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">24,917,186</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total short-term and long-term investment securities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,169,544</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">108,668</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,060,876</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901191824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We measure certain financial assets and liabilities
at fair value on a recurring basis in the condensed consolidated financial statements. The fair value hierarchy ranks the quality
and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities
carried at fair value to be classified and disclosed in one of the following three categories:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 1 &#150; quoted prices in active markets for identical assets and liabilities;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 2 &#150; inputs other than Level 1 quoted prices that are directly or indirectly observable; and</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 72px; padding: 0.75pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 3 &#150; unobservable inputs that are not corroborated by market data.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of June 30, 2016 and December 31, 2015, the
fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying
value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="background-color: white">At the
time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (&#147;Manhattan&#148;)) with Ariston Pharmaceuticals,
Inc. (&#147;Ariston&#148;) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the &#147;5% Notes&#148;)
in satisfaction of several note payable issuances.&#160;&#160;The 5% Notes and accrued and unpaid interest thereon are convertible
at the option of the holder into common stock at the conversion price of $1,125 per share.&#160;&#160;Ariston agreed to make quarterly
payments on the 5% Notes&#160;equal to 50% of the net product cash flow received from the exploitation or commercialization of
Ariston&#146;s product candidates, AST-726 and AST-915.&#160;&#160;We have no obligations under the 5% Notes aside from (a) 50%
of the net product cash flows from Ariston&#146;s product candidates, if any, payable to noteholders; and (b) the conversion feature,
discussed above.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="background-color: white">The cumulative
liability including accrued and unpaid interest of the 5% Notes was approximately $16.8 million at June 30, 2016 and $19.9 million
at December 31, 2015. </font>No payments have been made on the 5% Notes as of June 30, 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2011, we elected the fair value option
for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that
market participants use in evaluating these financial instruments.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of December 31, 2013, as a result of expiring
intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we
have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature
was used to estimate the 5% Notes&#146; fair value as of June 30, 2016 and December 31, 2015. The assumptions, assessments and
projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of
different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could
result in significantly different estimates of fair value and the differences could be material to our condensed consolidated financial
statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following tables provide the fair value measurements
of applicable financial liabilities as of June 30, 2016 and December 31, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Financial liabilities at fair value as of June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 1</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 2</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 3</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">5% Notes</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Financial liabilities at fair value as of December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 1</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 2</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 3</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">5% Notes</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Level 3 amounts above represent the fair
value of the 5% Notes and related accrued interest.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table summarizes the changes in
Level 3 instruments during the six months ended June 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 88%"><font style="font-size: 8pt">Fair value at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Interest accrued on face value of 5% Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">463,161</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Conversion of 5% notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(30,601</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in fair value of Level 3 liabilities</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(553,545</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fair value at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The change in the fair value of the Level 3 liabilities
is reported in other (income) expense in the accompanying condensed consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6734480000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Preferred Stock</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our amended and restated certificate of incorporation
authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common
stock, <font style="background-color: white">issuable in one or more series. Upon issuance, we can determine the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights,
voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series
or the designation of such series, any or all of which may be greater than the rights of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Common Stock</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our amended and restated certificate of incorporation
authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="background-color: white">In December
2014, we filed a shelf registration statement on Form S-3 (the &#147;2015 S-3&#148;), which was declared effective in January
2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3,
we amended our 2013 At-the-Market Issuance Sales Agreement with MLV &#38; Co. LLC (the &#147;2015 ATM&#148;) such that we may
issue and sell additional shares of our common stock, having an aggregate offering price of up to $175.0 million, from time to
time through MLV &#38; Co. LLC (&#147;MLV&#148;) and FBR Capital Markets &#38; Co. (&#147;FBR&#148;, each of MLV and FBR individually
an &#147;Agent&#148; and collectively the &#147;Agents&#148;), acting as the sales agents. Under the 2015 ATM we pay the Agents
a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the Agents.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="background-color: white">During
the six months ended June 30, 2016, we sold a total of 396,811 shares of common stock under the 2015 ATM for aggregate total gross
proceeds of approximately $3.6 million at an average selling price of $9.00 per share, resulting in net proceeds of approximately
$3.5 million after deducting commissions and other transaction costs.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">The
2015 S-3 is currently our only active shelf registration statement. After deducting shares already sold, including under the 2015
ATM, there are approximately $178 million of common stock that remain available for sale under the 2015 S-3. We may offer the
securities under the 2015 S-3 from time to time in response to market conditions or other circumstances if we believe such a plan
of financing is in the best interests of our stockholders. We believe that the 2015 S-3 provides us with the flexibility to raise
additional capital to finance our operations as needed.&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Equity Incentive Plans</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The TG Therapeutics, Inc. Amended and Restated
2012 Incentive Plan (&#147;2012 Incentive Plan&#148;) was approved by stockholders in June 2015. As of June 30, 2016, no options
were outstanding and up to an additional 4,183,861 shares may be issued under the 2012 Incentive Plan.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><u>Restricted Stock</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Certain employees, directors and consultants
have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table
summarizes restricted share activity for the six months ended June 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Shares</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Grant Date Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">7,359,915</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">7.83</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">14,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(570,600</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7.07</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(33,231</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">11.79</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">6,770,084</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7.85</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Total expense associated with restricted stock
grants was approximately $1.6 million and $6.2 million during the three months ended June 30, 2016 and 2015, respectively, and
$3.3 million,  and $11.6 million during the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, there
was approximately $17.3 million of total unrecognized compensation cost related to unvested time-based restricted stock, which
is expected to be recognized over a weighted-average period of 1.9 years. This amount does not include, as of June 30, 2016, 411,172
shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,234,958 shares
of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the measurement
date. The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount
of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting
date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><u>Warrants</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table summarizes warrant activity
for the six months ended June 30, 2016:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted-average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercise price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Aggregate Intrinsic Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 55%; background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at December 31, 2015</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">1,186,749</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">2.37</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">11,341,452</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">--</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">--</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(22,041</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Expired</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">1,164,708</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2.37</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,291,924</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">We
did not grant any stock options during the six months ended June 30, 2016 and 2015.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: normal 8pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)">The
following table summarizes stock-based compensation expense information about restricted stock and stock options for the three
and six months ended June 30, 2016 and 2015:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="7" style="font-size: 8pt; text-align: center"><font style="font-size: 8pt">&#160;<b>Three months ended June 30,</b> </font></td><td style="font-size: 8pt">&#160;</td>
    <td colspan="7" style="font-size: 8pt; text-align: center"><font style="font-size: 8pt">&#160;<b>Six months ended June 30,</b> </font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 8pt; text-align: left">Stock-based compensation expense associated with restricted stock</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1,648,397</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">6,242,986</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">3,347,362</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,600,014</font></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">Stock-based compensation expense associated with option grants</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">1,648,397</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">6,242,986</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">3,347,362</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,600,014</font></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6734456752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The following is a summary of notes payable:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="11" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;<b>June 30, 2016</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="11" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;<b>December</b> <b>31</b>, <b>201</b>5</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Current portion,&#160;net</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Non-current portion, net</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Current portion,&#160;net</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Non-current portion, net</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 34%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Convertible 5% Notes Payable</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">90,564</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#151;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">90,564</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">211,549</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#151;&#160;&#160;</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">211,549</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;Total</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">90,564</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#151;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">90,564</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">211,549</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">&#151;&#160;&#160;</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">211,549</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Convertible 5% Notes Payable</i></b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 8, 2010, Manhattan entered into
an Agreement and Plan of Merger (the &#34;Merger Agreement&#34;) by and among Manhattan, Ariston and Ariston Merger Corp., a
Delaware corporation and wholly-owned subsidiary of Manhattan (the &#34;Merger Sub&#34;).&#160; Pursuant to the terms and conditions
of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the &#34;Merger&#34;), with Ariston being
the surviving corporation of the Merger.&#160; As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The 5% Notes and accrued and unpaid interest
thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share.&#160;&#160;Ariston
agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization
of Ariston&#146;s product candidates, AST-726 and AST-915.&#160;&#160;<font style="background-color: white">We have no obligation
under the 5% Notes aside from a) 50% of the net product cash flows from Ariston&#146;s product candidates, if any, payable to
noteholders; and b) the conversion feature, discussed above.</font> Interest accrues monthly, is added to principal on an annual
basis, every March 8, and is payable at maturity, which was March 8, 2015.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="background-color: white">The
cumulative liability including accrued and unpaid interest of these notes was approximately $16.8 million at June 30, 2016 and
$19.9 million at December 31, 2015. </font>No payments have been made on the 5% Notes as of June 30, 2016.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2011, we elected the fair
value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions
that market participants use in evaluating these financial instruments (See Note 4 for further details).</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6734523376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LicenseAgreementDisclosureTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>BET</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In May 2016, as part of a broader agreement with
Jubilant Biosys (&#147;Jubilant&#148;), an India-based biotechnology company, we entered into a sub-license agreement (&#147;JBET
Agreement&#148;) with Checkpoint Therapeutics, Inc. (&#147;Checkpoint&#148;), (see Note 8), for the
development and commercialization of Jubilant&#146;s novel BET inhibitor program in the field of hematological malignancies.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Under the terms of the agreement,&#160;we
paid Checkpoint an up-front licensing fee of&#160;$1.0 million&#160;and will make additional payments contingent on certain
preclinical, clinical, and regulatory milestones, including commercial milestones totaling up to approximately&#160;$177
million&#160;and a single-digit royalty on net sales.&#160;TG will also provide funding to support certain targeted
research efforts at Jubilant.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>TG-1101</i></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In November 2012, we entered into an exclusive
(within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea
and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including
the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand,
Philippines, Vietnam, and Myanmar.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">An upfront payment of $2.0 million, which was
received in December 2012,<font style="background-color: white"> net of $0.3 million of&#160;income tax withholdings</font>, is
being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of
the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is
earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense
agreement. We recorded license revenue of approximately $38,000 for each of the three months ended June 30, 2016 and 2015, and
$76,000 for each of the six months ended June 30, 2016 and 2015 and, at June 30, 2016 and December 31, 2015, have deferred revenue
of approximately $1.4 million and $1.5 million, respectively, associated with this $2.0 million payment (approximately $0.2 million
of which has been classified in current liabilities at June 30, 2016 and December 31, 2015).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may receive up to an
additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong
will make royalty payments to us on net sales of TG-1101 in the sublicense territory.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6604333456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b><i>LFB
Biotechnologies</i></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">On
January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC,
all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the &#147;LFB License Agreement&#148;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">Under
the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred expenses
of $2.3 million and $2.2 million during the three months ended June 30, 2016 and 2015, respectively, and $2.3 million and $2.4
million during the six months ended June 30, 2016 and 2015, respectively, which have been included in other research and development
expenses in the accompanying condensed consolidated statements of operations. As of June 30, 2016 and December 31, 2015, we had
approximately $1.7 million and $2.1 million, respectively, recorded in accounts payable related to the LFB License Agreement.
In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require
payments in advance of services performed or goods delivered. Accordingly, as of June 30, 2016 and December 31, 2015, we recorded
approximately $4.7 million and $3.0 million, respectively, in prepaid research and development for such advance payments.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b><i>Other
Parties</i></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">In
March 2014, we entered into a shared services agreement (the &#147;Opus Shared Services Agreement&#148;) with Opus Point Partners
Management, LLC (&#147;Opus&#148;) in which the parties agreed to share the costs of a rented facility and certain other services.&#160;
Our Executive Chairman and Interim Chief Executive Officer is a Managing Member of Opus. During the three and six months ended
June 30, 2016, we incurred expenses of approximately $0.02 million and $0.1 million, respectively, principally for rent, related
to this agreement. The Opus Shared Services Agreement is no longer in effect as we began occupying new space in April 2016. As
of June 30, 2016, we had approximately $0.1 million recorded in accounts payable related to this Opus Shared Services Agreement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">In
October 2014, we entered into an agreement (the &#147;Office Agreement&#148;) with Fortress Biotech, Inc. (&#147;Fortress&#148;),
to occupy approximately 45% of the 24,000 square feet of New York City office space leased by Fortress, which is now our corporate
headquarters. The Office Agreement requires us to pay our respective share of the average annual rent and other costs of the 15-year
lease. We approximate an average annual rental obligation of $1.1 million under the Office Agreement. We began to occupy this
new space in April 2016, with rental payments beginning in the third quarter of 2016. Mr. Weiss, our Executive Chairman and Interim
CEO, is also Executive Vice Chairman of Fortress.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">In
connection with the Office Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other
current assets in the accompanying condensed consolidated balance sheets as of June 30, 2016 and December 31, 2015. </font><font style="font: 8pt Times New Roman, Times, Serif">During
the six months ended June 30, 2016, <font style="background-color: white">we agreed to pay Fortress $2.0 for our portion
of the build out costs</font>, which have been allocated to us at the 45% rate mentioned above. The allocated build-out costs have
been recorded in Leasehold Interest and will be amortized over the 15-year term of the Office Agreement. After an
initial commitment period of three (3) years, Fortress will assess actual office space utilization annually and if our
utilization differs from the amount we have been billed, we will either receive credits or be assessed incremental
utilization charges.&#160; <font style="background-color: white">As of June 30, 2016, we had approximately $1.1 </font>million
recorded in accounts payable related mostly to the upfront leasehold interest. <font style="background-color: white">Also
in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for
the Office Agreement, which has been recorded as restricted cash in the accompanying condensed consolidated
balance sheets.</font></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">In
July 2015, we entered into a Shared Services Agreement (the &#147;Shared Services Agreement&#148;) with Fortress to share the
cost of certain services such as facilities use, personnel costs and other overhead and administrative costs. This Shared Services
Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we </font><font style="font: 8pt Times New Roman, Times, Serif">incurred
expenses of <font style="background-color: white">approximately $0.4 million for shared services for the six months ended June
30, 2016, primarily related to shared personnel.</font></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white"></font>In
May 2016, as part of a broader agreement with Jubilant, an India-based biotechnology company, we entered into the JBET Agreement
with Checkpoint, a subsidiary of Fortress, for the development and commercialization of Jubilant&#146;s novel BET inhibitor program
in the field of hematological malignancies. We paid Checkpoint an up-front licensing fee of $1.0 million as part of the JBET Agreement.
As of June 30, 2016, we had approximately $1.2 million recorded in accounts payable of which $1.0 million related to the licensing
fee. Mr. Weiss is also the Executive Chairman of Checkpoint.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6898518256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_BusinessDescriptionPolicyTextBlock', window );">Business Description</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a biopharmaceutical company focused on
the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,
the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered
monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also
developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic
origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical
development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1
receptor-associated kinase 4) inhibitors, BET (Bromodomain and Extra Terminal) inhibitors, and anti-PD-L1 and anti-GITR antibodies.</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We also actively evaluate complementary products,
technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received
approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our
drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The accompanying unaudited condensed consolidated
financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial
information and with the instructions to Quarterly Report on Form 10-Q and Article&#160;10 of Regulation&#160;S-X of the Exchange
Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements.
All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation
of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for
the year ended December 31, 2015. The accompanying condensed December 31, 2015 balance sheet has been derived from these statements.
The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may
be expected for the entire fiscal year or any other interim period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LiquidityDisclosure1PolicyTextBlock', window );">Liquidity Disclosure</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have incurred operating losses since our inception
and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of June 30, 2016,
we have an accumulated deficit of approximately $187.9 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our major sources of cash have been proceeds
from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates
and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become
profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for
our drug candidates; successfully completing any post-approval regulatory obligations; and successfully commercializing our drug
candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues
from our drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of June 30, 2016, we had approximately
$75.8 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash
equivalents and investments will be sufficient to fund our anticipated operating cash requirements for approximately 18 to
24 months from June 30, 2016. The actual amount of cash that we will need to operate is subject to many factors, including,
but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon
significant future financing to provide the cash necessary to execute our current strategic plan, including the
commercialization of any of our drug candidates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock is listed on the Nasdaq Capital
Market and trades under the symbol &#147;TGTX.&#148;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2016, the
Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU No. 2016-11, &#147;Rescission of SEC Guidance Because of
Accounting Standards Update 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting&#148;
(&#147;ASU 2016-11&#148;).&#160; ASU 2016-11 rescinds certain SEC guidance from the <i>FASB Accounting Standards
Codification</i> in response to announcements made by the SEC staff at the Emerging Issues Task Force&#146;s March 3, 2016
meeting.&#160; Specifically, ASU 2016-11 supersedes SEC observer comments on the following topics:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Upon the adoption of ASU 2014-09:</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Revenue and expense recognition for freight services in process (ASC 605-20-S99-2)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for shipping and handling fees and costs (ASC 605-45-S99-1)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for consideration given by a vendor to a customer (ASC 605-50-S99-1)</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Accounting for gas-balancing arrangements (ASC 932-10-S99-5).</font></td></tr></table>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Upon the adoption of ASU 2014-16</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in"><font style="font: 8pt Symbol">&#183;</font></td><td><font style="font-size: 8pt">Determining the nature of a host contract related to a hybrid financial instrument issued in the
form of a share under ASC 815 (ASC 815-10-S99-3).</font></td></tr></table>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">ASU 2016-11 is effective upon the adoption of
ASU 2014-09 and ASU 2014-16.&#160; The adoption of ASU 2016-11 is not expected to have a material impact on the Company&#146;s
condensed consolidated financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In March 2016, the FASB issued ASU No. 2016-09, &#147;Simplifying the Accounting for Share-Based Payments&#148; (&#147;ASU
2016-09&#148;). ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment transactions for both
public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements,
as well as classification in the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after
December 15, 2016, including interim periods within those annual reporting periods. The provisions of this standard are not expected
to significantly impact the Company.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Other pronouncements issued by the FASB or other
authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated
financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The preparation of financial statements in conformity
with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material
to the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We treat liquid investments with original maturities
of three months or less when purchased as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We record cash pledged or held in trust as restricted
cash. As of June 30, 2016 and December 31, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line
of credit as a security deposit for an <font style="background-color: white">Office Agreement </font>(see Note 8).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investment Securities</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Investment securities at June 30, 2016 and December
31, 2015 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity
securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities
are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are
amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest
method.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A decline in the market value of any investment
security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The
impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges
would be included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and long-term
investments. The Company maintains its cash and cash equivalents, short-term investments and long-term investments with high-credit
quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We recognize license revenue in accordance with
the revenue recognition guidance of the FASB Accounting Standards Codification (or &#147;Codification&#148;). We analyze each
element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include
payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties
on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements
unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings
process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement
of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the
milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement
of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone
payment and recognize it as revenue over the estimated period of performance under the contract.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Generally, research and development costs are
expensed as incurred. Non-refundable advance payments for goods or services that will be used or rendered for future research and
development activities are deferred and amortized over the period that the goods are delivered or the related services are performed,
subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations,
or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices
received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting
period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of
those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress
to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With
respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract.
Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment
of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the
recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals
related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified
in the specific clinical study or trial contract.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prepaid research and development in our consolidated
balance sheets includes, among other things, certain costs related to development and manufacturing services. These development
and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of June
30, 2016 and December 31, 2015, we recorded approximately $14.5 million and $9.2 million of prepaid development and manufacturing
services, respectively, in prepaid research and development related to such advance agreements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Income taxes are accounted for under the asset
and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases,
operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment
date. If the likelihood of realizing the deferred tax assets or liability is less than &#147;more likely than not,&#148; a valuation
allowance is then created.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We, and our subsidiaries, file income tax returns
in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination
for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss
carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
We recognize interest and penalties, if any, related to uncertain income tax positions in income tax expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We recognize all share-based payments to employees
and non-employee directors (as compensation for service) as noncash compensation expense in the condensed consolidated financial
statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value
of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at
the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For share-based payments to consultants and other
third-parties (including related parties), noncash compensation expense is determined at the &#147;measurement date.&#148; The
expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards
to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated
based on the then current fair value, at each subsequent reporting date.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, because some of the options, restricted
stock and warrants issued to employees, consultants and other third-parties vest upon achievement of certain milestones, the total
expense is uncertain. Compensation expense for such awards that vest upon the achievement of milestones is recognized when the
achievement of such milestones becomes probable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Basic net loss per share of our common stock
is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding
for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially
dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either
because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money
and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the
calculation were 6,449,737 and 5,668,134 for the three and six months ended June 30, 2016 and 2015, respectively. The following
outstanding shares of common stock equivalents were excluded from the computation of net loss per share attributable to common
stockholders for the periods presented because including them would have been antidilutive:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Three and Six Months Ended June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 65%"><font style="font-size: 8pt">Unvested restricted stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 8pt">5,270,084</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">4,431,430</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,164,708</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,218,749</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon note conversion</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">14,945</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">17,803</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">152</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">6,449,737</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">5,668,134</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock', window );">Impairment Of Tangible and Intangible Asset Including Goodwill</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Long-lived assets are reviewed for potential
impairment when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may
not be recoverable. Management&#146;s policy in determining whether an impairment indicator exists, a triggering event, comprises
measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of
a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds
its estimated future cash flows, an impairment charge is recognized.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Goodwill is reviewed for impairment annually,
or earlier when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process.
The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying
value of the reporting unit is greater than fair value, the unit&#146;s goodwill may be impaired, and the second step must be
completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting
unit&#146;s goodwill is compared with the carrying amount of the unit&#146;s goodwill. If the carrying amount is greater than
the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to
perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value
of an asset may not be recoverable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_BusinessDescriptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the description of business of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_BusinessDescriptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure related to policy for impairment of tangible and intangible asset including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_LiquidityDisclosure1PolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_LiquidityDisclosure1PolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Readily Determinable Fair Value<br> -URI http://asc.fasb.org/extlink&amp;oid=65888395<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62652-112803<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901414736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Three and Six Months Ended June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 65%"><font style="font-size: 8pt">Unvested restricted stock</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font-size: 8pt">5,270,084</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">4,431,430</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,164,708</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,218,749</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Shares issuable upon note conversion</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">14,945</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">17,803</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">152</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">6,449,737</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">5,668,134</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6600418992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%"><font style="font-size: 8pt">Money market funds</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 8pt">8,514,029</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 8pt">8,265,583</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Checking and bank deposits</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,063,803</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">46,795,746</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">28,577,832</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">55,061,329</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6734578320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Held-to-maturity Securities</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following tables summarize our investment
securities at June 30, 2016 and December 31, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Amortized cost, as adjusted</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding gains</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding losses</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Estimated fair value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Short-term investments:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%"><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between July 2016 and June 2017) (held-to-maturity)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">25,680,319</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,601</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">25,702,920</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;Long-term investments:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between July 2017 and January 2018) (held-to-maturity)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">21,435,015</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">80,328</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">21,515,343</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total short-term and long-term investment securities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,115,334</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">102,929</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,218,263</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Amortized cost, as adjusted</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding gains</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Gross unrealized holding losses</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Estimated fair value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Short-term investments:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 44%"><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between January 2016 and December 2016) (held-to-maturity)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,166,512</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,822</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">22,143,690</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">&#160;Long-term investments:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Obligations of domestic governmental agencies (maturing between January 2017 and December 2017) (held-to-maturity)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">25,003,032</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">85,846</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">24,917,186</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total short-term and long-term investment securities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,169,544</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">108,668</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">47,060,876</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27405-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6435544&amp;loc=d3e41834-113960<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5086-111524<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901176000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following tables provide the fair value measurements
of applicable financial liabilities as of June 30, 2016 and December 31, 2015:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Financial liabilities at fair value as of June 30, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 1</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 2</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 3</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">5% Notes</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Financial liabilities at fair value as of December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 1</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 2</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Level 3</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 52%"><font style="font-size: 8pt">5% Notes</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 0%; border-bottom: black 1pt solid"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Change In Level Three Fair Value During Period</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 88%"><font style="font-size: 8pt">Fair value at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">211,549</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Interest accrued on face value of 5% Notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">463,161</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Conversion of 5% notes</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(30,601</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Change in fair value of Level 3 liabilities</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(553,545</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Fair value at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">90,564</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6625469856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Shares</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Weighted Average Grant Date Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 76%; background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at December 31, 2015</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">7,359,915</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 8pt">7.83</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">14,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9.43</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(570,600</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7.07</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(33,231</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">11.79</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">6,770,084</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">7.85</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ScheduleOfWarrantsActivityTableTextBlock', window );">Schedule Of Warrants Activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted-average</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercise price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Aggregate Intrinsic Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 55%; background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at December 31, 2015</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">1,186,749</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">2.37</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 12%; text-align: right"><font style="font-size: 8pt">11,341,452</font></td>
    <td style="width: 1%; padding-bottom: 3pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">--</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">--</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(22,041</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Expired</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">--</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="background-color: #CCEEFF"><font style="font-size: 8pt">Outstanding at June 30, 2016</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double">&#160;</td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">1,164,708</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">2.37</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1.5pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1.5pt double; text-align: right"><font style="font-size: 8pt">4,291,924</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock', window );">Schedule Of Share Based Compensation Expense</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 8pt">&#160;</td>
    <td colspan="7" style="font-size: 8pt; text-align: center"><font style="font-size: 8pt">&#160;<b>Three months ended June 30,</b> </font></td><td style="font-size: 8pt">&#160;</td>
    <td colspan="7" style="font-size: 8pt; text-align: center"><font style="font-size: 8pt">&#160;<b>Six months ended June 30,</b> </font></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><font style="font: 8pt Times New Roman, Times, Serif"><b>2015</b></font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 8pt; text-align: left">Stock-based compensation expense associated with restricted stock</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1,648,397</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">6,242,986</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%; font-size: 8pt">&#160;</td>
    <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">3,347,362</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td><td style="width: 10%; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,600,014</font></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">Stock-based compensation expense associated with option grants</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">1,648,397</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">6,242,986</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">3,347,362</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,600,014</font></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Share based compensation expense during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ScheduleOfWarrantsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for warrants activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ScheduleOfWarrantsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6584995904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;&#160;<b>June 30, 2016</b></font></td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;<b>December</b> <b>31</b>, <b>201</b>5</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Current portion,&#160;net</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Non-current portion, net</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Total</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Current portion,&#160;net</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Non-current portion, net</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center; vertical-align: bottom"><font style="font-size: 8pt"><b>Total</b></font></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 28%; font-size: 8pt; text-align: left; padding-bottom: 1pt">Convertible 5% Notes Payable</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">90,564</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">90,564</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">211,549</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 8pt; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">$</td><td style="width: 8%; border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">211,549</td><td style="width: 1%; padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;&#160;Total</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">90,564</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">90,564</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">211,549</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">211,549</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6732926960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</a></td>
<td class="nump">6,449,737<span></span>
</td>
<td class="nump">5,668,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</a></td>
<td class="nump">5,270,084<span></span>
</td>
<td class="nump">4,431,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</a></td>
<td class="nump">1,164,708<span></span>
</td>
<td class="nump">1,218,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Share Issuable Upon Note Conversion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</a></td>
<td class="nump">14,945<span></span>
</td>
<td class="nump">17,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733109168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (187,881,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (158,133,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,449,737<span></span>
</td>
<td class="nump">5,668,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows', window );">Period Anticipated Sufficient To Fund Operating Cash Flow</a></td>
<td class="text">18 to 24 months<span></span>
</td>
<td class="text">18 to 24 months<span></span>
</td>
<td class="text">18 to 24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments, Total</a></td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted Cash and Investments</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PrepaidManufacturing', window );">Prepaid Manufacturing</a></td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid manufacturing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6903190512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 8,514,029<span></span>
</td>
<td class="nump">$ 8,265,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Checking and bank deposits</a></td>
<td class="nump">20,063,803<span></span>
</td>
<td class="nump">46,795,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total</a></td>
<td class="nump">$ 28,577,832<span></span>
</td>
<td class="nump">$ 55,061,329<span></span>
</td>
<td class="nump">$ 60,300,086<span></span>
</td>
<td class="nump">$ 55,713,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733274112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized cost, as adjusted</a></td>
<td class="nump">$ 47,115,334<span></span>
</td>
<td class="nump">$ 47,169,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains', window );">Gross unrealized holding gains</a></td>
<td class="nump">102,929<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">47,218,263<span></span>
</td>
<td class="nump">47,060,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized cost, as adjusted</a></td>
<td class="nump">25,680,319<span></span>
</td>
<td class="nump">22,166,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains', window );">Gross unrealized holding gains</a></td>
<td class="nump">22,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">25,702,920<span></span>
</td>
<td class="nump">22,143,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other Long-term Investments [Member] | US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized cost, as adjusted</a></td>
<td class="nump">21,435,105<span></span>
</td>
<td class="nump">25,003,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains', window );">Gross unrealized holding gains</a></td>
<td class="nump">80,328<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 21,515,343<span></span>
</td>
<td class="nump">$ 24,917,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in debt securities classified as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized gain before loss on investments in held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized loss before gain on investments in held-to-maturity securities. Excludes write-down for other than temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901285952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">5% Notes</a></td>
<td class="nump">$ 90,564<span></span>
</td>
<td class="nump">$ 211,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Totals</a></td>
<td class="nump">90,564<span></span>
</td>
<td class="nump">211,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">5% Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Totals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">5% Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Totals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">5% Notes</a></td>
<td class="nump">90,564<span></span>
</td>
<td class="nump">211,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Totals</a></td>
<td class="nump">$ 90,564<span></span>
</td>
<td class="nump">$ 211,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733042096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at December 31, 2015</a></td>
<td class="nump">$ 211,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings', window );">Interest accrued on face value of 5% Notes</a></td>
<td class="nump">463,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_ConversionOfNotes', window );">Conversion of 5% notes</a></td>
<td class="num">(30,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of Level 3 liabilities</a></td>
<td class="num">(553,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at March 31, 2016</a></td>
<td class="nump">$ 90,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_ConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_ConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733407808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Unvested Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_EquityIncentivePlansRestrictedStockActivityLineItems', window );"><strong>Equity Incentive Plans Restricted Stock Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding at Beginning Balance | shares</a></td>
<td class="nump">7,359,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(570,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(33,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding at Ending Balance | shares</a></td>
<td class="nump">6,770,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at Beginning Balance | $ / shares</a></td>
<td class="nump">$ 7.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">9.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">11.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding at Ending Balance | $ / shares</a></td>
<td class="nump">$ 7.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_EquityIncentivePlansRestrictedStockActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_EquityIncentivePlansRestrictedStockActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733406512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_EquityIncentivePlansWarrantActivityLineItems', window );"><strong>Equity Incentive Plans Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Outstanding at Beginning Balance | shares</a></td>
<td class="nump">1,186,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightIssued', window );">Warrants, Issued | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightExercised', window );">Warrants, Exercised | shares</a></td>
<td class="num">(22,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightExpired', window );">Warrants, Expired | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Outstanding at Ending Balance | shares</a></td>
<td class="nump">1,164,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Weighted - average exercise price, Outstanding at Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice', window );">Weighted - average exercise price, Issued (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice', window );">Weighted - average exercise price, Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice', window );">Weighted - average exercise price, Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Weighted - average exercise price, Outstanding at Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at Beginning Balance (in dollars) | $</a></td>
<td class="nump">$ 11,341,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_WarrantOrRightAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at Ending Balance (in dollars) | $</a></td>
<td class="nump">$ 4,291,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_EquityIncentivePlansWarrantActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_EquityIncentivePlansWarrantActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the aggregate intrinsic value of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the weighted average exercise price of warrants Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the number of warrants expired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the weighted average exercise price of warrants Expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the weighted average exercise price of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the weighted average exercise price of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6626248672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - Unvested Restricted Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock-based compensation expense associated with restricted stock</a></td>
<td class="nump">$ 1,648,397<span></span>
</td>
<td class="nump">$ 6,242,986<span></span>
</td>
<td class="nump">$ 3,347,362<span></span>
</td>
<td class="nump">$ 11,600,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock-based compensation expense associated with option grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,648,397<span></span>
</td>
<td class="nump">$ 6,242,986<span></span>
</td>
<td class="nump">$ 3,347,362<span></span>
</td>
<td class="nump">$ 11,600,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6733392288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total</a></td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation, Total</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 3,347,362<span></span>
</td>
<td class="nump">$ 11,600,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_CommonStockAvailableForSale', window );">Common stock available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tgtx_ATM2015Member', window );">2015 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross proceeds from sale off common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale off common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tgtx_IncentivePlan2012Member', window );">2012 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">4,183,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,183,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_CommonStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_CommonStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tgtx_ATM2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tgtx_ATM2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tgtx_IncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tgtx_IncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901205168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_NotesPayableLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, Current portion, net</a></td>
<td class="nump">$ 90,564<span></span>
</td>
<td class="nump">$ 211,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, Non-current portion, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">90,564<span></span>
</td>
<td class="nump">211,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=tgtx_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_NotesPayableLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, Current portion, net</a></td>
<td class="nump">90,564<span></span>
</td>
<td class="nump">211,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, Non-current portion, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">$ 90,564<span></span>
</td>
<td class="nump">$ 211,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_NotesPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_NotesPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=tgtx_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=tgtx_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901204496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - Convertible Notes Payable [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2010</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument, Interest Rate During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Mar.  08,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Ariston [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt', window );">Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tgtx_AristonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tgtx_AristonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6898230368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue</a></td>
<td class="nump">$ 38,095<span></span>
</td>
<td class="nump">$ 38,095<span></span>
</td>
<td class="nump">$ 76,190<span></span>
</td>
<td class="nump">$ 76,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_UpfrontFeeReceivedFromSubLicense', window );">Upfront Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones', window );">Additional Amount Receivable On Achievement Of Pre Specified Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Proceeds from Fees Received</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tgtx_JBETAgreementMember', window );">JBET Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_UpfrontFeeReceivedFromSubLicense', window );">Upfront Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones', window );">Additional Amount Receivable On Achievement Of Pre Specified Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tgtx_TgOneOneZeroOneMember', window );">TG One One Zero One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects potential milestone payments to be received upon achievement of pre-specified milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_UpfrontFeeReceivedFromSubLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount received for sub license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_UpfrontFeeReceivedFromSubLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tgtx_JBETAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tgtx_JBETAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tgtx_TgOneOneZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tgtx_TgOneOneZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744668064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 03, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">$ 12,966,574<span></span>
</td>
<td class="nump">$ 9,902,214<span></span>
</td>
<td class="nump">$ 24,196,989<span></span>
</td>
<td class="nump">$ 18,181,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PrepaidResearchAndDevelopment', window );">Prepaid Research And Development</a></td>
<td class="nump">14,510,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,510,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,151,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="nump">1,968,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,968,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_UpfrontFeeReceivedFromSubLicense', window );">Upfront Fee Received From Sub License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AgreementTypeAxis=tgtx_LfbLicenseAgreementMember', window );">LFB License Agreement [] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AgreementTypeAxis=tgtx_SharedServicesAgreementMember', window );">Shared Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs and Expenses, Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PlacementAgencyAgreementAxis=tgtx_LfbGroupMember', window );">Lfb Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PrepaidResearchAndDevelopment', window );">Prepaid Research And Development</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PlacementAgencyAgreementAxis=tgtx_OfficeAgreementMember', window );">Office Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_AverageAnnualRentalPayments', window );">Average Annual Rental Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PercentageOfOccupancy', window );">Percentage of Occupancy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lessee Leasing Arrangements, Operating Leases, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PlacementAgencyAgreementAxis=tgtx_FortressMember', window );">Fortress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_PlacementAgencyAgreementAxis=tgtx_JBETAgreementMember', window );">JBET Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tgtx_UpfrontFeeReceivedFromSubLicense', window );">Upfront Fee Received From Sub License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=tgtx_OpusMember', window );">Opus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs and Expenses, Related Party</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_AverageAnnualRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The yearly payments due under the lease entered into in connection with the possession of the office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_AverageAnnualRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Occupancy percentage of the office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_UpfrontFeeReceivedFromSubLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount received for sub license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_UpfrontFeeReceivedFromSubLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_AgreementTypeAxis=tgtx_LfbLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_AgreementTypeAxis=tgtx_LfbLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_AgreementTypeAxis=tgtx_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_AgreementTypeAxis=tgtx_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PlacementAgencyAgreementAxis=tgtx_LfbGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PlacementAgencyAgreementAxis=tgtx_LfbGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PlacementAgencyAgreementAxis=tgtx_OfficeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PlacementAgencyAgreementAxis=tgtx_OfficeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PlacementAgencyAgreementAxis=tgtx_FortressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PlacementAgencyAgreementAxis=tgtx_FortressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tgtx_PlacementAgencyAgreementAxis=tgtx_JBETAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tgtx_PlacementAgencyAgreementAxis=tgtx_JBETAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tgtx_OpusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tgtx_OpusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M H6L H6L H6L H6L!0I9"Q2R%BAD+5#(6J"0M?@@*^O^#!^] E!+ P04
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M_,(N7$+@.#YG$0Q65] [G73N^\>)S>(!^>J5Y+_B/J"^-M1>7Z XS 4?Z[2
M#HC#^AEL$=7^@7%/!142*'T06H-%.&+8>=PA2A))#)@C1FCGX(4![-GU?HQP
M(6UNE^$PS]P?,\DBB:#?_TY/EXSL=C#;(Y3N;T\#<5@AI;#D:ST!O;WI*KTY
M+CAV(JW?"]Z%1%VPN)H$V$'G383,L!PR!W 'Q2'%N=(!DA2E&96HC'2AE&#:
MR @J!$?44.XB>D/3IIC2!_.E/.9[W&T.G(\Y8Q\"HV)GZD+TYG@-;%&]*9OC
MGM*^C1>T^9! 1Z.JHMTG2@K.L!/KH+7H9R_1!T?HXQ#M6$$I)'G6_N8BI!K
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M6?& BBQ.\WC>W&B/ MT,/7)>5"&$<H;0SM"CYV44U#.$?H8>0<]ZA7YUV4U
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M!P72L9T XKOLQ-K)]X ]*,)I0/@(@,EM:.W1M#UZM$=@CZP]=N4'BATHDFE
M[ 3$UKX8 8!B.0U(G(#$VE<C %#@8)JP<!(6X,>/B-I*$D" A 1X1IV63L@2
M(,Y.B0'226:TRLJ)6($_&BE5)XFG$3AP,NRTCI",%*O7! $.YQ0,8S>JVYIC
MO=5K9G07)FX*[$\\UF"=ALSH,!RZ*;"-"1ZC=!HR@^+>[!CV,@F__W/VG2:.
MHCA)R-=>0W>';,7$Q5X^TCOR:ZW@C!UFAPMN:T]U]"G/TH9>V"\J+D4MO0-7
M^JBW)_*9<\5T$L&3[OA<7\'#H&1G95X79BO I00#Q9O^CATN^NP_4$L#!!0
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M1]NZ[JI8E?AL%MFN*C?7+X=JV_6'+AXWN'>&7[KZ/&X%7O<C5_\#4$L#!!0
M   ( %6 "4D!8'B600(  ",(   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULC9;=CJ(P&(9OA7 !TO(K!DE&)IN9@TTF<[![7+4*&:!L6V7V[K?MAZR:
M@GH@;7W>KT_YJUG/^)<H*97.=U.W8NV64G8KSQ.[DC9$+%A'6_7+@?&&2-7E
M1T]TG)*]"36UYR,4>PVI6C?/S-@'SS-VDG75T@_NB%/3$/YW0VO6KUWL7@8^
MJV,I]8"79]Z8VU<-;47%6H?3P]I]P:L"&\00ORK:BZNVH^6WC'WISOM^[2+M
M0&NZD[H$48<S+6A=ZTIJYC]#T?]SZN!U^U+]AUFNTM\200M6_Z[VLE2VR'7V
M]$!.M?QD_1L=UA#I@CM6"_/M[$Y"LN82<9V&?,.Q:LVQAU_B9(C9 _X0\,<
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MV]55-)G/JN*W_SP<A\^S_T638)8VH,& C@9C/VD#%@S8NP%'#7@PX%-[$,%
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MUU]D<E\WIT*?E^93R%S4ZM1]V?6?E[/_4$L#!!0    ( %6 "4G)X>FOCP0
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MXP&TB Y\^^QN1TGOW\^:2&A=".]];-*52HG#87D@ZRNM_@)02P,$%     @
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MYT\V'D"+Z,"WS^YVE/3^_:R)A-:%\,'')EVIE#@<E@>ROM+J'U!+ P04
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M$-[YV*0KE1*'_?Q EE=:_@-02P,$%     @ 58 )204?G<BD 0  L0,  !D
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MJ^AZ%PJL*MG*:X0";05J8J ]T,?-_E@$1 3\%##9BYB$WD^(;R'YWAQH%EH
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MU8-T)XW2@EJWU"TQO09:!Y+@)$N2:R(HD[@LPMZ3+@LU6,XD/&ED!B&H_G<
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MIRMH#R=QY4+&EL&@),G3V&G?X"J#@PA)3\E]0\AI"%E#T'66!K.>,.@ZIGH
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MOY^Q#4DZAW@O 3OGGGONY6!N<1+]F]QSKJ*/MNGD(MXK=7A,$KG>\[:2#^+
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M2#1SI(N1ND^&LS>=*HOW$J5ID;P/1%<89##/%@-O(Y:.!>,)DV@%7ADH]J5
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M=6!,$N43/B4!J-3MY-*AY"!U,U-M;L]KVY&L&ZX?ESM0\1=02P,$%     @
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MRFSH>UNRPX=:?K+NG;@2$BVX8;4P3V]S$)+1$\7W*/ZV:]68M;-?)J&C#1.
M(X">T.<9)L2.$)\)\"X!.@)\-D/B",E-AL#6;DYNB27.,\XZ3[18_T[13,&Y
M%E'*GCHNH3IA-+GI19X=<S"%67#40E<88# +BTG!.&1I(5&/")2!01? '\H
MK(OQ!(5%I/$=#P]%5O^)C-J,KVW&]K!B=UC)8P%X+0"M '0"Z-ID8S"I/0N+
MB1"<Q--T'%=8' (03"=W])86%\<PC1$8QZU<W@B%81C!QQ4F@Q4FKL)!Y\A6
M:#'A.*)XB%@^1*QN$:.%H,%"D"MD<J=5Z,E6H2=;A9YL%;K7JN!B#%#"]V8
M"V_##HVT/W8?[6?\*]!CY":^B&9%-!!?JCO!CO"S?)ZU>$]^8KZO&N&MF53#
MR\R8'6.2*,_ABSKL4MU:_:8F.ZE?4]T%.\CM1K+V="WU=V/^#U!+ P04
M" !5@ E)U^^[:?D"  "[#   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6R-E]MNHS 0AE\%\0"%X4Q$D)I0M'NQ4M6+W6N:. DJX"QVFN[;KT_0-+6!
M7 0PW\S_>\#6D%UQ_T9."%'KHVTZLK9/E)Y7CD-V)]16Y &?4<?N''#?5I1=
M]D>'G'M4[450VSB>ZT9.6]6=G6=B[+G/,WRA3=VAY]XBE[:M^G\;U.#KV@9[
M&'BICR?*!YP\<\:X?=VBCM2XLWIT6-N/L"HAYH@@?M?H2F[.+6[^%>,W?O%S
MO[9=[@$U:$=YBHH=WM$6-0W/Q)3_JJ2?FCSP]GS(7HKI,ONO%4%;W/RI]_3$
MW+JVM4>'ZM+0%WS]@=0<0IYPAQLB_JW=A5#<#B&VU58?\EAWXGB5=Q)7A>D#
M/!7@C0&CCC[ 5P'^9T P&1"H@& ,\*850A40+E6(5$!T%^#(8HE2%Q6M\JS'
M5XN<*_X"PHKA/4_",ENLOH0].I&S%P\OS]YS+TTSYYTG^L)X@ME()O;,2"$1
M& F'&="Z\&R=@B==F 6VDHC]"0^S29[FDY0J23@_$__K3 )93U_$1W<2G4!D
MW$8BX,J?&2R6@J4!-%H/M-8#:=W3"272ND3<!]<%,U4LHDH=970<:AV'TG$T
MX3A<Y'@15>HHH^-(ZS@2*?S[IWG+% .S0"36BL0J@?9)QK(NDH'8-[Y;$BP,
MH-%2HK64*$M3ZT(R$,XOC,5D:2*-]E.M_539#R8J*AF(9@JZ3=4RFRN\TO2#
MV->O2<D]*5TA#,'\#,'53E$,\SF&$YX4!'&RM)X >C50:M&"%)X^A:=2Q!-O
MR@"E40(+UA/H-W7PE50R51L%14LKH]^%(5!:Z926@L*E6OK]$^2.YL.2%/H-
M#=1N!=J-4ZUL!4TMZ6^(V8A^TP.UZX%VK0Q&)!1 XB?1A./" $I3SDVCU:+^
M*'IB8NWPI:.R+QA'Q[[[T>.-VMWX!E9;T(P7L'J27?5G^CP[5T?TJ^J/=4>L
M5TQ9>RBZN /&%#'/[@/K(T_L2V*\:-"!\M.8G?>RMY87%)^'3X7Q>R7_#U!+
M P04    " !5@ E).T,O# X"  #M!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6R5E=N.FS 0AE_%X@'6G$Q"1)!V657M1:757K373N($M 93VPG;
MMZ]/T"0R2?8F/O#/SS>3P2X&QC]$38@$GRWMQ#JHI>Q7$(IM35HLGEA/.O5D
MSWB+I5KR Q0])WAG@EH*XS#,8(N;+B@+L_?&RX(=)6TZ\L:!.+8MYG]?"&7#
M.HB"<>.].=12;\"R@%/<KFE))QK6 4[VZ^ Y6E51J"5&\:LA@SB; PV_8>Q#
M+W[LUD&H&0@E6ZDML!I.I"*4:B?UYC_.]/\[=>#Y?'3_9M)5^!LL2,7H[V8G
M:T4;!F!']OA(Y3L;OA.7 ]*&6T:%^07;HY"L'4,"T.)/.S:=&0?[) U=F#\@
M=@'Q%!"E-P,2%Y!<!4!+9O)ZQ1*7!6<#$#W6_W:T4G*N390S4,D(52?CR4VE
MRN)4)E%2P),VNM#$1O-B-?&\HG(*-$F@ O!2Q)<4=O,Y=A3I?8/DTB"U!HDS
M0)>0G=$L;!I6DX<H2^=5E57%4832_#Y-ZJ5)'4WF>T]F::PFG%=4UXI9".2%
M0#;=_ 8#NET1QX&^5)',"Y.YBBSN&RR\';)XO$.67H+EK0YQ]5@^5(_EE^J1
M>VGR!SHDO]LAUXI9B"CT4ICMN1YQ7\VHN?/9.)FW*O#L8.KQ@?S$_-!T FR8
M5&><.8KVC$FB?,(G%(!:W3W3@I*]U-.%FG-[&MN%9/UXN4PW7/D/4$L#!!0
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M3.<;F!-D))X.WT0I#O&2=L,>=B\$3 -JC-R>UG\ZZ-'[H#(",-9H2T^8>(8
MF'BS7#VGLTV!:]0'%.>I<C;[<''?Z0]Z Q_&\=(LB$'S##X&44RX>7<Y_!Y
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MLRUYOD-4?=#VYUYD&$,U*NGM1(VI2-DID@.$<CI@EK9N@GP>_$ES+75M)'0
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M>#81W@?T$C/AL<Q#VQ34,@3X(]D!/$0-.-1\7?PS)E:97+4&Z929]S$$=B\
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MP,YM#/9%A@+O.C$JA,Y76I"MI?5G\:*<63YL:(AJ['R2?Z=N;<(ZU21#K;D
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MAF!%S<V!P"!N10$*Q7&PH;\>GM&SDLQ]=?<,/ X[YN&</T1AD01+QN'K39
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MQ:63\2&S>IC3?Y<[I2QTQTG\&5 HG#M=]+1>&H=<'^EB,KGSY6A8[[9YYZ7
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MUV2OFQ_.I@_8W0.35C_<7SYL0]E:+'MK>L NK;M(D,YM0SBIIU&-\'XUK<!
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MXJU.D-6ZZ<=O\[SX[?\#4$L! A0#%     @ 58 )24PZ:/JV 0  %!<  !,
M             ( !     %M#;VYT96YT7U1Y<&5S72YX;6Q02P$"% ,4
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M>6QE<RYX;6Q02P$"% ,4    " !5@ E)Z1P-GH,#  !+#   #P
M    @ &!$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 58 )25 @XOE.
M @  ] <  !@              ( !,14  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( %6 "4GK0C7U7 0  )L4   8              "
M ;47  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !5@ E)
M 6!XED$"   C"   &               @ %''   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ 58 )26:ZVUN*!   IQ,  !@
M     ( !OAX  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M %6 "4GHG5_S:@,  &H.   8              "  7XC  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " !5@ E)R>'IKX\$   7%0  &
M            @ $>)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ 58 )27KWMB:D 0  L0,  !@              ( !XRL  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %6 "4EZ(47*HP$  +$#
M   8              "  ;TM  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " !5@ E)!&(T7*,!  "Q P  &               @ &6+P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 58 )21E%HX>D
M 0  L0,  !D              ( !;S$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " !5@ E)\7??U*(!  "Q P  &0
M@ %*,P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %6
M"4F%=M(]HP$  +$#   9              "  2,U  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ 58 )2=:P].*D 0  L0,  !D
M         ( !_38  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " !5@ E)!1^=R*0!  "Q P  &0              @ '8.   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %6 "4DH):6M5P(  .L(
M   9              "  ;,Z  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ 58 )26M*4]RB 0  L0,  !D              ( !03T
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !5@ E)VZ_R
MXZ8!  "Q P  &0              @ $:/P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( %6 "4EPJM#9I0$  +$#   9
M  "  ?=   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M58 )26*&6U:Q 0  %@0  !D              ( !TT(  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " !5@ E)!?R%T<$!  ![!   &0
M            @ &[1   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( %6 "4D;.!5)I $  +$#   9              "  ;-&  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 58 )2:Z;H?%J @
MG @  !D              ( !CD@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " !5@ E)#F 4&%("  !H!P  &0              @ $O
M2P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %6 "4E-
MPXNW"P(  -<%   9              "  ;A-  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ 58 )25$X1[/E @  EPL  !D
M     ( !^D\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %6 "4F?=+P?. (  "<'   9              "
M <]<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 58 )
M2=?ONVGY @  NPP  !D              ( !/E\  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " !5@ E).T,O# X"  #M!@  &0
M        @ %N8@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( %6 "4ED7Y3H-P(  !H'   9              "  ;-D  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 58 )2:<T70/# @  B L
M !D              ( !(6<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " !5@ E),9Q%RA,$   Z%0  &0              @ $;:@
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %6 "4D#G3C7
M#U0  "DL 0 4              "  65N  !X;"]S:&%R9613=')I;F=S+GAM
7;%!+!08     +  L .8+  "FP@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>199</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - CASH AND CASH EQUIVALENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CashAndCashEquivalents</Role>
      <ShortName>CASH AND CASH EQUIVALENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVESTMENT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/InvestmentSecurities</Role>
      <ShortName>INVESTMENT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/LicenseAgreements</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/CashAndCashEquivalents</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - INVESTMENT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables</Role>
      <ShortName>INVESTMENT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/InvestmentSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/StockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/NotesPayableTables</Role>
      <ShortName>NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/NotesPayable</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - CASH AND CASH EQUIVALENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - INVESTMENT SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails</Role>
      <ShortName>INVESTMENT SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/InvestmentSecuritiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/StockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/NotesPayableDetails</Role>
      <ShortName>NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/NotesPayableTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/NotesPayableTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - LICENSE AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual</Role>
      <ShortName>LICENSE AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/LicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tgtx-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tgtherapeuticsinc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tgtx-20160630.xml</File>
    <File>tgtx-20160630.xsd</File>
    <File>tgtx-20160630_cal.xml</File>
    <File>tgtx-20160630_def.xml</File>
    <File>tgtx-20160630_lab.xml</File>
    <File>tgtx-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001654954-16-001302-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-16-001302-xbrl.zip
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MML$O%DVQ.2C5/>F](9BR>P)E0;U=U>(5_0*Y@$O$H$S@6BG/X;#O=X7=0DW
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MEDOAGL3HRU#^%*P[%#^QB-4:"Y=;:<#VH$?'Y7JK?9J%#Q -?7+5- O-7LY
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M212F@7LV"OTP>F7=W7@)&^T7B=Z]!*;!;</6X5,136"+G]\)ZT[PS9F!]2/
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M58PEVQ2J/\% #::>)9Y?'-_"L7DX@$BX##U3&F^@PD6.U!0<G!019]=-4XX
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MFB&<*!!NJ1Q8S+OG=(<PP Z;C*7O7OSC+4DT_/2P;/Y#:?HM4=8L1.X'/X$
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MEV0-1+8V*K,F-F <F,+:GJARE:OMQ1Z[V-\N#J>:'KB_'EOF9D:M[/"*C8I
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MW"BBX-@VR\8J1+67P50813UC%/66;K0 XY+$]S+2>\:,3-;7^=@'D*\9 [^
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M[A>S1\_)<G' 5_X)GRE=INJ%Z2V ]+JO<R&OYLBC0B J+R'OJ(A^7K5*Z;V
MKY.C^FFP,QXB1?/!1%>,GSGL8>SYH*?II$\E$"/"J''GF.. 0/S=^?VETM.Z
M+4-KW0^'+>-'R?]3XG_&V"*K@ZD]G^,O* ]3^,>AOS"@)@^Y\ R>A.>=+O%<
MESP_99Y;V0R0,K%!(:#'9"KPPPC^CCZ5PB-J<%L2YG<UR?S39_[$#%J/IL,/
MOU7,3(&$<WK8-C"G@ISN@IN_ ZNE#RM]V"/9 ZM]6 CRI$8[(8WVGH7,G]DN
MA<[ 5!>+ I@[ ;,U!8>%,DY47_;Y:2[<HDT7C[X]4L9)GL=.R@IQ\L9VDW00
MZ,H9?R6E;)4(MK>OH(8<Z%VN*N&'6%6V3U)5OKB"/'Y=O3L RVMEDT5VH+#Q
M&(]+?@(9*U%3/!^8AMODEF=45S8G]5"NX>*%7"^DD,\26V)JPIHF  S;B?;#
M;(Z;1L" R7/376028P0*[*T1!HU4C@D\QQ[1#DMW51 ?\Q><O3Q7#R!@%>EE
M3"$F"6:%\IQE&6)MF,T0WP,+'$ HUFP%WXW*0"WJ/%;B^F*:E%7R65M"4:R1
MS=RF4@'"%/ %;4 X8%C$=!0S0 D)4'Y(%/,@,#'DP+4B>)((RYS#HH1I#3F@
MI\$\30F.>?3HV!;)KNNYXC?LV,9A217T+HY+QE@7EK2IO4P)S>_XZ#@]+EBE
M]Z&\1:'G+_ )Y=D.IU//H7?Y>+XCOTD^4 D,,U">P2H#CDK^U@RA^5/A1?0M
M,Y@J8\=[#O)$R^U9A-"DNB^L-_=\ GM.W9J!\LA 5,A.F6/89 3#>V9165+1
MNZJ0D!1]&[M%[%GR D2'0/,"5KG,&6W\N>\]V0&1GE@'4 8BFZZ@ <ON?@($
M-$  NXAHX(;.(M[_F<W_5G<P77Z(%,U6%L3V%;4%VM' >P\?Y<(5 9M\&R=]
MGW)"'"0EG D>ETE,5<81.2VI(*$>#8A3(-ZX/#+,G,/VM,B]]/@G&9:A#O<B
M/Z>(N>^R6AFGA=)-:WG+IU2EI^5E&DB"]W9@.5X "!ZV#+C&)5WYFN2[C_$/
M5&WZ>'U!-+VPO9!94]=SO GHK+0<13\EW\E[@"_MT6Q-AORNVS].S8)_ZQ)H
MOYJ@+\$NM#52M(8*RA^-#O/)U:?2(:A$T+T!;D!'='>;<?L(WZ@@ $J!^:KR
MX>&2/H1]:LY9!'$6SY?"PS_AWSY^O!06!ZS-,Q@D9]'RGEU8-X@> WMDFS[:
M7%#4^'HZ15?ET0JO!Y**&8%%=KQY;([0:(;1=WMF/BKOJ(J:F'M\2=R<GG2_
MY,JU4C2/0S2_8AC)S2]P$./8Q-,J92+)+,B7 Q%P*BL\C2M*[%DQ01F<Y0[*
MBVLX9\KO#!T-['Y)*C_<I8?U?S#.VLK,=ASTA? E\(&1?##BKR*(IP"8,@.,
MI^ % 3(CY=?(9?$>Z\5M"5V5:O3<MF&%7+QT:94.+[ OKQ38W[=9YWEJ@^=-
MH<TC8Z[PK7AL3_L5GV?DGN,K,L0C0&+"Q XAFG%RA42'5UGLDQI99*47-P"C
MUTB?+ .>^(!M7158 )NG)C??8/1]#_=Y"!@I/^AG_2+1]/B#(O98R?,%ML(#
M"= ])P\BDPVIE+<S@N"&6E/_ \X .<>D!XL:J5K4E!&8_RA .IF/WA-3$U%-
M5"NZQN$S\B=*%*<0;>&U\[ A;N'$[XZ>J(D$")HL!*3&/ TLA)EM#SWF$7.
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MP@"D1[-LNMR>P,T?9W$*X&;XOB=PX\//WK/ \FU^,</+';JQ;*<P$4K1$!B
M.;@(,PB/(YI%B8T :&PK0A,AHD$>Q21'N:GU-#G7VF #3'$Q)MJ!BQ8.WN1T
M,O<JH]"S9S-4FR,[H#, SQ1Q&(RS4!,P1.LK*C0!!!6WGDFU^>8<WQ=B"$VM
M6AE#4# ##Q]:NJ[IRKM,W]:/O))&<*O*Q%E8'G.!F(S%GA_(B0?JSL5&;)"/
M1V^$65[,M]"2%$Z*DR<(*U L?T5@3^=@LN8LZ=U_;VCT_0E#SR]"/]O%1G\,
M4B]:SF(VGWK6(A3FBI@5!\49I!\^?&GIAF:08?=\GM"(#[96[F[:_\)VB]!,
MC2;/_(@/ R\>HJ%'J2$93""@C=4^/TY5\$&IU*J"B0#:6CQ;Y=L3FZ>9;8R'
M'3R8D@S2(\-^9?  L!%6F&>P?8X]C@=;J0H9@:O[1)F:(MX7$'DD3,)G8VR)
M' @6Q/(HLUFJ) T;L&UM$CGR4E9(04:BR#YB7 ^XM^*WQVX&12QB%>7FR_F_
M.LH[2F\X+/IFNRT]SIJP.="Y90:!![L!K3/\%819Z?R8L@$V*SH.[RY\;^:-
M8!,+&EY]AZ!*>:#I*=/)?X'V"(A,Z^Y]ZZ.>_OKAYN%++(N(4JG#>Q#7]PTV
MHO_.-R;F&ZF^K3 0YHB?O#>;.SS'!]XP"-$HLN(QAVRO:JP]00)M$?*!-"6N
MG$KN)C8O3.VYFM7!^,6?Z.GX3F#%F^.&0U^&R[9'3>MJDK'$_G21F<QT3N'V
M2R)-DSN;N!T\2HLJ(S^:*!8>:\8[X$E4%TB;;XQT/TW0^ Q> 4LEZX!FPXV.
M>3$WP9_>+S*J<<JU\/ZW.M+P4,P31JX9C>R0YPFK,H9EDP3 ;I_QMC8_#2=\
M?L03J<.O9_=G@D%D,BQ46LBI="9"M&DXB /(QH?S\SM5""=O14E6%O$7FI)4
MKR?9&3[#*4:.0(/^F]<P8=4O-":#=N\:K9"NM?[-9^=P*M9A*1=T#47Q"YM$
M#BV0_N6^]7]Q(';UW9KBI#R/P*RPT%T(CZ#(+D@T1<LI%D#BKQ?A'WM>Z.()
MF''.BBK?2 5Q0@-N[I!5C-41#%B,&*&L<::0DV#Z/&V-2Z()%W[2+-.21(&\
MB\!@/1IS3M2PPET#4OHX*\3PK!=4+#3>I(PABD..!ZANBJ6D#28"2_IRST"H
M<5)YRAP*Y>&'8*-W$BC!U(L@,G_$TH')G8JR_M6,Q*\!%/UGL)JB$ EJBI_M
M62)5_\JE\ZD6Q9-H)37%I4V8XKGT=+YTF=8#1K ]T >*RT8!6Y(-7 :8%3G%
MCN1$#U?W:16+HV)R+)8(3 ""<J&QN:>D;R)>C(00MH$H[J73IO&Z6"?$?A"(
MZ8&81"R:GUN(/'!^_NTX=;4(XM8'81"S_>.G[X^^8_^,_\*O_P]02P,$%
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MH*4+FY(*DE>UJC%\>5N,$EVH6?N4A:@TP)KO&IO$6.=54D-VH/,*ZFYR#1\
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MC%*UJO8X?3.1!&/P /R(54T@VW#6*1I===]C%\Y)83%-0T*RM[A;8][]\ J
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MS*>=G2EZUW+%:_&B$M'05)L;9]HV*8 3W%I/9-G7C1 B$0??&4+?3OZ@@RE
MW#8TA462/4M)NM@(@S# W&ZW2&DMT'%D4;4-0+XLU#6UY),Y!-:6ZQ1[!MK!
M'(NF-4@(2D)=5$O>VCP 9"V Z?N1Y8WQTRT/#V["!G7S3J=H%09<.:@'=6JO
MS  [><LO6,. 5;ELKV%KL&&Q3X.DZBT)FG,"R"8&L0"C^<BVH[7EVT431#R4
MB]JV1MD<"6CZEI$:+6U5EI+9!4&WY+*LD+HU^)66B89HU3Q+236!01  , !6
MX/H+$R%2?";VQ*,U(%M ?T&^ \$4H-5HWH5^B+!BZ!A7ZZ]MJ!\B)<T.JB;
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MAW=OK]Y>?FA=OOW[U>N7&27]QDGHO[-?_L?5S=OOV7\^3BZ__W3U]M/ENW\
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M'48H!)S;!R/7$3 <>\V!@+S'"PB'>QN0Y R,R-QC= <)2S+BH\%O"03B.TQ
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M,8;UPN -@QC6EH3]K8; FZPP\2/QIY/PSDG2R$M68^*R/ZF QD]AE$Q(Q#O
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M/56"P+&]'[*M7C\,YIJ@J?K9WM#7!@XF$!S@W3G_#"/&7YS?)>/M:Z0+&W@
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M<$E>GT!@]=D[[YR&9V3Y(A8+2F!.[$)#KU*%Q.)%XE()U:SYW_N.F]^'GY/
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MF=+?_#]02P$"% ,4    " !5@ E)SQ7^*D*6  !6Z04 $0
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M+3(P,38P-C,P7VQA8BYX;6Q02P$"% ,4    " !5@ E)F#C_"!HM  !.[ (
M%0              @ %2&0$ =&=T>"TR,#$V,#8S,%]P<F4N>&UL4$L%!@
0   &  8 B@$  )]& 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
